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Abstract
This research utilised mixed methodology to gain insight into community pharmacists’
adoption of medicines and services related to two key innovative policy interventions
aimed at enhanced minor ailment management; namely the ongoing legal status
reclassification of medicines; and the introduction of the Scottish Minor Ailment Service.
Prompted by the lack of qualitative and large scale quantitative evaluation from the
pharmacists’ perspective, the aim was to investigate pharmacists’ adoption of these
innovations. Data were generated to evaluate the process related aspects of innovation
adoption from community pharmacists’ perspectives; and to identify and quantify key
factors associated with the adoption of these innovations, thereby considering the wider
relevance to new community pharmacy services.
A range of methods was used including: formal systematic review of peer reviewed
published literature on factors associated with innovation adoption following methods
recommended by the Centre for Reviews and Dissemination at the University of York;
extensive review of policy documents of all the devolved UK Governments; qualitative
focus groups and interviews with 20 community pharmacists from four Scottish Health
Boards; and lastly a cross sectional survey of the pharmacists responsible for non-
prescription medicines from all Scottish community pharmacies (N=1138). The theoretical
framework of diffusion of innovations was adopted to design the quantitative research
instrument and interpret the data. Rigour was enhanced by consideration of aspects of
validity and reliability at all stages. The highest standards of research governance and
ethics were applied throughout the study.
Qualitative interviews provided insight into the process related aspects of innovation
adoption. Where current changes were embraced reluctantly by many who deemed the
pace as fast and furious, others were keen to contribute to developments taking place
within pharmacy and were eager to play a more proactive role in leading and introducing
change to the public. Regardless of practice setting and ownership model, the merits of each
innovation appeared to be considered at the individual practitioner level. Hence an
organisational level decision to implement an innovation did not necessarily translate to
adoption at the individual practitioner level. Using descriptive, bivariate and multivariate
quantitative models informed by the results of the qualitative interviews and systematic
iv
review of the literature, the quantitative study showed pharmacists’ perceived attributes of
innovations (such as benefits to their professional role development and patients); and
patient demand and use of services had the highest association with whether or how far
innovations were adopted. Issues such as differences in availability of resources were less
able to explain differing level of innovation adoption by the pharmacist respondents. These
findings suggest that as innovations around minor ailment management have not yet
required reorientation of existing services, the issue of how pharmacists’ perceive the
characteristics of the innovations such as: potential for financial benefits to pharmacy,
professional role development and patients; is key to predicting whether future innovations
of a similar nature will be successfully adopted by pharmacists.
Keywords: Community pharmacy, pharmacists, reclassified medicines, e-MAS (electronic
Minor Ailment Service), Scotland, acceptance, adoption, innovation.
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Foreword from the Author
This thesis describes my work over the past three years or so, in which I have sought to
gain understanding of how community pharmacists in Scotland inform their decision
making in relation to adopting changes around enhanced minor ailment management. This
experience has developed my research abilities, as well as aims to make an original
contribution to knowledge in this emerging research area.
My longing to pursue ‘a’ PhD was mainly passed to me from my dad, who also had this
desire, but pressures of academia and politics prevented this. Hence I started the journey
from Nepal by coming to Aberdeen to pursue an MSc Degree in Clinical Pharmacology at
the University of Aberdeen. Prior to this, I had completed my B Pharmacy from Pakistan,
again, far from home and supported by a regional scholarship. During my MSc, I
researched anticancer activities of some novel chemotherapeutic agents in human
leukaemic cells. Here I realised that I had less interest in laboratory based research
Nevertheless, I completed the course with a distinction and being first in the class. I had
decided to seek an exciting opportunity to undertake a PhD in pharmacy practice.
Apart from undertaking my doctoral research, I gained valuable experience as a
demonstrator in medical statistics to MSc and PhD students at the University of Aberdeen;
and to undergraduate pharmacy students at the Robert Gordon University School of
Pharmacy & Life Sciences. I have recently taken up a position as Research Assistant at the
Robert Gordon University investigating pharmacovigilance activities of non-medical
prescribers, funded by the Medicines and Healthcare Regulatory Agency (MHRA). Time
with RGU SPORT was also memorable, representing my University at the Scottish Inter-
University Table Tennis Championship in 2008.
Throughout this thesis, I have provided details of background to the research, my aims,
objectives, methodology, methods, results, discussions and conclusions. I have been
privileged to have received formal trainings to undertake the research in the best possible
way from a number of internationally recognised method experts and training
organisations. These appear in Appendix X (General).These lists are apart from my
extensive reading of books and online materials during these three years and my learning
through doing.
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The first Chapter introduces the area of minor ailments followed by an extensive, in-depth
review of policy documents from England, Scotland, Wales and Northern Ireland
demonstrating how policies and services within the area of minor ailment management had
evolved during the past 25 years. This is followed by a review of UK peer reviewed
literature to identify research gaps. I also have reviewed and critiqued the available
theoretical models to debate why Rogers’ diffusion of innovations provides an appropriate
foundation to undertake this research.
Chapter 2 details debates of different methodologies and methods; and draws conclusions
about the suitability of the mixed methodology approach. I have argued that paradigm
debates should be left aside and the choice of methodology and method need to be mainly
guided by the research aims and objectives. The difficulty of undertaking a systematic
review with literature using diverse methodologies is also discussed along with defence of
the approach to synthesise the findings.
Chapter 3 to 6 relate to investigation of the ongoing legal status reclassification of
medicines. In Chapter 3, I have presented results from the initial exploratory qualitative
investigation around pharmacists’ perspectives of ongoing changes in practice in general;
and around minor ailments management in particular. Key facilitators/barriers to adoption
of newly reclassified medicines are presented.
In Chapter 4, I provide a systematic review of literature, specifically to review the peer
reviewed literature around pharmacists’ perspectives of the adoption of newly reclassified
medicines into practice. This further informed the design and content of the research
instrument to undertake large scale quantitative evaluation in the next phase of the
research.
In Chapter 5, I have detailed development of the content and design of the survey
questionnaire using findings of the systematic review, qualitative work and theoretical
model of diffusion of innovations.
Chapter 6 presents findings of the quantitative survey. Factors associated with innovation
adoption were extracted from these analyses.
xiii
Chapter 7 presents results of qualitative work specific to the pharmacists’ adoption of e-
MAS. Key facilitators/barriers to the service adoption were identified.
Chapter 8 presents results relating to pharmacists’ adoption of e-MAS and key factors
associated with innovation adoption from quantitative evaluation.
From Chapters 4-9, I have discussed key findings and how these compare to the literature.
Discussion of research strengths and limitations of most of the research phases are given in
Chapter 9, prior to discussing relevance and importance of all findings. Potential future
research questions are presented before a summary of study conclusions.
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1 CHAPTER 1: INTRODUCTION
1.1 INTRODUCTION TO THE CHAPTER
This Chapter introduces the area of self care and minor ailments followed by an extensive,
in-depth review of policy documents from England, Scotland, Wales and Northern Ireland
demonstrating how policies and services within the area of minor ailment management had
evolved over the past two and half decades. This is followed by review of UK peer
reviewed literature around enhanced minor ailment management from community
pharmacy to identify research gaps enabling the formulation of aims and objectives for this
PhD. Review and critique of relevant theoretical models for their appropriateness to
undertake this research are also presented.
1.2 SELF CARE
Self care, as defined by the World Health Organisation (WHO), is what people do for
themselves to establish and maintain health, prevent and deal with illness [1]. In historical
terms, self care signifies the importance of patient ‘autonomy’ and ‘independence’ which
relate to people initiating actions by themselves as well as making their own decisions
about care [2]. Lately, however, the definition encompasses shared models of care [3] which
stress the balance between patient autonomy in decision making as well as dependence on
health professionals where necessary [2].
The principles of self care which can be applied to prevention and management of illnesses
are known to have arisen from a number of theoretical models such as the theory of self
regulation. Self regulation models emphasise the importance of self- efficacy [4], which
relates to an individual’s belief in their ability to learn and perform specific behaviours; and
self-management [5] which relates to adoption into practice of such behaviours.
Emphasis on greater patient participation in managing their own health has been stressed
in recent health service policies across the UK and beyond. Terminologies like ‘expert
patient’ [3] and patient ‘empowerment’ [6] have been used to underline this emphasis.
1.3 SELF CARE OF MINOR AILMENTS
Minor ailments are self limiting conditions requiring little or no medical intervention [7,8].
Colds, coughs and indigestion are some of ailments defined as ‘minor’ both in the
published literature [9] and community pharmacists’ practice guidelines [10]. The concept
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of self care also applies to the management of minor ailments as it does to the prevention
and management of long term and complex ailments. The level of professional support
however, is known to increase with increasing complexity of illness. Much self care can
involve no professional at all (figure 1.1).
Figure 1.1: Spectrum of care showing that most care is shared care and can involve a small or
large component of self care.
Reproduced from [11]. 1ry: Primary; 2ry: Secondary; 3ry: Tertiary
Self care of minor ailments may require access to non-prescription medicines. The
following section describes the regulatory requirements around patient access to non-
prescription medicines in the UK.
1.4 MEDICINES CLASSIFICATIONS: REGULATORY
PERSPECTIVES
The ‘Medicines Act 1968’ [12], which regulates the supply of medicines in the UK,
categorises medicines into three classes, described overleaf. In addition to the retail
pharmacy supply, these regulations also apply to any other forms of supply such as via the
internet and mail order.
Chapter 1: Introduction 3
1.4.1 Prescription Only Medicines (POM)
Prescription Only Medicines can be obtained from a registered (registered as per the
requirements of Section 72 of the Medicines Act 1968) [12] pharmacy premises by patients
under a prescription issued by an appropriate practitioner (a doctor, dentist, nurse
independent prescriber, pharmacist independent prescriber or supplementary prescriber)
[13].
The term ‘non-prescription medicines’ or ‘over-the-counter medicines (OTC)’ refers to
medicines other than prescription only medicines, and are described as ‘pharmacy
medicines’ and ‘general sales list medicines’. The term non-prescription medicines will be
used throughout this thesis.
1.4.2 Pharmacy Medicines (P)
Members of the public can obtain these medicines without a prescription but only from a
registered pharmacy, supplied by a pharmacist or pharmacy support staff under the
supervision of a pharmacist [12].
1.4.3 General Sale List Medicines (GSL)
These medicines can be obtained by members of public from any retail premises with a
locked facility including pharmacies. Medicines must, however, be supplied in the original
manufacturer’s packaging [13].
In addition to the regulations of the Medicines Act, the sale of medicines from pharmacies
including internet based pharmacy supplies is regulated by the Royal Pharmaceutical
Society of Great Britain’s (RPSGB) ‘Code of Ethics for Pharmacists and Pharmacy
Technicians’ and ‘Professional Standards and Guidance for the Sale and Supply of
Medicines’ [14]. These documents set out seven principles of ‘ethical’ practice (figure 1.2)
and ten standards of the supply of non-prescription medicines, with emphasis on self care
(figure 1.3). In addition, standards of supply of non-prescription medicines through internet
services also are provided [14].a
a At the time of preparing this thesis, the demerger of RPSGB was taking place with the subsequent introduction
of the Royal Pharmaceutical Society (RPS) and the General Pharmaceutical Council (GPhC), which will have an
impact on regulatory and practice standards
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Figure 1.2: RPSGB’s seven principles of ethical practice for pharmacists and pharmacy
technicians.
Make the care of patients your first concern
Exercise your professional judgement in the
interests of patients and the public
Show respect for others
Encourage patients to participate in
decisions about their care
Develop your professional knowledge and
competence
Be honest and trustworthy
Take responsibility for your working
practices
Reproduced from [14]
Figure 1.3: Key excerpts from RPSGB’s standards of supply of non-prescription medicines.
Pharmacists or Technicians to intervene and professional
advice be given wherever possible
P medicines should not be made accessible to the public by self
selection
Sufficient information is obtained from the patient to either
advice self-care or to recommend a suitable product
If sale is not considered suitable, reason is explained to patient
and referred to other healthcare professionals where
appropriate
All staff involved in supply be adequately trained and
consideration given to the medicines that may require personal
intervention of a pharmacist e.g. those that have become
recently available without prescription or subject to misuse,
abuse
Be able to refuse where there are reasonable grounds for
suspecting misuse
Particular care exercised when supplying to vulnerable groups
like children
Patient right to confidentiality and privacy are respected
Information about the medicines provided to patients are up to
date, accurate and reliable
Pharmacy staff to keep up to date with new policies governing
supplies and to national and local health promotional
initiatives
Reproduced from [14]
From an international perspective, the category of non-prescription medicines requiring
pharmacists’ supervision or involvement in sales also exists in countries such as
Switzerland [15], Australia, New Zealand [16] and Germany [17]. In contrast, in the United
States, only one category of non-prescription medicines, the ‘over-the counter’, category
exists and does not require sales to be restricted to pharmacy premises [18]. Although such
regulations could be debated to be enabling greater patient access to all non-prescription
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medicines through availability in both pharmacy and non-pharmacy premises, wider
patient safety implications also take prominence in such debates.
Data from non-peer reviewed sources indicate that over 930 million packs of non-
prescription medicines were purchased from UK pharmacies in 2006 [19]. Research also
reflects the increasing market share of these medicines over time. For example in the US
alone, non-peer reviewed data suggest that sales of non-prescription medicines were
reported to have increased nearly ten times since 1971 which equated to $17 billion
accounting for the treatment of 57% of all the health problems [20].
1.5 CASE FOR PHARMACISTb SUPPORTED SELF CARE OF
MINOR AILMENTS
The burden on the NHS resulting from the costs of ‘unnecessary’ patient visits to general
practitioners (GPs) is a much talked about issue in the public and professional press [21,22].
Data from non-peer reviewed literature suggest that currently minor ailments in the UK
account for an estimated £1.5 billion a year in lost GP hours alone [9]. The top ten minor
ailments that account for three quarter of all GP consultations are reported to be back pain,
dermatitis, heartburn/indigestion, nasal congestion, constipation, cough, sprains/strains,
migraine, acne and headache [9]. Freeing up GPs’ time from minor ailment management
has been argued to enable focusing more towards complex and more serious illnesses,
reducing patient waiting times [23,24], apart from the potential financial savings to the
NHS.
The professional expertise of pharmacist in minor ailment management is another reason
why they are considered appropriate to manage these ailments. Despite being considered
relatively safe, many non-prescription medicines are also known to contain potent
pharmacological agents with potential for adverse drug reactions and drug interactions.
Hence their use demands an equal degree of care to the prescription medicines [25]. In
order to ensure that widespread consumption of non-prescription medicines incurs
minimal harm, their use along with professional advice has been deemed a ‘rational’
approach to self care [26].
b Pharmacist/s will refer to community pharmacist /s throughout the thesis except explained otherwise
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The issues of free access to professional advice without requiring any appointment is
another factor associated with greater emphasis on pharmacist supported management of
minor ailments. This has received support from the pharmacists’ professional body, which
states that the provision of self care support around minor ailments is a positive
contribution to the pharmacist’s professional role and image in the society [8].
1.6 REVIEW OF LITERATURE -I
The literature review has been divided into two parts. The first part reviews the Health
Policy documents of each of the devolved Government dating from 1995 in order to fully
understand their perspective and emphasis on pharmacy management of minor ailments.
This is followed by the peer reviewed UK literature around enhanced minor ailment
management from community pharmacy. Identified gaps and limitations in the research
will inform the questions for this doctoral research.
1.6.1 Enhanced management of minor ailments from community
pharmacy: a chronological review of major health policy
documents in the United Kingdom
This section is derived from health policy and related documents dating back from 1986 till
date published by the UK Government and devolved Governments of Scotland, Wales and
Northern Ireland after devolution. Those sections of the policy documents with relevance to
the enhanced management of minor ailments from community pharmacy were reviewed.
Documents were identified from the websites of Health Departments of each of the
devolved Governments [27-30]. Other key events not listed in the documents but relevant
to the discussion here are also presented.
The foundation for modern UK community pharmacy minor ailment services could
arguably be claimed to have been laid in 1986 with the publication of the report of the
Nuffield inquiry [31]. The following statement summed up the position of community
pharmacy during those years:
“It (pharmacy practice) is in the area of health services…that the greatest weaknesses
are to be found. There is too little information available, relatively weak structures
and very little funding” [32] page 415
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The report encouraged community pharmacists to move away from routine dispensing
work and to be involved in advice giving to patients, among many other roles [31]. It
highlighted the importance of further training before pharmacists could undertake the
advice giving role. These recommendations around pharmacists’ developing roles were
endorsed by the British Medical Association (BMA) and Royal College of General
Practitioners (RCGP) [31].
In September 1995, the RPSGB launched a consultation Pharmacy in a New Age [33]. It
highlighted that pharmacists’ expertise could be utilised to a greater extent, citing enhanced
management of minor ailments as one of four key areas where they could make the greatest
contribution to patient care. This consultation was hailed by some as the ‘most successful’
RPSGB initiative with more than 5,000 pharmacists contributing to the professional body’s
vision [34].
In 1997, advice giving by pharmacists in relation to minor ailment management was also
endorsed in a proposal put forward by the newly elected UK Labour Government, covering
a ten year plan to reform NHS [35]. Pharmacists were to be given the opportunity to
provide a ‘distinct’ contribution to community development and health improvement in
their local areas.
In 1998, two documents were published by NHS Wales, namely Putting Patients First [36]
and Better Health, Better Wales [37], which set out initiatives encouraging pharmacists to
contribute to reducing health inequalities in society. Pharmacists would be encouraged to
‘collaborate’ with other health professionals rather than ‘compete’ for the greater benefit of
patients. Pharmacists would be supported and encouraged to provide advice on life style
matters for disease prevention through introduction of modern technologies and
development of staff capacity [37].
Devolution of power to three of the four UK nations: Scotland, Wales and Northern Ireland
took place in 1999. Health was among matters which each of these nations would have
power and responsibilities over setting policies, legislating [38] and dealing with any health
challenges they faced [39]. These nations, despite devolution, still work in close cooperation
around devolved as well as UK Governments’ reserved matters and therefore regulatory
frameworks for pharmacies are also similar across UK nations [40]. Although subtle
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differences, however, around approaches to the reform of health service have been noted
[41], detailed discussions of these are out with the remit of this review.
In 1999, a Whitec paper, Saving Lives, Our Healthier Nation, was unveiled by the English
Department of Health (DoH), aiming to set out measures to reduce mortality in key disease
areas such as cancer, coronary heart diseases, mental health, stroke and accidents [42].
Health professionals would also be encouraged in the future to advise patients about
‘appropriate’ places of contacts for disease management including minor ailments. One
year later, in July, 2000, the English DoH published the NHS Plan, which stressed the need
to increase the quality and range of services offered by the NHS [43]. Ten core principles of
the NHS were set out which included providing universal services to all regardless of
ability to pay and presented Governments’ vision that inequality in the health was the
greatest injustice. The importance of ‘empowering’ patients around the self care of minor
ailments was highlighted. NHS Direct would encourage people to get advice from
pharmacists not limited to minor ailment matters. To facilitate pharmacists taking on new
roles, measures to shift pharmacy income away from prescription dispensing were to be
introduced, rewarding instead for professional services. This document also promised the
Government’s vision to reclassify more medicines to be available on a non-prescription
basis (section 1.7.1). As per the vision of this document, new legislation to allow
pharmacists to supply certain Prescription Only Medicines within strict protocols (Patient
Group Directions, PGDs) was introduced by the UK Government in August 2000 [43].
Later in September 2000, Pharmacy in the future: Implementing the NHS Plan [43] was
published by the English DoH, which presented measures to meet the ambitions set out by
the NHS Plan [44]. A vision for new contractual frameworks for pharmacies was presented.
Campaigns such as Choose the Right Remedy and Ask Your Pharmacist would further be
promoted. Delivering the NHS Plan [45] published in April 2002 (DoH), laid out specific
funding plans to undertake these initiatives. Focus was placed on reducing NHS patient
waiting times, tackling health inequalities and improving health outcomes.
In January 2001, the National Assembly for Wales published a ten year plan to reform the
health care system to offer people faster access to high quality services [46]. This plan aimed
to extend pharmacy services by reinforcing capacity development in pharmacy and
c White Papers are issued by the Government as statements of policy, and often set out proposals for legislative
changes, which may be debated before a Bill is introduced. Green Papers set out for discussion proposals which
are still at a formative stage.
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modernising the profession. February 2001 saw Scotland introducing its national health
plan [47] which aimed to improve health of Scottish people and reduce health inequities. In
order to do so, national standards of care were to be set and delivered locally across
Scotland. Access to care was to be improved by making patients’ ‘journey of care’ easier by
improving standards across NHS services and by strengthening primary care staff, enabling
them to work together in an effective way. This document also aimed to support
availability of smoking cessation medicine to be available out with prescription. In the same
year, two other documents were published by the Scottish Government. Key ambitions
were to build a national effort to improve health and secondly to reduce health inequalities
[48]. A vision was proposed to establish pilot projects allowing the pharmacy supply of
non-prescription medicines to patients exempt from prescription charges [48]. Further
investments would be made to endorse provision of advice around self care and healthy
living in high street pharmacies [49], as well as in rebuilding and renovating pharmacies
[48]. The publication of The Right Medicine [50] in February 2002 by the Scottish Government
put forward an agenda for pharmacy modernisation for the next four years. This delivered
the Scottish Government’s promises that pilot projects that were being run in some regions
of Scotland to allow free supply of non-prescription medicines to those exempt from
prescription charges would be rolled out nationwide. Plans for free provision of Emergency
Hormonal Contraceptives (EHCs) and smoking cessation services through pharmacy were
also discussed. The Right Medicine emphasised the need for community pharmacies to use
the NHS logo in their premises so as to encourage more people to use their services.
In February 2002, an ‘independent’ Wanless report Securing Our Future Health: Taking A
Long-Term View [51] was published which assessed the resource requirement of UK NHS
departments for the next 20 years and associated reforms around resource allocation and
efficiency. A vision of the NHS in 2022 was proposed, which included more patients
seeking advice from pharmacists for wide ranging health issues. An update on the progress
on these recommendations made by the Wanless report was published in 2004 [52]. It
highlighted that level of patient engagement in self care around and out with minor
ailments would proportionally influence health care expenditure by 2022-23. This was
postulated to be influenced mainly by the level of improved health status based on the
patient level of such involvement (figure 1.4).
March 2002 saw the Northern Ireland Department of Health, Social Services and Public
Safety launch an investigation to design a framework to tackle health inequalities [53]. A
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shift from treatment to prevention of illness was highlighted. May 2002 saw another
important development in the area of pharmacy management of minor ailments. The UK
Government endorsed proposals by the Medicine Control Agency (MCA) which would not
require amendment of legislation each time the legal status of a medicine was changed
(section 1.7.1), thereby significantly shortening the process of medicines reclassification
from one legal status to another [54].
Figure 1.4: Projection of UK Health Expenditure (% GDP).
Reproduced from [51]. The solid lines represent level of patient involvemen
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English DoH in July 2003 [57]. A White paper also by the English DoH published in the
same year: A Vision of Pharmacy in the new NHS [58], set out further plans of actions in four
key areas namely: improving patient access to medicines (such as by further reclassification
of medicines); helping people to get best out of their medicines (such as by enabling
community pharmacy to deliver medicine management services); redesigning services
around patients (such as by introducing local pharmaceutical service schemes aimed at
deprived areas; a new contractual framework for pharmacies and pharmacist
supplementary prescribing); and enabling high quality pharmacy service provision through
competent staff (such as by commissioning training for pharmacists around clinical
governance). Yet another document published by the English DoH in 2003 [59] committed
continued support to ease restrictions on opening of new pharmacies, expanding ranges of
medicines available without prescriptions; and promoting minor ailment schemes for
members of public exempt from prescription charges (Section 1.7.1 and 1.7.2).
In 2003, The Welsh Assembly Government announced the abolition of prescription charges
to come into effect by 2007 and the Scottish Executive announced the same in 2005 for
abolitions to take place by 2011 [60]. These were argued to be addressing the problem of
inequality in service access by patients and to reduce NHS emergency admissions relating
to minor ailments; though wider implications for stakeholders such as pharmaceutical
industries and Government were widely discussed [61].
The decision of the health departments of England, Scotland and Wales to reject the
recommendations made by the Office of Fair Trading (OFT) (which is a non-ministerial
Government department and is a UK consumer and competition authority) suggesting
plans to abolish the Control of Entry Regulations (CoE) for community pharmacies in the UK
has been hailed as another important event in securing services around enhanced minor
ailment management from community pharmacy in 2003 [62,63]. The CoE regulation,
which limits the granting of licenses for dispensing NHS prescription (which accounted to
as much as 80% of pharmacy turnover) based on the number of new pharmacies already
existing in the area, was blamed by OFT to be responsible for the slow increase in the
number of new pharmacies per year which accounted average of four pharmacies in a year
from 1991-2001[40]. However a review committee of House of Commons reported against
such deregulations citing the following concern
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“…deregulation concerns the provision of services which may be time-consuming,
unprofitable, or have social stigma attached to them …whether pharmacies in
supermarkets would be happy to provide compliance aids and home delivery services or
drugs for addicts, emergency contraception and sexual health advice... make certain
pharmacies unviable, potentially leaving some of the most vulnerable communities, who
have the greatest health needs and are least able to travel long distances, without any local
pharmacy provision …” [63] page 9.
Only a part reform to the provision was however introduced later in August 2004 whereby
the Government reviewed entry barriers only in certain areas so that opening a pharmacy
would be made ‘simpler and faster’ [64].
Also in 2004, The Welsh assembly published Remedies for Success- a Strategy for Pharmacy in
Wales which set out a ten year vision for the pharmacy profession to deliver high quality
services [65]. Greater management of minor ailment from pharmacies was among the four
key priority areas where expertise of pharmacists would further be supported, with
management of long term conditions among others.
The five year NHS Improvement Plan published in the same year in June 2004 by the English
DoH aimed to enable more medicines to be available without prescription, promote minor
ailment schemes (Section 1.7.2), and develop a new community pharmacy contract to allow
‘fair’ remuneration for the extended service provision through pharmacy [66]. Modernising
NHS Community Pharmacy in Scotland also published in 2004 delivered similar commitments
for fairer remuneration [67]. This set out a vision for the new community pharmacy contract
including the introduction of the Minor Ailment Service (Section 1.7.2) nationwide in
Scotland. This also set out plans to seek advice from pharmacists about an amended
definition of the supervision of non-prescription medicines by pharmacists. The new
contractual framework to support service delivery was also highlighted by an English
command paper in the same year to enable pharmacists to contribute to a healthy society by
maximum use of their skills, providing them with opportunities to offer patients services
around self care of minor ailments along with healthy living, smoking and alcohol cessation
and sexual health [68].
The Northern Ireland Government published Making it Better- A Strategy for Pharmacy in the
Community in 2004 [69] which highlighted revised contractual frameworks to support
extended service provision in assisting patients with self care of minor ailments.
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Detailed proposals for the better use of staff working in pharmacies were set out in the
consultation paper Making the Best Use of the Pharmacy Workforce [70], published in
December 2004 in England (also adopted for consultation by the National Assembly of
Wales), February 2005 in Scotland and April 2005 in Northern Ireland [56]. These
documents put forward proposals for amendments in the requirement of supervision of
POM and P medicines by pharmacists.
In January 2005, the English DoH published Self Care- a Real Choice: Self Care Support- a
Practical Option [11]. This emphasised the need to promote pharmacists managing a greater
number of minor ailments such as through minor ailment schemes, annual health check
schemes and enabling self diagnosis of diseases. It presented the Government’s
commitment to: extend the expert patient programme and national services framework
(NSF) to further disease areas and future initiatives such as enabling self care support
networks in local communities. It also committed a self care agenda feature in all future
health policy documents. The social care Green paper published in 2005 also by the English
DoH called Independence, Well Being and Choice emphasized the importance of pharmacists
working alongside other health professionals in achieving similar aims [71].
A twenty year vision of health and well being was unveiled in Northern Ireland in 2005 (A
healthier future). It aimed to enhance community pharmacy involvement in partnership
projects to develop services to meet local needs and priorities [72]. Pharmacists were
regarded as core professionals delivering services around and out-with minor ailments.
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Figure 1.5: Pharmacists within a Multi-Skill Network
Reproduced from [72]
In April 2005, Choosing Health through Pharmacy [73] was published by the English DoH.
This was a ten year programme for promoting public health through pharmacy which
delivered Government’s greater support for self care, greater working partnership of
pharmacists with local authorities, health and social organisations and getting more
pharmacists to work as public health practitioners. In the same year, the Welsh Assembly
Government also published a ten year vision to reduce health inequalities [74]. Providing a
wider range of services and advice around healthy living and disease prevention were the
future roles focused for community pharmacy.
Building a Health Service: Fit for the Future was published by the Scottish Government in
2005, highlighting the need to revise ‘outdated’ models of health service to align with
changing demographics and social needs [6]. In the same year in November, Delivering for
Health presented a vision for a modernised contractual framework to enable community
pharmacists to provide extended services [75]. The Scottish Executive promised through
this document to continue to take initiatives to increase pharmacists’ professional roles.
Delivering Care, Enabling Health [76] also published at the same time set out plans to achieve
these ambitions such as by enabling joint working across the disciplines.
The Health Act 2006 [77] allowed UK ministers to redefine the strict requirement of
supervision and personal control by pharmacists for the supply and dispensing of
prescription and non-prescription medicines as set out by the Medicines Act 1968. This was
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intended to allow pharmacists to redeploy their skills in other areas recently introduced
[78]. As a result, all the devolved Governments began consultations to redefine the
supervision requirements. Also in 2006, an English White paper [79] emphasised extending
pharmacists’ roles and pharmacists working alongside other primary care service providers
as a ‘joined-up’ system.
In 2007, Our NHS Our Future: NHS Next Stage Review published by the English DoH set out
a ten year vision to make the NHS ‘fairer, more personalised, effective and safe’ [80].
Pharmacists were to be directing patients to appropriate care services. In the same year, it
also published a White paper Trust, Assurance and Safety: The Regulation of Health
Professionals, which proposed a key reform in the professional regulation of pharmacists by
requiring the development of a new professional representative body for pharmacy [81].
The role of RPSGB being the professional representative body was deemed to be conflicting
with its role as regulator of the profession. Based on these recommendations, legislation
changes would be sought so as to establish General Pharmaceutical Council (GPhC) that
would regulate pharmacists, technicians and pharmacy premises. This ultimately came into
force in 2010. The regulation around non-prescription medicines sales and supervision will
now be under the control of GPhC as opposed to the RPSGB. This also brought periodic
mandatory continuous professional development (CPD) training requirements to be
undertaken by the pharmacists so as to ensure public trust in pharmacists’ extended service
provision [81].
Also in 2007, the Scottish Government put in place systems to electronically transfer
prescriptions from GPs to community pharmacy and to ease patient access to any
community pharmacy. In the same year two policy documents were unveiled [82,83] which
aimed to provide patient walk in access to a wider range of community pharmacy services
[82]. An agenda to encourage and facilitate self care through pharmacy by taking patients
as partners was proposed.
In 2008, the White paper Pharmacy in England: Building on Strengths- Delivering the Future,
was published [84]. This White paper aimed to set out a vision for building on the strengths
of pharmacies, to enable the UK Government vision of ‘safe, effective, fairer and more
personalised’ care of patients. This also proposed easing current restrictions on dispensing
doctors selling non-prescription medicines in rural areas where pharmacies were not
unviable allowing easier access for patients to manage minor ailments. In addition to
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ensuring further support for pharmacy management of Minor Ailment Services, further
programmes to promote and support health literacy including healthy lifestyle advice and
support on self care of long terms illnesses including disease risk assessment from
pharmacy were proposed. Proposals that in the future, pharmacy services would be
registered with Care Quality Commission established by the Health and Social Care Act
2008 in England were presented.
The English DoH published a five year plan for the NHS (2010 to 2015) in 2009 which
identified pharmacies as ‘crucial local partners’ for advice around health and well being of
the community [85]. A framework of healthy living pharmacies would be developed to
promote health and well-being. Yet another Green paper Shaping The Future Of Care
Together was also unveiled by the DoH in the same year, aiming to deliver easier access to
self care for minor ailments for the vulnerable groups such as the elderly at home.
The newly elected coalition Government in 2010 published a White paper Equity and
Excellence: Liberating the NHS. Several reforms around the regulation of primary care
services were proposed [86]. Power would be given to GP consortia to manage the funds for
much of the primary care services but certain pharmacy services were to be exempt from
such regulations. It further vowed to enhance pharmacists’ roles in enhancing the rationale
use of medicines. Pharmacies would be remunerated ‘appropriately’ for the services they
provide and the prospect of performance based incentives for pharmacies was laid out.
1.6.2 Summary of the literature review I
The review of the literature has provided reflection on key developments proposed
contained within the health policies proposed by the UK Government and the devolved
Governments with particular emphasis on enhanced minor ailment management supported
by pharmacy. The Nuffield report had highlighted the need for reform of the nature of
community pharmacy services, funding and research in the forthcoming decades.
Subsequent key White and Green papers from the UK Health Departments, prior to and
post devolution, were reviewed. It appears that all of the devolved Governments are keen
to enhance pharmacy’s role in minor ailment management and to support patient self care
through professional advice and guidance. Extra funding and professional development
opportunities for pharmacy were promised and also identified that enhanced minor
ailment management from pharmacy would bring: professional role development
opportunities; extended use of professional skills; enhance reputation with the society; as
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well as contribute to freeing up GPs thus reducing waiting times; and bringing about
significant health benefits in the longer term. Greater collaborative working among health
professionals was stressed, along with greater patient access and the need to ensure trust
amongst members of public in pharmacy services. Two key policy interventions aimed to
increase such access to services were identified. These are discussed in detail below.
1.7 DETAILS OF KEY POLICY INTERVENTIONS AROUND
ENHANCED MINOR AILMENT MANAGEMENT FROM
PHARMACY
The ongoing reclassification of medicine and the introduction of minor ailment services
were identified as the key policy interventions aimed at increasing patient access to non-
prescription medicines; and hence pharmacy management of minor ailments (figure 1.6).
The former has greater relevance to those members of the public who pay prescription
charges, whereas the minor ailment services introduced across the UK are relevant to those
members of public exempt from prescription charges. In Scotland, this service is known as
the electronic Minor Ailment Service (e-MAS).
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Figure 1.6: Key policy interventions around enhanced minor ailment management from
community pharmacy
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follows via the MHRA, and CSM is finally consulted for any new safety concerns identified
during this process before a decision to reclassify is made [89].
Any medicines reclassified to P status then remain under this status for a certain while
during which, if no new concerns around safety are raised [12], it could then be considered
for reclassification to GSL class [87]. If any new safety concerns are raised during the non-
prescription availability, the legal status of medicines could be reverted back to POM status
[87].
Figure 1.7: Process of reclassification of legal status of medicines
Reproduced from [87]
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within similar therapeutic areas have taken place in other European nations [90,91] and in
the US [25].
Table 1.1: Prescription only medicines reclassified to pharmacy status in the UK
(Note: this table extends to two pages)
Medicine Date Medicine Date
Loperamide 1983 Nicotine chewing gum 4mg 1994
Ibuprofen oral 1983 Hydrocortisone pellets 1994
Terfenadine 1983 Triamcinolone dental paste 1994
Hydrocortisone topical 1% 1987 Hydrocortisone rectal
ointment and suppositories
1994
Dextranomer topical 1987 Diclofenac
diethylammonium (external)
1994
Ibuprofen s/r oral 1987 Felbinac topical 1994
Ibuprofen topical 1988 Piroxicam topical 1994
Astemizole 1988 Flunisolide nasal spray 1994
Mebendazole 1989 Ranitidine 1994
Dextromethorphan c/r 1989 Minoxidil 1994
Hyoscine Butylbromide 1991 Ibuprofen suspension 1994
Nicotine chewing gum 2mg 1991 Hydroxyzine hydrochloride 1995
Vaginal imidazoles
-Clotrimazole
-Econazole
-Isoconazole
-Miconazole
1992 Pyrantel embonate 1995
Hydrocortisone/crotamiton 1992 Fluconazole 1995
Paracetamol/dihydrocodeine 1992 Ketoconazole shampoo 1995
Nicotine replacement patches 1992 Hydrocortisone rectal 1995
Carbenoxolone granules 1992 Cadexomer iodine 1995
Loratadine 1993 Budesonide nasal 1995
Aciclovir 1993 Azelastine nasal 1996
Ketoprofen topical 1993 Nizatidine 1996
Acrivastine 1993 Hydrocortisone/ Lignocaine
(Lidocaine) HCl Spray
(Perinal)
1996
Cetirizine 1993 Mebeverine Hcl 1997
Beclomethasone dipropionate 1994 Sulconazole 1997
Cimetidine 1994 Clotrimazole and
hydrocortisone cream
1997
Famotidine 1994 Domperidone 1998
Sodium cromoglycate 2% eye
drops and ointment
1994 Hydrocortisone and
miconazole topical
1998
Tioconazole 2% vaginal 1994 Levocabastine 1998
Aluminium chloride 1994 Nedocromil sodium 1998
Adapted with revision from [92].
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Medicine Date Medicine Date
Ketoconazole Cream 2% 1998 Flixonase (Fluticasone)
Allergy nasal spray
2002
Hydrocortisone 0.5% and
nystatin 3%
1999 Grisol (griseofulvin) 2003
Aspirin 75mg (packs of 100) 1999 Omeprazole 10mg 2004
Isosorbide mononitrate 1999 Simvastatin 2004
Terbinafine 1% cream/spray 2000 Hyoscine transdermal
patch
2004
Nicotine nasal spray 2000 Emla (lidocaine and
prilocaine) cream 5
percent
2005
Lodoxamide trometamol eye-
drops
2000 Chloramphenicol eye
drops
2005
Triamcinolone acetonide nasal
spray
2000 Amorolfine nail lacquer 2006
Levonorgestrel (emergency
hormonal contraception)
2001 Sumatriptan tablets 2006
Prochlorperazine 2001 Chloramphenicol
Ointment
2007
Fenticonazole nitrate 2001 Naproxen 2008
Clobetasone butyrate 0.05% 2001 Domperidone maleate 2009/10*
Flurbiprofen 2001 Diclofenac
ethylammonium
2009/10*
Diphenoxylate hydrochloride
and atropine sulphate
2002 Tamsulosin
hydrochloride
2009/10*
*Accurate date listings could not be retrieved
1.7.2 Minor Ailment Services
Almost 50% of the total population of Scotland is exempt from prescription charges and
their prescriptions account for more than 90% of the total number of dispensed items [93].
Despite the reclassification of medicines, many of these members of public are likely to
continue using GP services and prescriptions as a means of obtaining the desired medicines
due to the cost factor. Hence, mainly to address this issue, minor ailment schemes have
been introduced in many regions throughout the UK. These schemes allow these members
of the public to register with one community pharmacy of their choice and have their minor
ailments treated by the pharmacist free of charge, or where appropriate, to get advice or
onward referral to other health professionals [94].
In Scotland, this scheme was initially launched as a pilot project entitled ‘Direct Supply of
Medicine’ in 2001 followed by the ‘Direct Care at the Chemist’ project at the end of 2003 in
two NHS boards: NHS Ayrshire & Arran and NHS Tayside [95]. The scheme was then
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officially launched in all community pharmacies of Scotland as a ‘core’ service under the
community pharmacy contract introduced in 2006 with the name ‘electronic Minor Ailment
Service’ (e-MAS) [96]. In England and Wales, such schemes appear as ‘enhanced’ services
and thus PCTs, after assessment of local needs in their area, can decide whether to
commission the scheme [97]. In Scotland, pharmacists are reimbursed for the cost of
medicines supplied and receive capitation payments based on the number of patients
registered [96]. E-MAS is being supported by a national IT network system known as e-
pharmacy which enables both identification of existing patient registrations and new
registrations using the patient’s unique community health index (CHI) number [98]. This
service also enables patient consultations and registration details from pharmacies to be
verified for reimbursement and remuneration purposes.
Medicine supplies by pharmacists within e-MAS are guided in Scotland by formularies laid
out by each NHS Board [10]. A national formulary has also been developed by Community
Pharmacy Scotland based on the local formularies [99].
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1.8 REVIEW OF LITERATURE II
GREATER PATIENT MANAGEMENT OF MINOR AILMENTS
FROM COMMUNITY PHARMACY: A CHRONOLOGICAL
REVIEW OF UK LITERATURE 1997- 2010
This section will present UK peer reviewed literature around enhanced minor ailments
management from community pharmacy to enable the identification of future research
need within this area.
1.8.1 Literature search strategy
Literature from ten years prior to the commencement of this PhD till date was searched
(1997- 2010) using databases namely: Ovid MEDLINE (R), International Pharmaceutical
Abstracts (IPA), CINAHL, EMBASE and PsychINFO. An example of the search strategy
used and those of the databases appear in Appendix I along with rationale for the use of the
particular databases. All the search strategies used to retrieve literature in this section and
beyond were recorded and maintained in a log book counter signed by the researcher and
principal supervisor for ensuring the transparency of the process.
Nurse led management of minor ailments was excluded from review. Only empirical
studies (literature other than expert opinions and systematic reviews) that were published
in peer reviewed journals were included. Literature around pharmacists’ perspectives of
health promotion and preventative services including smoking cessation, emergency
hormonal contraception, cholesterol management with no specification of minor ailment
management were excluded from this review.
1.8.2 Literature overview
A total of 27 studies investigated issues related to greater management of minor ailments
from community pharmacy. A summary of methodology, aims/objectives, method, setting
and number of research participants and key findings are presented in table 1.2 below.
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Table 1.2: Literature around enhanced management of minor ailments from community pharmacy (note: this table extends to five pages)
Author(s)
and year
Methodology Aims/ objectives Method, setting, and number
participating (response rate)*
Key findings
Erwin et al
1997 [100]
Quantitative Investigate GPs’ attitudes to
pharmacy supply of H2
receptor antagonists
Cross sectional survey of GPs from eight
randomly selected FHSA†s in England
515 (60.5%)
54% agreed to pharmacy availability of H2
receptor antagonists.
Hassell et al
1997 [101]
Qualitative Understand patient decision
making process around
visiting pharmacy for minor
ailments
Telephone interview of patients receiving
advice from nine different pharmacies,
participant observations of pharmacy
staff and users
44 patients
Pharmacy regarded by patients as an
appropriate setting either for minor
ailments or onward referral to GP visit.
John and
Evans 1997
[102]
Quantitative Investigate patient attitude
to advice giving in
pharmacy and non-
prescription medicine
purchases
Cross sectional survey of Cardiff
residents in Wales
810 (37%)
Approximately 83% believed pharmacists
were experts in minor ailment
management.
Bradley et al
1998 [103]
Quantitative Investigate patient attitudes
to non-prescription
medicines and associated
professional advice
Cross sectional survey of consecutive
patients from six GP practices in West
Midlands of England
2765 (91.3%)
Over 54%patients would be willing to buy
OTC medicines if recommended by
doctors; 83% regarded pharmacists as a
good source of advice on minor ailments.
Bleiker and
Lewis
1998[104]
Quantitative Investigate GPs’ attitudes to
extension of pharmacists’
roles in patient care
Cross sectional survey of all GPs of South
and West Devon health commission;
299 (81.2%)
Approximately one third respondents were
concerned with commercial interests of
pharmacy to extend their role in minor
ailment management.
Hassell et al
2000 [105]
Qualitative Explore influences on
patient utilisation of
community pharmacy for
minor ailments
Observational study of 44 pharmacy
users from ten pharmacies in North West
England and household study involving
549 individuals
Process factors such as lay evaluation of
illness and symptoms key in the use of
community pharmacies.
Iversen et al
2001 [106]
Quantitative Investigate of public attitude
to extended roles of
community pharmacists
Cross sectional survey of random sample
of patients from North East of Scotland
173 (55%)
Majority were unsure or disagreed to
reclassification of medicines such as
antibiotics for minor respiratory infections.
*information presented where available in the literature; †Family Health Service Agency
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Author(s)
and year
Methodology Aims/ objectives Method, setting, and number
participating (response rate)
Key findings
Morris et al
2001
[24]
Quantitative Investigate GPs’ attitudes to
minor ailment management
Cross sectional survey of one GP from
all practices in eight Health
Authorities, England
414 (54.5%)
Approximately 78% stated pharmacists
should be consulted prior to GPs for minor
ailments.
Philips et al
2001 [107]
Quantitative Investigate cost effectiveness
of pharmacy led free head lice
treatment scheme to patients;
to measure acceptability to
stakeholders
32 pharmacies, 5710 patients in
Nottingham, analysis of PACT* data
and questionnaires to patients (n=336),
GPs (n=60) and pharmacists (n=42) in
Nottingham, England
Self referral to pharmacy without GP
contact rose approximately twice when
compared to baseline. Around 70% would
use pharmacy in the future. GPs reported
marked decrease in consultation rate.
Whittington
et al 2001
[108]
Quantitative Investigate patient transfer
from GPs to pharmacies for
minor ailment management
Pragmatic study of patients requesting
appointment for minor ailment
consultation in one general practice in
Merseyside
1522 patients
Transfer of a total of one third of GPs’
minor ailment work load were achieved
with 576 opting to use pharmacy instead of
GPs. Only 21 patients required GP referral.
Bednall et al
2003 [109]
Quantitative Determine frequency of
patients attending A & E
department for minor ailment
management
Retrospective review of 2636 patient
records (aged >16) attending A & E
department at one hospital in London,
England
8% of the cases identified were eligible to
be appropriate for management through
pharmacy.
Morris et al
2003 [110]
Quantitative Identify prevalence of minor
ailment presentations at GP
surgeries from patient and GP
perspectives
Cross sectional survey of consecutive
patients attending surgery sessions
from two GP practices in West
Midlands, England
240 (96.4%)
40% of the patients identified themselves
as suffering from minor ailments, majority
of whom (51%) whereas were identified by
GPs as to be more serious ailments.
Walker et al
2003 [111]
Quantitative Evaluate the use of a “Care at
the pharmacy” minor ailment
scheme and determine its
impact on triaged calls
RCT of 1,888 households allocated to
control group of each of the Pharmacy
Medicine Access Group (PMAG)
group which were provided free
medicines and advice if exempt from
prescription charges
1,888 households
During 11 weeks of trial, PMAG patients
made fewer calls to the triage.
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Author(s)
and year
Methodology Aims/ objectives Method, setting, and number
participating (response rate)
Key findings
Baylis and
Rutter 2004
[112]
Quantitative Investigate GPs’ attitudes to
the ongoing reclassification
and pharmacy management
of minor ailments
Cross sectional survey of GPs from
five randomly selected PCTs in
England
135 (31%)
66% agreed that pharmacists had expertise
to counsel patients for reclassified
medicines usage, 47% agreed that
pharmacists could diagnose minor
ailments.
Bojke et al
2004 [113]
Quantitative Evaluate minor ailment
scheme for the effect on
number of GP consultations
and to identify factors
affecting patient preferences
Pragmatic study in GP practice in
deprived area of Bootle involving
1113 patients who requested GP
appointment for minor ailment and
were given option to visit pharmacy
1113 patients
Total number of GP consultations
unaffected, but decrease in the number for
minor ailments by approximately a fifth
during intervention; type of minor ailment
key to patient choices.
Langley et al
2004 [114]
Quantitative Evaluate the attitudes of non-
users of a ‘Pharmacy Direct’
minor ailment scheme
Cross sectional survey of patients
from Eastern Birmingham PCT who
refused to use the scheme
24(80%)
80% agreed they trusted doctors more than
pharmacists, a third reflected concern
about pharmacists’ skills.
Hammond
et al 2004
[115]
Quantitative Investigate patient
presentation of minor
ailments to GPs
Cross sectional survey of consecutive
patients in 13 general practices in
West Sussex
3984 (94%)
GPs identified 7% of patients visiting for
minor ailment management; 59% of these
patients disagreed with GPs’ views.
Parmentier
et al 2004
[116]
Quantitative Evaluate schemes offering
free minor ailment
management service to
refugees
Case series analysis of refugees who
were offered vouchers for a free
minor ailment scheme
184 patients
264 items supplied, with respiratory
illness, headache and musculoskeletal pain
covering over 50% of ailments that were
managed.
Boardman et
al 2005 [117]
Quantitative Quantify reasons for patient
visits to community
pharmacy
Cross sectional survey of random
sample of adults (≥35 yr) in North
Staffordshire
6322 (67%)
40% patients visited pharmacy for
purchasing non-prescription medicines in
the preceding month with cold and flu as
the most commonly presented symptoms
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Author(s)
and year
Methodology Aims/ objectives Method, setting, and number
participating (response rate)
Key findings
Cantrill et al
2006 [118]
Qualitative Investigate how patients
define minor ailments and
explore reasons for seeking a
GP consultation about minor
ailments
Face to face interviews with
purposive sample of patients
consulting one GP from two GP
practices in the West Midlands,
England
19 patients
Patient knowledge and severity of illness
were key to how patients define minor
ailments; greater perceived severity of the
ailments and quicker relief using POM
medicines were identified as key reasons to
prefer GPs against pharmacy
Dhippayom
and Walker
2006 [119]
Quantitative Investigate if reclassified
omeprazole had an impact
on prescribing and sales of
ulcer healing drugs
Retrospective analysis of three
years’ data of 22 Local Health
Boards in Wales over three years
from 2002 to 2005.
The number of prescription items for ulcer
healing drugs across Wales was found to
have increased in each year of the study.
Porteous et
al 2006 [120]
Quantitative Determine the relative
importance of factors that
influence patient decision
making in the management
of minor ailment associated
with analgesic use
Cross sectional survey of members
of public in Scotland selected from
a previous survey
293 (51%)
Self care was the most preferred practice to
manage minor ailments and pharmacy was
the preferred primary care health service
provider for minor ailments. GP waiting
time and cost of service were two
important factors determining choice
Vohra 2006
[121]
Quantitative Investigate patients’ views of
a minor ailment scheme
Cross sectional survey of patients
attending the scheme in Chorley
and Ribble PCTs in England
123 (40%)
Almost all were positive about the scheme.
Approximately 72% indicated they had no
objections to seeing pharmacy for minor
ailment management in the future.
McCaig et al
2008 [122]
Quantitative Examine community
pharmacists’ early
experiences of reclassified
omeprazole
Cross sectional survey of random
sample of GB community
pharmacists,
1156 (57.8%)
78% of the participants agreed that
omeprazole was a welcome addition to the
range of pharmacy medicines; 73.4%
expressed confidence in sales and supply.
Pumtong et
al 2008 [123]
Qualitative Investigate community
pharmacists’ perceptions of a
minor ailment scheme
Semi-structured interviews with 26
pharmacists in Nottingham PCT
involved in the scheme
Pharmacists were positive about the
service, benefits to pharmacy profession
and patients identified. Lack of privacy in
pharmacy was deemed a barrier.
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Author(s)
and year
Methodology Aims/ Objectives Method, setting, and number
participating (response rate)
Key findings
Walker and
Hinchliffe
2009 [124]
Quantitative Investigate impact of
chloramphenicol
reclassification on
prescription volume of the
medicine
Retrospective analysis of UK
prescription items and sales
data from 2003 to 2008
Chloramphenicol reclassification had no
significant impact on the number of
prescription items dispensed; no savings to
Government realised.
Blenkinsopp
et al 2009
[125]
Quantitative Investigate uptake of
Pharmacy First minor
ailment scheme directed at
children; and investigate
attitudes of mothers and
health professionals.
Pragmatic study, cross sectional
survey and focus groups (n=18)
of mothers in intervention and
control groups. Intervention
related to health promotion
campaigns and pharmacy minor
ailment scheme
A total of 1364 consultations were recorded
in the scheme. There was no significant
difference between the intervention and
control groups in numbers of GP
consultations for the minor ailments.
Attitudes towards consulting a pharmacist
were positive in both groups.
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Most of the literature that were identified related to either patient or GP perspectives of
enhanced minor ailment management from community pharmacy. Patient perceptions of
minor ailments and/or factors affecting their choice of different health professionals for
managing the ailments were the focus of ten studies [102,105-107,113,114,118,120,121,125].
Six studies evaluated specific newly reclassified medicines or services aimed at enhanced
pharmacy minor ailment management from the patient perspectives
[106,107,113,114,121,125]. Patients in general, as reported by most of these studies were in
favour of getting minor ailments managed and receiving advice at pharmacies. Patients
reported high levels of confidence around the professional competence of community
pharmacists [102,103,112]. Perceived severity of illness was often reported as key to patient
decision making about the choice of health professionals; with greater the perceived
severity, more the tendency to visit GPs [105,113,118]. Costs of non-prescription medicines
as well as the issue of access were key to such decision making. Patients were often
reported to diagnose minor ailments differently from health professionals [109,110,115].
Studies from patient perspectives would benefit from further in-depth investigation of
patient decision making processes using prospective designs. Such research could also aid
the identification of appropriate interventions to modify patient behaviour so as to enable
them, where possible, to present minor ailments to appropriate health professionals. In
addition, further large scale evaluations of different models of care for minor ailments
focusing on economic and humanistic outcomes are required to enhance the evidence
around pharmacy provision of minor ailment management.
A substantial number of studies also researched GPs’ perceptions of managing minor
ailments and/or their attitudes towards shifting the role to community pharmacy
[24,100,104,112], including the management of peptic disorders [100]. Most of these studies
suggested that GPs seem to be in favour of enhanced minor ailment management from
community pharmacy. Further research from the GP perspective should focus on areas
such as barriers to GPs recommending patients for pharmacy management for minor
ailments, an area in which the identified studies lacked information.
Research from the community pharmacists’ perspective, despite the policy documents
identifying them as major stakeholders of the change (section 1.6), was limited. Only three
studies investigated pharmacists’ perspectives of enhanced minor ailment management
from pharmacy [108,122,123] of which one related to the management of peptic disorders
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[122] and two related to attitudes towards minor ailment schemes to those patients exempt
from prescription charges [108,123].
Two of the above studies which evaluated pharmacists’ views and associated
facilitators/barriers to the adoption of services around the policy intervention aimed at
those exempt from prescription charges were based in England [108,123]. Both studies used
a qualitative methodology. There has been no peer reviewed literature published on
pharmacists’ perspectives of e-MAS provision in Scotland, neither prior to nor after the
nationwide rollout. In the evaluation of Minor Ailment Scheme in Nottingham PCT,
benefits of the scheme highlighted by pharmacists were opportunities to: increase
professional roles and image in society; provide greater and convenient access to medicines;
and reduce GPs’ workloads. Barriers highlighted were: paperwork; lack of privacy in
pharmacy premises; abuse of the scheme by some customers; issues with protocols; and
lack of support from GPs. Whittington et al interviewed community pharmacists from eight
pharmacies participating in the Care at the Chemist scheme in Merseyside, England [108].
Pharmacists were found to be supportive of the scheme and highlighted the importance to:
the profession in terms of maximizing the utilization of professional skills; and to patients
in terms of offering greater accessibility as the service required no appointment and open
for longer hours than GP surgeries. Problems highlighted mainly related to the limited
scope of the scheme formulary. Within this study, no details on how many pharmacists
were interviewed were provided and there were scant details on the nature of the interview
topic guide and analytical approach.
Although four other publications evaluated minor ailment schemes to patients exempt from
prescription charges [111,113,116,126], pharmacists’ attitudes to such extended role were
not presented. Within one paper, the perspectives of pharmacists were missing despite
listing such exploration of the attitudes as one of the key objective [126].
Despite reclassification of many medicines for the management of minor ailment from
community pharmacy (table 1.1), there was a dearth of literature identified which measured
pharmacists’ perspective of medicines reclassification. As the literature around therapeutic
areas such as contraception and cholesterol lowering were excluded, only one study could
be included in the review which related to reclassification of omeprazole. This related to
reclassification of omeprazole to non-prescription status immediate post reclassification
[122]. Pharmacists’ support for the reclassified status of medicines was high, as well as the
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confidence to supply. Responses to open questions reflected pharmacists’ issues around
retail price of the reclassified medicine limiting supply decisions and lack of novelty of
omeprazole’s therapeutic area as compared to existing ranges of medicines.
1.8.3 Summary of literature review II
The current position of research in the area of enhanced minor ailments management from
pharmacy in the UK seems to have derived from the notion that: given the patients are
ready to opt for pharmacies for minor ailment management and that there is a readiness for
GPs to ‘shift’ responsibility of managing minor ailments to pharmacy; pharmacists’
perspective around the changes is minor. It was astonishing to note that few studies
investigated pharmacists’ perspectives within this key area of change. Indeed, the lack of
rigorous studies, both qualitative and quantitative around adoption of innovative
medicines and services around enhanced minor ailment management was identified.
Roberts et al citing Kanter (1992) explain that ‘the point of view of those who think they are
creating change as an intentional process will be different from those who are on the
receiving end’ [127]. Elements of practice within both the ongoing reclassification of
medicines and the minor ailment services have demanded a shift of pharmacists’ role from
routine dispensing towards more personalised and cognitive tasks. It is imperative that
future studies have greater focus on how service adoption by community pharmacists can
best be facilitated given the centrality of their role in provision of extended services. As
adoption into practice of new services in pharmacy is an area of professional practice
change, it thus becomes important to understand how research around adoption of new
services or innovations [128] is best undertaken.
1.9 INNOVATION
Innovation is defined as the intentional introduction and application of ideas, processes,
technologies, medicines, services [129] that are perceived to be ‘new’ to the relevant unit of
adoption [130]. Adoption here is defined as the decision to make use of an innovation by
individuals, groups, or organisations [131]. Implementation relates to putting innovations
into routine practice [130,132]. When adoption of innovation takes place as a result of
responses to external (to individual or organisation) changes, the process of adoption is
argued to require on the part of the individual or organisation, changes in behaviours or
characteristics [133].
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1.9.1 Innovation in health care
Iles and Sutherland distinguish between the following types of changes that take place in
health care settings [128]:
1.9.1.1 Planned versus emergent change
These categories relate to whether changes are anticipated by the unit of adoption. Planned
changes are usually deliberate and they results due to ‘conscious reasoning and actions’. In
contrast, emergent changes are those that occur in a ‘spontaneous and unplanned way’.
1.9.1.2 Episodic versus continuous change
This categorisation refers to frequency of changes. Episodic refers to infrequent or
discontinuous changes; whereas, continuous changes refer to ‘ongoing, evolving and
cumulative’.
1.9.1.3 Developmental, transitional and transformational change
This categorisation refers to the extent and scope of change. Developmental change relates
to changes to improve skills or processes. Transitional changes relate to episodic planned
changes and could involve a three stage change process namely ‘unfreezing’, ‘moving’ and
‘refreezing’ [134]. Transformational changes are those requiring significant alterations in
individuals’ or organisations’ culture, structure or ways of working.
1.9.2 Key elements of innovation adoption research
Content, context and process are the three key elements of innovation research [135,136].
Content refers to identifying features of innovations that are likely to be associated with
innovation adoption decision by the adopting unit [136]. Internal context relates to
organisational conditions ‘external’ to the individual [136], for example, availability of
resources and motivation for change. External context relates to conditions outside the
organisation [136,137]. ‘Process’ relate to phases through which an individual or system
adopts the innovation and the key players involved [127,136].
Lack of consideration of processual and contextual dimensions of practice change by
healthcare practitioners has been argued to be commonly linked to failure to achieve
change [129,138]. Theoretical models are best able to provide the framework to consider
these key elements of innovation research.
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1.9.3 Use of theoretical models to research innovations
Use of theoretical models in innovation adoption research allows researchers to
systematically collect, analyse and or interpret the data [139]. Previous research in
community pharmacy practice change has mostly used organisational theory as a basis of
research tool development or for the interpretation of data [127,130,139-144]. However,
because organisational change starts with and is mediated through new behaviours and
decisions on the part of individuals [132,138,145], individual perspective of change deserves
no less attention. Greenhalgh argues that individuals within health care organisations
should not be regarded as passive adopters of innovations [146] and that the individuals
also go through the complex adoption process such as ‘seeking innovation as well as
experiment, evaluate, develop attitudes about, challenge, complain and gain experience
and/or modify it to fit their needs’ [146]. Failure to understand conditions under which
individuals are likely to undertake new behaviours have been often blamed for resistance to
change by potential adopters [145,147-149]. It is essential that key members of organisations
are active supporter of change and are ready to adopt it, otherwise, implementation is
usually deemed ‘impossible’ [150].
Theoretical models based on behavioural change theories such as ‘the theory of planned
behaviour’ has also been applied in community pharmacy [151,152] as well as ‘the theory of
goal directed behaviours’ to understand pharmacists’ intentions to provide pharmaceutical
care [151,153] or to understand the factors associated with differences between intentions of
pharmacists to provide pharmaceutical services and actual behaviours [153,154]. Others
have used ‘human error theory’ to understand and change pharmacists’ behaviours non-
compliant to established norms [155]. However, practice change and more importantly their
sustainability have been argued to have been limited [139]. Research into enhanced
management of minor ailments from pharmacy also inherits these limitations. Hence there
is a need to apply fresh perspectives to research innovation adoption by community
pharmacists. Using theoretical models that have been useful in other schools of thoughts
such as business, management, economics and law to undertake community pharmacy
practice research is argued to be one way forward in addressing these limitations [156,157].
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1.9.4 Rogers diffusion of innovations model as a tool to
research community pharmacy innovations
Understanding processes of adoption of innovations by health care practitioners and key
factors associated with adoption decisions is an area of diffusion research [158]. Such
research in healthcare has lately been argued to be likely to benefit from application of the
diffusion model [146,159]. Rogers’ diffusion model defines ‘diffusion’ as a ‘process through
which an innovation is communicated through certain channels over time among the
members of social system’ [131]. The key elements in the diffusion process are the
innovation, its adopter, communication channels, time and the social system and its
members [131] . In addition to the characteristics of innovations (content), organisational
contextual factors and contexts external to the organisation and factors that are reliant on
characteristics of the individual adopters themselves are also argued to be associated with
innovation adoption (table 1.3).
Rogers’ diffusion model states that individuals assess the innovation from their own
perspective such as need and benefit [149]. Individuals also deal with uncertainty about the
consequences of adopting innovations into practice [130]. During such processes,
individuals go through gaining awareness of the innovation, forming an attitude towards
innovation (positive or negative), making a decision whether to adopt it. Individuals may
also deal with uncertainty such as fear of loss of control as well as feeling concerned about
their own competence in the changed context [128,131] which could lead them to resist or
reject innovations [128]. Therefore, the method around how awareness to innovations is
raised, as well as how potential adopters are motivated, is key to facilitating innovation
adoption [160]. Gathering such sequences of events about how innovations are adopted is
referred to in diffusion research as ‘process’ research [130] and is best known to be
undertaken through qualitative methodology (Chapter 2). Rogers exemplifies the use of
diffusion model in studying change process as “something like the use of radioactive
tracers in studying the process of plant growth: it helps illuminate processes” [131] (p 104).
Understanding the cause of individuals adopting or rejecting innovations by studying
interrelationships between the context, content and individual characteristics (figure 1.8) in
diffusion research is generally known as ‘variance research’ [131]. Such research is usually
known to employ cross sectional designs, allowing researchers to collect data around
innovation adoption by the adopters in one time frame.
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Figure 1.8: The theory of diffusion of innovations illustrating the variables determining
the adoption of innovations.
dfdf
Adapted with modification from [131].
II. Types of innovations
1. Optional
2. Collective
3. Authority
III. Communications
channel (e.g. Mass media
or interpersonal)
I. Perceived attributes of
innovations
1. Relative
advantage
2. Compatibility
3. Complexity
4. Trilability
5. Observability
IV. Nature of the social
system (e.g., its norms,
degree of network of
interconnectedness)
V. Extent of change agents’
promotional efforts
Rate and extent of
adoption of innovations
Dependent variable that is
explained
Variables determining adoption
of innovations
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Table 1.3: Factors associated with innovation adoption by individuals.
Factors
associated with
innovation
adoption
Categories
within the
factors
Description of categories
Attributes of
innovation
Relative
Advantage
Advantage over existing services. Greater perceived relative
advantage by potential adopters enables faster and greater
adoption of innovation.
Complexity The degree of difficulty involved in learning about and
adopting innovation. Greater perceived complexity of
adoption by potential adopters produces slower adoption or
rejection of innovation.
Compatibility The perceived ‘fit’ of innovation with existing structures,
procedures and values. Greater compatibility leads to faster
and greater adoption of innovation.
Trialability Degree to which a new service may be experimented on a
limited basis without major investment of time or resources.
Opportunity to adopt innovation in a limited basis before
full implementation is carried out help adopters to make a
decision about implementation.
Observability Extent to which outcomes of changes are visible. Greater
observability leads to faster and greater adoption of
innovation.
Re-invention Degree to which an innovation is changed or modified
during the adoption process.
Adopter
characteristics
Innovators Usually venturesome and play key role in launching new
ideas in the system by importing innovation from outside of
the system boundaries. These members are usually willing
to take risk.
Early
adopters
Individuals usually within the system that adopt
innovations relatively quicker than others and usually ‘check
with’ innovations before adopting. Possess opinion
leadership to help others adopt innovations.
Early majority Those adopting new ideas before the average members of
the system usually deliberate for some time. Possess opinion
leadership to help others adopt innovations.
Late majority Adopt innovations later than above categories mainly due to
necessities such as economic or peer pressure and are
usually cautious. Possess opinion leadership to help others
adopt innovations.
Laggards Usually the last set of individuals to adopt individuals and
possess no opinion leadership to others, are suspicious of
innovations and change agents.
Organisational
factors
Resources, time and support, leadership and management
External Change agents
Adapted from [128,131,161]
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Figure 1.9: Factors and their interrelations claimed to be associated with innovation adoption.
Adapted with modification from [162]. Readiness reflects the extent to which an individual or
individuals are cognitively and emotionally inclined to accept, embrace, and adopt an
innovation [162].
The utility of diffusion models in understanding innovation adoption by practitioners has
have been highly recommended [146,163]. Despite its extensive application in other areas of
research within and outside healthcare settings [146], its application in pharmacy practice
research has so far been limited and mostly relates to ‘variance’ research as described above
[159,164-166]. Only a dearth of literature has utilised its application in undertaking
processual aspects of innovation adoption [167]. Further application of diffusion models in
both of these areas is necessary and has been advocated recently by pharmacy practice
researchers [168].
1.10 AIM AND OBJECTIVES
This doctoral research focuses on community pharmacists’ perspectives of adoption of the
two key innovations aimed at enhanced minor ailment management from community
pharmacy, namely the ongoing reclassification of medicines and the inception of e-MAS in
Scotland. As identified above, despite relevance to different sets of population, both the
ongoing reclassification of medicines and the minor ailment schemes aim to: increase
patient access to medicines, reduce GP burden of minor ailments, and increase pharmacists’
professional roles in patient care. It is hence relevant and appropriate for the context of this
research to evaluate both of these initiatives alongside. Considering the directions achieved
by the chronological review of literature around UK policy and research, as well as the
review on the theoretical model of change, the following research aim was formulated:
Content
Attributes of the
innovations being
implemented
Context
Environment
where innovations
are to be
implemented
Process
Steps involved in
adoption decisions
Adopter
characteristics
Characteristics of
individuals
adopting the
innovations
Readiness/
decision to
adopt
innovations
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1.10.1 Aim
To investigate Scottish community pharmacists’ adoption of innovations aimed at enhanced
management of minor ailments.
1.10.2 Objectives
Objectives relevant to each of the innovations are presented separately.
1.10.2.1 Objectives relevant to innovation of ongoing reclassification of
medicines
Phase I: Qualitative interviews and focus groups (Chapter 3)
1. To investigate community pharmacists’ views on ongoing changes around
enhanced management of minor ailments from pharmacy.
2. To evaluate the process related aspects of innovation adoption from community
pharmacists’ perspectives.
3. To explore the key facilitators/barriersd associated with adoption into practice of
reclassified medicines by community pharmacists.
Phase II: Systematic review of literature (Chapter 4)
Phase I led to the focus of the remainder of this PhD on quantification of community
pharmacists’ facilitators/barriers to innovation adoption of medicines and services around
enhanced minor ailment management. A systematic review of literature was required at the
outset of such quantitative evaluation with the following objectives:
1. To review and critique the methodologies, methods and models to investigate
factors associated with community pharmacists’ decision making around
reclassified medicines described in peer reviewed published literature.
2. To list and describe the importance of facilitators/barriers to community
pharmacists’ decision making around reclassified medicines.
d For most facilitators there is usually an equal and opposite barrier. For example where remuneration is a
facilitator, lack of remuneration could be a barrier. Hence the term facilitators/barriers will be used throughout
the thesis.
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Phase III: Pilot survey (Chapter 5)
1. To develop survey instrument for phase IV
2. To pilot the survey to a small sample of community pharmacists to enhance face and
content validity as well as to estimate sample size for phase IV
Phase IV: Main survey (Chapter 6)
1. To quantify the level of community pharmacists’ support to and adoption of
medicines recently reclassified for diverse therapeutic indications.
2. To quantify facilitators/barriers associated with pharmacists’ adoption of newly
reclassified medicines into practice.
3. To investigate the utility of Rogers’ diffusion model in exploring objectives 1 and 2
above.
1.10.2.2 Objectives relevant to pharmacists’ adoption of electronic Minor Ailment
Service (e-MAS)
Phase I: Qualitative interviews and focus groups (Chapter 7)
1. To identify community pharmacists’ views and attitudes to the introduction of e-
MAS in Scotland.
2. To identify facilitators/barriers to Scottish community pharmacists’ adoption of e-
MAS.
3. To explore community pharmacists’ views on future provision and potential
usefulness of practice performance feedback from e-MAS as a facilitator of service
adoption.
Phase III: Pilot study (Chapter 5)
Same objectives as phase III above.
Phase IV: Main survey (Chapter 8)
1. To quantify the adoption of e-MAS into practice by Scottish community
pharmacists.
2. To quantify facilitators/barriers associated with adoption of e-MAS by Scottish
community pharmacists.
3. To investigate the utility of Rogers’ diffusion model in exploring objectives 1 and 2
above.
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Introduction of future services within community pharmacy, focused around and out with
the enhanced minor ailment management from community pharmacy may benefit from
consideration of the facilitators/barriers; as well as from the identification of pharmacists’
issues around processual aspects of innovation adoption, extracted from this study.
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2 CHAPTER 2: METHODOLOGY
2.1 INTRODUCTION TO THE CHAPTER
This Chapter will review the methodology and methods that were applied throughout this
research. Approaches to data collection and generation, analysis and interpretation of
findings will be summarised along with arguments for the choice of such approaches as
well as their drawbacks, where appropriate.
2.2 PHILOSOPHICAL PARADIGMS
Philosophical paradigms are researchers’ beliefs that are claimed to guide their actions
[169]. These paradigms are also termed researchers’ epistemological and ontological stances
[170-172]. Ontology refers to researchers’ notions about the nature of reality [169] and what
is known about it [173]. The ontological position Realism assumes that external reality is
independent of peoples’ thoughts, beliefs and understanding; whereas, Idealism assumes
that external reality is what we know through the human mind and socially constructed
meanings [173]. Epistemology relates to how one can know about the social world [173].
Four distinct philosophical paradigms, each of them relating to different epistemological
and ontological positions, are known to exist and are described below.
2.2.1 Positivism
This paradigm assumes that the world is independent of the researcher [173] and facts and
values of the social phenomenon can be fully measured using scientific methods [169-171].
Human behaviour under this paradigm is known to be governed by ‘law like regularities’
and thus is measurable [173]. Understanding ‘cause and effect’ relationships based on priori
theories or hypotheses is the goal of research and is undertaken using an empirical
approach [171]. Hypotheses relate to statements of expected research outcomes [174].
Empirical relates to knowledge being derived through experience and direct data collection
rather than derived through logic [174].
2.2.2 Constructivism or Interpretivism
Unlike positivism, this paradigm assumes that there are multiple realities [170] and that
facts are determined through the perspectives of participants and the subjective
understanding of the researcher [173,175]. Researchers acknowledge that their own
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personal, cultural and historical values influence the interpretation of findings [169,173].
Facts therefore rely more on the skills of the researcher, who acts as a research instrument,
rather than on the research method [176]. Theories are induced from the data [169].
2.2.3 Advocacy/participatory
This advocacy paradigm is reported to have emerged through the criticism that the
positivist paradigm is inadequate to address the issue of marginalised individuals, for
example, about emancipating them from injustice such as inequality, oppression and
domination [175]. Various research communities, with interests in a dedicated research
area, have been argued to fall under this paradigm. For example, feminists working with the
issue of female gender [177] (such as those interested in the issue of feminisation of
pharmacy workforce) and, critical theorists who work around issues of race and social class
[169,178] (such as understanding of health services utilisation by minority ethnic
populations).
2.2.4 Pragmatism
Pragmatists are claimed to be not committed to any one epistemological or ontological
position. Truth is considered as that which works at the time and relies on the notion that
desired outcomes guide methodological approach [169,179]. Researchers are thus free to
choose their methods, techniques and procedures to answer their research questions rather
than adhering rigidly to any one approach; including the application of qualitative and
quantitative methodology (section 2.4 and 2.5) within one research study [169,180].
2.3 METHODOLOGY AND METHOD
Methodology is the way of studying social reality [172]. Methodology defines practical
approaches to quest for knowledge- and thus relates to methods which are set of task-
oriented procedures and techniques for gathering and analysing data [172,181].
Methodology is argued to be influenced by both ontology and epistemology [176] but this
notion has been challenged recently and will be discussed later in section 2.6.
2.4 QUALITATIVE METHODOLOGY
2.4.1 Introduction
Qualitative methodology allows researchers to understand social phenomenon/research
problems through the meaning that people bring to them [169,170,182]. This also referred
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to as naturalistic inquiry as data are generated in participants’ ‘natural’ settings [169,183].
The term ‘qualitative’ is known to refer to the quality around the features, characteristics,
complexities or hallmarks of the phenomenon under study [184]. Research using qualitative
methodological approaches typically provide answers to what, why and how questions
[173]. It is the concepts and categories arising from the data that are regarded as important
for interpretation of the phenomenon under study as opposed to any incidence and
frequency [183]. The written reports of qualitative research usually include the voices of
participants, referred to as ‘quotes’, along with description and interpretation of the
problems from the researchers’ perspectives [169]. Features of qualitative research are
summarised in figure 2.1.
Figure 2.1: Ten key features of qualitative research
Data collection in natural settings
Researcher acts as key instrument
Gather data from multiple sources
Analysis is inductive or uses ‘bottom-up’ approach
Focus on participants’ meanings
Research process is emergent, process may change or shift
after the researcher enters the field and begin to collect data
Theoretical lens to view the studies, such as the concept of
culture
Researchers make interpretative inquiry of what they see,
hear and understand
Taking a holistic account by developing a complex picture of
the problem or issue under study.
Adapted from [169].
Qualitative methodology is suited for the exploration of issues that have been under-
investigated in the past or are complex or sensitive in nature [173]. Brannen (citing
McCracken (1988)) exemplifies the utility of qualitative methodology as –it being not suited
to ‘survey the terrain’ but to ‘mine it’ [183]. It also enables in-depth understanding of
research problems from the perspectives of participants [185]. Application in health services
and pharmacy practice research has been increasing in recent years [156,186], with the
notion that not all research problems can be explained by hard fact numbers and graphs.
For example, although quantitative methods (section 2.5) such as randomised controlled
trials are suited to measuring outcomes relating to interventions, qualitative research is best
suited to understanding the process by which any intervention may produce a
desirable/undesirable outcome [186].
Some critiques of qualitative research have labelled qualitative methodology as being
‘unscientific’ or ‘anecdotal’, as findings may be based on subjective accounts [170,187] and
that they provide context to what people say as opposed to what they do [187]. However, a
number of strategies that are deployed through processes of qualitative research allow the
undertaking of research in a transparent way so that findings are valid and reliable. Such
measures have been adopted throughout the stages involving qualitative methodology in
this research.
2.4.2 Data collection
Data in qualitative research are mainly textual materials obtained either through talking
with people or observation [184]. In most instances, researchers act as the instruments of
data collection [182,183], though the use of research instruments, traditionally devised to
collect quantitative data are being increasingly used to collect qualitative data in health
services research [188] (figure 2.2).
Figure 2.2: Use of quantitative tools to collect qualitative data and vice versa
1. Congruent
2. Incongruent
E.g. Quantification of
answers to semi- or
unstructured interviews or
observations in participant
observation
3. Incongruent
E.g. answers to open-
ended questions in a
structured interview
4. Congruent
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quantitative
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Reproduced from [189] page 71
One to one interviews, focus groups, observation and case studies are the most popular
methods of data collection in qualitative research [190]. One to one interviews usually use
an ‘in-depth’ approach which allows participants enough time to develop their own
accounts of the issues important to them [187]. In semi-structured approaches, the
researcher uses a pre-determined agenda, based around the research question, and allows
the participant to determine the kind of information produced as per the importance to
T
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them [187]. Other less common approaches used in health services research such as the
narrative interview requires participants to adopt a story telling approach for data
generation [187]. The use of telephone interviews and focus groups conducted via video
conferencing are some of the adaptations to qualitative data collection brought about by
technological advances in the research world [191].
2.4.2.1 Use of focus groups in qualitative data collection
The focus group is a method by which data are collected through group interaction led by a
researcher [192] ‘focused’ around a particular topic or set of issues [193]. It allows relatively
quicker data collection as opposed to in-depth interviews [193] and thus is also deemed to
offer cost effectiveness to researchers as compared to in-depth interviews [182]. Though
focus groups have been argued to ideally suit research problems where the study of group
norms and processes is desired [194], their applications extend beyond these limits.
Focus groups have also been argued to afford offer greater opportunities to collect more
‘natural’ data than interviews in that focus groups allow a range of group communication
processes taking place amongst participants, such as storytelling, joking and arguing [193].
Group settings are also argued to facilitate personal disclosures rather than inhibiting them,
by allowing participants to react to and build on the responses of other group members
[182,193]. Focus groups have been noted to be of great importance in generating
preliminary data or hypotheses that could be tested or quantified through quantitative
methods (section 2.5) [194].
Despite the above advantages, focus groups have been reported to require greater skills on
the part of researcher to: control group discussions focusing on the agenda; control any
effect of dominant group members; and to persuade ‘shy’ speakers to express themselves
[190,195]. In addition, reduced time for individual participants to speak as compared to one
to one approaches mean that ‘micro-analysis’ of the differences in individual views, as
suggested by some authors, is difficult to undertake [182]. Focus group methods have been
deemed to be extremely valuable tools in understanding decision-making processes by
health professionals [194] and research described in this thesis utilises its application in this
area. The exploratory nature of the research presented in Chapter 3 as well as the benefits
this method offers over in-depth one to one interviews made it the method of choice.
However, problems around recruitment of participants encountered during focus groups
led to the consideration of telephone interviews as an alternative data collection measure. A
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discussion of the merits and demerits that telephone interviews offers against focus groups
appear in Appendix II.
2.4.3 Sampling
Sample sizes in qualitative studies are generally small and mainly determined by the
‘diminishing’ returns of new information achieved [185]. Resource constraints around data
collection and analysis are also known to play a part [185]. The sampling strategy suited to
inductive approaches of qualitative data analysis (section 2.4.4.1) involves a purposive
sampling technique which allows participants to be chosen from a sampling frame based on
participant demographics or other desired characteristics. Less common sampling
approaches in qualitative research are probability sampling and convenience sampling. The
former allows random selection of participants from the population where everybody has
the equal chance of selection. Convenience sampling also known as ad hoc sampling; allows
samples to chosen as per ease of access. However, with this approach, the relationship of
the data to the wider population is unknown [185]. This is therefore only really justifiable in
research with ‘invisible’ participants such as the investigation of health service utilisation
by sex workers or during participatory or democratic consultations where ‘anyone’ who
wants to have a say are given the opportunity to participate [185].
2.4.4 Analysis and reporting of qualitative work
Strauss and Corbin define qualitative data analysis as the interplay between the researcher
and the data [172]. Analysis and reporting in qualitative research is usually said to lack
rigid guidelines as compared to quantitative research; and hence the concepts arising from
the data are likely to be evolving and changing constantly [169]. This can often impose
problems in communicating to readers through the process of analysis [169]. Three key
techniques of qualitative data analysis exist and are discussed below.
2.4.4.1 Grounded theory
Traditionally, data analysis in qualitative research is usually said to be inductive where
ideas are generated from the data as opposed to ideas leading to data [172]. Grounded
theory is one of such inductive techniques where theory is allowed to emerge from the data
[172]. With this approach, researchers do not begin a project with a pre-conceived theory in
mind. The researcher usually conducts data collection so as to identify key concepts arising
from the data and then turns to studying one key concept at a time carrying out the
sampling process all over again until data are saturated [196] and until another theory is
Chapter 2: Methodology 47
generated [176]. Generalisation of results from qualitative work is usually ‘assertional’
rather than ‘probabilistic’ [185]. Representational generalisation relates to within cases and
empirical generalisation relates to other similar cases [185]. Application of this technique to
health service research is less common. Claims of applications of the grounded theory
approach in research reports have also been criticised as often being a means of legitimising
findings that are deviated from the original line of query [197].
2.4.4.2 Framework technique of qualitative data analysis
The application of qualitative research in scientific communities has led to the demand that
analytical procedures are carried out in a more transparent way which allows researchers’ a
priori theories or expected concepts to be incorporated in the analytical process [198,199].
The framework technique is one of such approach which allows priori concepts to be
incorporated in the analytical process; and was used in the analysis of the qualitative data
in Chapter 3. Ritchie and Lewis define the framework method as a “matrix based analytic
method which facilitates rigorous and transparent data management such that all the stages
involved in the ‘analytic hierarchy’ can be systematically conducted” [200]. The framework
technique thus gets its name from the ‘thematic framework’ where data are categorized into
a matrix system based on emergent themes and categories [200]. The analytical process
begins during transcribing by listening/re-listening and reading/re-reading the transcript
so that the researcher becomes immersed in the data. A basic step involved in this
technique is the ‘coding’, which is also common to inductive techniques of analysis [172]
and involves reducing the data into a smaller number of themes. Key themes describing the
data are listed in columns while each participant is assigned a space in each row below. The
construction of the initial thematic framework is guided by the research aims and objectives
and questions introduced to participants from the topic guides. These are then followed by
any new themes emerging during the analysis process. This method, therefore, although
being deductive, also offers unique flexibility to allow expression of themes that are
emergent during the analysis process [200]. This approach of qualitative data analysis is
usually facilitated through Computer Assisted Qualitative Data Analysis Software
(CAQDAS) such as QSR NVivo8®.
2.4.4.3 Content analysis
In health services research, the use of so called ‘quasi-qualitative technique’ or content
analysis is also common. This refers to coding of open questionnaire items, thus allowing a
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quantitative output from a qualitative data [185]. This technique was used in the data
analysis for the analysis of open questionnaire items in Chapter 5.
2.5 QUANTITATIVE METHODOLOGY
2.5.1 Introduction
Quantitative methodology deals with numbers as opposed to the concepts and themes of
qualitative research. The focus is mainly on stating hypotheses based around cause and
effect relationships and using validated instruments to yield statistical data to accept or
reject these hypotheses [175]. Statistics refers to the science of collecting, summarising,
presenting and interpreting numerical data [201]. Examining the relationship among and
between variables is central to answering questions in quantitative research [175]. Variables
are constructs, traits or characteristics that are measured and are likely to vary as per
observations [174]. Variables which are used as the basis of analysis in quantitative
research may be the outcomes of qualitative research [183]. Other key differences between
qualitative and quantitative research are presented in table 2.1
Table 2.1: Some distinctions between qualitative and quantitative methodology
Quantitative Qualitative
Role of research Preparatory Exploration of actors’
interpretations
Relationship between
researcher and subject
Distant Close
Researchers’ instance in
relation to subject
Outsider Insider
Relationship between theory/
concepts and research
Confirmation Emergent
Research strategy Structured Unstructured
Scope of findings Nomothetic Ideographic
Image of social reality Static and external to
actor
Processual and socially
constructed by actor
Nature of data Hard, reliable Rich, deep
Reproduced from [185]
2.5.2 Data collection and sampling in quantitative methods
Data in quantitative research are mainly based either on experimental or survey methods.
Experimental methods are best suited to test the impact of an intervention through
measurement of effects, also known as outcomes [175]. Although experimental methods are
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known to be stronger in identifying cause and effect relationships, they are only deemed
appropriate in situations where independent variables are capable of manipulation and
which random assignment of participants to any one intervention or control group is
feasible [196]. Sampling techniques in quantitative research are usually random as
described in section 2.4.3. As most surveys utilise probability sampling techniques, they are
known to offer greater external validity (Chapter 9) as compared to randomised
experiments, although are weak in terms of internal validity (Chapter 9) due to self
administered approaches (table 2.2).
Table 2.2: Controlled experiments versus surveys
Internal validity External validity
Controlled experiment + + - -
Surveys - - + +
Reproduced from [202]
2.5.2.1 Mailed questionnaire survey for quantitative data collection
Surveys are a systematic approach to gathering information. A survey is able to provide a
quantitative or numeric measurement of views, attitudes, trends or opinions of participants
[175]. These measurements are noted to be of great value in health services research as
peoples’ views and attitudes influence their behaviour [174]. Such values explain why a
survey requires as much planning and consideration as experimental methods [174] and
also the reason its application was used for data collection in Chapter 4 and 5 of this thesis.
Mailed self administered questionnaire techniques offer the opportunity to survey a large
number of people in a relatively short period of time [171]. When sent to a cross section of
population at a single time point, these are called cross sectional surveys [196].
2.5.2.2 Approach to survey data analysis
The strength of measures such as views and opinions obtained from surveys is usually in
the form of numbers [203]. These variables are analysed either descriptively (presentation
of data in natural form), normatively (comparisons across groups or to categorise one
variable against another, known as univariate analysis [203]) or to establish correlations
amongst variables [174]. Correlations amongst variables are most strongly noted and the
findings become rigorous when several variables are analysed together [174]. Such
methods of analysis, termed multivariate approaches, were thus used in the analysis of
selected survey data presented in Chapter 5.
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Despite the potential of multivariate analysis adding rigour to the findings, it has been
highlighted that to obtain meaningful results from such analyses, there needs to be a strong
justification behind the choice of variables that are analysed together [174]; which otherwise
can reveal erroneous interpretations [174]. Therefore, qualitative studies and review of the
literature, undertaken prior to quantitative phase, as has been used in this research, are best
placed to inform such decisions by the analysts.
2.6 MIXED METHODOLOGY
2.6.1 Introduction
Questions are raised by purists (researcher aligned to one particular philosophical
paradigm), whether use of qualitative and quantitative methodologies within one research
study is considered an acceptable practice. Such opinion has been mainly based on the
assumptions that qualitative and quantitative methodologies are aligned to different
ontological and epistemological positions. Quantitative research methodology is often
labelled as positivist or realist whereas qualitative researchers are claimed to follow social
constructivism and idealism [196,198]. Thus, those who view knowledge as hard, objective
and tangible should ideally stick to quantitative methodologies; whereas if knowledge is
seen as being subjective and softer in nature, then qualitative methodologies are more
appropriate [176]. Epistemology is argued to be defined by ontology; methodology is
influenced by both ontology and epistemology [176]; and hence qualitative and quantitative
methodologies are claimed to be mutually exclusive. Such mixing of methodologies are
hence only possible when the researcher ‘neglects’ the philosophical paradigms; or in other
words disconnects methodology from philosophical foundations.
Another argument against using qualitative and quantitative methodologies in one research
study is the notion that use of more than one approach may actually ‘widen or deepen’ the
research problem rather than solving it; as each of the methodological approaches are
unique in what they are capable of delivering [185]. However, the above assumption has
been challenged recently [170,186,196,198] with the argument that philosophical
assumptions do neither ‘determinate’ implications for selecting a particular methodology
nor that there is a one-to-one correspondence between a philosophical paradigm and a
methodology [196]. The research question itself is deemed more important in informing the
choice of methodological approach rather than which philosophical paradigms reflect the
researcher’s stance [196]. For example, constraints such as the issues of researcher skills,
funding and available financial resources often have huge implications around selecting a
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particular methodology [183]. The excerpts from a few books below provide illustration of
this side of argument.
“…the practice of research is a messy and untidy business which rarely conforms to the
models set down in methodology textbooks…it is unusual, for example, for epistemology or
theory to be the sole determinant of method. The cart often comes before the horse, with the
researcher already committed to a particular method before he or she has taken due time to
consider the repertoire of methods suited to exploring the particular research issues.” [183]
page 3-4
‘…a great many decisions about whether and when to use qualitative methods seem to have
little, if, any recourse to broader intellectual issues.” [196] page 108
“…the medical researcher is not supposed to become a social scientist even when during
qualitative inquiry.” [204] page 486
Researchers from scientific backgrounds also acknowledge that no study, irrespective of the
methodology used, can provide findings that are universally transferable [204] and that few
findings can be claimed with absolute certainty [186]. Therefore, it has been controversially
proposed that the key to ensuring that any methodological approach encompasses scientific
quality is to set the philosophical foundations aside and to follow the basic principles of
undertaking ‘rigorous’ research [204].
2.6.2 Benefits of mixing qualitative and quantitative
methodologies
Qualitative and quantitative research can be combined within one research study for both
complementary (where one phase assists the development of other phase) as well as for the
integration of the findings (where findings from two research phases are combined). In each
case, a combined approach should be of relevance and appropriateness to the research
questions under investigation.
When used for complementary purposes, pre-eminence of qualitative over quantitative has
been reviewed to be the common practice [183]. In these cases, the quantitative stage offers
the opportunity to test hypotheses generated through qualitative stage; or where the
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qualitative can aid the identification of variables allowing scale construction, and
interpretation of relationships between variables such as for survey design [183]. For
example, the use of focus groups findings to aid development of questionnaire scales has
been argued as the ‘most practical’ and most widely used approach of combining
qualitative and quantitative methodology [192] as has been used in this study. Amongst the
less common complementary approaches include qualitative work preceded by a quantitative
stage where, for example, the qualitative stage allows clarification or exploration of findings
from quantitative data which require further explanations; for example exploring the
perspectives of a subgroup identified from a larger quantitative phase. On occasions,
because quantitative research is efficient at identifying structure whereas qualitative
research is stronger in terms of ‘processual’ aspects, these strengths are brought together in
a single study [189]. For example quantitative outcome studies can reveal a link between
intervention and outcome, but are less able to explain the process by which the
interventions are translated into the outcome. Qualitative research used alongside
quantitative studies, is best able to illuminate these issues [186].
Some authors have argued that for a methodology to be called ‘mixed’, integration of the
either data or joint interpretation at some stage of the research process is essential [205].
Such process of integration is also termed triangulation [206]. The term triangulation
however also applies to the integration of: results obtained by applying different theories to
same data [182,183,186]; interpretation of the same data by different analysts with unique
perspectives [182,183]; integration of data collected at different time points with same or
different methods [183] or with different populations [199].
Both complementary as well as integrative application of mixed methodology has been
increasingly used in pharmacy practice research owing to the above explained benefits
[206]. These applications have been extensively applied and explained throughout this
thesis.
2.7 EVIDENCE SYNTHESIS THROUGH SYSTEMATIC REVIEW
OF LITERATURE
Identifying the existing evidence within a subject area through review of the literature has
been suggested to offer a number of benefits to the researcher. Literature reviews when
conducted using a pre-defined strategy to literature search and retrieval and to extract and
critically appraise the information are referred to as systematic reviews [207]. A systematic
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review has been deemed to be scientific ‘research in its own right’ and uses the studies
meeting the pre-defined criteria as ‘subjects’ [208]. Conducting a systematic review prior to
or during the course of an empirical study can offer many advantages. A review, for
example conducted prior to an empirical study, can aid: synthesising existing research
evidence [208]; identifying, justifying and refining any hypotheses for future work [209];
enabling the researcher to understand and avoid pitfalls of previous work [171,209];
indicating problems that the researcher might come across during the course of research
[171]; and warning against ‘meandering’ in an already explored area of research [209].
Due to the varied applications that systematic reviews can offer during the course of
research, there exists no hard and fast rule about where a literature review should be
presented in a written report or academic thesis [208]. For example, Creswell highlights that
a researcher undertaking an exploratory qualitative study is most likely to offer limited
literature at the outset given the lack of research in the subject area [175].
Synthesis of evidence through systematic review requires good critical appraisal skills so
that evidence is judged based on the quality and scientific merit of the study [210]. Many
critical appraisal tools relate to the quality of evidence merely based on the method/design
of the study. For example, findings from multicentre randomised controlled trials are rated
as the highest quality of evidence [211]. Some research communities disregard findings
from any other type of research other than obtained from randomised controlled trials
(RCTs) as a source of ‘evidence’. However, lately, this criteria of quality judgement has been
relaxed amongst the research community mainly based on the notion that RCTs are not
always feasible due to practical or ethical considerations [210] or that RCTs are not a
suitable design to generate evidence for every subject area in health services research. This
has led to resurgence of systematic reviews comprising diverse methodological
applications, including qualitative research, within one review.
2.7.1 Challenges to the inclusion of qualitative and quantitative
research within one systematic review
The traditional notion within scientific communities that evidence from quantitative
studies, especially RCTs resulted in the best form of evidence led to systematic reviews
traditionally focusing only on published studies using RCT designs [212]. Study power and
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precision/bias through further statistical analysis of aggregated datasets are often
undertaken through the process known as ‘meta- analysis’ [208,209].
With more health services researchers employing both qualitative and quantitative
approaches, the inclusion of qualitative research evidence within the systematic review is
receiving more attention. Dixon-Woods et al relate reluctance to integrating diverse
methodologies within one systematic review to both methodological ‘prejudice’ and
‘difficulties’ [213]. Prejudice relates to anticipation and fear that such an approach to
evidence synthesis from qualitative studies will be unacceptable by those who are less
aware of its methodological foundations. For example, as late until 2001 (no recent figures
could be retrieved), only 5% of the citations of the Cochrane methodological database
references were for qualitative research [213]. Difficulties relate to a lack of precise and
robust techniques devised to include qualitative research in systematic reviews [197,213].
Such difficulty and challenges mainly relate to how to make the process of synthesis more
transparent and findings more reproducible.
Overcoming challenges to the synthesis of qualitative data within systematic reviews has
been dedicatedly researched by a number of collaborations in the UK such as The Evidence
for Policy and Practice Information and Co-ordinating (EPPI) Centre [214]; Cochrane Qualitative
Research Methods Group [215] and in Australia by Joanna Briggs Institute [216]. One challenge
is to deal with the problems brought about by ‘distinct’ traditions of qualitative and
quantitative research. For example formulation of the systematic review questions is often
the product/outcome of qualitative research rather than the starting point of the review,
whereas, an outcome is tested for proving or disproving an hypothesis in quantitative
studies [217]. Thus collating these two approaches within one review requires careful
planning and formulation of research questions on the part of the researcher.
2.7.2 Approaches to reviewing qualitative and quantitative
research within one systematic review
Syntheses of evidence from both qualitative and quantitative studies have been known to
be undertaken using both aggregative and interpretative approaches.
Narrative synthesis is one approach of aggregative synthesis where qualitative and
quantitative findings are ‘juxtaposed’ side by side [218]. This relies primarily on the use of
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words and texts to summarise and explain the findings of the review [219]. Popay et al
distinguish traditional narrative literature reviews with narrative synthesis in that the later
refers to ‘a specific approach to that part of a systematic review process concerned with
combining the findings of multiple studies’ [219]. Interpretative methods such as the
‘Critical Interpretative Synthesis’, (another example include the EPPI-centre approach [214])
have been argued to be using a grounded theory approach to synthesis and thus avoids
specifying any concepts in advance [218]. Unlike the narrative synthesis, this approach to
review yields theory as an output rather than the aggregation of data [213,218,220].
However, some overlap across these two approaches has also been suggested where
although the approach to synthesis could be primarily interpretive or integrative; every
integrative synthesis is noted to include an element of interpretation, and every interpretive
synthesis to include elements of interpretation [218]. However, only a very few worked out
empirical examples of such an interpretative approach exist [218]. In addition, grounded
theory not being the approach required for the systematic review in Chapter 4, the narrative
approach to synthesis of evidence was embraced in Chapter 4 (systematic review of
literature).
2.8 SUMMARY OF CHAPTER 2
This Chapter reviewed the meanings and applications of qualitative, quantitative and
mixed methodologies; thereby conferring relevance to different phases of this research.
Approaches to data collection and analysis within these methodologies were also reviewed.
Discussions around why choice of methodologies should mainly be influenced by the
research question and not by the philosophical foundation were presented. Mixed
methodology was considered appropriate for the purpose of this research through
consideration of debate for and against its use. Focus groups due to their exploratory utility
will allow questions such as ‘how’ and ‘why’ to be asked in the preliminary phase of the
research. Focus group data also provide good foundations on which to develop quantitative
research instruments for undertaking surveys. The cross sectional survey is an efficient
technique to measure and quantity behaviours of large numbers of research participants by
gathering views and attitudes through numbers. Opportunities and challenges to
synthesising evidence from both qualitative and quantitative research in systematic reviews
were also presented. Narrative syntheses of results were shown to be appropriate to
synthesise data from primary literature within the systematic review undertaken within
this thesis (Chapter 4).
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3 CHAPTER 3: QUALITATIVE RESEARCH
3.1 INTRODUCTION TO THE CHAPTER
This Chapter presents data from the qualitative phase undertaken to study community
pharmacists’ perspectives of ongoing changes in practice around enhanced minor ailment
management. Data relevant to the following objectives are presented in this Chapter.
3.2 OBJECTIVES
1. To investigate community pharmacists’ attitudes to ongoing changes around
enhanced management of minor ailments from pharmacy.
2. To evaluate the process related aspects of innovation adoption from community
pharmacists’ perspectives.
3. To explore the key facilitators/barriers associated with adoption into practice of
newly reclassified medicines by community pharmacists.
3.3 METHOD
3.3.1 Data collection method
Focus groups were considered the method of choice, primarily to stimulate and encourage
discussion between participants. In addition, none of the objectives was considered to
potentially generate sensitive information requiring in depth one to one interview methods.
Generating and analysing naturally occurring data using methods such as observational
studies were considered inappropriate, mainly due to the need for interaction between the
researcher and participants.
However, problems were encountered during recruitment of participants for the focus
groups with very few pharmacists attending two of the sessions. Hence alternative
qualitative methods were considered. Semi-structured telephone interviews were adopted
as the method of choice for supplementing focus group data based on merit around
recruitment and low resource implications to the researcher [221].
3.3.2 Sample selection and identification of potential
participants
Sampling within this phase of the research was informed by e-MAS utilisation data of
Scottish Health Boards, a service that was evaluated alongside in the qualitative phase
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(results Chapter 7). A two stage sampling approach was undertaken. For the focus groups,
four of the fourteen Health
to high utilisation of e-MAS based on the percentage of
service [222] (figure 3.1).
health care services at the local level in line with the national health care agenda and
represent geographical divisions
populous Health Board whe
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each pharmacy could participate. Pharmacists refusing to participate were not contacted
further.
Recruitment of pharmacists for telephone interviews was conducted in only those two
Health Boards (II and III) where there was low focus group recruitment. A further 20 and
15 pharmacies were randomly selected from two Health Boards (II and III) respectively,
who were sent with a study invitation pack. These numbers were based on the assumption
that response rates to telephone interviews are usually higher than that of the focus groups
[221]. No prior contact by telephone was made in this instance.
3.3.3 Invitation
Invitation packs were mailed to pharmacists 25 days in advance of the scheduled date of
the focus groups or telephone interviews. The pack contained an invitation letter,
participant information sheet, consent/copyright clearance form, reply slip and pre-paid
envelope (Appendix II). Pharmacists were asked to send the reply slip along with
consent/copyright clearance form in the prepaid envelope or via fax within the given
deadline if they were willing to participate.
Focus groups and telephone interviews were planned to last no more than 90 minutes and
20 minutes respectively. The invitation pack for the focus groups also contained a map of
the venue and requested information regarding any dietary or mobility needs. The
telephone interview reply slip requested the most convenient date and time for interview.
All study documents were packed in a sophisticated manner to minimise the risk of papers
being left missing inside the envelope when opening [202]. The dates of the focus groups
were selected to avoid local holidays or important local events. Other measures to
potentially increase participation which were used, together with the evidence for them are
listed in table 3.1.
Reminders were sent to non respondents 10 days after the mailing of the first invitation.
Those not replying were contacted by telephone to confirm they had received the invitation
pack. Reasons for non-participation were not asked as this seemed unethical but were noted
if volunteered.
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3.3.4 Evidence used to encourage participation
Evidence mainly from the systematic review by Edwards et al was applied where
appropriate to encourage participation [224]. Although relevance to maximise the response
rate of postal questionnaires was made in this review, those applicable to focus group
recruitment were considered.
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Table 3.1: Description of evidence used to encourage participation (note: this table extends to two pages)
CI: confidence interval) **Significant at <0.01
Item Strategies Odds ratio
(95% CI) from Edwards
et al [224]
Evidence from any
other reviews
Strategy used in this research
Incentives Monetary incentives vs no
incentives
2.02
(1.79-0.27)**
[225] No monetary incentives used due to
resource constrains
Non monetary incentive vs
no incentive
1.19
(1.11-1.28)**
- Light supper and reimbursement of travel
expenses
Appearance Brown envelope vs white 1.52
(0.67 -3.44)**
- Brown
Coloured ink vs standard 1.39
(1.16 -1.67)**
- Coloured ink (blue)
More personalized vs less
personalized
1.16
(1.06 - 1.28)**
[226,227] Named invitation where appropriate and
researcher’s signature printed in ink
Identifying feature on
return vs none
1.08
(0.78- 1.51)**
- Participants asked to reply with their
names
Delivery Recorded delivery vs
standard
2.21
(1.51- 3.25)**
- Standard due to resource constraints
Stamped return envelope vs
business reply or franked
1.26
(1.13 -1.41)**
- Pre-paid envelope due to financial
constrains
Work address vs home
address
1.16
(0.89-1.52)
- Work address
First class outward mailing
vs other class
1.12
(1.02 -1.23)
- Other (second) class due to financial
constrains
Pre-paid return envelope vs
not pre-paid
1.09
(0.71 -1.68)**
- Section 3.3.3 above
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**Significant at <0.01
Item Strategies Odds ratio
(95% CI) from Edwards et
al [224]
Evidence from
other reviews
Strategy used in this research
Origin University sponsorship
vs other organization
1.31
(1.11 - 1.54)**
- Both University and the NHS
Sent by more senior or
well known person vs
less well known person
1.13
(0.95 - 1.35)
- Names of senior members of the research
team included but signed by student
researcher
Contact Pre-contact vs no-
precontact
1.54
(1.24 - 1.92)**
[225] Phone contact made to obtain name and
inform participants about the research
Follow up vs no follow
up
1.44
(1.22 - 1.70)**
- Reminder and phone follow up for non-
respondents made
Mention of follow up
contact vs none
1.04
(0.91 - 1.18)
- Reminders sent without mention of
follow up.
Precontact by
telephone vs post
0.90
(0.70 - 1.16)
- Section 3.3.2 above
Communication Explanation for not
participating requested
vs not requested
1.32
(1.05 to 1.66)
[225] No ethical approval for such requests/
noted only if the information were
volunteered
Appeal stresses benefit
to participants vs
others
1.06
(0.92 to 1.22)
- Benefit stressed both to the participants
and NHS
Response deadline
given vs no deadline
1.00
(0.84 to 1.20)
- Same deadline used in the initial
invitation and the reminder
Choice to opt out from
study given vs none
0.76
(0.65 to 0.89)
- Given, due to ethical reasons
Explanation for not
participating requested
vs not requested
1.32
(1.05 to 1.66)
- Noted only if volunteered, no contacts for
no-show up.
Chapter 3: Qualitative research 62
3.3.5 Development of Topic Guide and Interview Guides
The content of the focus group topic guide was informed by the research objectives. To
facilitate development, the researcher spent one day in each of three local community
pharmacies in different Health Boards to allow familiarisation with the activities around
minor ailment management. The topic guides are given in Appendix III. A ‘funnel’
approach to questioning was employed, with introductory general questions around
‘change’ followed by specific and more focused questions about ongoing reclassification of
medicines and e-MAS. A tentative duration for discussion was allocated for each question.
The topic guide was reviewed for validity of content and clarity of terminology by an
‘expert group’ of academic staff at RGU, who were also practising community pharmacists,
and by the NHS collaborators, as listed below:
i. Members of the supervisory team
ii. Mr Brian Addison, practising community pharmacist and lecturer in Pharmacy
Practice, RGU
iii. Mrs Gwen Gray, practising community pharmacist and lecturer in Pharmacy
Practice, RGU
iv. Mrs Ruth Edwards, practising community pharmacist and lecturer in Pharmacy
Practice, RGU
v. Mrs Trudi McIntosh, practising community pharmacist and lecturer in Pharmacy
Practice, RGU
vi. Ms Sharon Hems, Lead Officer, NHS National Medicine Utilisation Unit
vii. Professor Marion Bennie, Director , NHS National Medicine Utilisation Unit
A practice focus group session of 90 minutes was held with four locum pharmacists who
were RGU staff members, who suggested minor changes in the introductory opening
questions. The focus group topic guide was modified to form a semi-structured interview
guide for telephone interviews and the questions were further condensed to cover those
areas requiring additional insight based on the review of focus group transcripts. In
developing both the topic guide, particular attention was paid to Morgan’s key
recommendations to developing topic guides (figure 3.2).
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Figure 3.2: Morgan’s recommendations for developing topic guide questions for focus groups
There are generally five different types of questions:
opening, introductory, transition, key and ending
Introductory questions should reflect the experiences and
connections of participants with the overall topics.
Question foster interaction but is not critical to analysis.
Key questions begin one third to one half way through the
discussion
Ask the first group about the feedback to improve further
focus groups
Do not ask the question ‘why’. But ask in other several
dimensions, for example, what prompted you to do this,
what features of that particularly interested you? or use
what or how questions.
Simple questions bring dynamic answers and more
answers, always ask simple questions.
Change the questions if the past questions lead you to
another level when conducting a series of focus groups.
Adapted with modification from [226]
3.3.6 Recording
A Marantz audio recorder and a digital recorder were used to record the interviews and
focus group discussions.
3.3.7 Note taking
Experienced university researchers with expertise in conducting and facilitating focus
groups assisted with note taking, primarily as assurance against record failure, but also to
note emerging issues from an ‘outsider’ perspective and to highlight issues such as body
language. Immediately following each focus group, the notes were discussed between the
researcher and note taker to identify agreement on key issues.
3.3.8 Transcribing
Transcribing was verbatim and was made by the research student. The principal supervisor
made a thorough check of all transcripts to ensure reliability of transcribing and to avoid
misinterpretation. Transcript of one of the focus groups appears in Appendix III.
3.3.9 Data management and analysis
The analytical process began during transcribing by listening/re-listening and reading/re-
reading the transcript to become immersed in the data. Framework approaches of
qualitative data analysis were employed and facilitated using QSR NVivo8® qualitative data
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management software. The method has been described in detail in Chapter 2. Two analysts
independently analysed one transcript. Only the first analyst (VP), however made use of
the QSR NVivo8® qualitative data management software. No major disagreements were
noted thus avoiding the need for a third analyst. Focus groups and telephone interviews
data were analysed together as they aimed to answer common objectives.
3.4 RESEARCH GOVERNANCE
3.4.1 Ethics and NHS R & D approval
This research was conducted in accordance with the RGU framework for research
governance. An initial Research Student Project Ethical Review (RSPER) form was
submitted along with the Research Degree Registration (RDR) form to the Ethical Review
Panel of the School of Pharmacy, Robert Gordon University.
Initial contact regarding the proposed research was made via email (19 Feb 2008) to the
North of Scotland Research Ethics Committee (NoSREC). The committee suggested that a
more detailed proposal be submitted to allow provision of advice on whether or not a
formal, full NHS application would be required. The detailed proposal was submitted on 27
Feb 2008 which also summarised a tentative plan for the mailed questionnaire that would
follow the qualitative phase. An e-mailed response from the acting scientific director of the
committee was received on the same day. Further clarifications were sought around
recruitment, format of the consent form to be used and anonymity of the data. Responses
were forwarded to the committee on 29 Feb 2008. NoSREC suggested minor editing of the
participant information sheet to include more information about the study. Model consent
forms and participant information sheets were provided by the committee and revised
participant information sheets and the consent forms were forwarded on 06 March 2008.
The acting scientific director, in consultation with the vice chair of the committee, advised
that the research, including the mailed survey, would not require a full ethical submission.
NoSREC were also consulted on potential modification to the method resulting from poor
focus group recruitment necessitating conduct of telephone interviews. The committee
advised that there was no need for a full ethics submission to conduct the telephone
interviews.
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As community pharmacists in Scotland are contracted by NHS bodies, it was imperative
that NHS Research and Development (R & D) committees were also approached for advice
on the need for any formal approval. The Multi-centre R & D committee in Scotland was
contacted with a copy of the full study correspondence as per NoSREC. No reply was
received within thirty days of the initial mailings despite reminders, and it was later
identified that the R & D committee was in the process of restructuring itself as Central
Access Point (CAP). A response was received from the CAP on 04 Apr 2008, advising that a
formal application was not required.
The issues of poor recruitment and attendance of pharmacists at focus groups requiring
modification to the data collection approach, multiple communications with the ethics
committee and lack of prompt responses from the R & D committee led to a significant
delay in the research project.
Copies of all communications with NoSREC and the CAP appear in Appendix III.
3.4.2 Informed consent and copyright clearance
Informed consent and copyright clearance were obtained from all participants as illustrated
in Appendix III.
3.4.3 Confidentiality, anonymity and minimizing harm to the
participants
All data were anonymised. Hard discs of the recordings along with participant contact
details were stored in locked university facilities. The transcripts were stored in a password
protected university computer. Access to data was restricted to the researcher and the
members of the supervisory team. All data will be kept for a maximum of five years after
the publication of last external output from the data after which they will be destroyed as
per university regulations. All data analysis was carried out within the university.
Participants were informed that they were free to withdraw from the research at any time
without giving a reason. Participants were also permitted to request that the recorder be
turned off at any time. In an attempt to minimize any harm, focus group participants were
requested that they refrain from disclosing any information which could generate
discomfort in the group setting.
Chapter 3: Qualitative research 66
3.4.4 Incentives
Focus group participants were provided a light supper in addition to reimbursement of
travel expenses at standard rates. No other incentives were offered.
3.5 RESULTS: PARTICIPANT DEMOGRAPHICS
A total of 20 community pharmacists took part in this phase of research, including nine
telephone interview participants. Initial listening and reading of the transcripts led to the
researcher to realise that saturation of the data in terms of ranges of themes was obtained
and hence further recruitment was not undertaken. The recruitment process and
demographic characteristics of participants appear in table 3.2 to 3.6.
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Table 3.2: Number of pharmacists approached and those participating in focus
groups and one to one face-to-face interviews.
Health
Board
code
Number of
pharmacies
telephoned to
identify potential
participants*
Pharmacists
unavailable
to take call
Refusing to
receive
invitation
pack
Number agreeing
to participate after
receiving invitation
pack+
Number of
actual
participants
I 50 1 2 6 4
II 50 1 3 5 1
III 50 0 6 6 1
IV 50 0 0 5 5
*50 pharmacies contacted in each Health Board +Refers to either verbal agreement or
consent form
Table 3.3: Further number of pharmacies approached and those participating in
telephone interviews**
Health
Board
code
Number of
pharmacies sent
invitations in the
Health Boards
Number of
pharmacists
agreeing to
participate†
Number of
actual
participants
II 20 4 4
III 15 5 5
†Refers to number of consent forms received; **No prior contact with telephone was
undertaken.
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Table 3.4: Demographic characteristics of focus group participants
No. First year
in
registered
as a
pharmacist
Qualification Health
Board
code
Pharmacy
ownership
Employer
(a) or
Employee
(b)
Age Prescriber
Yes(Y)/
No(N)
Sex
Male(M)/
Female(F)
Area
1 1984 BSc, Suppl.
Prescriber
I I a 54 Y F Rural
2 2006 M Pharm I I b 27 N F Rural
3 1993 BSc (Hons)
MSc
I I a 37 N M Rural
4 1978 BSc, Suppl.
Prescriber
I I b 53 Y F Rural
5 1976 BSc, Prescriber
qualification
IV L b 55 Y M Urban/Suburban
/Rural*
6 1985 BSc IV S b 46 N F Suburban
7 1972 BSc IV I a 66 N M Rural
8 1975 BSc IV L b 56 N F Suburban
9 2003 MPharm IV L b 28 N M Urban
*Relief pharmacist and thus related to more than one practice setting; I: Independent (1-4 pharmacies);
S: Small multiple (5-30 pharmacies); L: Large chain (>30 pharmacies)
Table 3.5: Demographic characteristics of face-to-face interview+ participants
No. First year
in register
as a
pharmacist
Qualification Health
Board
Code
Pharmacy Employer
(a) or
Employee
(b)
Age Prescriber
Yes(Y)/
No(N)
Sex
Male(M)/
Female(F)
Area
10 1991 BSc (Hons) II L a 39 N M Suburban
11 2005 MPharm,
PG Cert
III L b 25 N F Urban
+ due to low participation of other pharmacists consenting to participate; L: Large chain (>30 pharmacies)
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Table 3.6: Demographic characteristics of telephone interview participants
No. First year
in register
as a
pharmacist
Qualification Health
Board
Code
Pharmacy Employer
(a) or
Employee
(b)
Age Prescriber
Yes(Y)/
No(N)
Sex
Male(M)/
Female(F)
Area
12 1988 BSc II S b 43 Y F Urban
13 1992 BSc/ Diploma II S b 44 Y F Suburban
14 2005 MPharm II I b 26 N F Suburban
15 2007 MPharm III S b 23 N F Rural
16 2003 MPharm III L b 28 N F Urban
17 2002 MPharm II S a 29 Y F Suburban
18 2005 MPharm III I b 26 Y F Urban
19 1983 BSc II I b 47 N F Urban
20 1977 BSc III I b 55 N F Urban
I: Independent (1-4 pharmacies); S: Small multiple (5-30 pharmacies); L: Large chain (>30 pharmacies)
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3.6 RESULTS- PARTICIPANTS’ ATTITUDES TO ONGOING
CHANGES IN PRACTICE
Key themes emerging from the data relating to participants’ views on ongoing changes
around enhanced management of minor ailments are presented with illustrative quotes.
Where opposing views around a particular subject were identified around the same theme,
all are illustrated otherwise the quotes will be representative of others. Three dots within
the quotes indicate that some text has been deleted if considered irrelevant to the
corresponding theme.
3.6.1 Contribution of new services to professional role
development
Participants expressed the view that the pharmacist’s role in healthcare has evolved in
recent years. Introduction of innovative patient focussed services were deemed to be
contributing to such role development. New roles allowing pharmacists to move away from
routine dispensing roles were deemed to be relevant to the pharmacist’s knowledge and
expertise.
“I think it [the role] is changing. Because, historically the perception of pharmacists was the
man in the white coat you never saw, possibly someone who is sending medicines through
the system. When I started the move, began with the campaign to ask your pharmacist. That
has, I think, obviously [changed]. I am talking nearly twenty years later. I’m happy that our
role is, if you like taking more responsibilities, getting bigger, ‘cause that’s what we were
trained to do.”
Male, 39 Years, Large Multiple
Less surprisingly, the ongoing reclassification of medicines and the introduction of e-MAS,
were noted to be key changes around enhanced management of minor ailments from
community pharmacy. The opportunity for members of public to access medicines they
could not previously access from pharmacy was regarded as reason why these changes
were labelled ‘significant’.
“The most significant change has been the… start of e-MAS. The Minor Ailment Service,
which has been a big change to community pharmacy within Scotland... and also there have
been several products which is switched from POM to P as well"
Female, 25 Years, Large Multiple
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3.6.2 Adoption of innovation into practice
Several sub-themes were linked to process of innovation adoption by community
pharmacists. These reflect the highly individual and diverse experiences of change.
3.6.2.1 ‘Desire’ and ‘Need’
Adoption of behaviours around new medicines and services into their day-to-day practice
was related by some, notably by the recently trained pharmacists, to both personal ‘desire’
to change and ‘need’ to keep pace with developments.
“Personally, I don’t have a problem with it [adopting new services]. I [am]… sort of quite
forward focussing. Now, I’m much pretty much the beginning in my career. I’ve only been
qualified for three years; this is quite something I’m going to be doing for a long time. And, I
feel that, if I don’t get a hold of changes quite quickly, I’m just going to be left behind, and
people are coming through who already have qualifications or experience of dealing with
things like minor ailment service in their degree, will then have more opportunities than I
would have. So, I have to keep abreast of changes to make sure that I’m up to date with the
things.”
Female, 25 Years, Large Multiple
3.6.2.2 ‘Old dogs new tricks’
On the other hand, a few participants regarded adopting change as being something
undertaken reluctantly. Changes were regarded being out with their comfort zone. These
participants were relatively senior and more experienced compared to participants who
were keenly looking forward for future change.
“I feel very reluctant to take on new things, you know, because… it takes me a while to feel
comfortable with something.”
Female, 54 Years, Independent
Some participants stressed that younger age was associated with ease of adopting changes
into practice. A younger participant also alluded to the benefit of having had training
around recently introduced services during their undergraduate education thus adopting
such change was perceived to be relatively easier.
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I haven’t had the problems with dealing with changes as we are so far and again, [I am] kind
of young…there is an old thing that you can’t teach old dogs new or tricks… if you’re young,
you take the information much better. You could adopt the change more and much easier.”
Female, 25 Years, Large Multiple
3.6.2.3 ‘Fast and furious’ pace
A few participants commented that the pace of recent change was ‘too rapid’ making it
difficult to integrate within the busy working environment of community pharmacy. They
suggested that introduction of one new community pharmacy service at a time would be
more sustainable, facilitating easier integration into practice. Of note, despite certain
participants being in favour of change for the greater good of the profession, they were
struggling to manage with all of the recent changes.
“And I’m quite for change, but I do find that there’s lot happening, it’s quite fast and furious
and I think in a busy working day when you’re particularly busy, you don’t always have
time to absorb it… so there’s a lot happening…”
Female, 56 Years, Large Multiple
Such discontent was also attributed to the deemed ‘unnecessary’ workload referred by one
participant as ‘bureaucracy’.
“I am quite happy to [adopt changes] … it doesn’t upset me too much. Occasionally found
[that] especially when there is excess bureaucracy …to put it in a great deal of work trying to
achieve the minimum amount of work required to meet the change.”
Male, 28 Years, Large Multiple
Lack of consistency in the process and nature of new services across different Health Boards
in Scotland and UK nations were stated to be resulting in difficulties for many pharmacists,
especially for those practising as locums. This was noted particularly, but not exclusively by
the participants, in relation to PGDs.
“…funds are going out much more localized. So it’s been costed [funded] locally…as a
pharmacist to travel across borders… I can supply the morning after pills, anywhere in *****
[name of a place] …but can’t in ***** [name of a place] because you have to be, registered. …I
can’t possibly be signed to all these different PGD …the funds [are] available locally for them
to decide how to spend it but it does make it quite difficult for us if we got local formularies
all over the place and if ***** [name of place] is doing one thing and even within ***** [name
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of place] we’ve got three different CHPs [community health partnerships] doing three totally
different things. So, I’ve concerns about sort of going from [one place to another]. Well,
again, even within Britain now, we have the English [pharmacists] doing MURs, Scotland
doesn’t. We’ve got minor ailments and urgent supply PGDs, they [English pharmacists]
don’t, we are charging five pounds they are charging £7.10 or the exemption rates, may be
good, may be not… There is now scope from massive differences between as to what we can
supply what we can’t, how you supply, will we be paid for it?”
Male, 55 Years, Large Multiple
3.6.2.4 ‘Steady’ pace
In contrast to those regarding the current pace of change in community pharmacy as fast
and furious, others deemed the pace as steady, expressing the view that change was
inevitable and that these new services were being introduced by the Health Boards/
Government steadily and appropriately. In addition, effective organisation of tasks within
pharmacy was also deemed key to steady adoption of changes into practice.
“So, they’ve had so many years… this minor ailment service… before the chronic… before
the electronic transmission of prescription comes in… the barcodes on the prescription…,
and then they get another time period before the chronic medication service kicks in. I think
the fact that [they are] staggered out, means that good for us to get used to it … and promote
one thing at a time and get the public used to the fact that this is how things are changing.”
Male, 39 Years, Large Multiple
3.6.2.5 Importance of self learning and staff training
The importance of participants’ own continuous professional development needs as well as
staff training along with preparation of necessary pharmacy documentation such as
standard operating procedures (SOPs) were considered key to the need for spreading the
introduction of change as one new service/medicine at a time.
‘’You need time to be able to tune up yourself and your staff and get all the information
together and sort of formulate SOPs and sort of establish what plan is in your shop?”
Female, 44 Years, Small Multiple
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3.7 RESULTS: RECLASSIFIED MEDICINES
The following section presents facilitators/barriers relating to pharmacists’ decision making
around newly reclassified medicines. Decision making here will relate to either adoption
into practice or support for the reclassified status of the medicines.
3.7.1 ‘Content’ related facilitators/barriers associated with
adoption into practice of newly reclassified medicines
Content here relates to the features of the newly reclassified medicines which participants
regarded as enabling or deterring supply decisions.
3.7.1.1 ‘Extra weapon in the armoury’
Most participants highlighted that, in general, the availability of wider ranges of medicines
available for non-prescription supply was a benefit to the pharmacy profession linked to
role development exemplified earlier in section 3.6.1.
“I think it’s a good thing for a pharmacy… to have a wider range [of medicines]”
Female, 47 years, Small Multiple
One participant voiced that newly reclassified medicines that offer pharmacists an ‘extra
weapon in the armoury’ were more likely to be embraced into practice as opposed to those
which were considered ‘me too’ agents conferring no additional benefits over existing
treatments.
“…changing from POMs to Ps is fine if it’s [reclassified medicine] given us an extra, a
weapon in the armoury”
Male, 55 Years, Large Multiple
Newly reclassified chloramphenicol was noted to be the newly reclassified medicine most
highly valued by community pharmacists. One of the reasons was related to high patient
demand. Although acyclovir, clotrimazole and loperamide had all been reclassified several
years earlier, these were also highlighted as being of particular value, deemed widely
adopted by pharmacists and patients.
“I think chloramphenicol has been best POM to P”
Male, 66 Years, Independent
Chapter 3: Qualitative research 75
“Most of them Zovirax [acyclovir], Canesten [clotrimazole], nicotine replacement therapy
have been welcomed. There’s a few [medicines] less welcomed than the others….”
Male, 37 Years, Independent
Sumatriptan and simvastatin were noted as some of the least successful reclassifications
with one stating that cardiovascular risk assessment and lifestyle management may be of
more value rather than initiating statin therapy for those at moderate risk of coronary
events.
“I would say Imigran [sumatriptan] has been a waste of time, Zocor [simvastatin] has been
a waste of time as well.”
Female, 46 Years, Small Multiple
Although participants expressed reservations over supply of newly reclassified simvastatin,
reclassification was deemed by one to be contributing to role development due to the
opportunity for advice giving around the associated medical condition. However, supply of
was largely deemed outwith the remit of expertise and resources normally available in
pharmacy.
“…certainly we can advise the patients on their diet and lifestyle changes and I am more
than happy to do that but I think in terms of [supply] …, [it is] may be good for identifying
somebody who has high cholesterol level who we can refer on but …in terms of treatment I
don’t think, unless you have the facilities or you’ve done the supplementary prescriber
course or independent prescriber [course], I don’t think we really have the time at
community pharmacies to go into that sort of details with patients.”
Female, 27 Years, Independent
Some explained that they were keenly anticipating reclassification of medicines within
certain therapeutic areas. Some of the examples included prochlorperazine for the
treatment of nausea and vomiting associated with migraine, trimethoprim for the treatment
of uncomplicated urinary tract infections and naproxen for the treatment of
dysmenorrhoea. Naproxen was reclassified post conduct of these focus groups and
interviews. Introduction of PGDs to allow pharmacy supply of existing POM medicines
was also deemed to have enabled enhanced minor ailment management from pharmacy.
“…trimethoprim, I’m really looking forward to [it] a lot.”
Male, 66 Years, Independent
Chapter 3: Qualitative research 76
Furthermore, all participants deemed that in general, pharmacists were competent in the
management of minor ailments but that the current lack of medicines within certain
therapeutic areas and restricted licenses of reclassified P medicines were viewed to be
limiting management of minor ailments. Examples of restrictions around the duration of
supply as well the range of indications, as opposed to the supply through prescriptions,
were cited.
“…you get folks in who’ve got skin infections and you know it’s infection, you send him to
doctor or GP. They either get Fusidin cream [fusidic acid] for impetigo and stuff and …how
far do we want to go with recommending [onto doctors], especially when doctors
appointments are getting more and more of a premium. And you know you’re here. I know
what you need. But, you will need to go and see the doctor.”
Male, 37 Years, Independent
However, some reflected that they would be confident to supply P medicines off-label if
deemed in the best interest of the patient. Patient care and need had the highest priority.
“In incidents …say, thrush products… you got all the guidelines there you have…but it’s
Friday and you know this person not gonna bear. Get an appointment until the following
Tuesday. Ok, if you stick hard and fast to the guidelines, you might say, well, no they don’t
meet that criteria but you send that person away to suffer all weekend, something that are
really uncomfortable…”
Female 53 Years, Independent
3.7.1.2 Evidence of medicine efficacy
Evidence of medicine efficacy was deemed by most participants to be important in
adopting newly reclassified medicines into practice. Instances were presented where
pharmacists perceived lack of evidence of efficacy was found to be militating against
supply decisions.
“Patients who want what is quicker to use and I’ve refused prescribing [supplying]
because may be quick to use but the evidence doesn’t back up its use. Now, that’s I think
what we should be doing. But, it can be quite difficult.”
Male, 55 Years, Large Multiple
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Specific examples, however, were related to non-prescription supply of simvastatin, which
was reclassified in 2004.
“Personally, it [simvastatin supply] is not something that I’ve become very involved in.
I’m not great advocate of selling the product OTC. I have reservations for the dose it is. I
think it’s far better …for the patient to have a thorough check out [from the doctors] …”
Female 53 Years, Independent
Lack of belief in an evidence base was also related to a lack of observable outcomes of
medicine usage, again exemplified with the case of non-prescription simvastatin.
“…you can’t see it [simvastatin] is making you better.”
Female, 25 Years, Large Multiple
In contrast, the high value placed on chloramphenicol and its subsequent extensive
adoption into practice was partly attributed to pharmacists’ perceived strength of evidence
supporting its efficacy. The importance of keeping up to date with new evidence around
reclassified medicines to inform practice was raised by some participants.
“… in relation to products which moved from POM to P…when Beconase [beclometasone]
was first launched, it was suitable for over the age of 12. Now its 18 …you go with the
information you have at the time and you’d have to trust the people that are bringing the
product to market, have done all the appropriate research … so we keep up to date with it.
It’s important that the members of staff kept up to date with that… ”
Male, 39 Years, Large Multiple
However, others reflected concern over the lack of updated information around evidence
base, highlighting that educational materials were likely to be received only during the
initial launch of the medicine under a newly reclassified status.
“I don’t think there’s a lot of literature really on OTC [over the counter] medications that
come in through our doors.”
Female, 27 Years, Independent
Of note, one participant expressed that she had to rely on the patient information leaflets
contained within the medicines packaging.
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“I think the only literature really is what’s in the patients information leaflets in the boxes in
a lot of cases unless in cases like something that have recently come from POM to P. You get
a bit form the reps coming in but there’s nothing specific.”
Female, 27 Years, Independent
Participants also considered patient feedback to be an informative tool to aid identification
of evidence of efficacy. However, such feedback was received only ‘occasionally’ and was
limited to either ‘very good’ or ‘very bad’ patient experiences.
“…it would be good to know, ‘cause sometimes you find you prescribed [recommended]
things, and people buy and its nice to get feedback if they’ve worked for the patient or if
they haven’t worked…”
Female, 27 Years, Independent
“The only feedback you get is very good or very bad.”
Male, 55 Years, Large Multiple
3.7.1.3 Safety
Participants highlighted that patient safety was a key factor in informing supply decisions
in relation to newly reclassified medicines. The wide acceptance of newly reclassified
chloramphenicol was further attributed to the low potential for risk (in addition to high
efficacy). There were also several examples presented where patient requests for newly
reclassified medicines were denied by pharmacists based primarily on safety fears.
“Chloramphenicol…this [reclassification] seems to make sense because the likelihood of
causing problem [to patients] is small.”
Male, 39 Years, Large Multiple
Limiting reclassified medicines to pharmacy sales was deemed important in ensuring that
safety measures around the use of medicines were promoted. For the same reason, one
participant mentioned that he preferred to recommend P over the GSL licensed medicines
to patients where possible, so as to encourage patients coming to pharmacy for repeat
supplies.
“Anything that goes GSL, you tend not to recommend to a pharmacy product or ones
excluded through pharmacy trying [to stop] folks going into the supermarkets.”
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Male, 37 Years, Independent
Safety concerns surrounding the supply of GSL medicines out with pharmacy were related
to uncertainty over stringent supply regulations in general stores.
“There’s problem when things go from P to GSL, are they been restricted or controlled
enough when they are sold outside pharmacy?”
Male, 55 Years, Large Multiple
3.7.1.4 Medicine retail prices
High retail prices of newly reclassified medicines were often related as barriers to supply
decisions. This issue was deemed as contributing to the low uptake of newly reclassified
omeprazole and simvastatin, in particular. High cost implication to patients was deemed a
bigger issue for those medicines indicated for long term use, such as simvastatin.
“…the company that I worked for was pushing it [simvastatin], because they thought that
this is gonna be a really big thing and that they are gonna sell masses of it and it was a
great opportunity for them to get into kind of a market which hasn’t previously been
there. And then, it certainly backfired because those people who came for cholesterol test
and they find out how much it was and they will need to take it every month, need to
come back every month and buy it and they didn’t do it.”
Female, 25 Years, Large Multiple
In contrast, greater uptake of newly reclassified chloramphenicol was partly attributed to a
more affordable retail price. Some participants regarded the prescription charge as a
benchmark for considering the appropriateness of the retail price of newly reclassified
medicine.
“That’s why I think chloramphenicol has been so successful because so many people
come in with eye infections and it is cheaper than prescription.”
Female, 25 Years, Large Multiple
For those considering prescription charges as the benchmark, it was not unusual for them
to voluntarily refer patients to their GP if treatment with newly reclassified medicines
meant higher cost implications.
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“…better off on to the doctor and I would advise to do that rather than buying an
expensive product.”
Female, 27 years, independent
Some regarded patients’ abilities to pay as an important factor, further driven by their
social status; and hence these decisions were mostly subjective.
“I think it depends as well on what area you are targeting, because if you are in a, an
affluent area, probably, ***** [an area], people may be motivated to pay …but if you’re in
a poorer area…”
Female, 56 Years, Large Multiple
With the abolition of prescription charges in Scotland by April 2011, pharmacists
highlighted that patients would be less inclined to buy the so deemed ‘often expensive’
newly reclassified medicines.
“…particularly with things like prescription charges [going] down in Scotland as well,
…you just tell them that it would be cheaper on prescription and then they quite happily
go to the doctor and get [the medicines] instead…”
Female, 25 Years, Large Multiple
3.7.1.5 Medicines for acute versus long term indications
Participants expressed doubts about whether resources available in community pharmacy,
in general, were appropriate for medicines for long term indications to be supplied, largely
due to the perceived complex supply procedures. In addition, expertise such as prescribing
qualification was thought to be required by some participants as imperative to undertaking
the supply.
“…certainly we can advise the patients on their diet and lifestyle changes and I am more
than happy to do that but I think in terms of [supply], … [reclassification of simvastatin is]
may be good for identifying somebody who has high cholesterol level who we can refer on
but …in terms of treatment I don’t think, unless you have the facilities or you’ve done the
supplementary prescriber course or independent prescriber, I don’t think we really have the
time at community pharmacies to go into that sort of details with patients.”
Female, 27 Years, Independent
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It was interesting to note however, that participants with a prescribing qualification did not
support the reclassified status of simvastatin either. General practitioners were considered
more appropriate for the management of long term conditions. A few also regarded that
patients were comfortable 'anyway' with management of long term conditions from GPs.
“We’re really kind first port of call for acute things and…really people are coming… if
there’s something wrong with them but if it’s a long term chronic thing, they come in and we
can direct into their GP for the long term chronic thing.”
Female, 46 Years, Small Multiple
3.7.2 ‘Context’ related facilitators/barriers associated with
adoption into practice of newly reclassified medicines
3.7.2.1 Sources of information/ training
Participants highlighted the importance of and need for timely information and training
around newly reclassified medicines to inform their practice. Externally provided training
events, such as those provided by RPSGB were attended if they contributed towards
pharmacists’ mandatory Continuous Professional Development (CPD) requirements.
“You’re more likely to read it [information] and do the questions afterwards, if it’s gonna
count towards your CPD.”
Female, 27 Years, Independent
Attending training sessions was thought more useful than solely relying on printed
information sources, due to the interactive nature and opportunity to ask questions.
Although company representatives were acknowledged to be a source of information, some
also noted that personal relationships and friendships could bias information and thus
potentially impact on pharmacists’ decision making. However, in some situations, it was
noted that the representative was really the only source of information, hence explaining
why their voice had a greater bearing on pharmacists’ decision making.
“I think a lot depends as well, you know the representative coming from company as
well, depends on the personal relationship and how far back you go with them and just
listen to what they say but the relationship that you tend to have with them… colour your
judgement, whether it’s right or wrong I don’t know.”
Female 53 Years, Independent
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It’s the reps [representatives] doing it [promoting], ‘cause it’s the only one [source of
information] that we get for POM to P for certain conditions.
Female, 46 Years, Small Multiple
A few participants however, considered that manufacturers’ information was ‘biased’
leading to a need for impartial’ sources of information. Information in the Pharmaceutical
Journal was largely considered impartial.
“… [I use] an impartial source, not the manufacturers’. I always get sceptical when I see
their data coming through.”
Male, 28 Years, Large Multiple
On the contrary, one participant highlighted the importance of using information from
multiple sources, including the manufacturers’ information for the distinct focus around the
information provided by each sources.
“The Society [RPSGB] information is always great for making sure that you’re absolutely
on the ball regarding the legalities of the situations what you should be and shouldn’t be
doing regarding the sale of the products. Em…, the manufacturers’ information will
always give you much more detailed information about potential side effects and things
and kind of gives more detailed information about the compositions and make
up…’cause you will always have people with weirdest queries em…, with, they got
bizarre diet they take into, can’t have anything with …all sorts of weird things in tablets.
So you can get that, mostly from manufacturers’ information.”
Female, 25 Years, Large Multiple
One participant considered personal experience as pivotal to decision-making, and noted
this to be superior to knowledge gained through information and training.
“But I’m still sceptical …, specially on the CPD things… that’s lovely, thanks for telling
that but I’m still not quite necessarily choose that product over, over something which
has been successful for, with other patients or customers before.”
Male, 28 Years, Large Multiple
3.7.2.2 Access to patient medical records
A desire for access to patient medical records was strongly voiced. However, this was
specific to supply of certain medicines such as simvastatin.
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“…whether the patient had a history of or a family history of stroke, whether diabetic…, in
isolation, I think it [simvastatin] was pretty much useless exercise.”
Male, 55 Years, Large Multiple
Participants were concerned for patient safety implications if supplies were made without
being fully aware of the patient’s medical history.
“Unless you have access to records… to see what we want…, the only way [to supply
simvastatin] is… if we had access to the records, kind of dangerous in a sense if you think
about it.”
Male, 66 Years, Independent
3.7.2.3 Risk assessment tools
Participants described the importance of risk assessment tools to promote safe supply of
newly reclassified medicines. This need was mentioned with reference to specific newly
reclassified medicines including simvastatin.
“…as long as they’ve been through the whole sort of questionnaire, the questionnaire that
they give you with the product information is quite good. It’s just reassurances it’s just so
many questions to go through it. It’s just impossible to remember everything but it definitely
has been great…”
Female, 27 Years, Independent
Others regarded risk assessment as a barrier, particularly in terms of resource implications.
“…time filling out whole Imigran [sumtriptan] [risk assessment form] … I find that taxing”
Male, 28 Years, Large Multiple
Participants shared common experiences around some patients being reluctant or
sometimes unwilling to undertake these risk assessment questionnaires. Many considered
that patients often regarded pharmacy as a place to obtain medicines rather than a place for
consultations.
“A woman came to buy a pack of Imigran, and I said, have you been interviewed about the
suitability to buy this product? No, the other chemist just sold me. So, I have to get the pack
out and go through the two page questionnaire with it to determine whether it was suitable
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for. And, this was almost ten minutes of her time to get sold the product she already had
somewhere else. Had she not been a local customer, I’m sure she would have just walked
out. Em…, that obviously, the fact that I was able to sell it her, was… able to explain to her
why… the reasons behind the questionnaire without scaring her too much. I suppose, this
was just down to the fact that she had the time and was willing to listen to what I had to
say.”
Male, 39 Years, Large Multiple
One participant cited an example of blood glucose testing in the community pharmacy
environment as more appropriate for the ‘short’ process involved. More complex risk
assessment procedures such as cholesterol testing were deemed to be more of a doctor’s
responsibility and hence a barrier to adoption of certain newly reclassified medicines.
“I think diabetes test one is good. You know, for people that just may be have the symptoms
or haven’t or have a family history and just want to come in quickly to pharmacy and do,
you know a quick blood glucose test, but, there’s certain areas that just requires too much
detail, that just need to be overseen by a GP and have the patients receive the proper
intervention or care... I don’t think we would have the time or the facilities anyway in our
place to give that level of care …”
Female, 27 Years, Independent
3.7.2.4 Direct requests for medicines
Participants had overwhelmingly negative attitudes towards the direct requests for newly
reclassified medicines. Direct requests were often regarded as ‘disrespectful’ to
pharmacists’ professional roles as medicines experts. Presentation of illness was considered
a more appropriate practice.
“…they don’t come in and [ask] what’ve you got for period pain? What’ve you got for
fungal nail infection? This is just can I say, can I have the stuff that’s advertised on the
television? Yes, I can treat your nail infection if you leave it just up to me, let me decide how
I going to treat you...You can’t walk into a GP practice and say to the doctor, I come on with
such and such I saw on telly [television]. The GP won’t listen to it. And, I found that quite
frustrating.”
Female, 46 years, small multiple
Participants highlighted that most of the direct patient requests for newly reclassified
medicines were influenced by mass media advertisements and information freely available
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on the internet. Nonetheless, verbal recommendations from other health professionals such
as the GPs and nurses at NHS24, suggesting to patients the name of the medicines to be
‘picked’ from pharmacy were also blamed to be contributing to direct requests.
“… hydrocortisone cream for example, its not licensed OTC for the face and you get, they’ve
had the product from the GP to use on the face. The doctor has said to them you can buy it...
I wish sometimes that information was made more clear [to the doctors’]… that leaves a lot
to be desired [by the patients] and sometime makes it difficult for us.”
Female 53 Years, Independent
3.7.2.5 Patient behaviour
Participants highlighted the importance of patient willingness to comply with pharmacist
and support staff advice so as to promote safe and effective use of newly reclassified
medicines. Only a few highlighted that patient behaviour was generally appropriate.
“We don’t tend to get a lot of people asking for anything [inappropriate requests], which is
good.”
Female, 29 Years, Small Multiple
“…when the partner comes in saying oh, ‘my wife or my other half is looking for a morning
after pill.’ ‘No I can’t sell it to you. I need to sell to the person who needs it and interview her
to make sure it’s appropriate’. ‘How come?’ ‘Because I need to know if that’s appropriate’”
Male, 39 Years, Large Multiple
Patient behaviour was deemed by a few to be ‘good’ in smaller towns and villages as
opposed to larger cities where verbal arguments with patients were often common place.
Such arguments were construed as disrespect to professional expertise of pharmacists.
“You spent four years doing your, your degree…the Master’s degree…the patients still come
in and argue.”
Male, 37 Years, Independent
Some patients were noted to move from one pharmacy to another in an attempt to get a
denied medicine. Participants accepted that decisions across pharmacies around similar
requests were not always consistent, further encouraging patients to ‘try’ across
pharmacies. Some participants were however often resigned to patient requests.
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“I think because we are very sort of customer oriented. Your customers can go wherever
they want, while with the GP they have to go there all the time. It will be very much sort of
bullied. You’re not…, giving them [medicines] to keep them happy …”
Female, 27 Years, Independent
Participants also highlighted that ‘disloyal behaviour’ from patients could be a barrier to
them anticipating future reclassification of medicines such as antibiotics. This was the same
participant as above who agreed to being often resigned to such disloyal behaviours from
patients. Lack of desire to see antibiotics reclassified was different to the view of most other
participants who mentioned trimethoprim as an appropriate candidate of reclassification.
“I don’t think I would like to see antibiotics because I think with this, we will be bullied a lot
by the customers, you know that insists on that they need antibiotics. I think that the doctors
are doing a great job trying to limit them at the minute. So that’s one thing I don’t think I
would like to see coming just and just yet anyway.”
Female, 27 Years, Independent
3.7.2.6 Supply guidelines
The importance of clinical guidelines was considered imperative in facilitating adoption of
newly reclassified medicines. Participants described ambiguity around labelling certain
ailments as ‘minor’, particularly when repeated requests for the same medicines over time
were received. The point at which patients should be referred to their GPs was not
considered to be straightforward in current guidelines.
“I think the question is at what point do you stop treating these minor ailments, because
we’ve quite a lot of patients who come in for a lot of lactulose on a regular basis and then
you try and explain to them, you know, well if its ongoing, you should maybe go and see
your doctor…there’s no definite point of what’s minor and what do you keep treating. You
know and that’s where I’m sort of lost.”
Female, 27 Years, Independent
“So, is it minor? You know, there’s a lot of grey areas about what is minor and what’s not.
Hay fever have been one of the crackers, as you know by August, it should hopefully have
died down. But how often do you go and treat em’? Or when do you tell them to go to the
doctor?. Or the one is, oh I got it from the last time from the doctor, can I get from you this
time? There’s not enough guidance.”
Male, 37 Years, Independent
Chapter 3: Qualitative research 87
3.7.2.7 Peer support
Peer discussion about innovation issues were considered almost non-existent. Further
collaboration among professionals to aid decision making around newly reclassified
medicines were considered important by a few participants.
“We don’t meet that often to discuss these things. You have to really do it yourself basically,
unless you phone somebody and [ask] what do you do in these instances?”
Female, 54 Years, Independent
3.7.2.8 Employer policies
Participants from pharmacies with a multiple ownership structure identified employer
policies being the key to stocking decisions around newly reclassified medicines. However
such policies did not ‘enforce’ supply. Decisions to supply were argued by participants to
be based on their own judgements, regardless of organisational decisions to implement.
“We’ve found that although there are more products available…the shelves don’t get any
bigger and our company dictates what we stock on shelves. So those that might be
advertised on telly [television], that isn’t necessarily something we are stocking.”
Male, 39 Years, Large Multiple
“If somebody demands, we stock as a matter of policy. I didn’t agree with it [simvastatin]. I
did it when it was contractually required me to… but I’ve never sold a pack of simvastatin in
life. Never had any intention to do it [the supply]”
Male, 55 Years, Large Multiple
3.7.2.9 Relationship and trust with support staff
Good working relationships with support staff were regarded as vital for the adoption of
newly reclassified medicines. A lack of trust and relationship with support staff was often
regarded as ‘barrier’ to anticipating reclassification of medicines.
“Fortunately, in the store I am working, I trust my staff members and I know that they go,
sort of sell appropriately and always refer to me or the pharmacist in-charge in a responsible
manner. Occasionally I have worked in stores where you don’t necessarily have that trust in
your staff and that’s where having these kinds of products [chloramphenicol, omeprazole]
available can be more problematic. My staff must know that they must refer to me for the
sale of certain products that I might be slightly less comfortable with, just so that I can make
sure that the requirement is absolutely definite and that it’s the most appropriate product for
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the patient and.. Em.., again it depends which stores you’re in, whether that’s actually
happening or not , so it comes down to I think, I don’t have a problem with the
reclassification of these products.”
Female, 25 Years, Large Multiple
3.7.3 Attitudes to current ‘processes’ leading to reclassification
The following section describes results relating to pharmacists’ issues with current
regulatory processes of medicine reclassification and notification of such decisions to
pharmacists. This section also highlights their views towards their future contributions to
the change process.
3.7.3.1 Desire to contribute to MHRA decisions to reclassify
Some participants expressed a desire to contribute to the professional consultation
processes of the MHRA that take place prior to reclassification of medicines. However, lack
of awareness of this process was highlighted, with a few not being able to recall any past
invitations. There was a clear need for further support and direction in this area,
particularly as they felt that they were an unheard voice with important views.
“I’ve never been involved in anything. No, I’ve never been asked about anything. I’m
interested to take part in consultations like that but …”
Female, 25 Years, Large Multiple
One participant recollected the invitation around the consultation of trimethoprim
reclassification but could provide no further details.
“…I think trimethoprim has been a long consultation process out. I think I did do, can’t
remember where it was.”
Male, 37 Years, Independent
3.7.3.2 Awareness of reclassification decisions
Participants felt strongly that there was a lack of timely communication to pharmacists
about the MHRA decisions to reclassify. Often no communications around decision to
reclassify the medicines was provided to community pharmacists by either regulatory
authorities, pharmaceutical industry or their own professional body. Newly reclassified
medicines on occasion just appeared ‘from nowhere’. Indeed one participant recounted an
occasion where he had become aware of a newly reclassified medicine through a television
Chapter 3: Qualitative research 89
advertisement which appeared well in advance of any communication to him either via the
product manufacturer or the professional body.
“I wasn’t even aware that there was an OTC naproxen coming out until it was pointed out
on television. To me, I would think I would read in my journal and chemist [Chemist and
Druggist] but it’s not as early, for cover to cover… then [patients] coming and asking for
OTC naproxen which I wasn’t even aware…I don’t know if I’m alone.”
Male, 55 Years, Large Multiple
Participants gave several examples of scenarios highlighting how a lack of timely
communication regarding newly reclassified medicines had put pharmacists in
professionally uncomfortable and potentially embarrassing situations.
“…before launch it’s often in glossy magazines or newspapers whether it is news or whether
it is promotional. I have been asked for something that appears on Daily Mail or whatever,
newspaper that does a new medical drug. Now if I don’t read that particularly newspaper, I
won’t have a clue what they are talking about …I think…, that doesn’t only happen with
over the counter drugs, it can also happen with prescription drugs. People asking about new
wonder drug for rheumatoid arthritis, which they read about in the Sunday Post, ‘Doctor’ on
Sunday Post.”
Male, 55 Years, Large Multiple
Indeed, one participant voiced that pharmacists should be ‘leading’ messages given to the
public about the availability of newly reclassified medicines from pharmacies, as opposed
to the current situation where pharmacists were often responding to customer requests,
deemed to be stimulated by direct to customer advertising.
“But if it’s driven by television advertising … that people coming and asking for potent
medication, I might not be satisfied. I think, it should be, led by us, not led by television. “
Male, 55 Years, Large Multiple
An ‘ideal’ way to communicate information around reclassification was also suggested.
“They [MHRA] can send us a sort of standardized card with all the information instead of all
promotional information, you got to fight the way through to find the information you really
want. The card would then allow to sort of pick changes and secondly would give you the
standard information.”
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Male, 66 Years, Independent
3.7.3.3 Role of television advertisements
Almost all participants had overwhelmingly negative perceptions about the role of
television advertising of medicines and the messages delivered to the public. They were of
the opinion that advertisements had the potential to place members of public under undue
‘pressure’ to medicate themselves, sometimes for what they perceived to be ‘inappropriate’
reasons.
“You tend to find that these advertisers hold a lot of pressure for the patients, wanting
[medicines]...”
Male, 37 Years, Independent
Participants also voiced strong opinions that advertisements could undermine the role of a
pharmacist’s input in medicine selection and management of minor ailments. Instances
where patients had made their mind up after watching the advertisement and before
visiting the pharmacy were described. In general participants deemed that patients held a
high regard for such advertisements.
“…[reclassified medicine] gets advertised on telly [television], oh… this [medicine] is great,
this is great stuff and they come in and, they ask for…They don’t come in and [ask] what’ve
you got for period pain? What’ve you got for fungal nail infection? This is just can I say, can I
have the stuff that’s advertised on the television? I think, Curanail [amorolfine] must be on
the telly just now as well. ‘Cause I’ve had somebody asking for that and that’s such an
expensive item, something I would not generally recommend first line, but, because it’s on
the television…”
Female, 46 Years, Small Multiple
Some participants went as far as suggesting banning the direct public advertising of
medicines altogether so as to encourage patients that all information around newly
reclassified medicines is obtained via pharmacies.
“…it’s fine if they don’t advertise, ‘cause we could control the sales. Since that advertising
we’re pushed into it [supplying the medicines]… by the patients.”
Male, 37 Years, Independent
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3.7.3.4 Names and pack sizes of newly reclassified medicines
Participants reported problems attributed to potential confusion created by similarity of
brand names of newly reclassified to those of the packs licensed prescription only. One
participant recounted a situation where an error in supply occurred as results of such
confusion.
“It’s quite confusing, when they have fancy [prescription] products like Cansten and they
bring out [over the] counter pack which is obviously…[with] the same [name]...its
misleading...Things like Canesten [fluconazole], I’ve given the POM pack you know”
Female, 56 Years, Large Multiple
The issue of similar nomenclature of POM and P packs was also deemed misleading to
patients, particularly where similarly named branded medicines actually contained
different active ingredients. There were concerns over risk management, patient safety and
more complex management of any overdose situation.
“… when you get the name ‘extra’ ‘plus’ and …… it’s confusing for the hospitals if there is
an overdose because, basically the database will actually show the product as being
salicylate product …I’d have liked to call some other than Feminax Ultra [naproxen] to be
honest …”
Male, 55 Years, Large Multiple
Debate over the pack sizes of newly reclassified medicines took place. Some participants
voiced that larger pack sizes of newly reclassified medicines were financially beneficial for
pharmacy.
“…and we’ve also found that the pack sizes of the products we are stocking are getting
bigger on the basis that a customer coming into the shop, if we can get them to buy the
bigger packet instead of 12 pack if we can get a 24 pack or 32 pack, that’s more money in the
till.”
Male, 39 Years, Large Multiple
Others raised concerns associated with stocking and safety of larger pack sizes.
“Perhaps, the industry could have helped ourselves in some ways of, not produced 30
quantities, 30 packs [of medicines].”
Female 53 Years, Independent
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3.8 DISCUSSION OF KEY FINDINGS
The objectives of this qualitative study relevant to the data presented in this Chapter were
to: investigate community pharmacists’ views on ongoing changes around enhanced
management of minor ailments from pharmacy; evaluate the processes aspects of
innovation adoption from community pharmacists’ perspective; and to explore key
facilitators/barriers associated with their adoption into practice of newly reclassified
medicines. Although most discussions were focussed around medicines indicated for acute
conditions, issues around adoption of newly reclassified medicines indicated for long term
indications also emerged during the discussion. This too added rich insight to the
understanding of community pharmacists’ innovation adoption decision making process.
Most participants deemed pharmacies were still suited to manage acute minor ailments.
3.8.1 Attitudes to ongoing changes
Participants’ identified that pharmacists’ roles are being enhanced by the innovative
services around minor ailment management. New services were deemed to be enabling
pharmacists to move away from routine dispensing role to enable greater interaction with
patients. The ongoing reclassification of medicines and the introduction of e-MAS in
Scotland were regarded as the key changes aimed at enhanced minor ailment management
from pharmacy.
Despite most participants agreeing the benefits offered by new services, in general, to
professional role development; adoption into practice of these innovations, were found to
be associated with many facilitators/barriers, perceived to be inherent within the
characteristics (or attributes) of medicines as well as related to organisational and external
contextual factors; and process related aspects of changes. Data around such
facilitators/barriers relevant to the adoption of newly reclassified medicines into practice
were presented in this Chapter.
3.8.2 ‘Content ‘related facilitators/barriers to innovation
adoption
Opportunities to increase pharmacists’ professional roles and image in society were
identified as one of the key desirable features that an innovation should possess to facilitate
adoption. Many of the newly reclassified medicines were regarded as an opportunity to
further enhance their roles by participants in this study. Many participants expressed that
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they were anticipating medicines from diverse therapeutic areas to be reclassified in the
future. Of the suggested medicines, naproxen has been recently reclassified into P status
[89]. The MHRA has also started consultation around certain POM medicines that
participants identified would be useful to further enable enhanced management of minor
ailments; such as trimethoprim for the management of urinary tract infection [89].
Opportunities for role development and enhancing professional image have also been
reported as key ‘motivators’ of community pharmacy practice change not limited to minor
ailment management in a previous qualitative study [127].
Both benefits and risks to patients were found to be assessed by pharmacists when making
decisions to adopt newly reclassified medicines into practice. A recent qualitative study has
shown that pharmacists are basically risk averse when making adoption decisions and that
lack of evidence of efficacy are less likely to deter pharmacists from supplying them [228].
However, in this study showed that perceived evidence of efficacy of newly reclassified
medicines could be of equal importance as the issue of patient safety, while making
adoption decisions; exemplified by participants with lack of efficacy being one of the
reasons for non-adoption of simvastatin.
The importance of medicine retail prices was often regarded critical to decision making.
Many participants cited referring their patients to their GPs where cost of therapy with
reclassified medicines would exceed the prescription charges. As noted in this study, the
cost of prescription charges as a benchmark to estimate the appropriateness of retail price of
medicines by pharmacists sits alongside the findings from previous studies [229]. Patient
based studies reflect that the issue of access is an important reason why patients choose to
go to pharmacy [105]. However in this study, it was not clear whether pharmacists took
account of this factor when making such referrals. The issue of abolition of prescription
charges in Scotland by 2011 [230] raises important research questions around how the
conflict of issue of access versus the retail price of medicines will affect the sales and
supplies of newly reclassified medicines.
This study did not identify the role of profits owing to sales of reclassified medicines to be
associated with the tendency to supply. Participants did neither allude to the financial
benefits when discussing the merits of ongoing reclassification of medicines. Any
preference of P medicines over GSL counterparts was explained in terms of encouraging
patients to use pharmacy for minor ailment matters in the future. From the participants’
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perspective, patients would benefit from pharmacy only supply. One previous study
reported that financial profits owing to sales were associated with pharmacists’ tendencies
to supply the medicines [231]. However references were mostly made to pharmacists’
choice of particular brand from the available ranges [231].
Not limited to the issue of cost implications, those medicines indicated for long term
conditions were regarded by the participants as less appropriate for pharmacy supply.
Resource requirements around the perceived risk assessment needs and greater expertise
were deemed barriers to adoption into practice of such medicines. This was despite the fact
that medicines are reclassified once MHRA is assured of the expertise and resources
available in pharmacy [87]. Of note, risk assessments such as cholesterol testing were often
deemed to be prerequisite for supply despite no mandatory need for such process within
the supply guidelines, such as with the case of non-prescription supply of simvastatin [232].
Greater harmony between pharmacists’ perceptions around the risk assessment need and
clinical guidelines around supply process is important.
The facilitators/barriers around ‘content’ aspects of newly reclassified medicines relate to
the factor attributes of innovations associated with innovation adoption as suggested by
Rogers’ diffusion model [131] (Chapter 1, table 1.3). Within the attributes of innovations, the
importance of relative advantage of having newly reclassified medicines (such as opportunity
for role development), perceived complexity of the supply process (such as need for risk
assessment), compatibility with pharmacists’ skills, experiences and expertise, observability of
benefits of adoption into practice (such as good feedback about efficacy from patients) and
re-invention (comfort to supply the medicines off license) were identified in the data.
However, there was no evidence to suggest that pharmacists adopt newly reclassified
medicines on a limited trial basis before supply to larger numbers of patients. Hence the
factor trialability was not identified. One reason for this might be that many of the newly
reclassified medicines discussed had surpassed the stage of trialability. Lack of the
importance of trialability has also been reported by other diffusion studies in pharmacy
investigating pharmacy based in house immunisation services in the US state of
Washington using a multi-stage survey design [233]. It is hence possible that not all
pharmacy innovations are predisposed to trialability. On the other hand, it is also possible
that late adopters are often known to use feedback from the more innovative adopters and
use as a measure of trialability whereas the more innovative ones do not have such
precedents available to inform their own practice.
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3.8.3 ‘Contextual’ factors
3.8.3.1 Organisational
Training opportunities were identified as facilitators to the adoption into practice of newly
reclassified medicines. A few participants complained more about the lack of diverse
training opportunities than others. Limited evidence from outside the area of minor ailment
management suggests that pharmacists from independent or small multiple ownership
experience greater problem with allocation of resources such as around staff capacity
development than those practising in large multiple chain ownership structures [234-236].
The issue of insufficient training opportunities for locum pharmacists was also raised. One
previous audit around availability of professional and operational information for locums
in community pharmacies in Greater Glasgow Health Board in Scotland showed that that
locum pharmacists usually encounter lack of information material in community pharmacy
[237]. It is imperative that their information and training needs are well researched given
that nearly a quarter of pharmacists involved in community, practice as locums [238].
Access to patient medical records was deemed essential for the supply of certain newly
reclassified medicines. Such access was again discussed in relation to the supply of
medicines indicated for long term conditions. With the increasing number of cognitive
services being introduced into pharmacy, not limiting to minor ailments management,
ways to enable access to patient medical records need further consideration by wider
stakeholders. This issue is discussed further throughout the thesis.
Apart form the issue of resources and training, the importance of trust and relationship
with support staff were also identified. Appropriate organisational management and
leadership skills could aid pharmacists in establishing healthy working relationships with
their support staff. This also has been claimed to be important to enable pharmacists
delegate the task of routine dispensing role if further innovative services requiring
pharmacists’ cognitive roles are to be introduced in the future [127].
3.8.3.2 External
Issues around support from patients, professional bodies, pharmaceutical industries and
wider stakeholders were the external facilitators/barriers associated with adoption of
newly reclassified medicines.
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Aggressive and non compliant patient behaviour was less of an issue for some participants
than others in this study. ‘Bad’ experiences around patient behaviour were often deemed by
participants to be deterring them anticipating future reclassifications where perceived risks
owing to lack of compliance were higher. Future interventions enhancing the awareness of
risks arising from non-compliant behaviour is imperative.
Participants in this study also suggested changes in the currently available information
from external sources, such as the RPSGB. The ambiguity relating to the point of patient
referral to the doctors was raised. This is interesting in that most RPSGB practice guidelines
around the newly reclassified medicines, do indicate the point of referral [232,239].
Nonetheless, some raised issues around lack of adequate external information and training
sources. Of note, some participants complained about having to rely on patient information
sources such as the PILs. For others, pharmaceutical industry representatives were the only
external information sources. External information sources are often labelled change agents
by the diffusion model who are regarded not only important in facilitating innovation
adoption, but also can raise the compatibility of innovations to potential adopters by
providing them with information around benefits and risks of the innovations [131]. The
lack of opportunities for peer networking among pharmacists to discuss issues associated
with innovation adoption is also worth noting. The need to facilitate such professional
networking among colleagues, who often work in isolation, has previously been
emphasised by other pharmacy practice researchers in the context of new pharmacy
services not limiting to enhanced minor ailment management [127]. The importance of both
vertical (from senior colleagues to junior colleagues) and horizontal (from peer to peer)
routes of learning has been highlighted through empirical evidence from studies with other
health professionals such as the doctors [240]. It has been known that despite their
independent medical practitioner status, doctors are usually known to benefit from
discussion of issues around new medical and surgical techniques among professionals of
similar hierarchy [240]. There is a scope for stakeholders in pharmacy to enable pharmacists
to exercise such opportunities.
The importance of support from and effective communication with health professionals
including GPs and nurses was unsurprising given the wealth of evidence around the
importance of inter professional relationships [144,241,242]. However concerns were often
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noted around the ‘inappropriate’ referral of patients to pharmacy by the professionals. It is
important that pharmacists’ desire to ensure autonomy in decision making is respected by
other health professionals.
3.8.1 The processual aspect of innovation adoption
As highlighted in Chapter 2, gathering sequences of events about how innovations are
adopted is referred to in diffusion research as ‘process’ research [130]. Such research is most
appropriately undertaken using qualitative methodology. A number of key process aspects
of innovation adoption were identified from the qualitative data presented in the results.
3.8.1.1 Communication around reclassification decisions
The current provision of information by ‘policy makers’, specifically the MHRA to
pharmacists, around when and how medicines are reclassified was criticised by
participants, mainly for the poor timing of such information. Consumer demands, deemed
to be generated by early media advertisements, were often blamed to be acting as key
drivers for pharmacists to adopt the innovations. Such early advertisements were often
putting pharmacists under pressure to adopt newly reclassified medicines at a very early
stage before appropriate CPD and training had been received. One qualitative investigation
in Australia showed that pharmacists did not identify demand from patients as key drivers
of practice change in relation to adoption of innovative services, mainly owing to lack of
direct to consumer advertising in Australia [127]. Perspectives of wider stakeholders are
necessary to be gathered to see if there is a need for any changes in the regulations around
advertisement of newly reclassified medicines.
3.8.1.2 The importance of adopter characteristics
The results highlight that diverse groups of pharmacists exist who embrace and adopt
innovations to a different extent and at different paces. It was worth noting that
participants who identified themselves as being forward looking also reflected a desire to
have a greater involvement in regulatory decision making processes as they apply to
pharmacy. The need to identify these pro-active pharmacists who can act as ‘movers and
shakers’ or attain the role of opinion leaders within their organisations and local practices
forums [243] has been previously highlighted [159].
Some participants stressed the importance of ‘delay’ before ‘getting used’ to the supply of
newly reclassified medicines to be adopted into practice. Rogers’ diffusion model regards
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time as an important variable in the process of diffusion [131]. Those who are known to be
on the higher side of the innovative scale are known to adopt innovations quickly as
opposed to the ones on the other side of the scale (table 1. 3) [131]. Given the small sample
size of this study, it was not fully possible to categorise participants as per their readiness to
change to the five categories of innovativeness as suggested by Rogers (table 1.3). It is
important for the regulators, professional and organisational leaders to tailor the pace and
support around innovative medicines and services to fit the need of these diverse groups of
individuals. The deployment of ‘contract champions’ [244] within Scottish Health Boards
from pharmacy proprietary associations such as Community Pharmacy Scotland aiming to
enable customised help to community pharmacists/pharmacies in delivering innovative
services is an example of how such concepts could be realised in practice. Such support
measures via other stakeholders of community pharmacy innovations could facilitate their
adoption by practitioners.
3.8.1.3 Personal adoption versus organisational implementation
Some participants, when doubting the benefits of innovations of reclassified medicines to
either themselves or to the patients; were often found to be dissociating themselves from
the organisational decisions to implement the innovations. Hence, for many, decisions at
the organisational level to implement an innovation did not necessarily translate to
adoption by individual practitioners. Any discordance around adoption at an individual
practitioner level versus implementation at the organisational level is more likely to be
relevant for larger organisations where implementation policy are likely to formulated at a
central and remote locations, often labelled by participants as ‘head office’. Given
pharmacists’ roles in imparting knowledge and onward training about new services and
medicines to support staff to prepare their pharmacy for the implementation, willingness to
adopt by pharmacists is important. The facilitators/barriers identified in this exploratory
study further enables understanding of how innovation adoption by individual
practitioners, around newly reclassified medicines are likely to be facilitated.
3.8.1.4 Naming the newly reclassified medicines
Participants expressed concern towards potential misunderstanding created due to the
similarities of P medicines to their POM counterparts. The nomenclature of innovations is
often known to be a delicate and important matter, especially for the perception they can
bring about in the potential adopters [127]. Although, there are regulatory provisions that
POM and P strengths of the same generics are required to have different brand names [89],
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errors owing to confusions from similar nomenclature were acknowledged by participants
in this study. Hence stringent measures to avoid such errors in the future are imperative.
3.9 SUMMARY OF CHAPTER 3
New services around enhanced minor ailment management were identified by the
participants of this study to be contributing to role development and professional image in
the society. Ongoing reclassification of medicines and the introduction of e-MAS in
Scotland were identified as the key changes in this area. However highly individual and
diverse experiences of changes were identified where individuals perceived the need as
well as current pace of change differently. The importance of good communications with
wider stakeholders including the regulatory decision makers was highlighted.
Facilitators/barriers to adoption of newly reclassified medicines into practice by
community pharmacists were also identified and presented in this study. These related to
perceived attributes of newly reclassified medicines such as retail prices, benefits and risks
of the medicines to pharmacists’ professional role and to the patients (such as evidence of
efficacy and safety); organisational contextual factors such as sources of information and
training; external factors, such as support from wider stakeholders. Many newly
reclassified medicines were highlighted by participants to have been highly adopted into
practice or were least/not adopted based on these diverse facilitators/barriers.
The strengths and weaknesses of the method adopted as well as relevance to practice of the
results will be detailed in Chapter 9 (General discussion).
The next stage of the research will quantify the so identified facilitators/barriers associated
for their importance in pharmacists’ adoption of newly reclassified medicines into practice.
Prior to the quantitative evaluation, a systematic review of literature will be undertaken to
facilitate the development of quantitative research instrument.
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4 CHAPTER 4: SYSTEMATIC REVIEW OF
LITERATURE
Reporting of this systematic review is based, where appropriate and relevant, on the
PRISMA statement 2009 which details the ‘Preferred Reporting Items for Systematic
Reviews (and Meta-analysis)’ [245].
4.1 INTRODUCTION TO THE CHAPTER
The qualitative data aided the identification of key barriers and facilitators associated with
pharmacists’ decision making around reclassified medicines. Decision making is defined in
this research and for the purpose of this Chapter as pharmacists’ adoption of reclassified
non-prescription medicines into practice; or support for the non-prescription availability of
medicines previously available only on prescription. There is a lack of a robust tool to
facilitate large scale evaluation of facilitators/barriers to pharmacists’ adoption of
innovations within this field. Hence there is a need to develop such an instrument for
quantitative evaluation. Undertaking a systematic review of literature is essential to inform
this development. Such rigorously developed research instrument could potentially serve
as a universal tool to undertake research around future reclassification of medicines even
out with the scope of this thesis.
4.2 OBJECTIVES
The following were the objectives for the systematic review
1. To review and critique the methodologies, methods and models to investigate
factors associated with community pharmacists’ decision making around
reclassified medicines as described in the peer reviewed published literature.
2. To list and describe the importance of facilitators/barriers identified from the peer
reviewed published literature to community pharmacists’ decision making around
reclassified medicines.
Achievement of objectives 1 and 2 will aid the design and content development of the
quantitative research instrument to be used in Phases III and IV of this research. Results
relevant to objective 2 will, in addition, facilitate triangulation of findings from the
qualitative interviews and focus groups. Any facilitators/barriers not discussed in the
qualitative interviews are also likely to be identified from the literature.
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4.3 METHOD
4.3.1 Protocol design
A protocol for the systematic review was prepared and reviewed by an expert panel,
including members of the supervisory team and one external advisor, Prof Dennis Tourish,
from the Business School at RGU. Standard guidelines and templates recommended by the
following institutes were used. Those recommendations explicitly relevant to clinical
intervention studies were ignored.
1 Centre for Reviews and Dissemination (CRD), University of York, Guidance for
Undertaking Reviews in healthcare updated in 2009 [246]*.
2 Cochrane Collaboration/Library Guidelines for Undertaking Systematic Reviews
published in 2008 [247].
*updated during the review
Any deviation from the systematic review protocol during the review process was recorded
following discussion amongst the review team. A copy of the protocol appears in Appendix
IV.
4.3.2 Study eligibility criteria
The following inclusion/exclusion criteria were defined
 Any literature providing empirical evidence around factors associated with
pharmacists’ decision making in relation to either: support for reclassified status of
medicines; pharmacists’ perspectives on future reclassification; pharmacists’
perspectives around temporary provisions allowing them to supply POM medicines
in over the counter settings other than through reclassification (such as through
PGDs); factors associated with supply of reclassified medicines.
 Literature around reclassification of medicines around preventative services such as
EHC and medicines for long term indications were also included given the lack of
literature realised in the general review of literature in Chapter 1 (section 1.8)
 Literature around perspectives of pharmacists based in practice settings other than
community, such as those based in hospitals, were excluded. Those studies with
participants from diverse settings were only included if the results were distinctly
presented for pharmacists from community settings.
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 Literature including reviews of literature based only on conceptual models and
lacking empirical evidence were excluded.
 Literature explicitly around ‘advice giving’ was excluded.
 Data collected using patients/ consumers/ members of public as main participants
were excluded.
 Language: English only
 Date limit: Initially, the first version of the protocol set 1994 to current as the dates for
the literature search. However, a scoping search conducted without the date limit
retrieved relevant literature from the early 1990s. Hence the protocol was amended to
include literature from 1990 onwards.
4.3.3 Literature sources
The following sources were used to identify relevant literature
4.3.3.1 Databases
Seven databases namely PsychINFO, Ovid MEDLINE (R), CINAHL, EMBASE,
International Pharmaceutical Abstracts (IPA), Business Source Premier (BSP) and Cochrane
Database of Systematic Review (CDSR) library were searched in addition to the other
search tools detailed below. Description of these databases appears in Appendix I and IV.
4.3.3.2 Manual searching of journals
The following core journals related to the pharmacy practice area were searched for
relevant titles via the journal websites covering every issue since 1990 (or first date of
publication after 1990) up till present date (or date when publication ceased) by browsing
individual issues and table of contents.
 International Journal of Pharmacy Practice
 Pharmacy World & Science
 Family Practice
 BMC Family Practice
 Annals of Pharmacotherapy
 Journal of Clinical Pharmacy and Therapeutics
 Journal of Social and Administrative Pharmacy (now published as Research in
Social and Administrative pharmacy)
 American Journal of Health Systems Pharmacy
 Journal of Pharmaceutical Marketing and Management (publication ceased 2008)
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4.3.3.3 Conference abstracts
Abstracts of the following conferences were searched for relevant titles, either via manual
searching of journals or through dedicated conference websites.
 International Social Pharmacy Workshop (Webpage)
 International Pharmaceutical Federation (FIP) congress (Webpage)
 British Pharmaceutical Conference abstracts (as published in IJPP),
 Health Services Research and Pharmacy Practice conference (as published in IJPP)
 European Society of Clinical Pharmacy (Webpage)
 United Kingdom Clinical Pharmacy (as published in PWS).
(IJPP: International Journal of Pharmacy Practice, PWS: Pharmacy World & Science)
4.3.3.4 Other search tools
NHS Scotland ‘Community Pharmacy’ e-library search fields (now known as NHS Scotland
Knowledge Network); and web based databases such as Google and Google Scholar were
also used to find relevant literature. Bibliographies of literature used for full text screening
were also used to find relevant literature. Grey literature was not searched due to time
constraints.
4.3.4 Search strategies
Search strategies applied to the databases are listed in Appendix IV.
User accounts within database hosts were registered with full details of search strategies
hence allowing regular updates of new outputs to be notified monthly via email alerts.
Web based databases such as Google and Google Scholar as well as the two other
databases, the NHS e-library for Scotland Community Pharmacy search field and the CDSR
did not offer such sophisticated search strategies and hence the keywords that were used in
other databases as detailed in Appendix IV were used in different combinations as
exemplified in the systematic review protocol (Appendix IV). ‘Full citation details’ were
imported into ‘Refworks’ where possible and all cited in this thesis and associated outputs
using Write-N-Cite version III software.
Initial screening of titles was carried out to identify potentially relevant papers, followed by
screening of abstracts; and by full paper screening against the inclusion/ exclusion criteria.
From among the thousands of titles that were retrieved through the search strategy, fifty
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titles were independently checked for consistency of inclusion/exclusion by VP and DS to
enhance reliability of the process.
4.3.5 Quality assessment of identified studies
Studies were not excluded from the review on the basis of failing any number of items in
the quality criteria listed in the quality assessment form. However, such assessment was
required to fulfil objective I of the systematic review. Three quality assessment forms were
designed, each specific for qualitative; quantitative (including mixed methods); and reviews
of literature. These appear in Appendix IV illustrating a completed example. The following
sources were used to develop the quality assessment form:
1. CRD’s Guidance for Undertaking Reviews in Healthcare 2009 [246],
2. UK government chief social researcher office publication on frameworks for
assessing research evidence [248]; and
3. Critical Appraisal Skills Programme (CASP) [249].
Quality assessments were conducted on all included studies independently by two
reviewers (VP and DS). The studies were assessed for whether they pass the listed quality
criteria and marked either Yes, No, Not applicable; or if unclear, marked so with details.
Key items were then converted into an excel matrix detailing the distribution. Any
disagreements were discussed and appropriate actions agreed for the next stage of
evaluation.
4.3.6 Data extraction
A data extraction form as per the Cochrane guideline [247] was developed with the content
developed on the basis of the results of the qualitative interviews and initial scoping of the
literature and appears in Appendix IV with an illustrative example.
4.3.7 Strategies to deal with missing data
No strategy to deal with missing data was formulated due to time constraints.
4.3.8 Synthesis of results
From the initial scoping search, outcomes of the research were found to be poorly described
in the literature. In addition, the inclusion of both qualitative and quantitative studies in the
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systematic review necessitated an approach that would permit the integration of evidence
from both these methodologies. Hence narrative syntheses of the results were conducted.
As highlighted in Chapter 2, narrative synthesis within a systematic review differs from
traditional narrative literature reviews with the former referring to ‘a specific approach to
that part of a systematic review process concerned with combining the findings of multiple
studies’ [219]. A dedicated training session of evidence synthesis from diverse methodology
was obtained from Cochrane Qualitative Research Methods Group and University of
Sheffield (Appendix X, General). Further details of this method are described in Chapter 2.
4.4 RESULTS
4.4.1 Study origin
A total of 39 studies were included in the final review. The majority were identified through
databases searches with five from the bibliographies of the studies included for full text
screening. Manual searching of journal titles, CDSR and NHS e-library Scotland community
pharmacy search fields did not produce any additional literature (figure 4.1).
Studies were largely based in the UK (n= 20) followed by USA (n= 8), Australia/ New
Zealand (n=9) and one each from Puerto Rico and South Africa (table 4.1). The list of
studies which were excluded after full text screening along with justification for exclusion is
given in Appendix IV.
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Figure 4.1: Flowchart of processes leading to inclusion and exclusion of identified literature
for systematic review.
*after removal of duplicates; n= number of titles/literature
For title screening
(n=7337)
Abstract screening
(n=737)
Excluded (n=6600)
For full text
screening
(n=38)
Excluded (n =699)
Bibliography of
included literature
for full text
screening (n=5)
Included in the review
(n=31)
Total included (n =39)
Excluded (n =7)
Hand searching of
core journals (with
conference
abstracts), internet
search, expert search
(n=3)
Medline, EMBASE
and PsycINFO
(n=2706)*
Web-based
search (Google
Scholar) (n=363)
IIPA, CINAHL and
BSP (n=4091)*
Cochrane database
of systematic
reviews (n=177)
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4.4.2 Description of included studies
4.4.2.1 Methodology and method
Thirty-seven empirical studies and two literature reviews were included. The majority of
the studies employed a quantitative methodology using cross-sectional surveys as data
collection tools (n=29). Eight studies used qualitative approaches including semi-structured
interviews (n=2), in-depth interviews (n= 4), focus groups (n=1) and case studies (n=1)
(table 4.5).
4.4.2.2 Study population
Eighteen cross sectional surveys used random samples of community pharmacists (table
4.1). Three studies used the entire population of community pharmacists from the
geographical area of interest (table 4.1). Only the most innovative pharmacists were invited
to participate in two surveys, for example, those attending education programmes or
conferences [250,251]. Unclear descriptions of sampling were given in three studies [252-
254]. All but four quantitative studies reported a response rate above 50% whereas response
rate could not be estimated in four studies [250,251,253,255]; either due to: lack of
information around how many pharmacists were approached or overtly complex
recruitment process.
In terms of the qualitative studies, one used purposive samples of community pharmacists,
selected based on demographic characteristics [256]. Three invited only those pharmacists
participating in non-prescription provision of EHCs [257-259]. Two qualitative studies were
part of a larger evaluation around privacy of consultations in community pharmacy
[260,261]. One study used a snowballing technique from initial samples that were identified
through an advertisement in a pharmacy newsletter [228]. One qualitative study invited
only those pharmacists shortlisted from those who applied for training around EHC of
which only those with prior health promotion training and reflecting ‘enthusiasm’ were
selected [262].
4.4.2.3 Therapeutic area
Of the 39 studies, all but five [251,263-266] made particular reference to at least one
therapeutic area in their study. Of these, 13 had sole focus on pharmacists’ perspectives of
non-prescription supply of EHC followed by five studies around non-prescription supply
of statins (table 4.1).
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Table 4.1: Authors, aims and objectives, study method, setting and key findings of included studies arranged in chronological order
(Note: this table extends up to eight pages)
A. Quantitative studies
Study Stated aims/objectives Study
design
(delivery*)
Setting(s) †, number of
respondents (response
rate)†
Key findings
Madhavan and
Scondelmeyer
1990 [267]
Assess pharmacists’ attitudes
towards reclassification of
prescription medicines to non-
prescription status.
Cross
sectional
survey
(mailed)
Random sample of
nationwide US
pharmacists
270 pharmacists (35.9%)
Majority of pharmacists were undecided or
disagreed with the proposed switch of
promethazine, terfenadine and naproxen.
Emmerton and
Benrimoj 1991
[264]
Analysis of influences on
pharmacists’ non-prescription
medicines stocking and
recommendations.
Cross
sectional
survey
(hand
delivered)
Randomly selected
Brisbane pharmacists,
Australia
57 pharmacists (97.0%)
Successful use of the medicines by patients,
feedback from patients were among key
influences on recommendations.
Igboko and
Thomas 1991
[266]
Determine attributes that
community pharmacists consider
important when making non-
prescription medicines supply
decisions.
Cross
sectional
survey
(mailed)
Stratified (based on State)
random sample
independent community
pharmacies selected from
eight US states.
634 pharmacists (45.2%)
23 attributes identified as ‘determinants’
which included factors such as financial
benefits, patient acceptance of medicines and
safety reputation of manufacturer.
Bond et al 1993
[268]
Community pharmacists’ attitudes
to their advice-giving role and to
the deregulation of medicines.
Cross
sectional
survey
(mailed)
Random sample of
community pharmacies
from Scotland
204 pharmacists (90%)
Top therapeutic groups for proposed
reclassification suggested by pharmacists
included eye, skin preparations and
infections.
Madhavan 1993
[263]
To identify US pharmacists’
preferences around US legal
classification of non-prescription
medicines and identify factors
associated with preferences.
Cross
sectional
survey
(mailed)
Random sample of US
pharmacists*
270 pharmacists (34.8%)
Limiting non-prescription medicines sales to
pharmacy only was the most preferred for
non-prescription medicines sale. Least
preferred was general sale.
* of questionnaire where identified; †information presented where identified
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Study
Stated aims/objectives Study
design
(delivery)
Setting(s), number of
respondents (response
rate)
Key findings
Emmerton and
Benrimoj 1994
[269]
To identify and quantify influences
on pharmacists’ preferences for
non-prescription cough
suppressants.
Cross
sectional
survey
(mailed)
Random community
pharmacies from across
Australia
261 pharmacists (66.8%)
Financial (e.g. profits, deals), social (e.g.
influence by colleagues) and clinical (e.g. side
effects) appeared to have influences on
preference for one medicine over another.
Emmerton et al
1994 [270]
To identify the underlying factors
associated with choices around
cough and cold medicines supplies
by pharmacists.
Cross
sectional
survey
(mailed)
Random sample of
community pharmacies
from Australia
777 pharmacists (66.0%)
Seven factors were extracted such as non-
scientific influences (e.g. preference for newer
medicines), social influences (e.g. of
colleagues).
Roins et al 1994
[271]
To determine and analyse the
factors that influence community
pharmacists’ choices when
recommending non-prescription
analgesics for a simple headache.
Cross
sectional
survey
Random sample of
Australian community
pharmacies
80 pharmacists (100%)
Four factors were found to influence choices
such as advertising influences, medicine
characteristics and economic influences.
Erwin et al 1996
[272]
Examine the views of community
pharmacists in England towards the
non-prescription availability of
specific medicines.
Cross
sectional
survey
Random pharmacies from
eight Family Health
Services Authorities
(FHSAs) in England
272 pharmacists (54.4%)
Majority of the pharmacists agreed to 10 of
the 14 drugs listed such as anti-fungal vaginal
pessaries to be available without prescription.
McCafferty et al
1996 [273]
To investigate pharmacists’
attitudes on the non-prescription
supply of H2 receptor antagonists
and to examine factors affecting
supply (or non-supply) decisions of
non-prescription H2-antagnosists.
Cross
sectional
survey
(mailed)
Pharmacists in charge of
each of the 189
community pharmacies in
Avon, UK
140 pharmacists (74.1%)
Majority agreed with non-prescription
availability of H2 receptor antagonists.
Medicine efficacy and safety were the most
important criteria for decision making.
Chapter 4: Systematic review of literature 110
Study Stated aims/objectives Study
design
(delivery)
Setting(s), number of
respondents (response
rate)
Key findings
Powis et al 1996
[229]
Determine community pharmacists’
views on ongoing reclassification of
medicines and recently reclassified
medicines
Cross
sectional
survey
All registered pharmacies
of two English counties of
Cornwall and Somerset,
UK
68 pharmacists (84.0%).
Majority agreed that ongoing reclassification
had enabled them to adopt a more clinical role
and approved of reclassification of medicines
such as acyclovir cream.
Roins et al 1998
[274]
Determine the factors considered by
community pharmacists in
recommending non-prescription
analgesics for three headache
scenarios.
Cross
sectional
survey
(mailed)
Stratified (State based)
random sample from
across Australia.
1025 pharmacists (68.3%)
Clinical factors and financial influences were
key to pharmacists’ medicine choices.
Roins et al 1999a
[275]
Determine the influences on
pharmacists’ choice of non-
prescription analgesics for three
types of headache.
Cross
sectional
survey
(mailed)
Stratified (State based)
random sample from
across Australia.
1025 pharmacists (68.3%)
Pharmacists’ brand recommendations were
significantly influenced by external factors
such as patient choices and demographic
characteristics such as pharmacists’
qualification and experience
Roins et al
1999b [276]
Understanding pharmacists’
decision making processes when
recommending non-prescription
analgesics for three headache
scenarios.
Cross
sectional
survey
(mailed)
Stratified (State based)
random sample from
across Australia.
1025 pharmacists (68.3%)
Models which assume that- after evaluating a
patient, pharmacists choose the non-
prescription analgesic brand rather than the
active ingredients were more relevant to
pharmacists’ decision making.
Kennedy and
Moody (2000)
[277]
Identify influences on pharmacists’
choices of non-prescription
medicines for a variety of
conditions.
Cross
sectional
survey
(mailed)
Stratified random sample
of community
pharmacists from Great
Britain
635 pharmacists (56.7%)
Factors such as evidence base, safety,
formulation, price to patient were identified
by majority of participants as key influences
on recommendations.
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Study Stated aims/objectives Study
design
(delivery)
Setting(s), number of
respondents (response
rate)
Key findings
Hariprasad 2001
[278]
Assess the attitudes and practices of
community pharmacists towards
non-prescription availability of
EHCs.
Cross
sectional
survey
(hand
delivered)
All pharmacies from
North and Southern
Central Durban, South
Africa
112 pharmacists (68.0%)
Majority of respondents indicated that EHCs
should be available without a prescription.
Wearn et al 2001
[252]
To identify the attitudes, hopes and
concerns of community pharmacists
in Great Britain about the proposed
deregulation of EHC.
Cross
sectional
survey
(mailed)
Great Britain community
pharmacists sampling
1,205 pharamcists (66.0%)
Majority were in favour of supply of EHC on
a non-prescription basis
Kotecki 2002
[279]
Analysis of influences on
pharmacists’ non-prescription
medicine recommendations.
Cross
sectional
survey
(mailed)
Random Indiana
pharmacies from US
430 pharmacists (73.1%)
Factors such as ease of self use of medicines
by patients and medicine efficacy were key
influences on recommendation.
Blenkinsopp et
al 2004 [280]
To investigate and appraise the
changes required in practice of
community pharmacists to enable
them to supply simvastatin 10mg
over the counter appropriately.
Cross
sectional
survey
200 randomly selected
pharmacists in the Leeds/
Bradford area, UK
100 pharmacists (50.0%)
Majority agreement could not be reached
around proposed reclassification of
simvastatin. Facilitators such as training,
supply protocol, and patient medical records
were deemed prerequisite for supply.
McKenney et al
2004 [253]
To determine attitudes and
perceptions of pharmacists
regarding the impact of non-
prescription statins.
Cross
sectional
survey
(online)
Drawn from a database of
2,552 licensed pharmacists
273 pharmacists in the US.
Majority agreed to reclassification of statins to
be available over the counter
Inch et al 2005
[281]
To identify Scottish community
pharmacists’ involvement with, and
attitudes to EHC provision.
Cross
sectional
survey
(mailed)
All pharmacists working
in community pharmacy
in Scotland
914 pharmacists (56.4%)
High adoption of EHCs reported by
pharmacists with an average of 132 patients
per pharmacy per year.
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Study Stated aims/objectives Study
design
(delivery)
Setting(s), number of
respondents (response
rate)
Key findings
Van Riper and
Hellerstedt 2005
[255]
Identify dispensing practices,
knowledge and attitudes of South
Dakota Pharmacists regarding
EHC.
Cross
sectional
survey
(mailed)
All pharmacists from
South Dakota, US
293 pharmacists
Majority of respondents opposed to non-
prescription status of EHCs.
Howell and
Brown 2006*
[254]
Report attitudes and experiences of
practising community pharmacists
about non-prescription simvastatin
10 mg.
Cross
sectional
survey
(mailed)
Portsmouth and Southeast
Hampshire, UK
64 pharmacists (20.3%)
Majority did not support the non-prescription
availability of simvastatin.
Fuentes and
Azize-Vargas
2007 [250]
Identify knowledge, attitudes and
practices of a group of pharmacists
regarding EHC (after its approval
by FDA)
Cross
sectional
survey
(hand
delivered)
Pharmacists attending a
national convention,
Puerto Rico
158 pharmacists
Majority agreed to non-prescription
availability of EHCs.
Hansford et al
2007 [282]
Describe community pharmacists’
views, attitudes and early
experiences of non-prescription
simvastatin.
Cross
sectional
survey
(mailed)
Random sample of
community pharmacists
from Great Britain
1156 pharmacists (57.8%)
Majority respondents agreed that they were
entirely confident about selling simvastatin,
however low reported supplies by
respondents.
Stewart et al
2007 [283]
Describe and compare the personal
views of community pharmacists
on non-prescription omeprazole
and simvastatin.
Cross
sectional
survey
(mailed)
Random sample of
community pharmacists
from Great Britain
1156 pharmacists (57.8%)
Support for non-prescription availability of
simvastatin by respondents lower as
compared to omeprazole owing to reasons
such as evidence base.
McCaig et al
2008 [122]
Examine early experiences of
community pharmacists in relation
to sales of omeprazole without
prescription.
Cross
sectional
survey
(mailed)
Random sample of
community pharmacists
from Great Britain
1156 pharmacists (57.8%)
Majority agreed that omeprazole was a
welcome addition to the range of pharmacy
medicines but had not sold any non-
prescription omeprazole in the last 14 days.
*Conference abstract/proceeding
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Study Stated aims/objectives Study
design
(delivery)
Setting(s), number of
respondents (response
rate)
Key findings
Prince and
Pharoo 2008
[251]
Assess the attitudes of Alabama
pharmacists regarding the creation
of a third class of drugs described
as “pharmacist- prescribed”.
Cross
sectional
survey
(mailed)
Alabama pharmacists
attending a continuing
education (CE)
programmes, US
157 pharmacists
Majority respondents agreed to a need of
medicine class equivalent to P class in the UK.
Whitley and
Moorman 2008
[284]
Determine pharmacists’ opinions
about the labelling change of EHC.
Cross
sectional
survey
(online)
Community pharmacists
in Alabama, US
47 pharmacists (15.3%)
Majority disagreed with the reclassification of
EHC to non-prescription status.
B. Qualitative studies
Study Stated aims/objectives Study
design
Setting(s), number of
participants
Key findings
Harper and
Barrett 1998
[260]
Examine attitudes of community
pharmacists towards the possible
deregulation of EHCs from
pharmacies.
In depth
interviews
Pharmacists from three
health authorities of South
Thames Region
18 pharmacists, UK
Pharmacist views were ‘overwhelmingly
negative’, largely attributed to moral and
religious grounds.
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Study Stated aims/objectives Study
design
Setting(s), number of
participants
Key findings
Barrett and
Harper 2000
[261]
Examine the views of community
pharmacists towards possible
deregulation of EHC.
In-depth
interviews
Pharmacists working in
three health authorities in
the South Thames Region,
UK
18 pharmacists
Pharmacists had overwhelmingly negative
attitudes to non-prescription availability
mainly owing to safety and misuse aspects.
Seston et al 2001
[259]
Explore the views of community
towards the reclassification of
EHCs from POM to P medicine.
Focus
groups
Pharmacists from Health
Action Zones in North
West of England, UK
14 pharmacists
Concerns owing to patient misuse and
litigation issues were expressed by
pharmacists around non-prescription supplies
of EHCs
Bacon et al 2003
[262]
Evaluate the role of facilitators and
barriers to non-prescription supply
of EHC from community
pharmacists’ perspectives.
Case
studies
Pharmacies from
Lambeth, Southwark and
Lewisham Health Action
Zone ,UK
22 pharmacists
Pharmacists were worried about potential
misuse of non-prescription EHCs. Training
around supply was identified as a key
facilitator to service provision.
Bissell and
Anderson 2003
[257]
Evaluate a scheme to provide free
EHC under non-prescription basis
via community pharmacies in the
North-West of England.
In-depth
interviews
Pharmacists participating
in the scheme at three
Health Action Zone, UK.
24 pharmacists
Almost all of the pharmacists that participated
in the interviews expressed positive views
about the scheme.
Bissell et al 2006
[258]
Describe pharmacists’ views and
experiences of supplying EHC via
PGDs.
In depth
interviews
Those pharmacists that
participated in the EHC
scheme from Manchester
and London UK
46 pharmacists
All but one pharmacist had positive views
about non-prescription EHC supply.
Gauld et al
2008* [256]
Investigate pharmacists’
experiences of the non-prescription
availability of oseltamivir
Semi-
structured
interviews
Purposive sample (based
on demographics) of
community pharmacists
from New Zealand.
27 pharmacists
Pharmacists expressed positive views towards
non-prescription availability of oseltamivir. 14
pharmacists had made the supplies in 2007.
*Conference abstract/proceeding
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Study Stated aims/objectives Study
design
Setting(s), number of
participants
Key findings
Hannah and
Hughes 2008*
[228]
Explore factors influencing
pharmacists’ decision making in
relation to non-prescription
medicines, and whether an
evidence base approach are used in
such decisions.
Semi-
structured
interviews
26 pharmacists
Northern Ireland, UK
Safety described as the ‘over-riding’ factor
influencing all decisions. Supplies were
mostly based on patient request and on a ‘do
no harm’ basis.
*Conference abstract/proceeding
C. Reviews of literature
Study Stated aims/objectives Study
design
Inclusion/exclusion
criteria
Key findings
Emmerton and
Benrimoj 1994
[265]
Review the methods used in the
investigation of medicine choice
behaviour by community
pharmacists.
Review of
peer and
non-peer
reviewed
literature
Studies explaining
measured behaviours and
attitudes. Literature based
on predictive models
excluded.
Methods such as case studies, observational
studies and surveys were identified to have
been used by identified literature. Authors
proposed application of the Fishbein
behavioural intention model to assess
underlying influences on preference for future
studies.
Anderson and
Blenkinshopp
2005 [285]
To review international peer-
reviewed evidence relating to
community pharmacy supply of
EHC
Systematic
review
Peer-reviewed
international research
from Jan 1990 to Jan 2005
24 studies included
Patient misuse and safety concerns key
perceived barriers for pharmacists to supply
non-prescription EHCs.
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4.4.1 Quality of included studies
4.4.1.1 Quantitative
Of the 28 quantitative studies (excluding one conference proceeding/abstracts), all but one
presented clear aims or objectives (table 4.2, figure 4.2). Only seven, however, explained the
rationale for selecting cross sectional survey approaches (table 4.2). Information about
ethical advice was missing from all but three studies which explained that ethical advices
were sought from relevant authorities (table 4.2). Three other studies made ambiguous
statements about ethical advice, for example, by stating ‘the institutional review board at
the University approved the study protocol’ [255]. Rationale for the inclusion criteria of the
study population could be identified from all but one study, however; only around 35% of
the quantitative studies provided any sort of justification for the sample size (figure 4.2).
Over 60% of the studies failed to provide details of recruitment strategies, for example how
potential participants from within a pharmacy were identified or invited to participate
[229]. No elements of study validity or the development of the data collection tool such as
piloting were presented in one in three studies. Only approximately one in five of the
studies justified the use of a particular analytical method. Missing values were often found
to be replaced with sample means without justifying the merit of such a technique in terms
of likely bias [265,270]. Over 28% of the quantitative studies reported conclusions that were
not supported by the reported findings (table 4.2).
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Table 4.2: Quality assessment of quantitative studies
Y:Yes; N: No; U:Unclear; NA: Not Applicable
Quality assessment criteria
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Were aims/objectives clear? Y Y Y U Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Were rationale for study design/method explained? N N Y N N N Y N N N N N Y Y Y N N N N N Y Y N N N N N N
Were limitations of study designs explained? N N Y N N Y Y N N N N N N Y Y N N Y N N Y N Y N N N Y N
Were information around ethical approval provided? N N N N N N N N N N N N N N N N N N N N N U U Y Y Y N U
Were rationale of study population explained? U Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Were justification around appropriateness of sample size provided? N Y N N Y U Y Y U N N N N Y Y Y N N N N Y Y N N N N Y N
Were participant recruitment strategies stated? N N N N N Y U N Y Y Y N N N N N N N N N Y Y N Y Y Y N Y
Were measures to enhance validity of data collection tool explained? Y Y Y N N Y Y N Y N Y Y Y Y Y N U Y Y N Y Y N Y Y Y N N
Could study settings might have biased the data? N Y N N N U U N N U Y U U N N Y U Y Y Y N Y Y N N N Y Y
Were quantitative data analyses method justified? N Y U N Y N Y N N N N N Y Y N N N N N N Y N N U N N N N
Were strategy to analyse open ended questions made explicit? NA NA NA NA NA NA NA NA N NA NA NA NA NA NA NA Y NA N NA NA NA NA Y Y Y NA NA
Were limitations of the findings discussed? N N Y N N Y Y Y Y Y N N Y Y Y Y Y Y N N Y Y Y Y Y Y Y Y
Were the conclusions made supported by findings Y Y U N Y Y Y N Y U Y U N N Y U Y N Y Y Y Y Y Y Y Y Y Y
Were generalisability of the findings discussed? Y N Y Y N Y Y Y Y Y N N Y N Y Y N Y N N Y Y Y Y Y Y Y Y
Were any bias/conflict of interest from researchers' position likely? N N N N N N N N N N N N N N N N N N Y N N N N N N N N N
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Figure 4.2: Stacked bar chart representing quality of quantitative studies
% of studies
4.4.1.2 Quality of qualitative studies
Of the six qualitative studies (excluding two abstracts/conference proceedings), all but one
were explicit in their aims or objectives. Five of the six did not explain whether ethical
approval was sought whereas one made an ambiguous statement (table 4.3, figure 4.3). All
studies provided the rationale of the study population but only two provided justification
around the number of study participants [258,262]. Only one study was explicit in
commenting on the aspects of validity of the data collection tool, such as the use of
literature to develop the content [258]. Due to the selection of only those pharmacists that
were already involved in the supply of medicine under evaluation, study settings were
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Were information around ethical
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Measures to enhance validity of data
collection tool explained?
Could study settings might have biased
the data?
Were quantitative data analyses methods
justified?
Were strategy to analyse open ended
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Were limitation of the findings discussed?
Were the conclusions made supported by
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Were generalisability of the findings
discussed?
Were any bias/conflict of interest from
researchers' position likely?
Yes
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Unclear
NA
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expected to have potentially biased respondents and corresponding data in four of the six
studies. A majority of the qualitative studies utilised more than one independent coder
during data analysis (table 4.3, figure 4.3).
4.4.1.3 Quality of reviews of literature
The quality of one of the reviews was disappointingly poor, achieving the standard for only
two of the sixteen quality criteria that were assessed [265]. Despite achieving the majority of
quality criteria, the other review lacked information about literature search strategy and
data synthesis methods [285] (table 4.4).
4.4.1.4 Quality of abstracts/ conference proceedings
Two of the three abstracts of conference proceedings failed to describe the study population
and none tackled issues of sample size and data saturation (table 4.5). Only one detailed
study piloting [254].
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Table 4.3: Quality assessment of qualitative studies
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Were aims/objectives clear? Y Y Y Y N Y
Were rationale for study design/method explained? N N N N Y Y
Were limitation of design explained? N N N N Y N
Were information around ethical approval provided? N N N N U N
Were rationale of study population justified? Y Y Y Y Y Y
Were justification around appropriateness of sample size/data saturation provided? N N N Y N Y
Were recruitment strategy stated? N N N Y N Y
Were measures to enhance validity of data collection tool explained? N N N N N Y
Could study settings might have biased the data? U U Y Y Y Y
Were independent coder of the data used? Y Y U Y Y Y
Were data analyses methods justified? Y N N Y N N
Were bias arising from analyst position explained? N N N N Y N
Were limitation of findings discussed? Y Y Y N Y Y
Were conclusion/s made relevant to findings? Y N Y Y Y Y
Were theoretical generalisability of the findings discussed? Y Y Y Y Y Y
Were any bias/conflict of interest from researchers' position likely? N N N N N N
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Figure 4.3: Stacked bar chart representing quality of qualitative studies
% of studies
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Table 4.4: Quality assessment of reviews of literature
Y:Yes; N: No; U:Unclear
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Were aims/objectives clear? Y Y
Were inclusion/exclusion of literature mentioned? U Y
Were literature search databases explained? N Y
Were literature search strategy detailed? N N
Were hand searching of core journals used? N Y
Were personal contacts with experts made? N N
Were unpublished literature searched? U N
Were non-English literature searched? U Y
Were quality assesment criteria detailed? N Y
Were more than one assesor of the quality of study? U Y
Were data synthesis/management method justified? N N
Were strenth of the review explained? N N
Were limitation of the review explained? N N
Were the conclusions made supported by findings N Y
Were generalisability of the findings discussed? N N
Were any bias/conflict of interest from researchers' position likely? N N
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Table 4.5: Quality assessment of abstracts/proceedings of conferences
Y:Yes; N: No; U:Unclear
4.4.2 Review of study framework and models used to investigate
pharmacists’ decision making around reclassified medicines
This section will review and critique the models and framework used by empirical studies.
Greater emphasis will be placed on the review of quantitative models as these are supposed
to inform the development of the quantitative research instrument.
4.4.2.1 Descriptive and univariate quantitative models
Five cross sectional surveys investigated pharmacists’ support for the non-prescription
status of newly reclassified medicines using descriptive and univariate statistics
[122,252,273,282,283]. Pharmacists’ agreement to reclassification of potential candidate
medicines were assessed by two studies in the UK [268,272] and two studies in the US
[253,279] also using descriptive statistics based on attitudinal scales. However these four
studies did not further explore reasons why certain medicines were more likely to be
accepted as reclassified medicines by pharmacists than others. One study in South Africa
[278] and three studies in the US [250,255,284] evaluated pharmacists’ support for the non-
prescription availability of EHC, using similar analytical models.
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Two studies in the US investigated pharmacists’ attitudes to creating a regulatory class
equivalent ‘P’ medicines in the UK [251,263]. Only one of these studies performed
univariate analysis to investigate how demographic variables were associated with support
or refutation of such regulatory changes relating to reclassified medicines [263].
Factors associated with recommendations of reclassified medicines were investigated by
requesting pharmacists to rate the importance of the listed items and analysed descriptively
by four studies [229,273,277,279]. Two used parametric analysis where a non-parametric
analytical method could be debated to have been more appropriate in analysing the Likert
type scales measuring the importance of the listed items in decision making [277,279].
4.4.2.2 Multivariate quantitative models
Pharmacists’ support for the reclassification of medicines to non-prescription status was
investigated by using three medicines namely: promethazine, terfenadine and naproxen,
which were evaluated using a multivariate design in one study [267]. Items on a scale
representing the likely factors associated with support for the proposed reclassification
were subjected to principal component analysis. Factor scores indicating acceptable
reliability were then subjected to a step-wise discriminant analysis in order to distinguish
between respondents with higher approval scores. Interpretation and labelling of the
factors retained from the principal component analysis were least convincing as items
measuring diverse areas of practice were labelled together as a single factor.
In investigating factors associated with pharmacists’ choices of non-prescription analgesics
for simple headache in a survey of Australian community pharmacists [271], pharmacists’
agreement to the listed items scale statements were measured and the results subjected to
principal component analysis. Pharmacists’ mean agreement scores of the items, rather than
median scores, constituted within each factors were reviewed for association with
demographic characteristics, using univariate techniques. Similar analytical limitations
were also identified in three other studies using similar multivariate approaches
[264,269,274].
The Myert and Alpert determinance model was used to evaluate pharmacists’ adoption of
particular medicines within a given therapeutic area [266]. ‘Determinance scores’ were
calculated by multiplying respondent score around the agreement on the importance of
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each of the listed items for medicine adoption decisions, to how far pharmacists perceived
those features to be different across the listed medicines [266]. Again limitations around
parametric- non parametric analyses were observed.
The technique of discrete choice modelling was used in one study [275]. Likert type scale
items were presented to pharmacists to measure the importance of each in medicines choice
decisions and subjected to principal component analysis. Factor scores along with
demographic variables were used as explanatory variables in the Logit model where choice
was used as the outcome. Similar regression models were also adopted by two other studies
around pharmacists’ adoption of reclassified EHC [255,281].
In investigating adoption of reclassified medicines into practice, only three studies required
pharmacists to rate the number of packs of medicines supplied in a retrospective time frame
and hence subject to recall bias [122,254,282]. However, key differences between high and
low adopters were not further explored in these studies.
4.4.2.3 Qualitative models
Six studies reported qualitative investigation around pharmacists’ agreement to non-
prescription provision of EHC [257-262]. Qualitative data obtained from open questions
from a quantitative survey in one study were used to compare pharmacists’ support for two
reclassified medicines [283].
One qualitative study by Hannah and Hughes also investigated via in depth interviews
community pharmacists’ key influences when making decisions about supplying
reclassified cough and cold medicines [228]. Another qualitative study reported issues
around supply of reclassified oseltamivir [256]. These papers lacked details around data
analytical approaches.
4.4.3 Review and critique of facilitators/barriers to pharmacists’
decision making around reclassified medicines
This section of the systematic review will list the facilitators/barriers to pharmacists’
decision making around reclassified medicines. These facilitators and barriers will be
described individually so that original, additional perspectives could be added to those
identified from the qualitative interviews and focus groups (Chapter 3). Shortcomings
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around quality issues within the included studies means that the results presented here
need to be interpreted with caution.
A total of 28 facilitators/barriers to pharmacists’ decision making were identified from the
included studies. From all studies, details around each of these facilitators/barriers were
brought together to draw narratives. These are listed in table 4.6 and further described in
the sections that follow.
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Table 4.6: Barriers and facilitators to pharmacists’ decision making around reclassified
medicines
4.4.3.1 Evidence of medicine efficacy
Pharmacists’ perceived strength of medicine efficacy was reported to be the ‘most
important’ influence on their recommendations of POM to P switched medicines in nine
studies. Results were presented using descriptive statistics [229,273,277,279], multivariate
analysis [269-271,274], or through ‘determinant’ attributes analysis [266]. Concerns were
expressed in two studies around the evidence of reclassified simvastatin hence making this
a barrier to supply [282,283].
Three studies reported pharmacists regarding there was no place for consideration of
evidence base in decision making in two quantitative [253,264] and one qualitative [228]
study. One showed that lack of knowledge about evidence base did not deter pharmacists
from supply decisions [254]. A substantial number of studies measuring pharmacists’ views
 Evidence of medicine efficacy [229,266,269-
271,273,274,277,279,282,283]
 Medicine safety [122,228,229,252-255,257,259-
261,263,266,267,269-274,277,278,283-285]
 Opportunity for pharmacists’ role
development
[229,252,254,257,258,268,280,282]
 Pharmacists’ confidence/ competence in
supply process [122,254-256,259,282]
 Pharmacists’ perceived risk assessment need
[252-254,260,262,267,273,277,282,283]
 Pharmacists’ information sources and training
[122,229,250,252,255-257,259,260,262,264,266,
269, 270,272,273,277,279,280,282,285]
 Need for access to patient medical records
[122,252,253,260,261,280,282-284]
 Support/ communication with medical
practitioners [258,260,280]
 Adoption by medical practitioners [266,269-
271,274,277,279]
 Financial benefits [266,269-271,274,275,277]
 Retail prices [122,229,252,254,256,257,264,266,
273,279,283]
 Colleagues’ opinions [264,269-271,273,274]
 Consumer advertisement [274,275]
 Employer policies/organisational
implementation decisions [270]
 Pharmacy resources e.g. space staff
[251,252,260,280]
 Patient acceptance/feedback to
pharmacists about the medicine [228,
256,260,264,266,271,274,275,277,279,2
83]
 Confidence in off-licence medicine
supply [273,283]
 Delegation of task to support staff
[122,282,283]
 Medicine novelty [122,270,274,279]
 Status as ‘pharmacy
only’[269,270,274,277]
 Manufacturers’ reputation
[264,266,270,271,274]
 Pharmacists’ experiences with the
medicines [256,270,271,273,277,279]
 Endorsement by professional/
practice body [266,269,270]
 Medicines for acute indications
[268,273,283]
 Guidelines/Protocols [122,
260,261,280]
 Moral/ethical issues
[252,257,258,260,261]
 Pharmacists’ beliefs in successful self
use of medicine by patients
[269,270,272,274,277,279]
 Medicine potential for misuse
[252,255,257-262,277,278]
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on recent or proposed reclassification did not assess the strength of evidence base relating
to medicine efficacy. Many studies realized the issues through the analysis of responses to
open-ended questions [122,282,283] or were never realised
[251,252,256,257,259,260,263,267,272].
Two studies asked for explanations on what community pharmacists considered as
evidence base. Pharmacists in one reflected that feedback from patients was an indicator of
evidence of efficacy [228]. Reference to ‘clinical trials’ were made in study by Stewart et al
[283].
4.4.3.2 Medicine safety
Concerns around aspects of safety such as the potential for drug interactions and adverse
events were also raised around supply of a number of reclassified medicines. This was the
case with reclassified H2 antagonists [122,272,273], statins [253,283], EHC
[252,255,257,259,261,278,284,285] and generally to be the case against the reclassification of
more medicines to non-prescription status [263,267].
Pharmacists’ low support for the reclassified status of statins was related to safety concerns
in one study [254]. Hannah and Hughes reported safety as the ‘over-riding’ factor in
pharmacists’ recommendations of non-prescription cough medicines and this was the only
reasons why a sale was as cited as ever being refused [228]. The key importance of safety as
an over arching factor was also supported by seven other studies [229,266,269-271,274,277].
Contrary to the above, one study found that the issue of medicine safety had no influence
on supply decisions [264]. Six studies identified that safety concerns pharmacists were
raising around particular reclassified medicines’ supply decisions could not be
substantiated through scientific evidence [255,257,259,260,278,285]. Safety concerns were
deemed by pharmacists to be minimised through limiting patient choice around service
usage to one pharmacy in one quantitative [280] and two qualitative studies [260,261].
4.4.3.3 Opportunity for role development
Reclassification was associated in four studies with pharmacists’ perceived opportunities
for role development [229,254,268,280]. One study showed that although a few pharmacists
disagreed with the non-prescription status of simvastatin, the reclassification was still
deemed an opportunity to increase their role through advice giving related to patient life
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style matters for cholesterol lowering [282]. Greater clinical responsibility was shown to be
reflective of the extension of pharmacists’ role in three studies [252,257,258] with specific
reference made to risk assessment prior to supply in one study [257].
4.4.3.4 Pharmacists’ confidence/ competence in supply matters
Higher confidence of pharmacists was reported to be associated with the sale of reclassified
oseltamivir in one study [256]. Higher confidence was further linked to pharmacists’
experiences of supply, despite the study being conducted immediately post reclassification
[256]. A few studies assessed pharmacists’ perceived confidence [122,282] and competence
around medicine supply decisions [254,255,259] but did not report whether higher
confidence and competence were associated with supply decisions.
4.4.3.5 Risk assessment and counselling need
Patient risk assessment and counselling need prior to supply were often regarded as
barriers to reclassified medicines supply, mainly associated with time and resource
implications [253,262,277] or to lack of patient willingness to undergo the process
[252,260,273]. Higher counselling needs related to less support for reclassification in one
study [267]. Pharmacists were found to perceive the need for risk assessment prior to the
supply even though such requirements were not stated in the regulatory guidelines
[254,283]. Pharmacists in a further two studies expressed confidence in undertaking risk
assessments [253,282].
4.4.3.6 Pharmacists’ sources of information and training
Key information sources used by pharmacists in informing the supply of reclassified
medicines were pharmaceutical industry [122,229,282], journal articles [122,250,255,277,282],
pharmaceutical publications [229], pharmacists’ professional society guidelines [122,282],
CPD meetings [122,282], internet [122,255,282], employer sources [229,282] and
pharmaceutical conferences [250]. One study reported demographic variation in the way
pharmacists rated the adequacy of sources of information around reclassified medicines
[229].
Five studies reported that adequacy of information sources was related to which medicine
pharmacists would recommend first line for a given therapeutic condition
[264,266,269,270,279].
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Training
Training programmes boosting pharmacists’ confidence in non-prescription medicines
supplywere reported by three studies [256,257,285]. Pharmacists in one UK study
identified the Centre for Pharmacy Postgraduate Education, RPSGB and the National
Pharmaceutical Association (NPA) as the most preferred training sources [280].
Pharmacists’ satisfaction with training around adoption of newly reclassified medicines
was reported to be high in three UK studies [122,272,282] and one NZ study [256]; whereas
additional training needs were identified in five UK studies [252,259,260,262,280]. Two
studies reported that pharmacists within a large multiple chain pharmacy were more likely
to have diverse training opportunities than those working under other pharmacy
proprietary setting [229,273].
4.4.3.7 Need for access to patient medical records
Lack of access to patient medical records was cited as a barrier to supply of reclassified
statins by pharmacists [253,280]. Pharmacists in three studies reflected difficulties arising
with verbal recall from patients about their medical history [260,261,283]. Lack of access to
patient medical records was also reasoned by some pharmacists to not eagerly anticipating
the reclassification of EHC in one study [261].
Access to patient medical records was described by pharmacists as one approach to
overcoming the potential misuse of non-prescription medicines [252,260] and to increase
the efficiency of repeat supplies [260]. From pharmacists’ perspectives patient medical
records could both be patient held [280] and pharmacist held [122,280,282,284].
4.4.3.8 Need for communication with medical practitioners
Three studies identified that greater support from medical practitioners was important to
ensure appropriateness of supply [258,260,280]. Pharmacists in two UK studies related
difficulties of contacting medical practitioners [262,272]
4.4.3.9 Adoption by medical practitioners
Seven studies reported doctors’ recommendations of medicines being associated with
pharmacists’ medicine choice decision for a given indication [266,269-271,274,277,279]. One
study identified that doctors’ recommendations were associated with decisions to stock
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medicines within the pharmacy but that this did not necessarily relate to pharmacist
recommendations to patients [264]. No qualitative perspectives could be identified.
4.4.3.10 Financial aspects
Levels of profit from sales were shown in seven studies to be associated with pharmacists’
tendencies to supply certain medicines [266,269-271,274,275,277]. Being a proprietor was
associated with a higher regard for financial implications in one study [277] but not in
another [271]. Desire to have more medicines within the ‘P’ or equivalent legal classification
were related to financial benefits, owing to the exclusive rights for pharmacy sales in two
studies [254,263]. Contrary to these findings, pharmacists did not identify the importance of
financial advantages in reclassified medicine supply decisions in two studies [264,279].
4.4.3.11 Medicine retail prices
Higher medicine retail price were related by pharmacists in eight studies to potentially
deter patients from buying non-prescription medicines [122,229,256,264,266,273,279,283].
Free patient access to non-prescription medicines related to pharmacists noting high
acceptance by patients in two studies [257]. On the contrary, pharmacists in another two
studies reflected that patients bearing the cost of the medicines could help increase patient
adherence and avoid misuse and overuse [252,254]. These studies did not explore what cost
pharmacists regarded as ‘appropriate’.
4.4.3.12 Colleagues’ opinions
Six of the studies which assessed the importance of colleagues’ opinions in pharmacists’
decision making reported pharmacists highly rating the importance of such opinions
[264,269-271,273,274]. Three studies reported little or no influence [266,277,279]. Again, no
qualitative perspectives could be identified.
4.4.3.13 Consumer advertisement
A majority of pharmacists reported that decision making was influenced by direct to
consumer advertisement in two studies [274,275]; with three other studies reported only a
minority of pharmacists considering such advertisements as influential [229,269,273].
4.4.3.14 Employer policy, directions
Pharmacists, through majority agreement in four studies, rated that they had full personal
control over medicine supply decisions, with a minority deeming employer directions were
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vital to decision making [229,266,273,277]. Only one study found that pharmacist
employers’ instructions were key to informing adoption decisions [270].
4.4.3.15 Adequacy of pharmacy resources
Pharmacy resources such as availability of consultation areas were related to pharmacists’
support for the reclassified status of statins [280] and EHCs [251,252,260].
4.4.3.16 Patient acceptance/feedback
Patient feedback and demand was positively associated in eight studies with pharmacists’
desire to supply reclassified medicines [256,264,266,271,274,275,277,279]. Low patient
requests were attributed by pharmacists in one study to low supply of reclassified medicine
[283]. One study demonstrated that pharmacists placed no importance on the role of patient
acceptance/feedback in informing decision making [269].
Pharmacists in four studies related patient requests to be more driven by consumer
advertisements [122,272,282,283]. Interestingly, one study reported pharmacists’ desires for
further advertisement to encourage patient requests [256].
Most of the quantitative studies evaluating the importance of direct patient medicine
requests around supply decisions reported that pharmacists were comfortable in declining
sales when they considered the requests inappropriate [256-258,261,272,273,282].
Qualitative studies however reflected that such patients requests were ‘usually’ difficult for
the pharmacists to decline [260] or that the supply/non-supply ultimately depended on the
patient [228].
4.4.3.17 Off-licence supply
Two studies which covered this aspect of supply reported that, when deemed appropriate,
pharmacists were prepared to supply the studied medicines ‘off-licence’ [273,283].
4.4.3.18 Task delegation to support staff
Pharmacists’ perceived need for personal involvement around the supply of reclassified
medicines was substantial in all three studies which assessed this aspect of practice
[122,282,283]. One study demonstrated that such reservations around task delegation were
medicine specific [283].
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4.4.3.19 Novelty
’Novel’ reclassified medicines were more likely to be recommended than those which
pharmacists perceived as providing little therapeutic advantages over the exiting ranges of
non-prescription medicines [270,274,279]. One study highlighted concerns about the lack of
novelty which were associated with reluctance to supply newly reclassified omeprazole
[122].
4.4.3.20 Status as ‘pharmacy only’
Three Australian studies [269,270,274] and one UK study [277] reported that medicines
available only through pharmacy were likely to be preferred by pharmacists over others
more widely available. However, these conclusions were not supported by two other
studies, each from Australia [264] and the US [279]. A further two US studies, however,
demonstrated that pharmacists were supportive of creating a regulatory class of medicines
which is the equivalent of the UK ‘P’ class [251,263].
4.4.3.21 Manufacturers’ reputations
Manufacturers’ reputations such as recent history of medicines recalls were shown to be
important in five studies in informing pharmacists’ medicine supply decisions
[264,266,270,271,274]. No qualitative details around the perceived importance could be
identified.
4.4.3.22 Pharmacists’ experiences
Pharmacists in five studies rated their own experience gained through self use of the
medicines to be important in informing supply decisions [270,271,273,277,279]. One study
related patient feedback key to experiences [269]. Pharmacists’ limited experiences with
supply were cited as key reasons for low reported sales of newly reclassified oseltamivir
[256].
4.4.3.23 Endorsement by professional/practice body
Two studies by Emmerton et al reflected that endorsement by the Pharmacy Guild of
Australia had positive influences on pharmacists’ adoption of reclassified medicines
[269,270]. A US study also reported that medicines endorsed by State formularies were
more likely to be supplied by pharmacists than those not listed in the formulary [266].
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4.4.3.24 Medicines for acute conditions
Two UK studies noted that pharmacists mostly cited medicines for acute conditions as
appropriate candidates for future reclassification [268,273]. No further details about the
reasons(s) for such preference could be identified from these studies. Pharmacists’ concerns
around reclassified simvastatin were shown to be partially related to the long term
indication and need for the medicine [283].
4.4.3.25 Guidelines/ Protocols
Two studies highlighted the need for protocols to be in place to facilitate the supply of
reclassified medicines [122,280]. Two qualitative studies around non-prescription supply of
EHC also highlighted the advantages of protocols in terms of protecting pharmacists
against litigation issues and promoting consistent decision making across pharmacies
[260,261].
4.4.3.26 Moral/ethical
Five studies identified that issues associated with pharmacists’ moral/ethical standings
deterred pharmacists from the supply of EHC [252,257,258,260,261]. Pharmacists’ moral
issues were mostly related to its perceived abortifacient action.
4.4.3.27 Successful patient self use of medicine
Five studies concluded that those reclassified medicines perceived by pharmacists to be
relatively easy for patient use were shown to be associated with their desire to recommend
[269,270,274,277,279]. Patient reluctance to accept pharmacists’ advice was reported as a
barrier to reclassified H2 antagonists supply [272].
4.4.3.28 Medicine potential for misuse
Pharmacists’ concerns around misuse were mainly identified in studies evaluating non-
prescription availability of EHC [252,255,257-262,278]. However, one study discussed the
importance of this issue generically for all therapeutic classes [277].
4.5 DISCUSSION
4.5.1 Discussion of findings
The objectives of this systematic review was to review and critique the methodologies,
methods and models to investigate factors associated with community pharmacists’
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decision making around reclassified medicines described in peer reviewed published
literature; and to list and describe the importance of facilitators/barriers identified from the
peer reviewed published literature to community pharmacists’ decision making around
reclassified medicines. A limited number of studies covering only a narrow range of
therapeutic areas were included despite over 80 medicines reclassified from POM to P
status in the UK. Studies included in the systematic review reflected that in those countries
where the ‘P’ or equivalent category of non-prescription medicines exists, pharmacists
expressed much support, in general, for ongoing reclassification of medicines. Studies from
the US also reflected that the majority of pharmacists studied were in favour of creating an
equivalent regulatory class of medicines.
A narrow range of methodologies and methods were adopted by the identified literature.
Use of descriptive and univariate models dominated the designs of quantitative studies.
Much of the literature evaluated the importance of facilitators and barriers individually.
Although perspectives around these individual facilitators/barriers are important, basing
pharmacy practice change models which focus on individual facilitators/barriers singly has
been cautioned as ‘will not to be successful’ [241]. This is basically due to practice change
being a complex phenomenon, involving interplay of multi dimensional factors, as has been
realised in the qualitative study in Chapter 3. This leads to the notion that multivariate
models are more appropriate to undertake such research.
The quality limitations of the studies utilising multivariate models, however, need to be
carefully considered before these models could be applied or adapted to future evaluation
within this doctoral research and beyond. For example, those studies utilizing a factor
analytical method did not employ cross researcher reliability in labelling of the factors.
Hence the factor labelling was arguable in many studies. The use of parametric statistics to
analyse ordinal variables also raises questions over the validity of the results that were
presented. Though parametric approaches to analyse such ordinal data are frequently
utilized for larger sample sizes, there is no accurate definition of what minimum size is
appropriate for such analysis [286].
Content wise, much of the focus of the descriptive, univariate and multivariate quantitative
models was on pharmacists’ perceptions of the ‘content’ or ‘attributes’ of reclassified
medicines. However, the lack of focus on wider social and organisational factors, such as
pharmacy resources, in decision making process was notable. Consideration of these wider
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factors should be included within future evaluations. The lack of a rigorous approach to
development of research instrument content could be attributed to a lack of use of
theoretical models in the identified studies. The use of theoretical models, as described
earlier, has been suggested to benefit gathering and interpretation of data [139]. One
literature review included in the study suggested that application of the Fishbein
behavioural model was relevant to future research in the area of pharmacists’ decision
making [265]. However the authors of the review cautioned the need for further empirical
testing before application of such a theoretical model could be ‘recommended’ for
pharmacy practice research.
No studies adopted a pragmatic research approach such as measuring actual adoption into
practice and relating supplies to the facilitators/barriers associated with decision making.
This highlights limitations in study design while at the same time reflects the difficulty of
conducting pragmatic studies in this research area. A few studies used a recall approach to
rate the frequency of supply to measure adoption into practice. However, the analytical
models did not compare participants’ ratings themselves across different levels of adoption
of the reclassified medicines so as to identify factors associated with decision making.
This is the first systematic review to list and review the importance of facilitators/ barriers
to adoption into practice of reclassified medicines which can be used in future evaluations
of the pharmacist perspective of medicines reclassification. It is interesting to note how the
studies differed in their conclusions around the importance of individual
facilitators/barriers in decision making. For example the issue of evidence base was
reported in a few studies as one of the most important features in pharmacists’ decision
making, while others reported no place for the evidence of efficacy in decision making
[228]. Such contrasting findings are also noted around the importance of medicine safety,
adoption of medicines by medical practitioners, financial benefits owing to sales of
medicines, retail prices of medicines, opinions of colleagues, consumer advertisement,
employer policy directions and direct requests for medicines. These contrasting findings
reflect that facilitators/barriers are often unique to the therapeutic areas, cultural settings,
legislative frameworks etc. and hence, the factors associated with decision making.
Such differing conclusions however, are not only limited to the reasons listed above.
Differences in study settings and countries, sampling and bias around participant selection,
and more importantly the analytical models and study quality may also explain variations.
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For example, although any sample size cannot be regarded as ‘small’ as long as it justifies
the appropriateness for the research questions, justification was missing from most
quantitative studies, and similarly data saturation was not addressed in any of the
qualitative studies. In addition, there was a general lack of information around participant
recruitment and associated bias. Although data for the systematic review were extracted
from the results sections of the included studies, conclusions drawn were often not
grounded in the data, with little discussion of limitations. Such lack of discussion around
limitations itself becomes a limitation of the study, potentially biasing conclusions [241].
Noting these limitations, facilitators/barriers to pharmacists’ decision making around
reclassified medicines were often similar to those from the qualitative work described in
Chapter 3. Results from these two approaches could be triangulated to gain additional
insight.
4.5.2 Discussion of systematic review method
The strength of this systematic review is exemplified from the lack of recent and robust
published systematic reviews in this field of research.
A wide range of databases was used to search the literature. Manual searching of core
journals for relevant titles, searching of bibliography for literature led to disappointing
results, hence raises questions around whether such process should be adopted in the
future. Experts based outside the university were not consulted for potentially missing
literature due to the time constraints of a PhD and similarly neither grey literature
including unpublished data nor missing data from published studies were considered due
to the same reason. Nevertheless, it is said that even the information retrieval experts are
able to retrieve only as much as 50% of the relevant literature [156].
Two researchers working independently in short listing titles retrieved added to the rigour
of the literature inclusion/exclusion decisions. In addition, this strengthened the review
process in terms of data extraction and quality rating.
Development of quality assessment forms as per standard guidelines [246,248,249] helped
to ensure that important elements around study quality were properly scrutinized.
Structured data extraction forms ensured that no relevant data were missed. A narrative
synthesis of findings allowed results from diverse methodologies and methods to be
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presented together and for the same reason meta-analysis of the results was not possible. A
clear, externally validated protocol, listing the process around every aspect of systematic
review meant that any deviations from the set procedures could also be recorded,
increasing transparency.
4.5.3 Future directions for doctoral research
The systematic review has provided a platform to progress with the quantitative evaluation
of newly reclassified medicines. Findings of the systematic review will have relevance to
the next stage of the research as described below.
4.5.3.1 Design aspect
1. Need to define the outcome: Outcome measures were poorly defined in the
literature and hence future evaluation should communicate key outcomes that are
being measured, with emphasis on validity, reliability and responsiveness
2. Multivariate models reviewed are appropriate for adaptation in the next phase of
the research. However, future evaluation is needed to address limitations noted.
3. While many facilitators/barriers are common to reclassified medicines, some were
found to be medicine specific. Hence, research around factors associated with
decision making is best undertaken through quantitative evaluation of reclassified
medicines from diverse therapeutic areas with the same sample of pharmacists.
4. Emphasis should be placed on theoretical frameworks.
4.5.3.2 Content aspects
1. The facilitators/barriers to pharmacists’ adoption of reclassified medicines
identified from the systematic review along with the results of qualitative interviews
will be used to develop the content of the quantitative research instrument.
4.6 SUMMARY OF CHAPTER 4
Methods and models used to study pharmacists’ decision making around reclassified
medicines were reviewed through a systematic review of literature. Strengths and
limitations of these methods and models were described using a systematic approach.
Within quantitative models, there was a lack of rigorous multivariate approach to
undertaking research to understand pharmacists’ perspective of decision making around
adoption of reclassified medicines. Lack of theoretical framework to undertaking research
was also identified in the included studies. A total of 28 facilitators/barriers to pharmacists’
Chapter 4: Systematic review of literature 139
decision making in relation to support for and adoption into practice of reclassified
medicines were also identified. These results are of relevance to the design and content
aspects for the development of the quantitative research instrument to be used in the next
phase of the research.
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5 CHAPTER 5: DEVELOPMENT AND PILOTING
OF SURVEY INSTRUMENT
5.1 INTRODUCTION TO THE CHAPTER
This Chapter details the development and piloting of the questionnaire used to undertake
the main survey. Results of the pilot survey (Phase III) and descriptions of any
modifications made prior to finalising the questionnaire (phase IV) are also presented.
5.2 OBJECTIVES OF THE MAIN SURVEY
1. To quantify pharmacists’ support for and adoption into practice of medicines newly
reclassified from POM to P status for diverse therapeutic indications.
2. To describe and quantify facilitators/barriers associated with pharmacists’ decision
making around reclassified medicines (support for the reclassified status and
adoption into practice).
3. To investigate the utility of Rogers’ diffusion model in exploring findings related to
objectives 1 and 2.
5.3 QUESTIONNAIRE DESIGN
5.3.1 Technicalities of design and administration
Indicators of best practice suggested by the American Association of Public Opinion
Research (AAPOR) [287], key messages from Dillman’s text on survey design [288]; and a
dedicated training session on survey design and administration [202] were followed. These
key messages are summarised in figure 5.1.
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Figure 5.1: Best practices for survey design and administration
Have specific goals for the survey
Take great care in matching question wording to the concepts
being measured and population being studied
Select samples that will represent the population to be studied
Use designs that balance costs with errors
Pre-test questionnaires and procedures to identify problems
prior to the survey
Maximise response rates within the limits of ethical treatment of
human subjects
Use statistical analytic and reporting techniques appropriate to
the data collected
Carefully develop and fulfil pledges of confidentiality given to
the respondents
Disclose all methods of the survey to permit evaluation and
replication
A well designed layout prevents items or answer categories
from being missed because of their location on the page
Formats to consider- A4 paper folded to create an A5 booklet
stapled along the spine
Consider layout to allow natural eye movements
For complex questionnaires, shaded background fields are very
useful and thus these help identify all answer spaces and
therefore reduce non-response
Do not split questions or answer categories between pages
Extracted from [202,287,288]
5.3.2 Evidence based strategies to encourage participation
Evidence based strategies known to increase the response rate, as described in Chapter 3
were used. However, strategies used in the survey differed from those used in the
qualitative phase as follows:
1. No monetary nor non-monetary incentives were used to facilitate participation in
the survey.
2. Invitations were anonymous.
3. No identifying features were supposed to appear on return.
4. No prior telephone contact with potential respondents was made.
In addition to the above strategies, the following innovative techniques were also utilised
with the aim of maximising the response rate:
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1. Three questions in very large and legible font were placed on the front page of the
questionnaire booklet to allow potential respondents to quickly check the relevance and
interest of the survey to themselves. These three questions were as follows:
Are you a community pharmacist? √
Do you deal with non-prescription medicines? √
Are you interested in issues about innovations? √
2. A ‘post it note’ was attached to the top right corner of the questionnaire cover page
containing a statement signed by the researcher in ink inviting pharmacists to
participate. This was based on limited previous research suggesting that such a strategy
may increase the response rate by up to 70% [289]. This message appears in Appendix V.
3. Questionnaire was designed in A5 size (half the A4) to make it look like a small booklet.
5.4 CONTENT SETTING
The draft questionnaire comprised three sections: reclassified medicines; e-MAS (Chapter
8); and respondents’ demographic characteristics.
5.4.1 Section A: Reclassified medicines
Newly reclassified medicines from diverse therapeutic areas introduced in the last five
years (during the period of this survey design) were evaluated. As identified in the
Chapters on the qualitative study and systematic review of the literature,
facilitators/barriers to decision making are often unique to each of the newly reclassified
medicines. Hence, factors associated with decision making may be best understood by
evaluating as many newly reclassified medicines from diverse therapeutic indications as
possible. Medicines were selected on the basis of legal reclassification within the preceding
six years; and that the indications encompassed acute and chronic indications. The
following newly reclassified medicines were evaluated:
1. Omeprazole: Reclassified in 2004 [92], a 10 milligrams dose of this medicine is
indicated for the relief of heartburn symptoms associated with acid reflux in adults
18 years or above [239].
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2. Simvastatin: Reclassified in 2004 [92], a 10 milligrams dose of this medicine is
indicated for prevention of first major coronary events in individual with moderate
risks [232].
3. Chloramphenicol eye drops: Reclassified in 2005 [92], a 0.5% w/v solution is
indicated for the treatment of acute bacterial conjunctivitis in children two years and
above and for adults and the elderly [290].
4. Naproxen: Reclassified in 2008, a 250 mg dose is aimed for the treatment of primary
dysmenorrhoea in women aged between 15 and 50 years [291].
5.4.1.1 Outcome measures
Two key outcome measures were used; support for the reclassified P status of the listed
four medicines by pharmacists (the acceptance); and level of supply of the reclassified
medicines by pharmacists or their support staff (adoption into practice). Acceptance was
measured by asking pharmacists “Please indicate how much you appreciate having these
reclassified products available for your OTC practice”. The responses were measured on a
five point semantic differential scale where the extremes indicated “Not-at-all” and “Very
highly”. Adoption into practice was similarly measured with the question “To what extent
do you and/ or your support staff supply these products?” The extreme categories in the
responses were “Not-at-all” and “Very frequently”.
5.4.1.2 Sources of information on reclassified medicines
Twelve sources of information identified from the qualitative interviews and the systematic
review of literature were listed to identify and quantify which listed source (s) pharmacists
were utilising.
5.4.1.3 24-item scale
A 24- item scale featuring diverse issues associated within decision making as identified
from the qualitative work, the systematic review of the literature and the theoretical
framework of Rogers’ diffusion model [131] was designed. Of these; 16 items represented
pharmacists’ perceived characteristics of new medicines, including benefits professionals;
benefits and risks to patients; three items on organizational aspects of innovation adoption;
five items on external support including those from patients, GPs and the professional
body. These scale items as they related to Rogers’ description of factors associated with
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innovation adoption by potential adopters [131], are also labelled in table 5.1. Descriptions
of the terms within Rogers’ diffusion model are explained in Chapter 1 (Introduction).
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Table 5.1: 24-Scale items of questionnaire (Note: this table extends to four pages)
Scale item Relevance of
the scale to
practice
Examples of supporting statement from
interviews
Rogers’
description
Rogers’ broader
category
This is/was a good opportunity to
extend my role as a health
professional
Role
development
“changing from POMs to Ps is fine if it’s
given us an extra, a weapon in the armoury” Advantage
Attributes of
innovations
This product has potential for good
financial returns for my pharmacy
Financial
aspects
“…because the company that I worked for was
pushing it, because they thought ...that they are
gonna sale masses of it and it was a great
opportunity for them to get into kind of a, a
market which hasn’t previously been there”
Advantage Attributes of
innovations
I believe that the OTC regimen for
this product is likely to be effective
Evidence base “I have reservations for the dose it
[simvastatin] is.”
Advantage Attributes of
innovations
I believe this product has potential
to engender patient satisfaction Feedback from
patients
“...people coming back to me and say.., that
product wonders, it was great”
Advantage Attributes of
innovations
This product matches with the
business/service ambitions of my
pharmacy
Financial
aspects
“the different areas you’re in, there will be
different products which would be utilized
more or less as well”
Compatibility Attributes of
innovations
I find the processes involved in the
supply of this product complex
Complexity of
adoption
process
“…time filling out whole Imigran (sumtriptan)
(risk assessment) … I find that taxing” Complexity
Attributes of
innovations
I believe that this product is a
welcome addition to the range of
pharmacy medicines
Pharmacists’
expectations
“Trimethoprim, I’m really looking forward
to, a lot” “Most recent one was
chloramphenicol, wonderful... We’d been
looking for that”
Compatibility Attributes of
innovations
Introduction of this product may
have represented a ‘step too far’ for
OTC products
Change match
with
expectations
We’re really kind of first port of call for acute
things...but if it’s a long term chronic thing, they
come in and we can direct into their GP
Compatibility Attributes of
innovations
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Scale measure Relevance of the
scale to practice
Supporting statement from interviews Rogers
description of
the theme
Rogers’
broader
category
I am happy to delegate the task
of supplying this product to
support staff
Complexity of
adoption process
“Occasionally I have worked in stores where
you don’t necessarily have that trust in your
staff and that’s where having these kinds of
products available can be more problematic”
Complexity Attributes
of
innovations
I feel confident about my ability
to supply this product
Pharmacists’
confidence on
supply process
“Unless I had some experience already[to
supply]...I am always more on the safe side you
know”
Complexity Attributes
of
innovations
The similarity of POM and P
packs of this product could
create confusion
Complexity of
adoption
“…you’ve got POM pack and P pack,
identical. I’m not always convinced”
Complexity Attributes
of
innovations
I believe there are high risks of
adverse events associated with
this product
Safety of
medicines
“Chloramphenicol is fine because its such an
obvious thing. You know and nothing much
[side effects] can happen.”
(Dis)Advantage Attributes
of
innovations
It is likely that customers could
misuse this product
Product potential
for misuse by
patients
“We’ve had three teenagers tryin’ to sign up
the... smoking cessation scheme. And we
reckon... what they’re needing, we reckon
they’re using it for other motives”
(Dis)Advantage Attributes
of
innovations
Lack of access to patient medical
records makes it difficult to
adopt this product into practice
Patient medical
records
“you have to have some more access to
records...to actually be aware of what you
actually treating someone actually, actually..,
needs treatment”
Complexity Attributes
of
innovations
It is easy for me and/or my
customers to know if treatment
with this product is effective
Observable
treatment
outcomes
“...whether people benefit and if they come
back after certain amount of time to see if it
[the condition] had improved”
Observability Attributes
of
innovations
I am/would be comfortable
going off guidelines to supply
this product
Flexibility for off
label supply
“I also like going off the formulary if I need
to.”
Re-invention Attributes
of
innovations
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Scale measure Relevance of
the scale to
practice
Supporting statement from interviews Rogers
description
of the theme
Rogers’ broader
category
Insufficient resources (e.g. staff,
space etc) within my pharmacy has
limited the practice of this product
Staff, space,
equipments
“I don’t think we really have the time at
community pharmacies to go into that sort of
details [cholesterol testing] with patients.”
Organizational
factors
Organizational
factors
I have access to sufficient sources of
information relating to this product
Access to
information
sources
“I think the only literature really is what’s in
the patients information leaflets in the boxes in
a lot of cases”
Organizational
factors
Organizational
factors
It has been my management’s
decision rather than my own as to
if/ how far to adopt into practice
Role in decision
making within
organization
“our company dictates what we stock on
shelves.”
Organizational
factors
Organizational
factors
Customers not accepting my advice
around this product makes me less
likely to adopt this product
Patient
cooperation
“I think because we are very sort of customer
oriented. I think with that, that’s one thing
[antibiotic], I wouldn’t like to see coming just
and just yet anyway.”
External
factors
External factors
My customers often complain about
the cost of this product (not
including e-MAS supply)
Retail price for
patients
“those people who came for cholesterol test
…find out how much it was and they will need
to take it every month...and buy it and they
didn’t do it.”
External
factors
External factors
Many customers ask for this
product by name
Patient
acceptance
“What a demand from the customers [for
chloramphenicol]”
External
factors
External factors
I get adequate support from my
professional body to adopt this
product
Support from
professional
body
“…that the trainings before these products
come out. It’s the reps doing it, ‘cause it’s the
only one that we get for POM to P for certain
conditions.”
External
factors
External factors
Lack of proper way to communicate
with the local medical practice is a
barrier to adopt this product
Communication
with GPs
“You know if they’re gonna be on it
[simvastatin], then their GP needs to know
about it.”
External
factors
External factors
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5.4.2 Section B: About e-MAS
Details of this section will be explained in Chapter 8.
5.4.3 Section C: Demographic characteristics and self
innovativeness
Section C of the questionnaire featured items around respondents’ demographic
characteristics. The categories used were the same as those in the Royal Pharmaceutical
Society of Great Britain’s census and register analysis reports [292,293] where possible so as
to enable estimation of the representativeness of the respondents to the total population.
Pharmacists were also asked to rank their perceived innovativeness in relation to new ways
of practice based on Rogers’ diffusion model which states that greater perceived
innovativeness relates to a higher adoption of innovations into practice [131]. The scale was
adapted from a previous study measuring pharmacists’ adoption of innovations around
non-medical prescribing [294].
5.5 REVIEW BY EXPERT PANEL
Development of questionnaire items followed an iterative process. Statements were
formulated and reworked to avoid any ambiguity. Apart from three academic supervisors,
the following panel of experts and peer evaluators checked for face and content validity of
the questionnaire.
1. Prof. Dennis Tourish - Professor, Aberdeen Business School, RGU
2. Mr Brian Addison - Lecturer in pharmacy practice, RGU, and practising locum
community pharmacist
3. Mrs Ruth Edwards - Lecturer in pharmacy practice, RGU, and practising locum
community pharmacist
4. Mrs Trudi McIntosh - Lecturer in pharmacy practice, RGU, and practising locum
community pharmacist
5. Mrs Gwen Gray - Lecturer in pharmacy practice, RGU, and practising locum
community pharmacist
6. Mrs Katie MacLure - Research assistant in pharmacist prescribing, RGU.
7. Ms Noelle O’ Drescoll - PhD student, RGU, and locum community pharmacist
8. Mr Alex Wilson - Consultant statistician for Robert Gordon University
9. Cat Graham - Wellcome Trust Epidemiology and Statistics Support Group, Clinical
Research Facility, Edinburgh.
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10. Dr Gordon Prescott - Senior Lecturer of Medical Statistics, Department of
Population Health, University of Aberdeen
Feedback from the expert panel was received in the form of either verbal, email or hand
written notes. Most of the suggestions related to improving the grammar and clarity of the
statements. Discussion with expert statisticians related to appropriateness of content
setting, scales and analytical approaches.
5.6 PILOT SURVEY
The following were the set objectives for the pilot phase:
1. To test the face and content validity of the questionnaire items to inform any
modifications to be made to the questionnaire prior to the use in the main survey
2. To predict the response rate likely to be achieved in the main survey so as to allow
estimation of the study sample size.
5.6.1 Method
5.6.1.1 Identification of potential participants for piloting
A list of all registered pharmacy premises in Scotland were obtained from NHS National
Education Scotland. Pharmacies represented in the qualitative work were excluded where
identifiable. A random sample of 50 pharmacies was extracted using Minitab version 15.
This number was based on the advice of experienced pharmacy practice researchers within
the school. The questionnaire was addressed to the pharmacist with the responsibility for
non-prescription medicine supply and hence was anonymous. A return pre-paid postage
envelope was provided. The questionnaire booklet also contained a detachable participant
information page.
5.6.1.2 Consent
No consent form was included in the invitation pack as any questionnaire returned
completed would imply respondents’ consent to participate.
5.6.1.3 Reminders
No reminders were sent during the pilot phase. A deadline of three weeks was suggested
for the participants to return the completed questionnaire.
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5.6.1.4 Data input and analysis
Data were entered into SPSS version 15 (SPSS Inc). Analyses of response rate and
demographic characteristics were performed. Any missing data were identified.
5.6.2 Results from pilot survey
5.6.2.1 Response rate
Thirteen replies were received giving a response rate of 26%.
5.6.2.2 Demographic characteristics of participants
The demographic characteristics of the pilot questionnaire participants are shown in the
table 5.2 below:
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Table 5.2: Demographic characteristics and perceived innovativeness of pilot survey
respondents
Title Categories Data from Pilot
samples n (%)*
Gender (N=13) Male 5 (39%)
Female 8 (62%)
Age (N=13) ≤29 years 3 (23%)
30-39 4 (31%)
40-49 2 (15%)
50-59 4 (31%)
60 or above 0 (0%)
Type of pharmacy ownership
(N=13)
Independent (1 store) 2 (15%)
Small multiple (2-4 Stores) 3 (23%)
Medium sized multiple (5-25 stores) 1 (8%)
Large multiple (over 25 stores) 7 (54%)
Position within pharmacy (N=13)† Owner 2 (15%)
Manager 11 (85%)
Relief 0 (0%)
Second 1 (8%)
Locum 0 (0%)
Non-store 1 (8%)
Number of years in practice (N=13) 5 years and under 4 (31%)
6- 10 years 2 (15%)
11-15 years 1 (8%)
16-20 years 2 (15%)
20 and above 4 (31%)
Postgraduate qualification (N=13) Yes 5 (39%)
No 8 (62%)
Location of pharmacy (N=13) Urban 3 (23%)
Suburban 6 (46%)
Rural 4 (31%)
Prescriber (N=13) Yes 3 (23%)
No 10 (77%)
Perceived innovativeness (N=13) I am venturesome and willing to
take risks with new ways of working 5 (39%)
I serve as a role model for others in
relation to new ways of working
4 (31%)
I deliberate for some time before
adopting new ways of working
2 (15%)
I am cautious in relation to new
ways of working; tend to change
once most peers have done so
2 (15%)
I resist new ways of working 0 (0%)
*%figure are rounded to whole numbers †multiple selections allowed
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5.6.2.3 Missing data
One respondent failed to rank the agreement scores relating to one item in the 24-items
scales.
5.6.2.4 Responses to open questions
Two respondents made comments under the open questions.
5.6.3 Discussion of pilot and any modifications for main
survey
5.6.3.1 Response rate
The response rate that was achieved without using any reminders (26%) was considered
appropriate to proceed to the main survey. This was also consistent with response rates
obtained from other pilot research phases within the pharmacy practice area in the
university. Based on this figure, it was decided that two reminders would be used in an
attempt to maximize the response rate in the main study.
5.6.3.2 Section on reclassified medicines
The responses from pilot survey respondents and feedback from peer evaluators implied
that respondents understood the questionnaire items.
A minor alteration was undertaken to one of the 24-items within the scale so as to overcome
the difficulty faced in coding of the responses as a result of piloting. It was unclear whether
the statement “Level of resources allocated by my pharmacy management has affected
supply decisions” was a ‘positive’ or a ‘negative’ statement. Therefore, it was rearticulated
as “Insufficient resources (e.g. staff, space etc) within my pharmacy have limited the
practice of this product” to be used in the main survey.
5.6.3.3 Innovativeness categories
The very high percentage of respondents belonging to the category of innovativeness
implying ‘venturesome’ necessitated the need to reverse the order of categories presented
within the questionnaire. For the main survey, the category hence would start from
‘resistant’ leading to ‘venturesome’.
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5.6.3.4 Missing data
All data above were considered random and thus no major changes were considered.
5.7 SUMMARY OF THE CHAPTER
The questionnaire was designed based on the qualitative data and systematic review of
literature and theoretical framework of diffusion of innovations. This was piloted to a
random sample of fifty community pharmacies within Scotland. Analysis of responses from
the pilot study and advice from expert panel indicated that the content was valid with no
need for major editing of the layout or content needed. The response rate achieved in the
pilot will be used to compute the sample size for the main survey.
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6 CHAPTER 6: MAIN SURVEY
6.1 INTRODUCTION TO THE CHAPTER
This Chapter presents the results of the main survey undertaken to achieve the objectives
listed in the previous Chapter. Attention will also be given to the discussion of key findings.
6.2 METHOD
Methods relevant to survey design and administration are in Chapter 5. This section details
mainly the computation of sample size and approaches to data analysis.
6.2.1 Sample size estimate
Sample size calculation for the main survey was based on the minimum sample size
required for the analytical steps to be followed. Principal component factor analysis,
bivariate correlation and logistic regression were the key analytical steps which required
sample size estimation. A minimum of 300 samples has been suggested to be required for
factor analysis [295], whereas, a sample size of 5 to15 is suggested for each explanatory
variable to be used for logistic regression analysis. Considering there would be a maximum
of 38 variables likely to be used in the regression analysis, a minimum sample size of 380
would be needed. Thirdly, for correlation analysis, it is required that for a standard P value
of 0.05 and a recommended power of 80%, 783 participants are needed to detect a small
effect size (r=.1), 85 participants to detect a medium effect size (r=.3) and 28 participants to
detect a larger effect size (r=.5) [295]. Based on above estimates and the projected response
rate of 46% with two reminders (pilot response rate plus 10% with each reminder), it was
decided that whole population of community pharmacies in Scotland (N= 1143) needed to
be sampled.
6.2.2 Data entry and analyses
SPSS version 15.0 was used to enter and analyse the data.
Diverse methods of analysis were used. Descriptive analysis was used to report response
rate, pharmacists’ responses to the outcome measures and responses to 24 items scale and
demographic characteristics. Non-parametric analyses such as median (interquartile range)
were also used to report ordinal and discrete variables. Bivariate correlation analysis was
used to understand correlation between two outcomes [295]. Principal component factor
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analysis and binary logistic regression analysis were used to quantify factors associated
with decision making [295]. Cross tabulation analysis of the outcome measures with the
explanatory variables (the 24 items and the demographic characteristics) was performed to
shortlist the explanatory variables for regression analysis. Only those variables showing
significant association with the outcome measures based on Chi-squared statistics (P≤0.05)
were used in the regression analysis. Fisher’s exact test was used where Chi-squared tests
could not be applied due to ≥20% of the cells showing an expected count of less than 5
[295]. Where the pattern of responses did not allow binary logistic regression analysis
(explained in section 6.6.2.5 and 6.6.2.6), bivariate correlation of the outcome measures with
the explanatory variables was used. Responses to open questions were analysed by content
analysis as detailed in Chapter 2 (section 2.4.4.3).
6.2.3 Strategies to deal with missing data
No strategy was used to deal with missing data. This was due to the demerits of using any
computational strategies being outweighed by the benefits of using such techniques [296].
6.3 RESULTS: SECTION A
6.3.1 Response rate
A log book was maintained whereby responses received each day were recorded and a
graph was plotted featuring cumulative response rate to the number of days from the initial
date of questionnaire mailing (figure 6.1). A total of 563 usable responses were received
over the course of approximately 80 days giving a usable response rate of 49.5%. Eleven
blank replies were also received which were excluded from the analysis. Of the responses
obtained, 55.1% were obtained after the first mailing; whereas 25.6% and 19.4% were
contributed by the first and second reminders respectively.
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Figure 6.1: Cumulative response rate over the data collection period, illustrating the impact of
reminders.
6.3.2 Demographic characteristics
6.3.2.1 Gender (N=553)
The majority of respondents were female (61.1%, n=338
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6.3.2.2 Age (N=554)
Median age of the respondents was 30-39 years (25.3%, n=130) (figure 6.2)
Figure 6.2
Age categories (years)
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6.3.2.3 Practice experience (N=555)
The median years of RPSGB registration as a pharmacist was 6-10 years (17.7%, n=98)
(figure 6.3)
Figure 6.3
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6.3.2.4 Size of pharmacy ownership (N=544)
The majority of respondents were employed by large multiple chains (52.1%, n=284) (figure
6.4).
Figure 6.4
*16 locums excluded from analysis
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6.3.2.5 Employment type (N=562)
The majority (72.4%, n= 407) of respondents were pharmacy managers (table 6.1).
Table 6.1: Respondents’ employment category
Employment category n (%)*
Owner (N=562) 97 (17.3)
Manager (N=562) 407 (72.4)
Relief (N=562) 40 (7.1)
‘Second’ pharmacist (N=562) 21 (3.7)
Locum (N=562) 16 (2.8)
Non-store (N=562) 1 (0.2)
* Numbers add up to >100% as multiple selections were allowed
6.3.2.6 Geographical area (N=503)
Respondents mostly worked in suburban areas (42.9%, n= 216). (Table 6.2)
Table 6.2: Respondents’ geographical area
Geographical area
(N=503)
n (%)†
Urban 157 (31.2)
Suburban 216 (42.9)
Rural 130 (25.8)
†40 reliefs and 16 locums excluded from this analysis
6.3.2.7 Postgraduate qualification (N=557)
A minority of respondents (16.3%, n=91) possessed postgraduate qualifications.
6.3.2.8 Prescribing qualification (N=557)
26.2% (n=146) were registered as prescribers with the RPSGB.
6.3.2.9 Perceived innovativeness (N=552)
Half of respondents (50.5%, n=279) rated themselves deliberating for sometime before
adopting new ways of working (table 6.3).
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Table 6.3: Respondents’ perceived innovativeness
Innovativeness categories (N=552) n (%)
I resist new ways of working (resistant) 0 (0)
I am cautious in relation to new ways of working; tend to
change once most peers have done so (cautious)
52 (9.4)
I deliberate for some time before adopting new ways of
working (deliberate)
279 (50.5)
I serve as a role model for others in relation to new ways of
working (role model)
146 (26.4)
I am venturesome and willing to take risks with new ways of
working (venturesome)
75 (13.6)
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6.3.3 Respondent sources of information on newly reclassified
medicines
6.3.3.1 Responses to listed sources of information (N=559)
Of the twelve different sources of information listed in the questionnaire, almost a third
(30.1%, n=168) of respondents cited using at least three different sources (mode=3). The
median number of information sources per respondent was 3 with an inter-quartile range
(IQR) of 1. More detail is provided in figure 6.5. The source of information utilised most
was manufacturers’ information sources (70.7%, n=395) followed by journals (61.7%,
n=345). (Table 6.5)
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Table 6.4: Respondents’ sources of information
Information source as per
questionnaire
(N=563)
Rank in
descending
order of n (%)
n*
(%)
Drug company training sources 1 395 (70.7)
Journals 2 345 (61.7)
RPSGB guidance 3 323 (57.8)
National/ Local formularies 4 211 (37.7)
Patient information leaflets 5 209 (37.4)
Fellow pharmacists 6 197 (35.2)
My pharmacy management 7 153 (27.4)
Professional leaders 8 49 (8.8)
Television 9 45 (8.1)
Senior colleagues 10 38 (6.8)
Newspapers 11 27 (4.8)
Contract champions 12 23 (4.1)
* Numbers add up to >100% as multiple selections were allowed
Sixteen respondents provided comments to the open question asking to list any other
information sources. The following is the summary of responses.
Table 6.5: Responses to open question around sources of information
‘Other’ sources of information used
by respondents (N=16)
n†
Pharmacy management/employer 6
Chemist and Druggist 2
Internet 2
30 minute tutors 1
Drug company training sources 1
Health Board PGDs 1
MHRA 1
NPA 1
Newsletters 1
S*** (Name of a person) 1
Unclear quote 1
† More than one comment made by some respondents
6.3.4 Outcome: Respondents support for reclassified status
‘Acceptance’
Of the four listed medicines, chloramphenicol was rated most highly with over 99% (n=551)
rating their support, 3 or above, in the five point scale. Support for the reclassified status of
simvastatin was very low with approximately 75% (n=412) rating their support either 1 or 2
(Table 6.6). Median (IQR) acceptance scores for omeprazole, naproxen, simvastatin and
chloramphenicol were 3 (2), 3 (1), 1(2) and 5 (0) respectively. (Table 6.6)
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Table 6.6: Pharmacists’ support for the reclassified status of medicines
How much do you appreciate having the following reclassified medicines into your OTC
practice?
Scale level
Medicines (N) 1*
n (%)
2
n (%)
3
n (%)
4
n (%)
5†
n (%)
Omeprazole
(N=555)
91
(16.4)
106
(19.1)
155
(27.9)
134
(24.1)
69
(12.4)
Naproxen
(N=552)
35
(6.3)
89
(16.1)
176
(31.9)
193
(35.0)
59
(10.7)
Simvastatin
(N=552)
278
(50.4)
134
(24.3)
94
(17.0)
30
(5.4)
16
(2.9)
Chloramphenicol
(N= 556)
1
(0.2)
4
(0.7)
9
(1.6)
30
(5.4)
512
(92.1)
* Labelled as “not at all” in questionnaire; † labelled as “very highly”
6.3.5 Outcome: Adoption into practice of newly reclassified
medicines
Over 98% (n=549) of the respondents ranked their adoption of chloramphenicol 3 or above,
on the five point. In contrary to this, less than 5% (n=27) respondents provided the same
score for simvastatin. Over a third of the pharmacists (n=201) were not supplying
omeprazole. Median (IQR) scores for omeprazole, naproxen, simvastatin and
chloramphenicol were 2 (2), 2 (1), 1(0) and 5 (0) respectively. (Table 6.7)
Table 6.7: Pharmacists’ adoption of newly reclassified medicines into practice
How much do you or your support staff supply the following reclassified medicines?
Medicines (N) 1**
n (%)
2
n (%)
3
n (%)
4
n (%)
5¥
n (%)
Omeprazole
(N=554)
201
(36.3%)
202
(36.5%)
100
(18.1%)
44
(7.9%)
7
(1.3%)
Naproxen
(N=557)
96
(17.2%)
197
(35.4%)
168
(30.2%)
82
(14.7%)
14
(2.5%)
Simvastatin
(N=557)
459
(82.4%)
71
(12.7%)
17
(3.1%)
5
(0.9%)
5
(0.9%)
Chloramphenicol
(N=557)
2
(0.4%)
6
(1.1%)
11
(2.0%)
79
(14.2%)
459
(82.4%)
* *Indicated in questionnaire as ‘not at all’; ¥indicated in questionnaire as “very frequently”
Chapter 6: Main survey 165
6.3.6 Correlation between acceptance and adoption scores
Bivariate correlation analysis showed that respondents’ acceptance and adoption scores
were significantly correlated for all four medicines. This implies that the more the support
for the reclassified status, the greater was the adoption into practice. Spearman’s rank
correlation was used for the measurement for omeprazole and naproxen. Due to excess tied
ranks on one side of the scale, Kendal’s T was the most appropriate statistical test for
simvastatin and chloramphenicol [295] (table 6.8). Highest correlation values were obtained
for omeprazole, with the lowest for chloramphenicol.
Table 6.8: Bivariate correlation between acceptance and adoption scores
Spearman’s rank Kendal’s T
Omeprazole
adoption
Naproxen
adoption
Simvastatin
adoption
Chloramphenicol
adoption
Omeprazole acceptance .666***
Naproxen acceptance .561***
Simvastatin acceptance .427***
Chloramphenicol acceptance .401***
** Correlation significant at P ≤0.001.
6.3.7 Summary of responses to outcome measures
Support for the reclassified status of medicines and their adoption into practice were rated
differently by the respondents. Scores on both the outcomes ‘acceptance’ and ‘adoption’
were highly skewed towards the higher side of the scale for chloramphenicol, implying
high support for the reclassified status and high adoption into practice. Responses, whereas
were skewed towards the lower side of the scale for simvastatin, meaning support for the
reclassified status and adoption into practice were rated low for this medicines. Responses
to naproxen and omeprazole were less skewed as compared to the above two medicines.
Both the outcomes correlated well with each other in bivariate analysis with the case of all
four medicines.
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6.4 RESULTS: SECTION B
6.4.1 Facilitators/barriers to decision making: Descriptive
statistics of 24 items scale
Responses to the 24 item facilitator/barrier scale are presented this section (table 6.9).
6.4.1.1 Opportunity to increase role
The majority reflected agreement that reclassification of omeprazole, naproxen and
chloramphenicol had offered an opportunity to increase their professional roles. The
majority were unsure or disagreed to role development offered by reclassification of
simvastatin.
Table 6.9: Descriptive statistics of responses around facilitators/barriers to decision making
(note: this table extends up to13 pages with descriptions in between until section 6.4.1.24)
This is/was a good opportunity to extend my role as a health
professional
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 556)
23
(4.1)
67
(12.1)
175
(31.5)
201
(36.2)
90
(16.2)
Naproxen
(N= 556)
11
(2.0)
42
(7.6)
154
(27.7)
268
(48.2)
81
(14.6)
Simvastatin
(N= 556)
81
(14.6)
122
(21.9)
161
(29.0)
129
(23.2)
63
(11.3)
Chloramphenicol
(N= 557)
2
(0.4)
5
(0.9)
13
(2.3)
115
(20.6)
423
(75.8)
6.4.1.2 Compatibility to pharmacy service ambitions
The majority agreed/strongly agreed that naproxen and chloramphenicol matched with
service ambitions of respondents’ pharmacies. The majority expressed being unsure or had
disagreement with omeprazole and simvastatin.
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Table 6.9
This product matches with the business/service ambitions
of my pharmacy
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 556)
31
(5.6)
80
(14.4)
220
(39.6)
146
(26.3)
79
(14.2)
Naproxen
(N= 556)
19
(3.4)
50
(9.0)
201
(36.2)
206
(37.1)
80
(14.4)
Simvastatin
(N= 556)
98
(17.6)
111
(20.0)
207
(37.2)
96
(17.3)
44
(7.9)
Chloramphenicol
(N= 558)
6
(1.1)
8
(1.4)
71
(12.7)
121
(21.7)
351
(63.0)
6.4.1.3 Financial potential of medicines
Only chloramphenicol eye drops received the majority of respondents agreeing or strongly
agreeing to ‘good’ financial potential for pharmacy. At least one in three respondents were
unsure of the financial potential of omeprazole and naproxen and almost half disagreed or
strongly disagreed that simvastatin had potential for good financial returns.
Table 6.9
This product has potential for good financial returns for
my pharmacy
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 550)
83
(15.1)
95
(17.3)
185
(33.6)
129
(23.5)
58
(10.5)
Naproxen
(N= 551)
45
(8.2)
74
(13.4)
205
(37.2)
171
(31.0)
56
(10.2)
Simvastatin
(N= 552)
144
(26.1)
116
(21.0)
167
(30.3)
84
(15.2)
41
(7.4)
Chloramphenicol
(N= 552)
17
(3.1)
30
(5.4)
165
(29.9)
144
(26.1)
196
(35.5)
6.4.1.4 Retail price of medicines
A high majority of respondents agreed or strongly agreed that they often received
complaints about the retail price from patients when supplying omeprazole and
simvastatin. This was not the case for chloramphenicol, with a high majority disagreeing or
strongly disagreeing to such complaints being common. Over one third were unsure about
this issue in relation to naproxen.
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Table 6.9
My customers often complain about the cost of this
product (not including e-MAS supply)
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 555)
41
(7.4)
73
(13.2)
138
(24.9)
152
(27.4)
151
(27.2)
Naproxen
(N= 555)
47
(8.5)
139
(25.0)
213
(38.4)
95
(17.1)
61
(11.0)
Simvastatin
(N= 553)
45
(8.1)
59
(10.7)
159
(28.8)
118
(21.3)
172
(31.1)
Chloramphenicol
(N= 553)
135
(24.4)
248
(44.8)
116
(21.0)
33
(6.0)
21
(3.8)
6.4.1.5 Pharmacy resource implications on supply
The majority of respondents strongly disagreed or disagreed that resource barriers within
pharmacy had limited the adoption into practice of any of the listed medicines.
Table 6.9
Insufficient resources (e.g. staff, space etc) within my
pharmacy has limited the practice of this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 556)
170
(30.6)
188
(33.8)
125
(22.5)
50
(9.0)
23
(4.1)
Naproxen
(N= 557)
176
(31.6)
204
(36.6)
120
(21.5)
38
(6.8)
19
(3.4)
Simvastatin
(N= 557)
159
(28.5)
162
(29.1)
122
(21.9)
73
(13.1)
41
(7.4)
Chloramphenicol
(N= 558)
234
(41.9)
216
(38.7)
85
(15.2)
9
(1.6)
14
(2.5)
6.4.1.6 Medicine potential for misuse
The majority of the respondents strongly disagreed or disagreed that customers could
misuse any of the four listed medicines.
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Table 6.9
It is likely that customers could misuse this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 556)
112
(20.1)
205
(36.9)
105
(18.9)
104
(18.7)
30
(5.4)
Naproxen
(N= 557)
85
(15.3)
196
(35.2)
121
(21.7)
132
(23.7)
23
(4.1)
Simvastatin
(N= 556)
146
(26.3)
243
(43.7)
99
(17.8)
54
(9.7)
14
(2.5)
Chloramphenicol
(N= 557)
129
(23.2)
227
(40.8)
93
(16.7)
87
(15.6)
21
(3.8)
6.4.1.7 Issue of patient compliance
The majority of the respondents disagreed or strongly disagreed that undesirable patient
behaviours in general, were a barrier to the adoption of chloramphenicol, with
approximately one third being unsure in relation to omeprazole, naproxen and simvastatin.
Table 6.9
Customers not accepting my advice around this product
makes me less likely to adopt this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 552)
85
(15.4)
151
(27.4)
160
(29.0)
124
(22.5)
32
(5.8)
Naproxen
(N= 553)
83
(15.0)
163
(29.5)
172
(31.1)
108
(19.5)
27
(4.9)
Simvastatin
(N= 553)
82
(14.8)
138
(25.0)
159
(28.8)
133
(24.1)
41
(7.4)
Chloramphenicol
(N= 554)
109
(19.7)
180
(32.5)
149
(26.9)
87
(15.7)
29
(5.2)
6.4.1.8 Complexity of supply process
A high majority of the respondents disagreed or strongly disagreed that the process
involved in the supply of omeprazole, naproxen and chloramphenicol was complex. Over
40% of respondents agreed or strongly agreed that the supply procedure for simvastatin
was complex.
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Table 6.9
I find the processes involved in the supply of this
product complex
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 553)
101
(18.3)
245
(44.3)
137
(24.8)
52
(9.4)
18
(3.3)
Naproxen
(N= 553)
99
(17.9)
276
(49.9)
131
(23.7)
37
(6.7)
10
(1.8)
Simvastatin
(N= 554)
74
(13.4)
137
(24.7)
107
(19.3)
144
(26.0)
92
(16.6)
Chloramphenicol
(N= 554)
177
(31.9)
275
(49.6)
71
(12.8)
23
(4.2)
8
(1.4)
6.4.1.9 Task delegation to support staff
A majority of the respondents disagreed or strongly disagreed that they were comfortable
in delegating supply task relating to omeprazole and simvastatin to support staff. However,
less than half would delegate the task for the supply of naproxen and simvastatin.
Table 6.9
I am happy to delegate the task of supplying this product
to support staff
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 553)
78
(14.1)
201
(36.3)
99
(17.9)
146
(26.4)
29
(5.2)
Naproxen
(N= 554)
62
(11.2)
172
(31.0)
96
(17.3)
194
(35.0)
30
(5.4)
Simvastatin
(N= 554)
156
(28.2)
241
(43.5)
66
(11.9)
67
(12.1)
24
(4.3)
Chloramphenicol
(N= 555)
64
(11.5)
153
(27.6)
61
(11.0)
198
(35.7)
79
(14.2)
6.4.1.10 Patient requests for medicines
A high majority of the respondents agreed or strongly agreed that direct patient requests
were common for reclassified chloramphenicol whereas most disagreed or strongly
disagreed to such requests being common for omeprazole, naproxen and simvastatin.
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Table 6.9
Many customers ask for this product by name
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 554)
186
(33.6)
228
(41.2)
83
(15.0)
50
(9.0)
7
(1.3)
Naproxen
(N= 553)
145
(26.2)
216
(39.1)
89
(16.1)
96
(17.4)
7
(1.3)
Simvastatin
(N= 555)
238
(42.9)
205
(36.9)
74
(13.3)
33
(5.9)
5
(0.9)
Chloramphenicol
(N= 555)
55
(9.9)
99
(17.8)
73
(13.2)
195
(35.1)
133
(24.0)
6.4.1.11 Confidence in supply process
A high majority expressed confidence in their abilities to supply all the four listed
medicines.
Table 6.9
I feel confident about my ability to supply this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 555)
9
(1.6)
20
(3.6)
43
(7.7)
253
(45.6)
230
(41.4)
Naproxen
(N= 556)
5
(0.9)
13
(2.3)
38
(6.8)
254
(45.7)
246
(44.2)
Simvastatin
(N= 556)
27
(4.9)
79
(14.2)
80
(14.4)
207
(37.2)
163
(29.3)
Chloramphenicol
(N= 556)
8
(1.4)
2
(0.4)
6
(1.1)
172
(30.9)
368
(66.2)
6.4.1.12 Compatibility to pharmacy ranges of medicines
A high majority agreed or strongly agreed that omeprazole, naproxen and chloramphenicol
were welcome additions to the range of pharmacy medicines. However, the majority did
not agree around reclassified simvastatin.
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Table 6.9
I believe that this product is a welcome addition to the
range of pharmacy medicines
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 556)
39
(7.0)
66
(11.9)
119
(21.4)
219
(39.4)
113
(20.3)
Naproxen
(N= 557)
18
(3.2)
42
(7.5)
107
(19.2)
259
(46.5)
131
(23.5)
Simvastatin
(N= 557)
132
(23.7)
159
(28.5)
132
(23.7)
83
(14.9)
51
(9.2)
Chloramphenicol
(N= 558)
4
(0.7)
2
(0.4)
6
(1.1)
101
(18.1)
445
(79.7)
6.4.1.13 Adequacy of information sources
The majority of respondents expressed agreement that information sources relating to all
four medicines were adequate.
Table 6.9
I have access to sufficient sources of information relating
to this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 553)
9
(1.6)
46
(8.3)
57
(10.3)
260
(47.0)
181
(32.7)
Naproxen
(N= 553)
5
(0.9)
33
(6.0)
52
(9.4)
277
(50.1)
186
(33.6)
Simvastatin
(N= 554)
18
(3.2)
65
(11.7)
68
(12.3)
232
(41.9)
171
(30.9)
Chloramphenicol
(N= 554)
4
(0.7)
9
(1.6)
24
(4.3)
260
(46.9)
257
(46.4)
6.4.1.14 Evidence base
Respondents’ beliefs in the evidence of efficacy were high with chloramphenicol, naproxen
and omeprazole. Less than one in five, however, agreed in relation to simvastatin, with
approximately a quarter being unsure.
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Table 6.9
I believe that the OTC regimen for this product is likely to
be effective
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 555)
30
(5.4)
99
(17.8)
123
(22.2)
221
(39.8)
82
(14.8)
Naproxen
(N= 554)
14
(2.5)
51
(9.2)
126
(22.7)
265
(47.8)
98
(17.7)
Simvastatin
(N= 557)
139
(25.0)
173
(31.1)
140
(25.1)
79
(14.2)
26
(4.7)
Chloramphenicol
(N= 557)
5
(0.9)
3
(0.5)
17
(3.1)
176
(31.6)
356
(63.9)
6.4.1.15 Naming of newly reclassified medicines
A high majority of the respondents disagreed or strongly disagreed that similarity of POM
and P packs could create confusion in practice. Approximately one in five agreed that the
similarity in the nomenclature of chloramphenicol POM and P packs could create confusion
during sales or supplies.
Table 6.9
The similarity of POM and P packs of this product could
create confusion
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 555)
159
(28.6)
249
(44.9)
100
(18.0)
36
(6.5)
11
(2.0)
Naproxen
(N= 555)
157
(28.3)
260
(46.8)
93
(16.8)
35
(6.3)
10
(1.8)
Simvastatin
(N= 554)
153
(27.6)
249
(44.9)
105
(19.0)
36
(6.5)
11
(2.0)
Chloramphenicol
(N= 555)
136
(24.5)
214
(38.6)
97
(17.5)
75
(13.5)
33
(5.9)
6.4.1.16 Observability of efficacy
A majority of respondents agreed or strongly agreed that it was easy for them or the
patients to know whether therapy with chloramphenicol, naproxen and omeprazole was
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effective. Approximately two thirds disagreed or strongly disagreed to the observable
benefits of simvastatin.
Table 6.9
It is easy for me and/or my customers to know if treatment
with this product is effective
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 551)
27
(4.9)
64
(11.6)
161
(29.2)
238
(43.2)
61
(11.1)
Naproxen
(N= 551)
8
(1.5)
39
(7.1)
145
(26.3)
275
(49.9)
84
(15.2)
Simvastatin
(N= 552)
175
(31.7)
187
(33.9)
136
(24.6)
44
(8.0)
10
(1.8)
Chloramphenicol
(N= 554)
6
(1.1)
13
(2.3)
71
(12.8)
207
(37.4)
257
(46.4)
6.4.1.17 Potential for patient satisfaction
Almost half of the respondents were unsure that simvastatin had potential to engender
patient satisfaction. The majority agreed or strongly agreed that naproxen and
chloramphenicol had potential to engender patient satisfaction with over 38% unsure for
omeprazole.
Table 6.9
I believe this product has potential to engender patient
satisfaction
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 533)
26
(4.9)
60
(11.3)
203
(38.1)
185
(34.7)
59
(11.1)
Naproxen
(N= 535)
20
(3.7)
57
(10.7)
187
(35.0)
209
(39.1)
62
(11.6)
Simvastatin
(N= 533)
71
(13.3)
148
(27.8)
231
(43.3)
63
(11.8)
20
(3.8)
Chloramphenicol
(N= 536)
20
(3.7)
37
(6.9)
102
(19.0)
172
(32.1)
205
(38.2)
6.4.1.18 Safety of medicines
Just under half of the respondents agreed or strongly agreed to naproxen possessing
potential for high risk of adverse events. Almost one third were unsure of the patient safety
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implications with simvastatin. A high majority deemed that safety was not an issue for the
supply of chloramphenicol.
Table 6.9
I believe there are high risks of adverse events associated
with this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N=552)
60
(10.9)
287
(52.0)
159
(28.8)
38
(6.9)
8
(1.4)
Naproxen
(N= 554)
19
(3.4)
129
(23.3)
167
(30.1)
202
(36.5)
37
(6.7)
Simvastatin
(N= 553)
34
(6.1)
168
(30.4)
176
(31.8)
140
(25.3)
35
(6.3)
Chloramphenicol
(N= 555)
100
(18.0)
312
(56.2)
116
(20.9)
24
(4.3)
3
(0.5)
6.4.1.19 ‘Step too far’
A high majority of respondents disagreed or strongly disagreed that reclassification of
omeprazole, naproxen and chloramphenicol was a ‘step too far’ for pharmacy. Over 40% of
the respondents, however, agreed or strongly agreed that reclassification of simvastatin was
a ‘step too far’.
Table 6.9
Introduction of this product may have represented a ‘step
too far’ for OTC Medicines
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 553)
157
(28.4)
252
(45.6)
91
(16.5)
37
(6.7)
16
(2.9)
Naproxen
(N= 554)
164
(29.6)
255
(46.0)
89
(16.1)
30
(5.4)
16
(2.9)
Simvastatin
(N= 554)
98
(17.7)
151
(27.3)
81
(14.6)
134
(24.2)
90
(16.2)
Chloramphenicol
(N= 553)
282
(51.0)
230
(41.6)
30
(5.4)
6
(1.1)
5
(0.9)
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6.4.1.20 Role in decision making
A high majority indicated that their professional decisions were more important or relevant
than recommendations of management or ‘head office’ around their adoption of the listed
medicines into practice.
Table 6.9
It has been my management’s decision rather than my own
as to if/ how far to adopt into practice
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 544)
172
(31.6)
162
(29.8)
102
(18.8)
75
(13.8)
33
(6.1)
Naproxen
(N= 544)
174
(32.0)
162
(29.8)
102
(18.8)
74
(13.6)
32
(5.9)
Simvastatin
(N= 545)
172
(31.6)
155
(28.4)
99
(18.2)
79
(14.5)
40
(7.3)
Chloramphenicol
(N= 546)
184
(33.7)
170
(31.1)
101
(18.5)
62
(11.4)
29
(5.3)
6.4.1.21 External support: Professional body
The majority of respondents reflected satisfaction with the support they were receiving
from their professional body. Approximately a third, however, were unsure about the
adequacy of such support for all four medicines.
Table 6.9
I get adequate support from my professional body to adopt
this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 551)
20
(3.6)
55
(10.0)
179
(32.5)
228
(41.4)
69
(12.5)
Naproxen
(N= 550)
19
(3.5)
55
(10.0)
182
(33.1)
228
(41.5)
66
(12.0)
Simvastatin
(N= 552)
28
(5.1)
63
(11.4)
188
(34.1)
212
(38.4)
61
(11.1)
Chloramphenicol
(N= 546)
15
(2.7)
37
(6.7)
147
(26.6)
250
(45.2)
104
(18.8)
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6.4.1.22 External support: Local medical practice
The majority of the respondents disagreed or strongly disagreed that lack of local medical
practice communication was a barrier to their adopting any of the four listed medicines into
practice.
Table 6.9
Lack of proper way to communicate with the local medical
practice is a barrier to adopt this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N=548)
101
(18.4)
210
(38.3)
175
(31.9)
50
(9.1)
12
(2.2)
Naproxen
(N= 548)
99
(18.1)
223
(40.7)
179
(32.7)
36
(6.6)
11
(2.0)
Simvastatin
(N= 549)
89
(16.2)
185
(33.7)
171
(31.1)
79
(14.4)
25
(4.6)
Chloramphenicol
(N= 550)
129
(23.5)
229
(41.6)
161
(29.3)
23
(4.2)
8
(1.5)
6.4.1.23 Access to patient medical records
Over 53% and 30% of the respondents had agreement that lack of access to patient medical
records was a barrier to adopting simvastatin and omeprazole into practice respectively.
The majority did not consider that access to patient medical records was important for the
adoption of chloramphenicol.
Table 6.9
Lack of access to patient medical records makes it difficult
to adopt this product into practice
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 553)
55
(9.9)
185
(33.5)
145
(26.2)
130
(23.5)
38
(6.9)
Naproxen
(N= 553)
60
(10.8)
206
(37.3)
143
(25.9)
116
(21.0)
28
(5.1)
Simvastatin
(N= 554)
42
(7.6)
113
(20.4)
104
(18.8)
204
(36.8)
91
(16.4)
Chloramphenicol
(N= 555)
148
(26.7)
263
(47.4)
95
(17.1)
30
(5.4)
19
(3.4)
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6.4.1.24 Supply off guidelines
Although a high majority of respondents disagreed or strongly disagreed that they were
comfortable supplying any of the listed medicines off guidelines, approximately one in five
indicated they supply chloramphenicol off guideline where required.
Table 6.9
I am/would be comfortable going off guidelines to supply
this product
Medicines
Strongly
disagree
n (%)
Disagree
n (%)
Neither
agree nor
disagree
n (%)
Agree
n (%)
Strongly
agree
n (%)
Omeprazole
(N= 550)
125
(22.7)
253
(46.0)
82
(14.9)
73
(13.3)
17
(3.1)
Naproxen
(N= 551)
130
(23.6)
265
(48.1)
79
(14.3)
60
(10.9)
17
(3.1)
Simvastatin
(N= 551)
162
(29.4)
269
(48.8)
71
(12.9)
34
(6.2)
15
(2.7)
Chloramphenicol
(N= 553)
120
(21.7)
241
(43.6)
73
(13.2)
87
(15.7)
32
(5.8)
6.4.2 Summary of descriptive statistics
Descriptive analysis reflected respondents’ key barriers and facilitators to decision making.
Support for the reclassified status and adoption into practice were rated very high by the
respondents with the case of chloramphenicol, followed by naproxen and omeprazole.
Respondents’ ratings of simvastatin around both the key outcomes acceptance and
adoption were very low. Key differences in respondents’ agreement were observed in 12 of
the 24 listed items. The differences in proportion lying within categories ‘agree’ or ‘strongly
agree’ across four medicines were mainly noted around 12 of the 24 items listed below.
Within these 12 items, proportion of respondents agreeing or strongly agreeing mostly
followed the pattern chloramphenicol > naproxen> omeprazole> simvastatin where items
were positive; and the reverse order where the items were negative.
1. Opportunity to increase role as a health professional
2. Customers complaints about the cost
3. Patients requests for the medicines
4. Belief that the medicine a welcome addition to the range of pharmacy medicine
5. Therapeutic area of reclassified medicine matching with business/service ambition
of pharmacy
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6. Financial potential of the medicine
7. Complexity of supply process
8. Comfortable in delegating the task of supplying the product to support staff
9. Believe in evidence of efficacy of the non-prescription dose of the medicines
10. Observability of efficacy
11. Medicine potential to engender patient satisfaction
12. Perceived need for access to patient medical records for the supply
Differences in such proportion across ‘agree’ and ‘strongly agree’ were less notable in items
measuring aspects of practice such as adequacy of resources to inform supply; adequacy of
information sources and external support.
6.5 ANALYSIS OF RESPONSES TO OPEN QUESTION
Eighty-two respondents provided comments in response to the open questions. These
responses were analysed by content analysis method as detailed in Chapter 2 (section
2.4.4.3) and are summarised in table 6.10.
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Table 6.10 Responses to open question on factors associated with decision making*
(Note: this table extends up to two pages)
Response
categories
Number of
responses
Exemplar quotes (Respondent code)
Retail price of
medicines/
patient cost
implications
33 “Cost affects my patients esp as I work in a low income/high
unemployment area” (R28)
“Price- pharmacy in quite deprived area. So I don’t keep
expensive items. ” (R29)
“The local market. i.e. patients will not pay for a new brand
medicine if they may be able to obtain it free on NHS
prescription. ” (R139)
“Don't recommend if expensive and there are other effective
but less expensive items available.” (R302)
Evidence base 9 “Is the dose effective? Many of the products have doses below
the apparent therapeutic dose of the prescription product.
Loads of questions about their effectiveness. ” (R332)
Pharmacy
resources
9 “Time- both talking to patient/ and or staff training.” (R509)
“No time to go through lengthy advice giving plus questioning
sessions.” (R528)
Patient
demand
6 “Purely cost/ demand. I don’t store Zocor (simvastatin)
because no one has asked for it. ” (R173)
Access to
patient medical
records
5 “With omeprazole + simvastatin need to check PMR (patient
medical records) held at GP and blood levels for
simvastatin.”(R61)
“The fact that I have been here 6 years, know all my patients
well, know my GPs etc. Confidence in their histories etc. ”
(R63)
Perceived risk
assessment
needs
(Complexity)
5 “Not able to carry out tests to monitor.”(R33)
“Complexity of some of the processes you must comply with
can be time consuming.” (R234)
Safety 4 “Potential side effects and interactions.” (R67)
“As an independent contractor I use my own professional
judgement on safety of products to sell as P's.” (R490)
Training 4 “Inadequate training material from manufacturers would
discourage me from stocking product.” (R287)
“Adequate plus robust training packaging for my staff.”(R106)
Acute vs
chronic
indication
3 “Long term treatment should be from GP!”(R195)
*Some respondents provided more than one comment
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Response
categories
Number of
responses
Exemplar cotes (Respondent code)
Pharmacists’
confidence
3 “Lack of confidence initially with new POM to P
products.”(R432)
“Gaps in our product knowledge- keeping up to date with
POM to P switches due to work demands.” (R390)
“Certain POM to P switch occurred before I qualified, not
always easy to find current info on them to be able to
recommend.” (R205)
Guidelines 2 “Health board PGD's. Health Board communications on their
opinion of product in area” R399
Past experience
with use
2 “Previous experience in use.” (R559)
Novelty/whether
a welcome
addition to
pharmacy
2 “Similar products already available (R155)
“If the product is a "me too" product I am likely to stick with
existing or less expensive products.”(R302)
Organisational
implementation
decision
2 “We have no choice, head office tells us, we are doing it.”
(R295)
Communication
with local medical
practice
1 “I would be comfortable as long as there is support and
communication with medical practice.”(R323)
Expiry date 1 “Expiry date of the product.”(R128)
Full time/part
time
1 “Whether full-time/ part time may be a factor.”(R77)
Patient
compliance issues
1 “Patients wanting/ expecting to purchase because wow OTC +
not listening to recommendations.” (R342)
Perceived
innovativeness/at
titudes to change
1 “My team and I embrace and welcome change.”(R53)
Pharmacy
business interests
1 “HC pharmacy. Very few OTC sales. ” (R143)
Prescribing
qualification of
respondent
1 “I am an independent prescriber.” (R170)
Unclear quotes 4 “Don't think that simvastatin should be OTC- waste of money,
time.”(R361)
“Confidentiality issues” (R73)
“When I don’t agree with the drug. e.g. Orlistat. ” (R79)
“I don’t feel Omeprazole or naproxen are necessary for OTC.
Naproxen, chloramphenicol useful particularly over a
weekend. ” (R159)
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6.6 BIVARIATE/ MULTIVARIATE ANALYSIS
Descriptive analysis as shown above were used to present responses to the outcome
measures and to the 24 items scales. So as to further understand factors associated with
decision making, it is also important to distinguish why, for example, some respondents
rated naproxen very highly, whereas others did not. Such understanding will be enabled
via multivariate/bivariate analysis as detailed below.
6.6.1 Principal component factor analysis
Factor analysis was performed on the 24 items scale measuring facilitators/barriers to
decision making using principal component analysis for each of the listed medicines. This
analysis was conducted to potentially reduce the 24 item scale to a smaller number of
meaningful factors so that these reduced items. Responses to all negative items were
reversed scored for this analysis to ease interpretation. Kaiser-Meyer-Olkin measure of
sampling adequacy (KMO) and Barlett’s test of sphericity was used to identify whether
factor analysis was appropriate for the results. KMO measure represents the squared
correlation between the variables to the squared partial correlation (correlation between
two variables while adjusting for the third variable) between the variables. KMO value
close to 0 indicates that the factor analysis is likely to be inappropriate, whereas value close
to 1 indicates that factor analysis should yield distinct and reliable factors [295]. Barlett’s
test of sphericity tests the strengths of correlations between the variables. A significant
correlation means it is apt to proceed for the factor analysis [295]. Cronbach’s alpha
measure was used to test the reliability of how closely the extracted items within a
component relate to each other. Components with Cronbach’s alpha ≥0.7 are known to be
considered reliable. Whereas, the alpha value for ‘if any item is removed from the scale’
should not exceed 0.8 [295].
6.6.1.1 Omeprazole
The KMO measure of sampling adequacy was 0.854 and Barlett’s test of sphericity was
significant (Chi square = 2882.86 p <0.001) reflecting it was appropriate to continue with
factor analysis. Visual inspection of the Scree plot (figure 6.6), the number of factors with an
eigenvalue greater than 1 and item loadings on factors well above 0.4 showed that six
components could be extracted (table 6.12). These six components accounted for over 52%
of the variance in the data (table 6.11).
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Figure 6.6: Scree plot for omeprazole principal component factor analysis*
Number of components
*Method of extraction used: Principal component with varimax rotation and Kaiser
normalization.
Table 6.11: Percentage variance of the six components that were extracted from factor analysis
of 24 items for omeprazole
Component
Initial Eigenvalues
Rotation Sums of Squared
Loadings
Total % Variance
Cumulative
% Total
% of
Variance
Cumulative
%
1 5.215 21.728 21.728 4.016 16.734 16.734
2 2.507 10.447 32.176 2.452 10.215 26.949
3 1.395 5.813 37.989 1.805 7.522 34.471
4 1.235 5.147 43.136 1.552 6.467 40.938
5 1.123 4.680 47.816 1.533 6.387 47.325
6 1.063 4.429 52.245 1.181 4.920 52.245
However, the rotated component matrix table (table 6.12) showed that items retained
within each components were difficult to interpret, with scale items having very different
meanings from both theory [131] and practice points of view. These six factors also failed to
meet the reliability test based either on Cronbach’s alpha ≥0.7 or Cronbach’s alpha for ‘if
items removed from the scale’ >0.8 [295].
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Table 6.12: Rotated component matrix showing factor analysis of 24 items for omeprazole*
Items Component
1 2 3 4 5 6
This is/was a good opportunity to extend my role as a
health professional .815 .081 -.032 -.066 -.024 -.088
This product matches with the business/service
ambitions of my pharmacy .810 .061 .040 -.137 -.004 -.042
This product has potential for good financial returns for
my pharmacy .684 -.164 .009 .056 .172 .151
I believe that this product is a welcome addition to the
range of pharmacy medicines .762 .119 .147 .233 .042 -.146
I believe that the OTC regimen for this product is likely
to be effective .707 .095 .090 .118 .125 -.086
It is easy for me and/or my customers to know if
treatment with this product is effective .578 .199 .037 .119 .187 .097
I believe this product has potential to engender patient
satisfaction .508
-2.67E-
005 -.018 .292 .142 .073
Many customers ask for this product by name .390 .073 -.368 .218 -.040 .222
It is likely that customers could misuse this product† .026 .709 -.013 -.110 -.022 .112
Customers not accepting my advice around this product
makes me less likely to adopt this product† .031 .660 .066 .180 .030 .133
Insufficient resources (e.g. staff, space etc) within my
pharmacy has limited the practice of this product† .026 .522 .249 .085 .134 -.093
I believe there are high risks of adverse events associated
with this product† .102 .482 .353 -.126 .055 -.077
I find the processes involved in the supply of this
product complex† .174 .470 .164 .458 .056 -.126
Lack of access to patient medical records makes it
difficult to adopt this product into practice† .188 .407 .423 .043 .258 .273
Introduction of this product may have represented a
‘step too far’ for OTC Medicines† .422 .310 .565 .097 -.057 -.090
The similarity of POM and P packs of this product could
create confusion†
-
.023 .010 .653 .201 .166 -.083
It has been my management’s decision rather than my
own as to if/ how far to adopt into practice† .017 .188 .554 -.134 -.084 .017
I am/would be comfortable going off guidelines to
supply this product .062 -.121 .073 .738 -.113 .010
I am happy to delegate the task of supplying this product
to support staff .140 .182 -.114 .573 .146 .076
I get adequate support from my professional body to
adopt this product .190 -.038 .027 .000 .761 -.069
Lack of proper way to communicate with the local
medical practice is a barrier to adopt this product† .069 .225 .379 -.009 .571 .316
I have access to sufficient sources of information relating
to this product .183 .360 -.113 .095 .525 -.372
I feel confident about my ability to supply this product .217 .369 .034 .267 .289 -.464
My customers often complain about the cost of this
product (not including e-MAS supply)† .035 .140 -.095 .100 .012 .664
*Method of extraction used: Principal component, Rotation used: Varimax with Kaiser
normalization. Values equal to or above 0.4 are highlighted; †Items reversed scored
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The following tables summarize the overall Cronbach’s alpha value and overall alpha value
if any item was deleted for each of the retained component (table 6.13).
Table 6.13: Reliability analysis for components 1-5 extracted from factor analysis of 24 item
evaluation scale of omeprazole. (Not this table extends up to five pages with descriptions in
between)
Component 1
Item
Scale
mean if
item
deleted
Scale
variance
if item
deleted
Corrected
item-total
correlation
Cronbach's
alpha if
item
deleted
This is/was a good opportunity to extend my
role as a health professional 23.91 26.614 .663 .814
This product matches with the business/service
ambitions of my pharmacy 24.13 26.353 .657 .814
This product has potential for good financial
returns for my pharmacy 24.43 26.616 .530 .831
I believe that this product is a welcome addition
to the range of pharmacy medicines 23.88 25.004 .723 .804
I believe that the OTC regimen for this product
is likely to be effective 23.99 26.255 .642 .815
It is easy for me and/or my customers to know
if treatment with this product is effective 23.96 28.246 .521 .831
I believe this product has potential to engender
patient satisfaction 24.05 28.822 .460 .838
Introduction of this product may have
represented a ‘step too far’ for OTC Medicines 23.51 29.219 .416 .843
Overall Cronbach’s alpha for the component .843
Component 2
Item
Scale
mean if
item
deleted
Scale
variance
if item
deleted
Corrected
item-total
correlation
Cronbach's
alpha if
item
deleted
It is likely that customers could misuse this
product 17.48 11.162 .386 .650
Customers not accepting my advice around this
product makes me less likely to adopt this
product
17.72 10.763 .462 .622
Insufficient resources (e.g. staff, space etc)
within my pharmacy has limited the practice of
this product
17.18 11.249 .407 .641
I believe there are high risks of adverse events
associated with this product 17.33 12.621 .374 .654
I find the processes involved in the supply of
this product complex 17.31 11.768 .407 .642
Lack of access to patient medical records makes
it difficult to adopt this product into practice 17.81 11.046 .438 .630
Overall Cronbach’s alpha for the component .843
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Component 3
Item
Scale
mean if
item
deleted
Scale
variance
if item
deleted
Corrected
item-total
correlation
Cronbach's
alpha if
item
deleted
The similarity of POM and P packs of this
product could create confusion 10.74 5.612 .270 .517
Introduction of this product may have
represented a ‘step too far’ for OTC Medicines 10.76 4.772 .460 .368
It has been my management’s decision rather
than my own as to if/ how far to adopt into
practice
10.99 4.805 .262 .542
Lack of access to patient medical records
makes it difficult to adopt this product into
practice
11.50 4.785 .352 .452
Overall Cronbach’s alpha for the component .544
Component 4
Item
Scale mean
if item
deleted
Scale
variance
if item
deleted
Corrected
item-total
correlation
Cronbach's
alpha if
item
deleted
I find the processes involved in the supply
of this product complex 4.99 2.797 .275 .262
I am/would be comfortable going off
guidelines to supply this product 6.38 2.867 .199 .395
I am happy to delegate the task of
supplying this product to support staff 5.93 2.407 .260 .282
Overall Cronbach’s alpha for the component .408
Component 5
Item
Scale
mean if
item
deleted
Scale
variance
if item
deleted
Corrected
item-total
correlation
Cronbach's
alpha if
item
deleted
I get adequate support from my
professional body to adopt this product 7.63 2.174 .347 .321
Lack of proper way to communicate with
the local medical practice is a barrier to
adopt this product
7.50 2.343 .278 .439
I have access to sufficient sources of
information relating to this product 7.11 2.321 .298 .406
Overall Cronbach’s alpha for the component .490
Component 6
Cronbach’s alpha value for component 6 was found to be negative due to a negative
average covariance among items. This violated reliability model assumptions and thus
results are not presented.
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6.6.1.2 Naproxen, chloramphenicol and simvastatin
Factor analysis of the 24-items scale relating to napoxen, chloramphenciol and simvastatin
also displayed similar issues in terms of items with dissimilar meanings aggregating
together as one factor, as well as failing the reliability tests. Table 6.14 summarises the
analysis. Details of factor analysis of these three medicines appear in Appendix VI.
Table 6.14: Summary of principal component factor analysis
Reclassified
medicines
Total number of
components
extracted
Number of
reliable
components
extracted
% variance
explained by
the reliable
component(s)
Omeprazole 6 0 0%
Naproxen 7 1 14%
Simvastatin 6 1 15%
Chloramphenicol 8 0 0%
6.6.1.3 Summary of factor analysis
Factors associated with decision making could not be extracted from principal component
factor analysis as described above. These results reflect that although items within the scale
align to theoretical constructs as shown in Chapter 5, each item within the 24-item scales is
more likely to represent unique issues to practice. Hence, each of the 24 individual items
within the scale were used in further analyses, attempting to differentiate respondents’
ratings of acceptance and adoption
6.6.2 Binary logistic regression analysis
Binary logistic regression analysis was performed to differentiate respondents scoring the
outcome measures of support and adoption differently. Factors associated with decision
making could further be understood by exploring from the regression analysis, for
example, why some respondents rated omeprazole very highly than others. For the purpose
of this analysis, the following variables were defined:
Outcome measures
Binary logistic regression analysis requires binary outcomes. Outcome measure scales (and
some explanatory variables discussed below) were redefined as per the approach of
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systematic review studies [250,255,272,281] for each of the four medicines, separately as
follows:
A. Respondent scores on ‘Acceptance’ scale. Those scoring 3 or above in the scale
(termed high acceptors) versus others (termed low acceptors)
B. Respondent scores on ‘Adoption’ scale: Those scoring 3 or above in the scale
(termed high adopters) versus others (termed low adopters)
Explanatory (dependent) variables
Respondent agreement with each of the items of the 24 items scale and the demographic
characteristics were used as explanatory variables. All responses on the 24-items scale and
four of 13 demographic characteristics were also modified to binary variables along with
perceived innovativeness.
A. Agreement: Agree and strongly agree as ‘high agreement’; and the remainder of the
responses as ‘low agreement’
B. Innovativeness: Resistant, cautious or deliberate; and role model or venturesome
C. Age: 39 years or under; and 40 years or over
D. Number of years registered with RPSGB: 10 years and under; and 11 years or over
E. Size of pharmacy ownership: Independent or small multiple; and medium or large
size multiple
Short listing of explanatory variables for regression analysis
Cross tabulation analysis of all the explanatory variables with both outcome measures for
each medicine were conducted using Chi-squared tests or Fisher’s exact test. Responses to
all negative items were reversed scored to ease interpretation of the output. Only those
explanatory variables that had significant association with the outcome measures, based on
P value ≤ 0.05, were entered into the regression analysis. Both the univariate and
multivariate statistics are reported for one of the analyses relating to the outcome
‘omeprazole acceptance’. Only the multivariate outputs are shown for other outcomes, with
univariate cross tabulation analysis appearing in Appendix VI. The items reported within
the multivariate analyses in the following sections has been based on the standards set out
by the American Psychological Association (APA) as detailed by Field (2005) [295].
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Regression method
Stepwise regression method, called Forward LR method was used. This is a method of
binary logistic regression, whereby the SPSS begins with developing a model starting with
only the regression constant and adds one explanatory variable at a time based on such
variables making significant prediction of the outcome measure. The analytical process is
proceeded until none of the remaining predictors make any further contribution to the
model. At each step, the SPSS also is known to examine if any of the explanatory variable
can be removed. Though other methods to conduct binary logistic regression are also
known to exist, Forward LR method is said to be suitable to conduct regression on research
where no previous similar models are known to exist [295].
6.6.2.1 Omeprazole acceptance
Eighteen explanatory variables showed significant association with the outcome in
univariate analyses. The cross tabulation analysis showed that: 81.4% of the respondents
that had high agreement that omeprazole has a good financial potential for pharmacy were
likely to have scored 3 or more in the five point ‘acceptance’ scale as compared to only
55.8% of those disagreeing or were unsure about the financial potential of the medicine. In
other words, the more the respondents saw the financial potential of the medicine, the more
they were likely to support the reclassified status of the medicine. The rest of the statements
should to be interpreted accordingly. Only significant associations are displayed in the table
below. Non-significant associations appear in Appendix VI.
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Table 6.15: Univariate cross tabulation statistics of explanatory variables and significant
association with the outcome ‘omeprazole acceptance’ (note: this table extends up to two
pages)
Scale items Categories¥ Low
acceptance
n (%)*
High
acceptance
n (%)*
P value
This product has potential for
good financial returns for my
pharmacy (N= 543)
Low agreement 159
(44.2)
201
(55.8)
<0.001
High agreement 34
(18.6)
149
(81.4)
This is a good opportunity to
extend my role as a health
professional (N= 549)
Low agreement
High agreement
157
(59.5)
38
(13.3)
107
(40.5)
247
(86.7)
<0.001
This product matches with the
business/service ambitions of
my pharmacy (N= 549)
Low agreement 168
(51.1)
161
(48.9)
<0.001
High agreement 27
(12.3)
193
(87.7)
Customers not accepting my
advice around this product
makes me less likely to adopt
this product† (N= 545)
Low agreement 122
(38.6)
194
(61.4)
0.039
High agreement 68
(29.7)
161
(70.3)
I find the processes involved in
the supply of this product
complex† (N= 546)
Low agreement 89
(43.0)
118
(57.0)
0.004
High agreement 103
(30.4)
236
(69.6)
I am happy to delegate the task
of supplying this product to
support staff (N= 546)
Low agreement 145
(38.9)
228
(61.1)
0.007
High agreement 46
(26.6)
127
(73.4)
Many customers ask for this
product by name (N= 547)
Low agreement 181
(36.8)
311
(63.2)
0.020
High agreement 11
(20.0)
44
(80.0)
I feel confident about my ability
to supply this product (N= 548)
Low agreement 50
(69.4)
22
(30.6)
<0.001
High agreement 143
(30.0)
333
(70.0)
I believe that this product is a
welcome addition to the range
of pharmacy medicines (N= 550)
Low agreement 142
(64.3)
79
(35.7)
<0.001
High agreement 52
(15.8)
277
(84.2)
I have access to sufficient
sources of information relating
to this product (N= 547)
Low agreement 58
(51.8)
54
(48.2)
<0.001
High agreement 135
(31.0)
300
(69.0)
I believe that the OTC regimen
for this product is likely to be
effective (N= 549)
Low agreement 140
(56.0)
110
(44.0)
<0.001
High agreement 53
(17.7)
246
(82.3)
¥High agreement refers to agree or strongly agree. Low agreement refers to either disagree,
strongly disagree or unsure* % represents proportion of respondents within row categories;
Low acceptance relate to respondents score 1 or 2 in the five point scale. High acceptance relate
to score 3 or above.† Items reversed scored
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Scale items/variables Categories Low
acceptance
n (%)
High
acceptance
n (%)
P
value
It is easy for me and/or my
customers to know if treatment
with this product is effective
(N= 545)
Low agreement 122
(49.0)
127
(51.0)
<0.001
High agreement 68
(23.0)
228
(77.0)
I believe this product has
potential to engender patient
satisfaction (N= 527)
Low agreement 130
(45.3)
157
(54.7)
<0.001
High agreement 54
(22.5)
186
(77.5)
Introduction of this product
may have represented a ‘step
too far’ for OTC Medicines†
(N= 547)
Low agreement 78
(54.2)
66
(45.8)
<0.001
High agreement 114
(28.3)
289
(71.7)
Lack of access to patient medical
records makes it difficult to
adopt this product into practice†
(N= 547)
Low agreement 121
(38.9)
190
(61.1)
0.040
High agreement 71
(30.1)
165
(69.9)
Experience (N= 547) 10 years and
under
116
(40.8)
168
(59.2)
0.011
11 years or over 79
(30.0)
184
(70.0)
Owner (N= 554) Yes 18
(18.6)
79
(81.4)
<0.001
No 178
(38.9)
279
(61.1)
Manager (N= 554) Yes 160
(40.1)
239
(59.9)
<0.001
No 36
(23.2)
119
(76.8)
† items reversed scored
The eighteen variables found to have significant association with the outcome were entered
into regression analysis using the Forward LR stepwise method. Six variables were retained
in the final binary logistic model. The strongest association was observed with the item
measuring whether omeprazole was a welcome addition to pharmacy ranges of medicines.
Those agreeing with this statement were approximately three times more likely to have
rated their support for the reclassified status of medicines 3 or more in the five point scale
than those having less agreement. Ownership status was also strongly related with owners
indicating more support for the reclassified status than employees. The significant Wald
statistic suggests that the B-coefficient is significantly different from zero, indicating that
each of the six variables was making a significant contribution to the model. The ‘model if
item removed’ statistic also indicates that each item has an important contribution to make
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to the final model, significantly altering the predictive power of the model if removed (table
6.16).
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Table 6.16: Binary logistic regression model of the outcome ‘omeprazole acceptance’ with the explanatory variables
Items retained in the model Wald
P
value
Exp(B)
(odds
ratio)*
95.0% C.I.for EXP(B) Model if item removed
Lower Upper Model LogLikelihood
Change in -2
Log
Likelihood
P value of
the
Change
This is a good opportunity to extend my role
as a health professional 11.543 0.001 2.582 1.494 4.463 -231.818 11.712 0.001
This product matches with the
business/service ambitions of my pharmacy 6.153 0.013 2.217 1.182 4.158 -229.101 6.279 0.012
I feel confident about my ability to supply this
product 5.763 0.016 2.291 1.164 4.508 -228.967 6.011 0.014
I believe that this product is a welcome
addition to the range of pharmacy medicines 21.883 0.000 3.374 2.027 5.616 -237.040 22.157 <0.001
I believe that the OTC regimen for this
product is likely to be effective 10.344 0.001 2.247 1.372 3.679 -231.096 10.267 0.001
(Not an) Owner 7.539 0.006 .385 .195 .761 -230.070 8.217 0.004
Regression constant 4.593 .032 .394
* for score 3 or above
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The highly significant model Chi-square value (p<0.001) in the table suggested that the
model significantly improved with the explanatory variables that were retained in the
model, than when only the regression constant was included. Both the Cox and Snell R
square and Nagelkerke R square values suggest that the explanatory variables were useful
predictors of the outcome (a value close to 0 suggests that explanatory variables are useless
and close to 1 indicates the outcome is predicted perfectly [295]). The Hosmer and
Lemeshow test goodness of fit statistics was not significant suggesting that observed data
were not significantly different from the values predicted by the model (table 6.17).
Table 6.17: Regression model statistics relating to outcome ‘omeprazole acceptance’ (Note:
this table is divided into three parts within this page)
Omnibus Tests of Model Coefficients
Chi-
square Df P value
Step 5.982 1 0.014
Block 198.098 6 <0.001
Model 198.098 6 <0.001
Df: degree of freedom
Model summary with -2 Log likelihood ratio and R2 values.
-2 Log
likelihood
Cox & Snell R
Square
Nagelkerke R
Square
451.924(b) .326 .449
Hosmer and Lemeshow Test statistics
Chi-square P value
5.1193.471 0.645
6.6.2.2 Omeprazole adoption
Twenty-two explanatory variables showed significant associations with this outcome in
univariate analysis (Appendix VI). Of these, seven were retained in the regression model.
The strongest odds ratio was obtained with the item measuring confidence in supply where
those reflecting greater confidence in supply matters were approximately five times more
likely to have rated their adoption 3 or more in the five point ‘adoption’ scale as compared
to those who stated low confidence in supply matters. The rest of the variables should be
interpreted accordingly (table 6.18). None of the 14 demographic characteristics were
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retained in the multivariate model although three of them showed association in the
univariate analyses (Appendix VI).
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Table 6.18: Binary logistic regression model of the outcome ‘omeprazole adoption’ with explanatory variables
Items retained in the model Wald
P
value
Exp(B)
(odds
ratio)*
95.0% C.I.for EXP(B) Model if item removed
Lower Upper Model LogLikelihood
Change in -2
Log
Likelihood
P value of
the
Change
This is a good opportunity to extend my role
as a health professional 4.681 0.031 1.955 1.065 3.588 -222.274 4.720 0.030
This product matches with the
business/service ambitions of my pharmacy 7.798 0.005 2.201 1.265 3.830 -223.882 7.936 0.005
I am happy to delegate the task of supplying
this product to support staff 8.207 0.004 2.024 1.249 3.278 -224.037 8.246 0.004
Many customers ask for this product by
name 11.966 0.001 3.478 1.716 7.048 -226.045 12.263 <0.001
I feel confident about my ability to supply
this product 4.505 0.034 5.050 1.132 22.529 -223.218 6.609 0.010
I believe that this product is a welcome
addition to the range of pharmacy medicines 3.929 0.047 2.004 1.008 3.984 -221.944 4.060 0.044
I believe that the OTC regimen for this
product is likely to be effective 9.345 0.002 2.460 1.381 4.381 -224.770 9.712 0.002
Constant 38.227 <0.001 .008
* for score 3 or above
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The model Chi-square value was highly significant (P <0.001). Both the Cox and Snell R
square and Nagelkerke R square values suggested the explanatory variables were making
important contribution. Hosmer and Lemeshow test goodness of fit statistics was not
significant suggesting that observed data were not significantly different from the values
predicted by the model (table 6.19).
Table 6.19: Regression model statistics relating to outcome ‘omeprazole adoption’ (note: this
table is divided into three parts with descriptions in between)
Omnibus Tests of Model Coefficients
Chi-
square Df P value
Step 4.720 1 0.030
Block 142.217 7 <0.000
Model 142.217 7 <0.000
Df: degree of freedom
Model summary
-2 Log
likelihood
Cox & Snell R
Square
Nagelkerke R
Square
439.828(b) .250 .361
Hosmer and Lemeshow Test statistics
Chi-square P value
3.471 .838
6.6.2.3 Naproxen acceptance
Seventeen variables showed significant association with the outcome ‘naproxen
acceptance’. Five were retained in the regression model. The highest odds ratio was
observed with the item ‘opportunity to extend professional role’ (table 6.20).
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Table 6.20: Binary logistic regression model of the outcome ‘naproxen acceptance’ with the explanatory variables
Items retained in the model Wald Pvalue
Exp(B)
(odds
ratio)*
95.0% C.I. for
EXP(B) Model if item removed
Lower Upper Model LogLikelihood
Change in -2
Log
Likelihood
P value of
the
Change
This is a good opportunity to extend my role
as a health professional 19.140 0.000 3.735 2.070 6.741 -188.584 19.558 0.000
This product matches with the
business/service ambitions of my pharmacy 9.824 0.002 2.823 1.475 5.400 -183.919 10.229 0.001
I believe that this product is a welcome
addition to the range of pharmacy medicines 10.819 0.001 2.623 1.476 4.658 -184.152 10.694 0.001
I believe that the OTC regimen for this
product is likely to be effective 9.234 0.002 2.348 1.354 4.070 -183.367 9.123 0.003
Size of pharmacy ownership (Medium or large
multiples) 3.962 0.047 1.735 1.008 2.984 -180.769 3.928 0.047
Constant
18.705 <0.001 .313
* for score 3 or above
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The model Chi-square value was highly significant (P <0.001). Both the Cox and Snell R
square and Nagelkerke R square values suggested the explanatory variables retained were
making important contributions. Hosmer and Lemeshow test goodness of fit statistics was
not significant suggesting that observed data are not significantly different from the values
predicted by the model (table 6.21).
Table 6.21: Regression model statistics relating to outcome ‘naproxen acceptance’ (note: this
table is divided into three parts with descriptions in between)
Omnibus Tests of Model Coefficients
Chi-
square Df P value
Step 3.928 1 .047
Block 157.203 5 <0.001
Model 157.203 5 <0.001
Df: degree of freedom
Model summary
-2 Log
likelihood
Cox & Snell R
Square
Nagelkerke R
Square
357.610(a) .279 .424
Hosmer and Lemeshow Test statistics
Chi-square P value
5.987 0.541
6.6.2.4 Naproxen adoption
The 26 variables that were significant in univariate analysis were entered into the regression
analysis. Using ‘Forward LR’ as the stepwise method, seven were retained in the final
model. The strongest association was observed with the item measuring respondent
agreement about whether naproxen was a welcome addition to pharmacy ranges of
medicines (table 6.22).
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Table 6.22: Binary logistic regression model of the outcome ‘naproxen adoption’ with the explanatory variables
Items retained in the model Wald Pvalue
Exp(B)
(Odds
ratio)*
95.0% C.I. for EXP(B) Model if item removed
Lower Upper
Model
Log
Likelihoo
d
Change in -2
Log
Likelihood
P value of
the
Change
This is a good opportunity to extend my role
as a health professional 8.044 0.005 2.160 1.269 3.678 -242.275 8.027 0.005
This product matches with the
business/service ambitions of my pharmacy 15.657 <0.001 2.624 1.627 4.231 -246.084 15.646 <0.001
My customers often complain about the cost of
this product (not including e-MAS supply)† 5.487 0.019 1.759 1.097 2.822 -241.034 5.545 0.019
Many customers ask for this product by name 7.199 0.007 2.172 1.233 3.829 -241.988 7.453 0.006
I believe that this product is a welcome
addition to the range of pharmacy medicines 21.127 <0.001 3.890 2.180 6.941 -249.520 22.518 <0.001
Innovativeness (Role model or venturesome) 10.502 0.001 2.128 1.348 3.359 -243.633 10.743 0.001
Size of pharmacy ownership
(Medium or Large multiples) 16.192 <0.001 2.742 1.678 4.483 -246.673 16.823 <0.001
Constant 89.572 <0.001 .031
† Item reversed scored; * for score 3 or above
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The model Chi-square value was highly significant (P <0.001). Both the Cox and Snell R
square and Nagelkerke R square values suggested the explanatory variables retained were
making important contribution. Hosmer and Lemeshow test goodness of fit statistics was
not significant suggesting that observed data are not significantly different from the values
predicted by the model (table 6.23).
Table 6.23: Regression model statistics relating to outcome ‘naproxen adoption’ (note: this
table is divided into three parts with descriptions in between)
Omnibus Tests of Model Coefficients
Chi-
square Df P value
Step 5.545 1 0.019
Block 171.032 7 <0.001
Model 171.032 7 <0.001
Df: degree of freedom
Model summary
-2 Log
likelihood
Cox & Snell R
Square
Nagelkerke R
Square
476.523 .306 .409
Hosmer and Lemeshow Test statistics
Chi-square P value
14.565 0.068
6.6.2.5 Simvastatin
With only a small minority of respondents rating their support for and adoption into
practice of simvastatin on the higher side of the five-point scale, it was not possible to
undertake logistic regression analysis with either of the outcome measures. This analysis, as
previously mentioned requires at least 5-10 respondents per explanatory variable on each
side of the binary outcomes that are to be entered into the regression analysis [295]. Hence
only the bivariate analysis was undertaken with the both the outcome measures to each of
the 24-items scale, demographic characteristics and self innovativeness without merging
any response categories using Kendal’s T measures. Correlation was deemed adequate for
Kendal’s T values ≥.2 and showing significant P values and are presented in table 6.24
below. Values in the order of .1 have been suggested as weak correlation [295].
Out of the 38 variables subjected to such correlation analysis, ten and eight items showed
correlation value of ≥.2 with the outcome simvastatin ‘acceptance’ and ‘adoption’
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respectively. The item ‘I believe that the product is a welcome addition to pharmacy
medicines’ showed the strongest correlation with both the outcomes having Kendal’s T
correlation values of .3 or above (table 6.24). The opportunity to extend professional role,
therapeutic area matching with pharmacy service ambitions, belief in evidence of efficacy
also showed strong correlations with both the outcomes (table 6.24).None of the thirteen
demographic characteristics or the perceived innovativeness demonstrated Kendal’s T
value of ≥.2 (Appendix VI). All bivariate correlation Kendal’s T values of <.2 appear in
Appendix VI.
Table 6.24: Bivariate analysis showing significant correlations with values ≥.2 of the outcome
‘simvastatin acceptance’ and ‘simvastatin adoption’ with the 24 items scale
Statements Kendal’s T values
with outcome
‘simvastatin
acceptance’
Kendal’s T values
with outcome
‘simvastatin
adoption’
This is/was a good opportunity to extend my role as a
health professional .454*** .290***
This product matches with the business/service
ambitions of my pharmacy .432*** .278***
This product has potential for good financial returns for
my pharmacy .273*** .202***
I am happy to delegate the task of supplying this
product to support staff .228***
¥
Many customers ask for this product by name .217*** .204***
Introduction of this product may have represented a
‘step too far’ for OTC products† .298***
¥
I believe that this product is a welcome addition to the
range of pharmacy medicines .490*** .311***
I believe that the OTC regimen for this product is likely
to be effective .321*** .246***
It is easy for me and/or my customers to know if
treatment with this product is effective .257*** .223***
I believe this product has potential to engender patient
satisfaction .253*** .220***
***P≤0.001 † items reversed scored; ¥ correlation values <.2 and hence appears in Appendix VI.
6.6.2.6 Chloramphenicol
Similar bivariate analysis was undertaken with chloramphenicol using Kendal’s T measures
as differentiation between high and low acceptors and adopters of the reclassified medicine
could not be made through regression analysis, with too few respondents on the lower side
of the outcome measures.
Six and eight items respectively showed correlation values ≥.2 respectively. The strongest
correlation for both outcomes was noted with items such as those measuring opportunity
Chapter 6: Main survey 203
for role development, financial compatibility, confidence in supply matter, belief that
medicine was a welcome addition to pharmacy ranges of medicines and evidence base
(table 6.25). Again, no demographic characteristics or self innovativeness showed a
correlation value of ≥.2 with the outcomes (table 6.25). These appear in Appendix VI.
Table 6.25: Bivariate analysis showing significant correlations with values ≥.2 of the outcome
‘chloramphenicol acceptance’ and ‘chloramphenicol adoption’ with the 24 items scale
Statements Kendal’s T
correlation values
with outcome
‘chloramphenicol
acceptance’
Kendal’s T
correlation values
with outcome
‘chloramphenicol
adoption’
This is/was a good opportunity to extend my role as a
health professional .383*** .280***
This product matches with the business/service
ambitions of my pharmacy .259*** .211***
This product has potential for good financial returns
for my pharmacy
¥ .252***
I find the processes involved in the supply of this
product complex†
¥ .228***
I feel confident about my ability to supply this
product .265*** .241***
I believe that this product is a welcome addition to the
range of pharmacy medicines .426*** .312***
I believe that the OTC regimen for this product is
likely to be effective .246*** .226***
Introduction of this product may have represented a
‘step too far’ for OTC products† .221*** .204***
***P≤0.001 † items reversed scored; ¥ correlation values <.2 and hence appears in Appendix VI.
6.6.2.7 Summary of binary logistic regression/bivariate analysis
The binary logistic regression and the bivariate analysis allowed quantitative explanation of
the factors key to pharmacists’ innovation decision making. Greater agreement around:
perceived opportunity for role development offered by the reclassified medicines; financial
potential of the medicines; compatibility of therapeutic area to: existing ranges of pharmacy
medicines, to pharmacy business interests and pharmacists’ expectations; whether the
medicine was a welcome addition to pharmacy ranges of medicines; benefits to patients
(evidence base); confidence in the supply process; and patient acceptance and affordability
of the medicines were related to higher adoption of the reclassified medicines into practice
and greater support for the reclassified status.
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Some unique factors specific to the medicines evaluated were also identified. For example,
respondents’ belonging to the larger size of pharmacy ownership were found to be
important with high acceptance and adoption of naproxen. Similarly the issue of task
delegation was retained to be important with the cases of omeprazole and simvastatin
decision making. Least useful in distinguishing respondents’ rating of ‘adoption’ and
‘acceptance’ differently related to their responses around items such as those measuring
perceived adequacy of pharmacy resources, availability of information sources, extent of
organisational influence in decision making and level of external support. Apart from
pharmacists’ status as a owner and the size of the ownership, none of the other 13
demographic characteristics showed association with decision making in either bivariate
and multivariate analysis.
6.7 NON-RESPONDENT ANALYSIS
Non-respondent analysis was performed to check the external validity of the findings. It
has been suggested that the demographic characteristics of late respondents are similar to
those of non-respondents [297]. Therefore, a non-respondent analysis was performed by
comparing the demographic characteristics of those respondents who replied after second
reminders (late respondents) to the rest. Cross tabulation analysis showed that only the
proportion of respondents in demographic characteristics ‘gender’ and ‘innovativeness’
were found to be significantly different amongst early respondents and late respondents
(figure 6.7). No other demographic categories were found significantly different across the
two response categories. Data for non-significant relationships for this analysis appears in
Appendix VI.
Approximately 70% of the respondents in the late respondent category were female
compared to approximately 59% in early respondent category (P= 0.037).
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Figure 6.7
Respondent categories (numbers within bars represent n)
Approximately 18% of the respondents in the late respondent category were “cautious” in
relation to new ways of working compared to 7% in early respondent category. In addition,
late respondents had noticeably half the proportion of respondents in the venturesome
category compared to early respondents (7.5% vs 15%) (overall Pearson Chi-square P=
0.003) (figure 6.8).
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Figure 6.8
Perceived innovativeness as per response time (N=552)
Respondent categories (numbers within bars represent n)
6.7.1.1 Summary of non-respondent analysis
The non-respondent analysis hence reflected that the sample of this survey was
representative of the rest of the population in most of the demographic characteristics.
6.8 DISCUSSION OF KEY FINDINGS
6.8.1 Sources of information on newly reclassified medicines
Respondents reported the use of diverse information sources to inform adoption decisions.
This might reflect the perceived need to reduce any bias as highlighted by some interview
participants. The proportion of respondents citing journals, manufacturers’ information
sources, RPSGB information sources and formularies were comparable to a similar previous
study in this field [282]. The extent of pharmacists consulting their peers is surprising in the
light of findings from the qualitative study where respondents described a lack of support
at organisational and external levels for peer networking. The high proportion of
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respondents using PILs and public media could be explained by the lack of timely
information from organisational or external sources and requires urgent attention
6.8.2 Pharmacists’ attitudes towards and adoption into practice of
newly reclassified medicines
Results specific to each of the four evaluated medicines will be discussed in this section,
along with comparison to any available literature with similar objectives undertaken in the
therapeutic area. Factors associated with decision making will discussed by comparing the
responses to 24 items scale across the medicines in this section and the section that will
follow (section 6.8.3).
6.8.2.1 Omeprazole
Respondents were fairly supportive of the non-prescription availability of omeprazole.
Compared with the study conducted with a random sample of 2000 community pharmacies
from GB, immediate post reclassification, where over 70% of the respondents were yet to
adopt the omperazole into practice [122], it could be postulated that, over time, more
pharmacists have adopted the reclassified medicines into practice.
Although medicines for peptic disorders such as cimetidine, ranitidine and famotidine had
been available on a non-prescription basis for over a decade when this survey was
undertaken [92], a majority of respondents still considered omeprazole a welcome addition
to the range of pharmacy medicines. The majority expressed confidence in supply matters.
However, a majority also rated low confidence in their support staff undertaking the
supply. Such low confidence around task delegation is most likely to be due to the
cognitive element associated with the supply process, and hence the issue is likely to be
medicine specific. This is supported by the finding that a high proportion of respondents in
this study showed willingness to delegate the task of supplying reclassified naproxen and
chloramphenicol. Comparisons of results with those of the McCaig et al study reflect that
pharmacists’ confidence in delegating tasks to support staff has not changed sharply in the
five years following reclassification despite likely accumulated experience [122].
Patient cost implications of non-prescription therapy were found to be one of the key
barriers to supply, perhaps influenced by the duration of indication, which is likely to last
for up to two weeks [239]. Such high cost might exceed the current prescription charge in
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Scotland. It is worth noting that the availability of generic versions of omeprazole, often
cheaper than branded, was delayed due to legal challenges by the patent owner [298].
The proportion of respondents doubting the evidence base of the non-prescription dose was
surprising given the licensed indication, allowing pharmacists to supply two 10 mg doses
(=20 mg) per day until symptoms of peptic disorders are alleviated [239]. Evidence in
support of the efficacy of both 20 mg [299,300] and 10mg [299] omeprazole in relieving
heartburn associated with acid reflux exist in the published literature [300], although
evidence is stronger in favour of the 20 mg dose [300]. The clinical efficacy of 20 mg
omeprazole for over the counter setting has been established in the US [301] where,
ironically, the lower strength of 10 mg dose is only available under prescription [302].
It is interesting to note that only a minority of the respondents did not regard the risk of an
adverse event as a barrier to supply or that the medicine was susceptible to patient misuse.
This was despite the issue of safety, as for example, liver toxicity had led to rejection of the
non-prescription status of this medicine in the US [303,304].
6.8.2.2 Naproxen
This survey was conducted less than one year after the reclassification of naproxen to P
status in the UK. Despite the short interval between the reclassification and this research,
over 80% of respondents had already adopted this medicine into their practice. Many
respondents, however, indicated receiving low numbers of patient requests, implying that
sales were mostly based around pharmacists’ recommendations.
Unlike omeprazole, many respondents considered the non-prescription regimen of this
medicine to be effective for its licensed indication. This high level of belief in evidence of
efficacy matches findings from clinical studies where naproxen has been shown to
consistently demonstrate superior efficacy over other Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) with doses as low as 200 mg for the management of dysmenorrhoea [305].
The high agreement on items referring naproxen as a welcome addition to pharmacy ranges
of medicines, and the opportunity to extend professional role could be as a result of the
specific novel indication of naproxen for primary dysmenorrhoea, which differs from the
other available NSAIDs. Analysis of other statements also reflected that the majority
expressed high confidence in the supply process and many were willing to delegate the
supply to support staff despite their short experience with pharmacy status of the medicine.
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Respondents’ concerns around the high risk of adverse events and the potential for
medicine misuse matched those of the regulators. MHRA had voiced concerns over gastro-
intestinal effects and had tentatively planned Periodic Safety Update Reports (PSUR),
against which the RPSGB had objected [306]. The US has a longer experience of non-
prescription naproxen, with 200 mg in 1994 [307] and reports from the spontaneous
Adverse Events Monitoring System (AERS) reflected similar concerns [308]. In April 2009,
naproxen was among the list of analgesics that the US Food and Drug Administration
(FDA) revised regulations for ensuring that non-prescription naproxen labels were updated
to include the risk of GI bleedings and liver damage [309]. Emerging evidence from meta-
analysis of safety studies, however, reflects that overall adverse events of naproxen at non-
prescription doses are comparable to placebo [310]. Further experience and monitoring of
non-prescription naproxen use in the UK should add to the understanding of the safety
profile.
6.8.2.3 Simvastatin
Most attitudes towards and questionnaire data around the adoption of simvastatin are
comparable with the findings from qualitative interviews. Adoption into practice was very
low and responses to attitudinal statements were overwhelmingly skewed towards higher
or lower agreements. Despite representing a very new therapeutic area, the perceived
opportunity to increase professional role and its compatibility with existing ranges of
medicines were poorly rated.
The responses around evidence of efficacy were negative and reflect the debate reported in
the literature during the time of and post reclassification [282]. The evidence of efficacy of
the 10 mg simvastatin has generated varying views, both in support of its efficacy [311,312]
as well as against it [313]. In particular, no evidence of efficacy; nor patient ability to
accurately self diagnose the need for the medicine had been demonstrated in the
community pharmacy setting at the time of reclassification [313].
Contrary to the concerns around evidence of efficacy, the majority were unsure of either
adverse effects or patient misuse as barriers to supply. Some have argued that the
likelihood of adverse events with large scale use as well as potentially discouraging patients
from the adoption of life style changes would outweigh any epidemiological benefits with
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reclassification [314,315]. These concerns even led to requests to reclassify simvastatin and
other statins in the US being rejected by FDA on several occasions [311].
Respondents reflected a very low level of patient requests for simvastatin. Anecdotal
evidence suggests that the reclassification was aimed at those ineligible for a free NHS
prescription [316]. However a recent study with 102 patients recruited from three
community pharmacies in Bristol has shown that willingness or lack of willingness to pay
did not relate to patients’ prescription charge- exemption status or the risk of heart disease
[317].
In one survey prior to reclassification, over 40% of the 200 randomly sampled community
pharmacists from the Leeds/Bradford area agreed or strongly agreed with the idea that
simvastatin should be available without prescription [280]. Though the population
sampled were different to this study, the same regulatory framework applies to both the
areas. Acceptance scores from this survey show that pharmacists now regard this medicine
being of less value to practice. The study by Hansford et al undertaken immediate post
reclassification showed that approximately 83% of the respondents had not supplied any
simvastatin in the last 14 days [282]. Hence, five years post reclassification, the proportion
of respondents not adopting the medicines into practice is very similar when compared to
data immediate post reclassification [282]. This reflects that pharmacists’ adoption is less
likely to change in the future and could be argued that other interventions in this
therapeutic area such as lifestyle and dietary advice could be of interest to stakeholders.
Findings from this survey suggest that even those respondents with a non-medical
prescribing qualification were no more likely to adopt the medicine into practice than with
no additional prescribing training, does not sit alongside the voice of some of the interview
respondents where additional skills and expertise were deemed to lead to greater adoption
of simvastatin into practice. One of the reasons for this could be due to the reason shown by
a recent study suggesting as many as one third of all pharmacists with prescribing
qualifications based in community are yet to use their prescribing expertise [318].
Despite such low adoption of simvastatin by respondents, a decline in the volume of GP
simvastatin prescriptions post reclassification has been reported recently. Fillion et al using
analysis of the General Practice Research Database (GPRD) showed that, post
reclassification, the prescription of both 10 mg and 20 mg simvastatin has decreased
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markedly [319]. However, as prescription items for other statins had also decreased in the
same period [319], such changes could not be attributed to the reclassification alone. A
majority of GPs are known to be against pharmacy supply of non-prescription simvastatin,
although, less against the issue of pharmacy based risk assessment to identify patients in
need of the medicine [320]. Hence it is unlikely that recommendations for pharmacy
purchases by GPs have been made.
6.8.2.4 Chloramphenicol eye drops
Respondents’ support for the non-prescription status of chloramphenicol and adoption into
practice was very high. This medicine has been advocated by pharmacists to be reclassified
for many years, until the decision was taken in 2007 [268]. The belief in medicine evidence
of efficacy was high. Results from the qualitative interviews and focus groups suggested
that positive patient feedback was adding to pharmacists’ belief in the evidence base.
Recent evidence, however, suggests that acute infective conjunctivitis, including bacterial,
are self limiting conditions and hence do not require an antibiotic [321]. However,
qualitative studies with patients [322] as well as GPs [323] have revealed that non-clinical
forces such as pressure from parents to help children (population where bacterial
conjunctivitis is prevalent) early return to school; and perceptions of the ‘magical’ effects of
antibiotics may supersede any clinical need.
Concerns around the issue of chloramphenicol safety, either the risk of adverse events or
misuse was very low. During the time of reclassification, there were concerns around the
safety of this medicine among the medical professionals and the MHRA [291], mainly
owing to the risk of haematological toxicity. There has been debate that emergence of
bacterial resistance may be exacerbated by the pharmacy availability of chloramphenicol
[324], as its use has been increasing disproportionately since reclassification. Studies have
reflected that an increase in overall pharmacy sales and supply of topical chloramphenicol
has been unaccounted for by any reduction in number of prescription items [325,326]. This
raises the notion that whether the reclassification has led to an overall increase in
consumption of this medicine. This also led to the active advocacy by the chief medical
officer of England against reclassification to pharmacy status of any further antibiotics
[325], despite GPs being in favour of non-prescription chloramphenicol at the time of
reclassification [100].
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With all four medicines that were evaluated, respondents’ responses to the 24-item
attitudinal scale also reflected that only a minority were dissatisfied with the adequacy of
information sources. In addition, only a few regarded the lack of available resources such as
staff mix and space within pharmacy to be a barrier to the adoption of medicines. This
suggests that, for the majority of pharmacies, pharmacy resources in Scotland should
promote pharmacists’ adoption and organisational implementation of future medicines to
be reclassified, given that other important criteria identified here are fulfilled for decision
making.
Support from the professional body was deemed adequate reflecting satisfaction over
guidance materials and associated training. The desire for enhanced access to patient
medical records was evident and hence any future enhanced access is likely to enable
pharmacists to eagerly anticipate reclassifications where the perceived need for access to
inform supply decision is high. The need for greater communication with GPs was less
strong, implying that issue of access to patient medical records is more important.
6.8.3 Factors associated with decision making: bivariate/
multivariate analysis
The bivariate/ multivariate analyses of the data further allowed for the quantification of
factors associated with support for the non-prescription status (acceptance) of the
reclassified medicines and their adoption into professional practice. The use of factor
analysis in reducing the 24-items to a fewer numbers of meaningful units did not produce
interpretable output. This implied that although the statements within the 24-items scale
were conceptually similar in theoretical terms, empirically however, individual items had
meanings unique enough to require separate analysis.
The items that were most strongly and commonly retained throughout the
bivariate/multivariate analyses to be associated with innovation adoption and acceptance
related to: opportunity for role development, financial potential of the medicine,
compatibility of therapeutic area to pharmacy service ambitions, confidence around supply
process, belief if the medicine was a welcome addition to pharmacy ranges of medicines,
benefits to patients and patient acceptance of the medicines. These factors are hence likely
to be relevant for other medicines and services not evaluated in this thesis. Factors
important in respondents’ decision making unique to particular medicine(s) that were
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evaluated were also identified. For example, respondents from larger pharmacy ownership
were found to have better embraced and adopted naproxen. Similarly, issue of task
delegation was found to be important with the case of omeprazole and simvastatin decision
making; and low perceived complexity were related to higher adoption of chloramphenicol.
The results reflected that adequacy of pharmacy resources, availability of information
sources and extent of organisational influence in decision making were least associated
with acceptance and adoption, implying that this issue take less prominence in decision
making as compared to how pharmacists perceive the merits of innovations. In order words
the ‘content’ issue took prominence over the ‘internal contextual’ factors. It is possible that
these reclassifications have least necessitated reorientation of existing services in pharmacy
and hence, pharmacists in diverse demographical settings might be coping well with the
resource requirements generated by these reclassifications. Being an owner and the size of
the ownership were the only two among the 13 demographic characteristics that showed
association with decision making in either bivariate or multivariate analysis.
From Rogers’ theoretical point of view [131], perceived attributes of innovations in this
study: the relative advantage was most strongly associated with both outcomes. Relative
advantages and their observability have been regarded so important in informing adoption
decisions about innovations by potential adopters that, where such advantages are less
obvious and visible, such as the case of use of preventative health services by the patients
(as against the use of curative services), adoptions are difficult to diffuse [131]. However,
although the importance of relative advantage was obvious, disadvantages (risks to patients)
of innovation were not associated with acceptance and adoption. This is against the
findings from the qualitative phase (Chapter 3); and another qualitative study around
pharmacists’ adoption of non-prescription medicines decision making, where safety has
been depicted as of paramount importance to pharmacists in non-prescription medicines
supply decisions above any perceived advantages such as the evidence of efficacy [228]. In
this survey however, even with the case of naproxen, where many respondents were
concerned about adverse events and misuse, respondents’ level of concern did not emerge
as a factor associated with decision making. Perceived benefits of medicines to patients
seemed to have superseded any harm that was likely.
Rogers’ diffusion model suggests that among the attributes of innovations, relative
advantage, observability and compatibility are positively associated with innovation adoption
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[131]; whereas, complexity of adoption process is negatively associated. This survey hence
did not identify any deviations in the direction of association so suggested, although the
strength of such association was variable across the medicines evaluated.
The perceived complexity of adoption and low self confidence around supply matters were
found to be negatively associated with decision making in this study. Perceived complexity
of adoption process is known to be diminished through experience and experimentation
[146]. Aspects of compatibility measured in this survey only related to whether the
therapeutic area of the reclassified medicine represented pharmacy business interests;
whether or not the medicine was a welcome addition to the existing range of medicines and
whether the reclassification was a step too far (measuring pharmacists’ expectations). The
importance of compatibility with socio-cultural norms and values was not assessed. As
reviewed in Chapter 4, these issues have been shown to be important in pharmacists’
decisions to supply reclassified medicines such as the EHCs [252,258,260,261].
The abundance of items relating to perceived attributes of innovations in the bivariate/
multivariate models fits within the tradition of results reported by diffusion research. The
current evidence is that the five of the above explained perceived attributes of innovations
(relative advantage, observability, compatibility, complexity and trialability) are known to explain
49-87% variance in the rate and extent of adoption of innovations by potential adopters
[131].
The importance of reinvention to decision making was hardly observed. A majority of
respondents were less keen to supply the listed medicines off guidelines. It has been
suggested that not all innovations are regarded as ‘fit to re-invent’ [146] and that such
practices are known to be more suited to innovations that arise spontaneously and through
informal, decentralised and horizontal social networks [146]. Despite some respondents in
the qualitative interviews suggesting that supplies of medicines off guidelines was the
norm where perceived need and confidence allowed such divergence, results of the survey
reflected that supplies off guidelines represented only a small proportion of all supplies
barely enough to quantitatively differentiate the level of adoption of the medicines that
were evaluated.
The relationship of perceived innovativeness with both outcomes was also rarely observed
in the multivariate analyses. The literature from which this scale was adapted reported
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perceived innovativeness related to actual readiness to change practice in both univariate
and multivariate analyses [327]. In this study, however, higher perceived innovativeness
was noted to be associated with innovation adoption on only one instance with the
outcome- adoption of naproxen. The reason for the lack of consistent association might be
attributed to two reasons. Firstly, establishing validity and reliability of the perceived
innovative scale may need further work, as the distribution of the percentage of
respondents across the innovativeness categories did not match with those known from
research within [165] and outside pharmacy [131]. Secondly, as reflected by the studies with
other health professionals, there are no universal adopters and innovators when it comes to
adopting new medicines [328,329]. This case has been further supported also by a study
reporting issues around innovation adoption by pharmacy organisations which mentions
that, for example, it is not always possible for a same PCT to be innovative in delivering
every potential pharmacy innovations [159]. Regarding all innovations as identical units
from the analytical point of view has been regarded as ‘dangerously incorrect’ [131],
especially for the difficulty in isolating the so called ‘idiosyncratic’ features of one
innovation and the true predictive power of the innovation attributes common to diverse
innovations [161]. The evaluation of four reclassified medicines from diverse therapeutic
areas selected so as to understand the factors associated with innovation adoption are
further justified by these notions.
Respondents in this study reflected their autonomy over decisions around whether to and
how far to adopt the reclassified medicines into their practice, with only a minority
deeming decisions of their management organisations as decisive. Because a majority of
respondents in this study were pharmacy managers, personal decision might have been
regarded equivalent in meaning to decision making by the pharmacy ‘management’. For
those respondents who were not the managers, the possibility also exists that the decision
making process is a two step process. Within such two stepped processes, often classified as
‘contingent’ decision making [131], practitioners choose whether to/how far to adopt the
innovations into practice after an initial decision by the organisational management. The
likelihood of this being relevant to many pharmacies, especially those with multiple
ownership structures, is supported by the results of the qualitative interviews. Even with
the so known ‘contingent’ decision making process, literature [131] as well as the results of
this survey and qualitative interviews reflect that individual practitioners are the ultimate
decision makers about the provision of services to patients. This further justifies the
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importance of research on individual practitioners’ decision making processes, the focus of
all phases of this doctoral research.
This study generated some comparable as well as contrasting results in relation to other
studies applying bivariate/multivariate quantitative models to quantify factors influencing
similar outcomes. The literature investigating ‘adoption’ as the outcome identified: financial
benefits owing to sales [269,271,275], evidence of efficacy [269,271], patient acceptance of
the medicines [275] and younger age or lesser practice experience [267] were amongst the
most commonly retained factors. Medicines safety (risks) was only rarely identified as
important [269]. Key factors positively associated with ‘acceptance’ to ongoing
reclassification were shown to be perceived benefits to professional roles [267] and patients,
compatibility with business interests and negatively associated with high counselling need
[267]. In addition to the limitations of these studies, already highlighted in Chapter 4
(systematic review), one of the drawbacks of studies measuring ‘acceptance’ as the outcome
worth noting here is the consideration of all potential reclassifications as one innovation
against the norm of diffusion research.
Results from this survey are also comparable to pharmacy innovation adoption studies
outside the area of enhanced minor ailment management utilising a diffusion model.
Perceived benefits to pharmacy, professional roles and patients were the most important
predictors of adoption of pharmacy based immunisation in a two staged survey of 526
community pharmacists from Washington State in the US (response rate: 46.9% and 42.1%).
Perceived complexity and compatibility, although found to be associated with the outcome
adoption, were not retained in multivariate analyses [233]. Financial benefits to pharmacy
were among the most important factors associated with adoption or rejection of
pharmaceutical care models in a study of 153 pharmacists in two US States [166]. Yet
another diffusion study of medication information to patients with 156 pharmacists in the
US state of Michigan around adoption of written medication information services for
patients reported complexity as the most important ‘deterrent’ to decision making; with
compatibility with pharmacists’ business needs, professional values and past experiences
showing the most positive influence on adoption [330]. The importance of observability of
benefits, compatibility, complexity of adoption process and trialability of innovation were
regarded as the most important desirable features of innovations in a study of 300 Dutch
pharmacists (response rate: 49.3%) exploring the implementation of patient oriented
education activities, although differences in the availability of resources influenced the
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intension to adopt the innovations [165]. Most of the findings reported by the literature
together with the results of this survey hence enable the conclusion that perceived
attributes of innovations are the most common predictor of successful adoption of
innovation by pharmacists. The notion about importance of investing effort in identifying
‘innovation’ differences (how perceived characteristics of innovation affect their adoption)
than ‘people’ differences (research into importance of adopter characteristics) as
highlighted by Rogers [131] are hence justified by these pharmacy literature and this
survey.
6.8.4 Response rate and demography of respondents
Surveys within the area of non-prescription medicines have recently been suggested to
have inflicted “research fatigue” on pharmacists [331]. However, the response rate obtained
in this study suggests that innovative methods used to encourage participation may have
been successful with a positive impact on the achievement of an ‘adequate’ response rates.
This response rate is comparable to the 42% rate obtained in a GB study of community
pharmacists conducted by RGU researchers at the same time [332]. The response rate
obtained should also be interpreted in the context of the questionnaire design which
included over 150 variables, arguably higher than that found in most conventional
questionnaires. The contribution of two reminders to increasing the response rate was
above the average of 20% (10% from each) as suggested by others [202].
The demographic characteristics of respondents compared well with a recent GB
community pharmacists’ census and register analysis [238,293] except that in this study
there was over-representation of pharmacy managers; under-representation of locum
pharmacists and those working in independent units; who represented approximately 29%,
36% and 31% respectively in 2008 census [238]. Statistical analysis on the differences of the
demographic characteristics of this study to those of the census and register data could not
be conducted due to vast differences in sample sizes. In addition, not all census and register
data specifically represent pharmacists practising within community [238,293].
Nonetheless, the results from the non-respondent analysis indicated that the responses
could be considered representative of the population of community pharmacists in
Scotland.
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6.9 SUMMARY OF CHAPTER 6
Newly reclassified medicines evaluated in this survey were, to a varying degree, adopted
by respondents of this survey. Chloramphenicol eye drops had the most support and
adoption into practice, whereas simvastatin was least supported and adopted. Despite
being the latest reclassification among the medicines that were evaluated, naproxen was
better adopted than simvastatin or omeprazole. Adoption of omeprazole into practice by
respondents was however, higher when compared to studies immediately post
reclassification. Patients are likely to benefit from easier access of these medicines available
from pharmacy, except with the case of simvastatin.
The evaluation of four reclassified medicines enabled quantification of important factors
associated with innovation decision making by pharmacists through descriptive, bivariate
and multivariate analysis. Such factors were often unique to medicines that were evaluated.
Higher agreement in the following issues offered by the newly reclassified medicines were
associated with higher regard for the reclassified status and adoption into practice namely:
1. Perceived opportunity for role development offered by the reclassified medicines
2. Financial potential of the medicines
3. Compatibility of therapeutic area to: existing ranges of pharmacy medicines; to
pharmacy business interests and pharmacists’ expectations
4. Belief whether the medicine was a welcome addition to pharmacy ranges of
medicines
5. Benefits of medicines to patients (evidence base of medicines efficacy), and the
observability of such benefits
6. Pharmacists’ confidence and low perceived complexity around supply process; and
7. Patient acceptance and affordability of the medicines
Both the key outcomes, support for the reclassified status of the medicines, and their
adoption into practice, were influenced by similar factors. Wide ranging sources of
information were used by community pharmacists for decision making, many of which had
not been previously realised by the literature. These factors are important in prediction of
successful adoption of future pharmacy innovations not limited to reclassified medicines.
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7 CHAPTER 7: PHARMACISTS’ ADOPTION OF E-
MAS (QUALITATIVE)
7.1 INTRODUCTION TO THE CHAPTER
The minor ailments service in Scotland, known as e-MAS, is another key intervention
(service innovation) aimed at enhanced management of minor ailments from community
pharmacy. The relevance of ongoing reclassification of medicines, as described in previous
Chapters, is more to those members of the public who pay prescription charges. In
Scotland, almost 50% of the total population is exempt from prescription charges [93]. E-
MAS, introduced nationwide in Scotland in 2006 as a core part of the community pharmacy
contract [96], allows those members of the public exempt from prescription charges to
register with one community pharmacy of their choice and have their minor ailments
treated by the pharmacist free of charge, or where appropriate, to get advice or onward
referral to other health professionals [94].
E-MAS is being supported by a national IT network system known as e-pharmacy which
enables both identification of existing patient registrations and new registrations using the
patient’s unique community health index (CHI) number [98]. This service also enables
patient consultation and registration details from pharmacies to be verified for
reimbursement and remuneration purposes. E-pharmacy is an effective, electronic data
capturing system, potentially allowing service activities to be recorded remotely within
NHS NSS, and is managed by the National Medicines Utilisation Unit (NMUU) within the
Information Service Division (ISD) of NSS. There is potential for these data to be
disseminated as a means of allowing pharmacists to reflect on their e-MAS practice.
‘The Right Medicine: A strategy for pharmaceutical care in Scotland’ published in 2002,
identified the need to set up the NMUU to provide NHS bodies with information regarding
how medicines are being used in the NHS [50]. The e-pharmacy programme within the
NMUU has the capacity to collate the e-MAS activity data from each pharmacy delivering
the service as each is now linked with the e-pharmacy system [222]. Hence there is scope for
a wealth of data to be utilised as a source of feedback of practice performance to community
pharmacists so as to potentially facilitate service adoption. Feedback can be defined as
‘summary of health care practice performance over a specified time period’ [333]. Feedback
of practice performance, similar to other educational strategies such as: printed educational
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materials, outreach visits, seminars and workshops, training sessions, medicine information
centres; has been shown to be useful in supporting the adoption of new services or
behaviours by health care practitioners [334]. Pharmacists have been utilised as a source of
feedback to doctors’ performances about medicines supply practice [335]. However, the
published literature around pharmacists’ feedback needs to support innovation adoption
sparse. Understanding the needs of potential users has been argued to be essential to
enable information providers to accurately plan and disseminate such feedback information
[335,336].
This Chapter presents results of data analysis from phase I, specific to the following
objectives:
1. To identify community pharmacists’ views and attitudes to the introduction of e-
MAS in Scotland.
2. To identify facilitators/barriers to pharmacists’ adoption of e-MAS in Scotland
3. To explore community pharmacists’ views on future provision and potential
usefulness of practice performance feedback from e-MAS as a facilitator of service
adoption.
7.2 METHOD
Aspects of design, method, research governance and ethics; and participant demographic
characteristics appear in Chapter 3. However, use of the illustrative materials specific to
objective 3 above has not been discussed previously.
7.2.1 Use of illustrative materials
Examples of e-MAS performance feedback data were generated in collaboration with the
ISD and were presented to the focus group participants (using Microsoft Power Point
software) to facilitate discussion around objective 3. Two visits to the NHS NSS head office
in Edinburgh were made by the researcher for the purpose. Data sets representing aspects
of service delivery, such as: type of medicines supplied, and number of patients registered
by individual/group of community pharmacies were presented. For telephone interview
participants, the same data sets were provided in print versions which were sent through
the mail or by fax in advance of the interview date. A copy of all such illustrative materials
that were used appears in Appendix VII. An example is presented in figure 7.1.
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Figure 7.1: Example of performance feedback data used as illustrative materials*
* Figure shows number of non-prescription medicine items supplied by a pharmacy in four
quarters through 2006 to 2008 through e-MAS. The most number of items supplied by the
particular pharmacy in any given quarter related to skin preparations.
7.3 RESULTS
Key themes are presented and illustrated with quotes which aligned to the main framework
of analysis, consisting of three broader categories namely: the attitudes towards the service,
facilitators/barriers to service adoption; and pharmacists’ views on future provision of
feedback of performance data from e-MAS. Themes and sub-themes within these broader
categories are also presented with illustrated quotes. Where opposing views around a
particular subject were identified around the same theme, all are illustrated. The three dots
within a quote indicate that some text has been deleted if considered irrelevant to the
corresponding theme.
7.3.1 Attitudes towards the service
Participants identified benefits of e-MAS to diverse groups of stakeholders including the
pharmacists and patients as well as the NHS.
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7.3.1.1 Benefits to pharmacists’ professional practice
Reference to both professionals and patients were made when highlighting the benefits to
professional practice. Provision to allow pharmacists to manage minor ailments free of
charge to patients in need was a feature of e-MAS highly valued by the participants.
“... I’ve been quite delighted when I can actually help people [in need] feel all right... that
helps me further.”
Male, 28 Years, Large Multiple
The perspectives of pharmacists working in socially deprived communities reflected that
service implementation was particularly important given the large number of patients
likely to benefit. One participant mentioned that sales of non-prescription medicines prior
to the service were limited due to patients’ inability to afford the retail price of medicines.
“Where we are here, it’s not a very well to do area. So we don’t tend to sell a lot of [non-
prescription] medication. Things like Zanprol [omeprazole], we just wouldn’t sell here...are
too expensive for people to buy here...that would more come under the minor ailment
[service]”
Female, 47 years, Small Multiple
The opportunity to ensure equity of access to service provision was appreciated. The
service was also valued for enabling pharmacists to ensure supply of even the so deemed
‘pricy’ newly reclassified P medicines to patients where needed; otherwise these were
deemed to be limited to patients of higher social status.
“The combination of POM to P switches along with the ability to prescribe them on the
minor ailments service means that, often, when these products become available to buy over
the counter, they are quite pricy. So, by being, enabling you to provide these [medicines] free
of charge to people who are exempt from prescription charges means that much more people
can get benefit of POMs to P switch as well”
Female, 25 Years, Large Multiple
The provisions to allow pharmacists to supply certain POM medicines under PGDs within
e-MAS were also valued highly for similar reasons as above.
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“We’ve got PGDs [of morning after pill] for age 13 to 19. Yes, there’s this for 25 pounds and
at which point they will go, ok I will not bother then. So, that person hasn’t got the treatment
that they possibly need because of price. So I think it helps where our professional care is
supported by either by the Health Boards or some other initiatives so that the person who
needs the medication can get it. Obviously the minor ailment service does that to a degree.”
Male, 39 Years, Large Multiple
Participants also alluded to benefits to practice offered by the requirement within e-MAS
where patients must register with ‘one pharmacy’ of their choice. Benefits of such
requirements highlighted related to strengthening the relationships between professionals
and patients.
“... the pregnant mothers who are coming in and they are having the service explained to
them and they come back and you see them right through their pregnancy and then the
women comes along. So you then kind of realize that actually you do get to know people
over a certain length of time and more and more faces become familiar and then more and
more people use the pharmacy for other prescriptions or other things as well. So you
definitely do get to know people, patients more efficiently.”
Female, 25 Years, Large Multiple
However, for many, this potential merit was yet to be realised, mainly due to the tendency
of patients to shift their registration status across pharmacies. This issue will be detailed
later in section 7.3.2.4. Nevertheless, participants were keen to see such registration
requirements to be extended to other services being delivered through e-pharmacy.
“If you are talking about registration with e-pharmacy, then, just, in general, you go to that
pharmacy for everything you do at the doctor’s.”
Female, 56 Years, Large Multiple
7.3.1.2 Benefits to the NHS
Participants were highly aware of potential NHS savings through greater pharmacy
management of minor ailments such as within e-MAS as compared to management through
other primary care services.
“... in lot of cases, the average cost of doctor’s script is 70 pounds and ours is 3 or 4 pounds.
The fact that people can walk in, there is no appointment. E-MAS itself saves the NHS
money.”
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Male, 39 Years, Large Multiple
Participants were also keen to know how their contributions to the e-MAS service had
brought any real term benefits to the NHS.
“I think it would be interesting to see for even like say, for example the
chloramphenicol...has their [GPs] prescription for eye infections dropped? ...[has] their
[patient] waiting list [dropped]?”
Female, 27 years, Independent
Some, however, were more sceptical of real term benefits to the NHS, mainly resulting from
overuse of the service by some patients. This issue will be discussed in detail later in section
7.3.2.4.
“It’d be interesting to know if it’s saving any money. Because, the whole idea was to save
doctor’s surgery time. Has it actually happened? Has the waiting time decreased, to be seen
by doctors, has gone down, for minor ailments?”
Male, 55 Years, Large Multiple
7.3.2 Facilitators/Barriers to adoption of e-MAS
Twelve key facilitators/barriers to adoption of e-MAS were identified from the data. Many
were common to those identified around ongoing reclassification of medicines (Chapter 3).
Details around these facilitators/barriers also provide important processual insights about
how these work in practice.
7.3.2.1 Remuneration and reimbursement
Appropriate remuneration was highlighted as a key motivation to pharmacies. Participants
were keen to add to their current roles and the ranges of services offered through their
pharmacies but emphasised the need for financial benefits to ensure the sustainability of
such initiatives.
“I think it is important that pharmacy in general is remunerated for that [extended service
provision]. I just hope that the funding for it [e-MAS] continues and makes [our time]
worthwhile”
Male, 39 Years, Large Multiple
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Participants’ views around current remuneration and reimbursement patterns, however,
were largely negative. They complained that payments were ‘unfair’ given the size of the
potential savings the service was likely to bring to the NHS.
“We are saving a lot more time for the others [doctors], who we’re helping the best to make
my time valuable because we’re getting paid c**p for it basically”
Female, 46 Years, Small Multiple
“... [e-MAS] loaded onto us simply to save doctor’s [time] and it’s unfair, it’s working at the
moment.”
Male, 55 Years, Large Multiple
Participants suggested that potential NHS savings through greater patient management
should be top-sliced and added into current pharmacy remuneration being provided for e-
MAS.
“...how much you saved on an individual GP’s cost by seeing so many of their patients,
‘cause they’re registered at that practice.”
Female, 46 years, Small multiple
Current e-MAS remuneration schemes requiring pharmacists to undertake and record at
least one patient consultation per year were criticised. Comparisons to GP remuneration
structures were often made to justify the argument that such requirements be abolished.
“... I think it’s unfair that... patient lapse after a year. You can register the GP,… they don’t go
to the GP for years, but the GPs still getting paid for that patient. If they [patients] haven’t
used it, why should we be penalized for they [patients] being healthy?”
Male, 37 Years, Independent
Participants also complained that existing remuneration structures could potentially
endanger the focus around continuity of care with pharmacies resourcing their effort
mainly towards increasing patient registration numbers.
“But then you have got loads of them every second day and you give something on the
minor ailments and you’re getting paid for the cost of the drugs and not for the hassles it is
causing.”
Male, 66 Years, Independent
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“...[many pharmacies] have not dispensed as many [they] have more people registered. They
are registering but not actually prescribing [supplying] so much for them.”
Female, 25 Years, Large Multiple
A fee per consultation was suggested as an improved method of remunerating pharmacies.
“...you are sort of driven by the amount of people that have signed up for. Back home in
Ireland, the person, the one signed to any particular pharmacy, it was just per consultation
which worked out a lot better you know.”
Female, 27 Years, Independent
The reimbursement which pharmacies received for any medicines supplied was also
criticised for not accounting for profits which pharmacies would have otherwise made
through the over the counter sales.
“I have worked out and I’m not sure if any pharmacist have worked out if the, the capitation
fee you get each month makes up for any loss of profit you’ve got over the counter.”
Male, 37 Years, Independent
With the proposed abolishment of prescription charges across Scotland in 2011, participants
were keen to learn, if at all, how far the patient eligibility criteria for the service registration,
would be extended by the Scottish Government. They noted that this would have
implications for the over the counter sales of medicines.
“I don’t know how is going to remain viable when prescription charges are abolished...If
everybody is eligible for e-MAS, people are just going to demand stuff and if there’s nothing
to take, then they just go empty handed and how can you make a profit if you have to give
everything away? We don’t get a dispensing fee for e-MAS. We just get reimbursed with the
cost of the product that we’ve given out. But it’s a trade cost that we’re reimbursed, it’s not
the profit that we would normally make in things.”
Female, 25 Years, Large Multiple
7.3.2.2 Financial rewards for individual pharmacists
Financial incentives were explained by a few participants to have been used by some
pharmacies as an impetus for pharmacists to register more patients. Such incentives were
mostly based on the number of patients they could register. Such incentives were regarded
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as an acknowledgement of the professional service pharmacists were working hard to
deliver.
“I have to say though, we are tasked in my company with hitting a certain amount of
professional service income and one of the methods of doing that is the number of [e-]MAS
registrations we have. So, that’s an incentive to us to try and boost that... our pay size is
actually very good. I think, one of the reasons for this is when we are doing with minor
ailment [service]. ...you can shine, you can actually show that you are working hard, you’re
doing this, you’re using the professional knowledge, you are dealing with the trust of the
public, you are benefiting from it. If I can actually demonstrate that what I am doing is
generating this amount of professional service, then I can hold my head up. I can’t blame for
the credit crunch, but you know at least I am doing what I was trained to do.”
Male, 39 Years, Large Multiple
However, a few objected providing monetary incentives for employees with the notion that
that such practice could potentially encourage competition across pharmacies for patient
registration. This was deemed to vie against the non-competitive norm of this innovative
service.
“And in some multiples and all, you know not naming names, but you know a staff had
been sent to sign up as many people as they can for the minor ailment scheme and some of
the incentives that they have, they get rewarded if they do it and some of them have to do it.
Their company requires them to sign up, may be fifty a week or you know, and that’s not
allowed.”
Female, 27 Years, Independent
7.3.2.3 Time and workload
The need for personal involvement of a pharmacist in every aspect of e-MAS consultations
generated comments. Such level of involvement was deemed impractical for routine
practice. Moreover the requirement was also noted to be in contrary with non e-MAS
related non-prescription medicines supplies, where, pharmacy support staff often
undertook consultations and made supply decisions under pharmacists’ supervision.
“ It is quite time consuming and now, when you have somebody coming in to buy Calpol
[paracetamol] when their kid when they have got teething, you get now the staff kind of
say..., getting on their minor ailments for their child’s name or whatever, goes in for a while
for prescriptions or waiting or whatever, when I get down, I have to go out and talk to them
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whereas prior to that the girls could have done the WWHAMe questions and sold it. So,
yeah..., has increased my workload.”
Female, 46 Years, Small Multiple
Some commented about the additional processes involved in e-MAS supplies.
“Just because [now] you have to go onto the computer system more frequently. Whereas
before, you just had hand over the bit of advice, now you actually have to go right down to
the advice and print off the prescription. So that takes more time.”
Female, 26 Years, Small Multiple
A few participants from independent pharmacies shared their experiences of difficulty in
ensuring personal involvement in e-MAS consultations and supplies in the light of limited
staff capacity.
“... tryin’ [to] produce a prescription rather than just a sales [for e-MAS medicines supply].
So it does, take a pharmacist. Like some shops have got two pharmacists which does make
easier. A lot of shops are one pharmacist, so the pharmacists goin’ stop doing a repeat
prescriptions, prescriptions, to go and do the [e-MAS] consultations... Ah! cause you know,
we are small community [pharmacy], its just the extra bit of paper work involved.”
Male, 37 Years, Independent
Such concerns were noted to be exacerbated by a lack of cooperation from patients who
wanted prompt services.
“I think when people come in, they want to be seen immediately and they don’t appreciate
that we still have prescriptions and extra responsibility. But most people are happy enough
to wait. But the only thing that benefits…is they don’t need appointment but at the same
time if people …as…everybody comes in and may be have a rush when parents dropping
children off to school and again its 3 o’ clock when they pick them up. Everybody...coming at
those times, it gets busy. That’s the only thing. You know a consultation may take between
10 and 20 minutes. So that’s the only sort of thing, time pressures.”
Female, 44 Years, Small Multiple
e A list of questions presented to patients to assess the suitability of medicines supply in pharmacy. Refers to
Who is it for?; What are the symptoms?; How long have the symptoms been present?; Any other medication
being used at present?; and what Medication has been tried already?
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E-MAS guidelines requiring pharmacists to generate a prescription for each consultation
also drew criticism. This was considered problematic when medicine supplies were not
made. Participants also explained that patients were reluctant to wait longer to sign the
computer generated e-MAS prescriptions; implying potential loss of capitation payments.
“I only use the prescriptions when I am dispensing [supplying the medicines]. I don’t, I
don’t do blank ones [generate prescriptions when medicines not supplied]…because you
have to go on to the file on the computer, finding them up to do and then you print it sign
off and then, all you saying is go to your doctor. That will just take a long time, they’re
[patients] not going to wait us doing that...Customers don’t want it either, they got to go
through big [hassles], they don’t worry.”
Female, 46 Years, Small Multiple
Some suggested that current procedures requiring patients to sign e-MAS prescriptions
following consultation be amended to allow pharmacists to obtain patient signature prior to
the consultation. This would allow pharmacists to obtain the appropriate remunerations for
the service provision.
“It could be that, someone wants to get advice using the service, they, may be have to sign
something first. Same as if you go to the dentist, you sign a form at the start.”
Male, 39 Years, Large Multiple
While some participants stated that they did not ‘bother’ to document ‘advice only’
consultations, others were torn between the need to complete documentation to ensure that
patients registration numbers were maintained for capitation payment and the strain such
processes were exerting on resources within the pharmacy.
“...and yes, they will be registered with me longer if I print off the form and get them to sign
it to show that they’ve been given advice or they’ve been referred to the GP. But it’s just, it’s
not feasible to do that... time is the main contributing factor.”
Female, 25 Years, Large Multiple
Some had adopted alternative strategies to fulfil the need for personal involvement. Where
expertise of their support staff was known or could be demonstrated, pharmacist
involvement in every aspect of consultation or supply was deemed less essential.
Participants also suggested that current guidelines be amended to allow more speedy
documentation.
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“We’ve elected within the pharmacy that I’ve worked for. If there’s any request for anything
on the minor ailments, it’s handled by a pharmacist. Initially, we go, you know, the counter
staff come for us, I like to say go back to basics, what are the symptoms etc. And if we decide
something that is appropriate, then we’ll say so..., choose it and then I pass back for the
actual physical part of it to be labelled and all the forms produced etc and then it comes back
to me for a final check. One of us finally checks before it actually goes over to the patient...
We have moved away from that [requirement].... nine times out of ten, I mean, the
dispensers and the healthcare assistants have been doing, they have been recommending
products for years, years and years. So often, they do have an idea that what’s gonna be
best... the dispensers know absolutely what to do.”
Female, 25 Years, Large Multiple
7.3.2.4 ‘Shopping List’: Issues of service misuse
The potential of service misuse by certain members of public was deemed a barrier. Misuse
was often cited to be the case relating to consultations, where a patient requested specific
medicines for reasons suspected by the pharmacist to be other than clinical need.
““Or is it, or we’re just actually created another group of ill people, that would have either
bought it [medicines] before or would’ve just left it or would have actually cleared up on its
own... we’ve had three teenagers tryin’ to sign up the minor [e-MAS] and the smoking
cessation scheme. And we reckon... what they’re needing, we reckon they’re using it for
other motives”
Male, 37 Years, Independent
Lists of medicines presented by patients to pharmacists suspected to be for storage
purposes were often depicted by participants as ‘shopping lists’; and the patients
presenting such requests were often the ‘worried well’. Participants often expressed ‘anger’
and ‘frustrations’ at these situations. Irrational uses of medicines were deemed to be
leading to potential patient safety implications.
“...a lot of people think they can just come with the shopping list and I don’t know if you
have that experience... a lot of people do come in and say that I need paracetamol and I need
ibuprofen and, I want this all in this e-MAS scheme.”
Female, 54 Years, Independent
Chapter 7: Pharmacists’ adoption of e-MAS (Qualitative) 231
“In the case of e-MAS, all these worried well and parents…, sort of all bloody shopping list.
That’s difficult…”
Male, 66 Years, Independent
Themes also reflected that some respondents were keen to educate patients to preclude
future encounters of a similar nature.
“So it’s trying to get round them, it’s [e-MAS] not the service that they use as and when
needed, it’s for a child who must be ill or…”
Female, 56 Years, Large Multiple
The issue of some patients switching registration across pharmacies in response to
pharmacists’ reluctance to entertain ‘inappropriate’ requests was deemed a key challenge.
Such switches had adverse implications for remuneration.
“They just go some place... You know because we’ve somebody asking for some irrelevant
items, sorry...then they re-register [at another pharmacy] and then they don’t come back.”
Female, 46 Years, Small Multiple
7.3.2.5 Communication with GPs and practice nurses
The need for greater inter-professional communication to enable pharmacists to curb e-
MAS misuse was highlighted by some participants.
“So there seems to be no communications between GP and pharmacy. I’m managing same
things [ailments], two or three times in a space of a week, to treat the same condition [of one
patient]. There’s nothing near to say right they have been round the corner that morning and
got the same thing or something similar to treat that condition and they are not, you know,
they are getting something in the morning and if its not works, they are going somewhere in
the afternoon to try and see if they get something else. ‘Cause again its back to this, we need
something that will treat it and cure it.”
Male, 37 Years, Independent
7.3.2.6 Direct requests for medicines by patients
Participants’ responses to patient direct requests for medicines raised similar concerns to
the requests received out-with e-MAS, as presented in Chapter 3. Any specific requests for
medicines were construed as being contrary to the aims of the service and were considered
Chapter 7: Pharmacists’ adoption of e-MAS (Qualitative) 232
by participants to indicate a lack of respect or awareness of the professional expertise of
pharmacists.
“So if you are living in that sort of society [where] there’s not enough respect for the role of
pharmacists and then coming in and asking for something in e-MAS rather than coming and
asking, say - can you give me something to treat for athlete’s foot? And that indicates to me a
lot of respect. I will say I will prescribe you what I think is suitable for you. I won’t say as
quite bluntly to the patient as this but ...., you tell me what your condition is and I will tell
you what is suitable in a much friendly way as to...”
Male, 55 Years, Large Multiple
Ironically, some participants indicated that decisions to deny ‘inappropriate’ specific
medicine requests within e-MAS, were more common than with the sales of medicines over
the counter.
“... if we don’t feel that it is [appropriate], we won’t be supplying it [the medicine], you
know. If you want to buy it yourself, then fair enough but it’s based basically on the [e-MAS]
consultation, you know that we have to go by that.
Female, 27 Years, Independent
One quote reflected how respondents often had to go through ‘awkward’ conversations in
an attempt to demonstrate their ‘control’ over the supply of medicines to the patients.
“We’ve got you know, same time... we want this, the minor ailment [service], and I tend out
to go the way we can go. Like what it is for? Take them right back to the beginning and go
out the way to prescribe something different what we are asked just to be awkward and just
to show I am in control.”
Male, 37 Years, Independent
Participants mentioned that patients often shifted their registration to another pharmacy
when direct request for medicines were denied.
“That’s not what it [e-MAS] is for. I’ve had a patient.... I said you can’t [have this product]. It
wasn’t set up to be like this. What he did was to turn around to another chemist [pharmacist]
and register wherever they want.”
Male, 66 Years, Independent
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Verbal directions from doctors and practice nurses to patients were also deemed to be
contributing to the high number of specific product requests for medicines. Participants
reflected antipathy over GPs and practice nurses sending patients to the pharmacy with
verbal prescriptions of medicines to be supplied under the service. Such verbal orders again
were construed as lack of respect for pharmacists’ expertise in decision making and lack of
awareness of the requirements of the e-MAS service.
“Annoying thing is, they come in to the pharmacies, can I have something and you start
questioning about and discover that NHS 24 has referred them and that really irritates me.
Because, in some cases telling me what I’ve got to prescribe by NHS 24 and that one is very
irritating.”
Female, 56 Years, Large Multiple
“And you feel that if you are a piggy in the middle [between the doctors and the patients].
The baddy...”
Female 53 years independent
Participants also recalled situations where referrals made by GPs were challenging due to
therapies being off-label or out-with the non-prescription license.
“….they have sat in the doctors… got their antibiotics and they have been told to go to the
pharmacy to get a bottle of Calpol [paracetamol] or ibuprofen and we go ok, there’s, we can
give you a 100 ml [bottle], but it’s to do them for two weeks and they [patients] go : - well,
why didn’t the doctor write the prescription?- I don’t know and that creates a wee bit, ‘cause
obviously the GPs don’t understand fully what the minor ailment service is about. It was
supposed to take the pressure off them in the first place, filter the consultations and they
should still be prepared to write prescriptions, I suppose to be for long time or a longer
period [of therapy].”
Male, 39 Years, Large Multiple
Patient safety implications arising from so deemed ‘irrational’ advice by other health
professionals were also highlighted, reflecting the importance of pharmacists as the
ultimate medicines decision makers.
“What I see recently... and again it’s linked to minor ailments [service] is, so many mums
come and asking for paracetamol suspension and ibuprofen at the same time. And whether
its right or not, I only recently discovered that, that apparently is information that NHS 24
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give to mums when they call in with kids with high temperature but you know now it seems
to be almost as you say that run of the mill they come in with looking for something for
teething etc and they want both [paracetamol and ibuprofen]. And that’s, that’s where
they’re new to me. You would have stuck to probably one or the other, and with the
situation with asthma. The amount of ibuprofen suspension that’s, that’s being sold or
supplied over the counter, we just wonder.”
Female, 53 Years, Independent
7.3.2.7 Technical elements of the service
The computerisation of documentation associated with e-MAS consultations was the basis
of complaints from some respondents. Such complaints mainly surrounded the resources
and expertise required as procedures were ‘taxing’. One deemed computerisation of
documentation activities within e-MAS as a major ‘change’ in the way non-prescription
medicines were supplied.
“It was quite a major change for us, sort of paperwork side of things and putting it through
the computer was quite difficult for us to start with.”
Female, 47 Years, Small Multiple
Discomfort with the ‘radical’ change deemed to be required for the pharmacists and
pharmacy support staff needed were expressed.
“They’re trying to get away from the paper. I’ve had an argument at other meetings and
they’re trying to get away from the paper based. ‘Electronics is the way is the way to go, we
should be going into electronic messages and checking on you , e-MAS computers, check
some kind of statistics’...I’m not interested...A paper thing coming through, then I would
open it and you could take it home”
Female, 46 years, Small multiple
However, others were supportive of computerisation and perceived benefits owing to
increased efficiency. Nevertheless, there were complaints that technical errors with the
current electronic system were frequently encountered, a common one being lack of
recognition of the generic versions of medicines by the e-MAS computer systems.
“They were on the e-MAS formulary but my computer system didn’t have that [generic
medicine] listed as a drug file, so I couldn’t physically prescribe it because it didn’t come up
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in the system. So, that has been the single biggest influencing factors on my prescribing
practices...”
Female, 25 Years, Large Multiple
Complaints were also noted around computer systems not allowing pharmacists to correct
any errors made during the supply process.
“It’s a nightmare...because, you picked, for some reason the wrong pack size, you cannot go
back and amend one either. Once you’ve pressed that button, it’s away and if somebody has
put in a wrong figure, a, a wrong letter in some of the boxes, back it [the medicine] comes
disallowed [for reimbursement].”
Female, 53 Years, Independent
7.3.2.8 Access to patient medical records
Helping pharmacists curb the potential service misuse was highlighted as the benefit of
greater access to patient medical records for e-MAS, in addition to other benefits of such
access presented in Chapter 3.
“I think, if we could get to see the patients’ histories, as you know towards e-MAS, as to into
everything they’ve got in any pharmacy, that the pharmacy can obviously be, you know,
blanked diced. You know, what they are getting, to pick up the people that have abused it,
that also pick on the people that, you know, have problems or do you need to be referred
on?”
Female, 27 Years, Independent
7.3.2.9 Formularies
The availability of a user friendly e-MAS formulary was deemed imperative to assist
pharmacists with rationale decision making when making medicine supplies. This was also
important to ensure that items supplied were within the list of medicines eligible for
reimbursement. However, both positive and negative opinions about existing formularies
were expressed. Supportive participants referred to clear lay-out and user friendly
presentations as positive features.
“it’s [formulary] very easy to use and access. It’s good, it kind of have certain categories of
the different kind of minor ailments, enlists the drugs in each category..., it’s so quite easy to
use.”
Female, 29 Years, Small Multiple
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Those negative referred to the restrictive nature, mainly for the limited ranges of medicines
included.
“There’s not enough choice of products in there [formulary], I would see but ...the groupings
is okay”
Female, 44 Years, Small Multiple
Comment was also made on the restrictions placed within e-MAS formulary for the
duration of the supply of certain medicines.
“The other Health Board projects that we are involved in.., the head lice project where we
can supply a full treatment whereas we are told under the minor ailment service, we can
only give one supply. For most products you need to repeat them after 7 or 14 days. So, it’s
kind of ridiculous under the minor ailment service saying that you could have that one
bottle, you can come back in 7 days to get your next one. That’s not appropriate.”
Male, 39 Years, Large Multiple
Concerns around lack of inclusion of generic medicines in e-MAS formularies were also
raised. Participants rued the missed opportunities to produce further NHS savings.
“...it’s easier to prescribe everything by brand, you can save things getting thrown back
[rejected for reimbursement].”
Male, 37 Years, Independent
Participants voiced that e-MAS formularies should ideally include only those medicines
that are eligible for reimbursement. This would require amendment of the current
guidelines which, in principle, claims that pharmacies are reimbursed for any P and GSL
medicines supplied.
“I mean did we, did we make the formulary bigger and scrap everything else and just allow
the things on this formulary, allowed in the minor ailment [service], which, I think is a great
idea because it would restrict a whole lot of things but as it stands just now with all these P
and GSLs…”
Female, 46 Years, Small Multiple
Chapter 7: Pharmacists’ adoption of e-MAS (Qualitative) 237
Because of the fear of missing out on reimbursements, some participants stressed the need
to adhere to formularies while making medicines supply decisions.
“...you know but what you have given is one of the things in the formulary any way. You’re
not, you’re not going out with the formulary to give something sort of.., differently.”
Female, 23 Years, Small Multiple
In contrast, others regarded formularies ‘just as a guide’ considering it not essential to
adhere as long as the medicines belonged to either the P or GSL categories.
“I mean..., its fine because of the fact that its not entirely rigid. I think..., the fact that we can
go off the formulary using our professional discretion. But, in the same aspect, having a
formulary in itself is also useful... I like the formulary, I also like going off the formulary if I
need to.”
Male, 39 Years, Large Multiple
The need to update formularies on a regular basis was also voiced, keeping abreast of the
changes taking place such as the inclusion of newly reclassified medicines and new brands
of existing non-prescription medicines.
“The formulary is out of date. There are things we don’t agree with.., the things being there
under…,things with.., I’m not saying that’s a wholesale thing, we want to make wholesale
changes to the formulary but formulary is designed as products on the market, now when,
the products is being released… [formulary]”
Male, 55 Years, Large Multiple
Participants from one of the Health Board valued recent formulary updates that were
taking place.
“Well, the formulary we’ve got now tell you generic names and brand names that can be
prescribed. So its clearer.”
Female, 28 Years, Small Multiple
Participants expressed a lack of acquaintance with the methods and processes for feedback
to Health Boards around updates in formularies. In addition, some participants voiced that
the formularies being produced at the Health Board level should be scrapped so as to
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enable universal implementation of the national formulary. This would remove any
ambiguities arising from multiple formularies across the Health Boards.
“There is now scope from massive differences between as to what we can supply what we
can’t, how you supply, will we be paid for it?... how do we feed in, can we feed into the, the
Government bodies for what we would like to see in formulary?... Here it’s now Scottish
system and but, why do we need local formularies and why then, say, how dare do you get
hold of people to say, we think this should be in the formulary now. ”
Male, 55 Years, Large Multiple
7.3.2.10 Clinical guidelines for decision making
The need for further clinical guidelines to support decision making was also voiced.
Participants reflected that current guidelines were less explicit in areas around decision
making in relation to management of minor ailments.
“So, is it minor? You know, there are a lot of grey areas about what is minor and what’s not.
Hay fever have been one of the crackers, as you know by August, it should hopefully have
died down. But how often do you go and treat em’? Or when do you tell them to go to the
doctor?...There’s not enough guidance.”
Male, 37 Years, Independent
7.3.2.11 Opportunities to advertise the service
Patient targeted promotional materials were highlighted as key to promoting patient
registration. Some appreciated the advertising materials designed by NHS National
Education Scotland in raising public awareness.
“With us it’s a case of, it’s great when they actually put the poster up in the window to
advertise because we weren’t basically allowed to advertise the scheme before that or
promoted it in any sense. But when the advertisement went up in the windows, I’m not too
sure what you call that, you know with the health promotion window that all pharmacies
have. That went up and then, basically we’re sort of rural community and people do talk to
each other more so, probably than the time when they’d have come in and sort of asking
about it and then you’re able to tell them but you weren’t actively allowed to promote it
before this advertisement came about.” Perhaps cut this down?
Female, 27 Years, Independent
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On the contrary, others complained that current advertising materials were insufficient to
promote the service and wished the Health Boards to legitimise the use of privately
sponsored campaigns by pharmacies relevant to their community needs.
“When it [e-MAS] was first launched, I think everyone in the pharmacy was excited about it.
Because it was the first step towards moving away from volume dispensing, in terms of
payment. I suppose we were, initially slightly disheartened. Head office provided lots and
lots of promotion material for it which the Health Board, then the NHS said you can’t use
because we need a levelled playing field. Having worked for a big company, you know, then
recycling of the information pack which the public, I think would have found useful and we
could have used that to promote it. It’s disappointing the fact that even now after a lapse of
time, mothers of, of children are coming in and going, no, I don’t know what you are talking
about.”
Male, 39 Years, Large Multiple
Participants described encounters with patients registered with the service who were still
naive about their registration status, implying a lack of awareness.
“...folks don’t seem to know one what they signed the form for. I’ve had several occasions
where they’ve got, oh, have you heard the minor ailment scheme? No, and then you go, you
will find them registered in another pharmacy. So, I’m not sure if that’s been the city they
signed it up. They just don’t know, they just don’t know what they’ve signed.”
Male, 37 Years, Independent
The need for further promotion was highlighted with pharmacists recognising that many
patients eligible to register were yet to do so. Such shortcomings were attributed by
participants to the lack of opportunities to promote the service.
“...how many people actually know about it. ‘Cause I think, the information we have is that
only about 20% of the people that could be registered, are registered.”
Male, 39 years, Large Multiple
Participants also identified the role for GPs in helping to promote the service.
“Well, like saying to patients, Oh! you could go and get this [medicine] from you pharmacy
without coming to see me sort of things. Not I am aware of, very occasionally, I think I’ve
had people coming in and say oh my GP said I could just get that here. So, obviously one or
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two GPs are [promoting at the moment] but…, I don’t know that many are [doing] at the
moment.”
Female, 55 Years, Small Multiple
7.3.2.12 Training
The importance of formal training to facilitate adoption of innovative services and
medicines was presented in Chapter 4. This was not raised as an issue by participants in
relation to e-MAS. However one participant recounted ‘not any training’ (Female, 28 Years,
Small Multiple) when e-MAS was first introduced. However, despite this the same
participant expressed no difficulty in ‘getting used to’ the system.
7.3.3 Pharmacists’ views on future provision of feedback of
performance as a potential facilitator to adoption of e-MAS
into practice
Key themes identified within this category related to: awareness and experience of feedback
of practice performance; participants’ preferences on the types of data from e-MAS usage;
issues of privacy and confidentiality around dissemination of feedback; preferred method
of data presentation and delivery from e-MAS and data from other areas of e-Pharmacy.
These key themes and subthemes are presented with illustrated quotes.
7.3.3.1 Awareness and experiences of feedback of practice performance
Participants reflected varying levels of awareness and experience of the use of feedback of
practice performance around e-MAS. Some explained that they were already receiving
feedback from their Health Boards, limited to either one or some of the following
categories: the cost of items supplied; medicines allowed and disallowed for
reimbursement; adherence with formulary; and data on patient registration.
“The Health Board, I think is responsible for generating that sorts of [data]...We get feedback
in terms of our number of [patient registration]...and also in terms of the number of [e-MAS]
prescriptions that we are writing so we can see whether we are over performing, or if we are
one of the better ones or we are less or so. That feedback is good...[but] we don’t get it all the
time”
Male, 39 years, Large Multiple
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Participants already receiving such feedback, however, complained that the data were
mostly outdated. A few demonstrated awareness of GPs’ use of feedback from electronic
prescribing systems.
“This is like the SPA [Scottish Prescribing Analysis] data, the doctors get back from the
prescribing, is that right?...GPs have a lot information they get feedback from prescriptions
but they then have targets to reach so many seventy year, seventy years olds with whatever
conditions to protect them from heart problems and in the long term it’s saving NHS loads
of money, hospital beds and whatever.”
Female, 46 years, Small multiple
7.3.3.2 Participants’ preferences on the types of data from e-MAS usage: supply
of non-prescription medicines
Feedback in the following areas around medicine supplies within e-MAS were of interest to
participants.
 Number of medicines supplied
The total number of medicines supplied from each pharmacy via e-MAS within a
retrospective time frame was of interest. Such feedback would enable pharmacists to move
away from manual counting of the labels if they wanted to reflect on their own practice. In
addition, benefits to stock controls within the pharmacy were highlighted.
“Total number of items we’ve dispensed, I suppose I can count the labels, but it’d be
interesting to get back, what, what we’ve done previous months.”
Female, 46 Years, Small Multiple
 Therapeutic categories of medicines supplied
Details of the therapeutic categories of medicines supplied classified according to British
National Formulary (BNF) were desired by participants. Only the individualised feedback
to pharmacies/pharmacists was expressed as being potentially more useful for their direct
relevance to pharmacists.
“Yeah, it would be good to know, wouldn’t it, to really know you have been prescribing
right things for the right reasons, isn’t it? Its good for CPD...”
Female, 26 years, Small Multiple
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There was a low level of interest in receiving nationwide or Health Board aggregated data
sets. Such low interest was mainly attributed to the lack of relevance to individual practice.
“It would just be of interest really. I don’t think it would make any difference to our own
practice.”
Female, 55 years, Small Multiple
Aggregated data sets were only deemed relevant if comparisons of practice were made
with individual pharmacies/pharmacists.
“It would be nice to see region wide analysis and that of specific shop analysis and the two
could be laid, literally one on top of the other…”
Male, 66 Years, Independent
Others explained that, as every pharmacy is unique in terms of patient demography and
hence the types of ailments, comparisons of individual pharmacist/ pharmacy
performances with local or national e-MAS performance could not be justified, unless the
comparisons were made between areas of similar demography.
“Obviously, I think, every pharmacy is different. You know we are a small independent in a
local community and you know, so comparing our data to a busy city centre pharmacy is
pointless, I would think. But other pharmacies in a similar situation would perhaps …kind
of similar to yourself, [with] similar GP surgeries, similar sort of social, deprivation or
affluence in an area. You know these would be the things I would want to compare with. So,
there is no point...”
Female, 44 years, Small Multiple
Only a few saw participants benefits in receiving aggregated data sets alone without any
comparisons to individual pharmacists/pharmacies. In relation to individualised feedback,
however, benefit of reflecting on practice where individual practice appeared to be very
different from national or local performances was highlighted.
“What I prescribe [supply medicines under e-MAS], which I kind of already know but seeing
it in writing, you know makes you more aware. And may be also look at areas where you
don’t prescribe enough. May be because we don’t understand or you know... just not many
patients are coming in for that ailment.”
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Female, 43 Years, Small Multiple
However, aggregated data sets relating to Health Boards or locales were deemed to benefit
pharmaceutical public health initiatives by enabling pharmacies to set up and work around
certain targets, for example, in containing locally prevalent problems.
“...because you obviously have all these sort of seasonal problems, cold and flu, hay fever,
things like that, possibly sort of …. head lice things. So I think that would be of benefit to
reflect on perhaps to organize yourself to the next sort of phase.”
Female, 44 Years, Small Multiple
“...to increase your work effort into promoting…thinking about head lice or something
similar, and then quantify how much that effort was rewarded with how many prescriptions
you received, getting close to business targets. …yeah, you could review your performance,
you could review your individual pharmacy’s performance how it is done …”
Male, 28 Years, Large Multiple
Some expressed high levels of confidence in their decision making in practice. They
perceived that although feedback data would be potentially ‘interesting’, it would be
unlikely to serve any benefits.
“...we know what we are prescribing [supplying]. It’s interesting, but it’s not something I
would need to look at.”
Female, 46 Years, Small Multiple
 List of medicines allowed/ disallowed for reimbursement
Losing out on reimbursement for certain medicines supplied within e-MAS was a key issue,
as presented earlier in section 7.3.2.1. A timely breakdown of the list of medicines allowed
and disallowed for reimbursement was deemed potentially useful in informing future
practices.
” ...you know we tend to quite a lot of…prescribe things which we do get sent back, just to
see things which we haven’t been paid for that. So, that’s useful.”
Female, 28 Years, Small Multiple
“Certainly would be worthwhile...so that we don’t do it [supply disallowed medicines]
again.”
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Female, 55 years, Small Multiple
 Adherence with the formulary
Those who advocated the need for adherence to the formulary expressed a desire to obtain
individualised feedback around formulary adherence to identify any training or
educational needs. The importance of such data was also particularly noted to be useful to
impress upon ‘locums’ who may potentially lack familiarity with the formulary, hence
possibly responsible for skewing pharmacy formulary adherence.
“…your compliance relation, compliance to the formulary related to anti-infective skin
preparations and emollients and corticosteroids, for example, even if it is split down even
further than that, but you just then knew that there was an area where I’m really not that
compliant. So, let’s go and review the formulary, review that what should I be giving out. So,
you then know that, that’s the area which I need to do some CPD and do some training to
review what I, I thought I knew or what the store, where the store going.., may not going
quite right.”
Female, 25 Years, Large Multiple
Data around formulary adherence was considered more relevant if formulary adherence
was to be incentivised.
“The GPs get incentivized for being percentage over guidelines [for cost effective
prescribing]. We don’t. But, if we get incentive payments, it’ll be very helpful.”
Male, 37 years, Independent
 Generic versus branded medicines supply
Participants were aware of the potential NHS cost savings arising from generic medicine
supplies through e-MAS. Given that e-MAS computer systems could, in the future, allow
supplies of generic versions, participants were very keen to obtain feedback on how much
each pharmacy was saving the NHS.
“list of figures in terms of prescribing generically, what kind of percentage [generic supply is
ours] as compared to kind of national average is... quite useful to see.”
Female, 29 years, Small Multiple
Some, however, explained that cost saving had less relevance if pharmacist decision making
was ethical, hence in the best interests of the patient.
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“I don’t think that’s [feedback on generic medicines supplies] of any benefit because if you
are prescribing ethically, anyway, then the price shouldn’t be an issue. The number of items
shouldn’t either be, and I’m prescribing something because it’s necessary not [for other
reasons].”
Male, 55 Years, Large Multiple
7.3.3.3 Participants’ preferences on the types of data from e-MAS usage:
Patient registration
 Number of patients registered
Although data around the number of patients registered within a pharmacy could be
retrieved through the pharmacy computer system, some participants commented that
there were anomalies between the number shown by the pharmacy computers and
capitation payments received from the Health Boards. Feedback data would therefore
enable pharmacists to ensure fairer remuneration.
“With the system..., that you have just generated information saying how much, many
people we have registered [for e-MAS]. But when we compare it with what the Health Board
said we had, there’s always a difference… Our computer thought it was registered but when
you actually check, nothing had got through… in fact, then we had an issue because we
couldn’t re-register them because our computer thought they were registered even though
the Health Board didn’t think that they were registered. So, knowing what the Health Board,
are paying us for each month would be a benefit to us”
Male, 39 Years, Large Multiple
Participants were asked to comment on whether local and national patient registration data
would be of use. Some deemed such information to be important for Health Board and the
Government but not for individual practitioners.
“Yes, that’s interesting to the Government and the Health Board, but that’s not interesting to
the individual community pharmacist.”
Female, 46 Years, Small Multiple
Others, however, commented that such data would be an ‘eye opener’, for example to
identify any need for greater effort in getting more patients to register. A few, however,
raised objections around dissemination of such data with the notion that it could incite
competition between pharmacies to increase patient numbers.
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“It’s always good to have a good criticism to be able to affect yourself. If you don’t have the
information, you don’t know where you could improve...So, it will be good to see where we
are over performing or underperforming or doing well.”
Female, 43 years, Small Multiple
“I don’t think minor ailment is a competitive thing. Its not you know you are trying to do
more than just down the road. We are trying to serve our customers as best as we can.”
Female, 47 years, Small Multiple
 Number of ‘active’ patients in the e-MAS register
Some reflected on the need to provide feedback to pharmacies with data on number of
patients that are being seen repeatedly for the service provision along with the numbers not
‘active’ in the system after initial registration. These data were deemed to have potential to
encourage pharmacies to focus on continuity of care.
“..if people [pharmacists and support staff] are just purely signing people [patients] up, it
really makes that meaningless. You really what you want to know is who is actually using
it.”
Female, 53 Years, Independent
 Number of patients lapsed from the register and those transferred to other
pharmacies
These two specific areas again had direct bearing on pharmacy remuneration. Participants
deemed data would serve as timely updates on the specific band of capitation remuneration
the pharmacy received through their Health Boards.
“...it will be good to know which patients are still on and which patients have lapsed. It
obviously helps. Higher the number of patients you have, the more, you know the,
remuneration you get. So we would have a way of knowing who is still on and who is not.”
Female, 43 years, Small Multiple
7.3.3.4 Feedback of performance relating to changes in practice guidelines
Participants were asked their opinions on receiving feedback around how changes in
national practice guidelines, such as amendments in formularies or changes in legal status
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of non-prescription medicines, affected their own e-MAS performance. Very low interests
in such feedback were observed.
“POMs to Ps, I would just kind of know myself, how that was going. I wouldn’t see really
any major need for...[this]”
Female, 29 years, Small Multiple
“I don’t need to be informed up to date. Your practice, don’t think changes dramatically
over short space of time.”
Male, 28 years, Large Multiple
7.3.3.5 Issues of privacy and confidentiality around dissemination of feedback
Participants reflected on issues around privacy and confidentiality that might arise with the
gathering and dissemination of feedback of e-MAS performance data. Participants were
strongly against the use of feedback data by either pharmacy management or Health
Boards to mandate practice changes at the individual practitioner level; for example, in
setting undue targets aimed at increasing performance. Participants further advised that
information should only be disseminated for supportive reasons. Apprehension around the
potential misuse of data by pharmacy management was mostly noted with respondents
from multiple chain ownerships.
“I’ll be little bit worried about one angle of having this. Now working for multiple
[pharmacy ownership], this may or may not happen but if…, put on e-MAS further up the
chain, so, well you, you have to achieve X numbers products in this category you supply in
given period of time. Why you are not doing ‘cause there are so many folk registered, you’re,
you’re below, below the national average or something like that.”
Male, 28 years, Large Multiple
However, a few had no issue with privacy or confidentiality and were happy for their
performance within e-MAS to be disseminated to others, including other pharmacists.
“Not, certainly not, where I am working at the moment. I don’t think that [disseminating
information to others] would be an issue. I think possibly if you are working for the big
multiple, then that would be more of an issue. Certainly, in my situation, I don’t think that
really is an issue...”
Female, 47 years, Small Multiple
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7.3.3.6 Preferred method of data presentation and delivery from e-MAS
Most participants explained that they worked in a busy environment and hence feedback
should use formats and presentations able to deliver key messages at a glance. Participants
were divided on the issue of whether electronic or postal methods of delivery would be
more appropriate.
“Four of us here will say paper [based feedback] and one will say computer [based]. This is
the age gap…”
Female, 54 Years, Independent
7.3.3.7 Data from other areas of e-Pharmacy
Participants were asked if there were any areas of practice other than e-MAS, which could
benefit from performance data feedback. Participants’ interests were mostly around the
activities within Acute Medication Service (AMS) such as the number of medicines
dispensed for each GP practice in a local area so as to estimate which of the GP contractors
were contributing to pharmacies’ income; demographics of patients using pharmacy
specific pharmacy and total medicines including prescription and non-prescription
medicines supplied to individual patients.
“The amount of prescriptions dispensed….sent from specific surgeries sent every month
sort of across the area.”
Female, 23 Years, Small Multiple
One quote also reflected the usefulness of data relating to, but not limited to minor ailment
management, around how innovative services are progressing in Scotland as compared to
the rest of the UK nations.
“...it’s interesting to see how pharmacy is progressing in this country compared to the rest of
the UK because it is something that nobody else is really doing... I do want to see pharmacy
progressing and moving on...”
Female, 25 years, Large Multiple
7.4 DISCUSSION OF KEY FINDINGS
This is the first qualitative evaluation around pharmacists’ adoption of e-MAS and
associated barriers and facilitators associated since Scotland wide e-MAS rollout in 2007.
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Participants’ attitudes towards the nationwide rollout of the service and key
facilitators/barriers to service adoption were identified to answer the study objectives.
7.4.1 Attitudes towards the service
Participants identified benefits to both professional practice and patients. The service was
commended for enabling pharmacists to make supplies of medicines, including the so
deemed ‘pricy’ newly reclassified, many of which certain patient groups might otherwise
find inaccessible.
Service regulations requiring patients to register at one pharmacy of their choice were also
noted, facilitating greater acquaintance between professionals and patients. However,
extension of the need for patient registration to other services may contradict health policies
which aim to increase patient choices [6].
Participants raised awareness of potential NHS savings through e-MAS and regarded such
savings as a motivation to service adoption. A few studies have demonstrated cost
minimisation brought about by similar minor ailment schemes. These economic savings
models are based on the reduced cost of pharmacy consultations as opposed to GPs
[111,113,337,338]. Such services have also been shown to be effective in reducing GP
workload specific to minor ailments [111,113], although overall GP workload has been
mostly shown to have been unaffected [113,339]. The long term economic impact of
nationwide rollout is yet to be explored. There are several factors which should be
considered and these are discussed in Chapter 9.
7.4.1 Facilitators and barriers to the adoption of e-MAS
Both ‘context’ and ‘content’ related facilitators/barriers were identified from the qualitative
data; many of these being similar to the adoption of innovations of reclassified medicines
into practice. Appropriate remuneration and reimbursement was regarded as a key
facilitator to adoption of the service. Although some deemed that service implementation
was leading to financial benefits to the pharmacy, many did not support the current e-MAS
remuneration patterns. These differences could be related to how implementation was
affecting individual pharmacies’ businesses relating to non-prescription medicine sales. It
may be that in rural pharmacies, with the predominance of elderly patients exempt from
prescription charges, e-MAS could reduce profits generated through either the over the
counter sales, or remuneration from dispensing prescriptions.
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Debates about the benefits of capitation-based versus ‘fee-for-service’ system need to be
considered. Criticisms of capitation-based systems as compared to fee-for-service systems
in general include the former encouraging a focus on new patient registration, shorter
consultation times and higher workloads and hence potentially compromising continuity of
patient care [340]. However, the published studies mostly relate to doctors’ practices and
the evidence itself has been suggested to be poor, limiting generalisability to other areas of
primary care [340]. Any issue about pharmacists’ potential disinterest in continuity of care
has been partly dealt under e-MAS which requires at least one consultation per registered
patient per year for the pharmacies to be eligible for the capitation payment. However, it
penalises the pharmacy for less than one and does not reward for more than one
consultation per year [341]. This lack of sufficient reward for repeated care accounting to
more than one consultation per year was deemed unfair by participants. Models that would
pay pharmacists per consultations were suggested as fairer by some participants. This type
of remuneration pattern was utilised in the feasibility study prior to the nationwide service
roll out, which paid pharmacists with a fee per consultation. Complaints around lack of
enough financial reward for service provision were also raised [342]. In other areas, where
such remuneration patterns for similar minor ailment schemes exist, for example in some
PCTs of Northern Ireland [343] and some PCTs in England [344], research into pharmacists’
attitudes towards such remuneration patterns have not been yet published. A qualitative
study into pharmacists’ perspectives of a similar minor ailment scheme in Nottingham PCT
also reported pharmacists’ dissatisfaction with the remuneration structure, but did not
detail the nature of remuneration [123]. The need for further evaluation around the effect of
different remuneration systems in pharmacists’ adoption of new services; and the effect of
these systems on clinical and economic outcomes has been recently outlined in a recent
systematic review on effectiveness of diverse remuneration structures [345]. The author
noted difficulties in concluding which was the most appropriate remuneration system.
Lack of patient willingness to countersign the e-MAS prescriptions due to time implications
was thought to have affected pharmacy remuneration. Alternative means of recording
consultations such as the use of automatic cards carried by patients and readable by the e-
pharmacy system could be an efficient technique to replace the counter signature
requirements. In addition, the current restriction placed on advertising e-MAS, which is
limited to leaflets and a poster designed by NHS Scotland [341,346] was also considered to
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limit patient numbers and hence remuneration. The potential role of GPs and practice
nurses in promoting the service as identified by participants was worth noting.
The walk in nature of the service was deemed by some to be leading to excess workload.
Although an appointment based system was deemed a possibility by some participants, the
walk in nature of the service is unlikely to be changed, as enhancing the image of
community pharmacy as the first point of contact for unscheduled care remains a priority
for the Scottish Government [347].
The mandate within e-MAS which requires pharmacists’ personal involvement in every
aspect of supply was deemed to contrast with the processes for non-eMAS supply of non-
prescription medicines. The cognitive elements involved in the service, for example the
systematic patient assessment, medicines supply and referral [94,95] might be the reason
why greater pharmacists’ involvement is mandated. However, a study in the UK has
demonstrated that as many as 90% of pharmacy consultations around non-prescription
medicines purchases are handled by support staff, covering conditions such as head lice
and acne [348]. Many participants in this study reported to have deviated from such
personal involvement requirements and putting alternative measures in place. On one
hand, such measures are likely to free up pharmacists’ time. Alternatively it might give
patients a negative impression; especially those moving from GP managed minor ailments.
Perceived expertise of health professionals has been identified as a key trigger in patients’
decisions around which professionals from whom they choose to receive care [101,105,120].
Amendments in the current provisions around personal involvement requirements should
be based on the balance between what is appropriate for patients against what is feasible to
undertake in a pharmacy environment.
Enhanced access to patient medical records was also considered necessary to enable
informed decision making around minor ailment management and issues around
reclassified medicines. Access to patient medical records is also important to enable
pharmacists to adopt other services integrated within e-pharmacy such as the Chronic
Medication Service (CMS). This is a service whereby pharmacists can manage patients’
long-term medication for up to 48 weeks under a shared-care arrangement with GPs [349].
A concept of an emergency card summary has been recently introduced in Scotland which
details the annual record of chronic and acute medicines prescribed to the patients. It is
anticipated that pharmacists will be able to obtain access by telephoning NHS24 [347].
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However, such access by pharmacists will require patient consent, and in addition is not
available at the point of care. Further debate about acquisition, use and governance of
patient medical records in pharmacy is urgently warranted.
The need for enhanced access to patient medical records and better inter-professional
communication were also voiced by participants to support pharmacists dealing with
suspected service misuse. Although the pilot e-MAS in Scotland showed an average of one
consultation per patient per year [350], respondents reflected concerns that some customers
might be tempted to misuse the service. Participants were strongly opposed to the issue of
direct medicine requests received from patients, many of which were initiated via by GP
and practice nurse referrals.
Opinions around the usefulness of e-MAS formularies were mixed. Some appreciated the
layout and content whereas others voiced that formularies were too restrictive. Restrictive
formularies might potentially lead to a greater number of GP referrals by pharmacists and
contribute to barriers to patient utilisation of the service. Some Health Boards seemed to
have updated their formularies frequently and recently, reflected in participant satisfaction.
Very limited evidence generated through qualitative interviews with seven GPs from
Nottingham PCT, England, reflects that GPs are also in favour of increasing the range of
medicines within e-MAS formularies including the inclusion of antibiotics [351]. There is a
need for further discussion among stakeholders regarding formulary extension.
The benefits, barriers and facilitators around the adoption of e-MAS by community
pharmacists identified in this study are consistent with previous studies, most of which
used qualitative methodology. Barriers to service adoption that were reported during the
feasibility study in England [342] are still being experienced by pharmacists. These also
match literature reports around evaluation of another similar scheme in Nottingham PCT in
England [123,352]. Positive aspects reported by others were: the contribution to extending
pharmacists’ skills; greater patient accessibility to minor ailment management, improved
relationships with GPs and patients; and reduced GP workload and financial benefits for
pharmacists [123,342]. Key barriers reported were the limited scope of the formulary and
restrictive protocols [123,342,352]; lack of privacy for consultations in the pharmacies
[123,342]; lack of support from local medical practices [123,342]; lack of opportunity to
advertise the service [123,342]; excessive paperwork [123,352]; ambiguous scheme protocols
[123,342]; abuse and misuse of the service by some customers [123,342]; lack of access to
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patient medical records [342]; presentation of proxy consultations [342]; and patient
pressure to prescribe medications for every consultation [352] thereby regarding pharmacy
as a place to obtain medicines without any patient assessment [342]. Compared to the
findings of other studies [123], the participants in this survey, however, did not raise the
issue of privacy as a concern. Lack of patient willingness to undergo detailed consultation
might have made the issue of privacy redundant. Further training for support staff was not
raised in this study as compared to previous findings [123], however, it should be borne in
mind that support staff currently have little role in the Scottish scheme.
Three studies around patient views of minor ailment schemes have been published. A
study of 143 patients (response rate: 14%) conducted in Nottingham PCT reported that ease
and convenience of access was the most important benefit of the scheme [353]. Interestingly,
higher patient satisfaction was related with lower patient income status which could
indicate that those of lower income are more likely to use the service. Patients voiced that
the ‘physical environment’ was the most important barrier. The very low response rate
limits the usefulness and generalisability of the findings. Vohra surveyed patients who had
accessed Minor Ailment Scheme in the Chorley and Ribble PCT (123 replies, response rate:
40%) [121]. Of those using the service, almost all were positive about the scheme and would
use it again. No appointment and the ‘free’ nature of the service were the key reasons for
planned reuse. Langley et al investigated patients in the Eastern Birmingham PCT who
were given the option to use the scheme instead of visiting their GPs for managing minor
ailments but had refused the offer [114]. Of the 24 out of 30 patients approached, common
concerns were related to privacy available in pharmacies, pharmacists’ expertise in
diagnosing minor ailments and expression of greater trust in doctors. These findings
suggest that many benefits, barriers and facilitators to service adoption are similar among
pharmacists and patients.
7.4.2 Performance feedback data as a potential facilitator to e-
MAS adoption by pharmacists
Diverse areas of practice were identified by participants where feedback could support
service adoption, such as by allowing review of performances around patient registration.
Feedback around formulary adherence was related to ensuring that reimbursements were
received for future medicines supplies made through the service. In addition, the e-MAS
computer system allowing, many participants were keen to follow cost effective medicine
supply practice and receive feedback around how much savings each practitioner was
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bringing to the Health Boards. Nevertheless, participants expressed a need to incentivise
the cost effective non-prescription medicine supplies through e-MAS. There is a
considerable amount of evidence from the medical literature that cost effective and
guideline adherent medicine supplies could be influenced by the use of feedback of
performance data recorded through the electronic prescribing systems [334,354-356]. A
recent systematic review around the benefits of audit and feedback to health care
practitioners suggests that changes in practice brought about by such feedback are largest
when baseline adherence to the guidelines or standard to practice is low [357]. Hence those
pharmacists who deemed adherence to formularies and service guidelines important and
those least adherent at baseline are most likely to benefit. Some examples of electronic
systems through which such feedback data has been used to support rationale medicine
supply practice of doctors include the Scottish Prescription Analysis (SPA) [358] and PACT
[359] in the UK, COMPASS in the Republic of Ireland and South Africa [360]. Similar
electronic systems are known to be in place to support electronic medicine prescribing by
doctors in Australia [361], Sweden [362], Canada [363] and the Netherlands [364]. Although
some evidence suggests that feedback information alone can be as effective as interventions
such as reminders, outreach, incentives and opinion leaders [333], evidence also reflects that
feedback of performance alongside educational outreach visits and computers reminders
are more effective than using feedback alone [361-367]. Future provision of feedback hence
would benefit from accompanying other educational intervention to support pharmacists’
service adoption where required.
Many participants expressed a desire for feedback around the total number of medicines
supplied and types of medicines supplied through e-MAS. Many related these to
identifying personal educational needs through reflection of areas where they would find
themselves ‘overprescribing’ or ‘under prescribing’. In many instances where feedback
around medicine supply practice and patient registration was sought, the importance of
comparison of performance with local/national service data was highlighted. Evidence
from the medical literature again suggests that feedback is most effective in encouraging
practice change where the receiver’s own practice is inconsistent with those of peers [357].
Feedback around individual practice was deemed by participants to be more desirable than
aggregated feedback to groups of pharmacies. It has been suggested that individualised
feedback, particularly because of the capacity to highlight individual need for change is
more consistent in bringing about change [361,363,368]. Participants’ concerns around
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‘aggregated’ feedback of performance related to a potential lack of relevance to individual
practitioners. The evidence around the importance of identifying the information needs
actually required at the level of patient care [335,369] is further strengthened by this
qualitative study.
The lack of expectations of any potential ‘advantage’ from feedback could explain why
some expressed little interest. The usefulness of feedback has been shown to be greater once
practitioners become familiar with the information [370]. Fears about the inappropriate use
of feedback by ‘head office’ are worth noting. Feedback which does not mandate use or
change , as desired by most participants, is known as ‘passive’ feedback [357]. This is
contrary to ‘active’ feedback associated with mandated use and change. It is important that
pharmacists’ wishes around feedback are respected. Evidence stresses that practitioners
need to agree about whether they want to review their performance [357], hence forcing
change is likely to have negative consequences.
Other barriers to accessing performance feedback as a tool to facilitate innovation adoption
in this study mostly reflect those identified in the literature around doctors’ use of feedback.
Barriers to the use of electronic feedback reported by the literature relate to: doubts about
the application of information to practice [371], lack of time in using the information [371-
373], convenience of access [371,374], issues about reliability of the source [373], difficulty in
interpreting the available information [371,374] and lack of individual motivation [375].
The desire for timely feedback as highlighted by the participants in this study is important
given that feedback is more effective in changing professional practice if provided when
recollection of actions and experiences are fresh in practitioners’ minds [376].
Limited evidence around the applications of performance feedback in enabling the
adoption of new behaviour by pharmacists exists. Most studies have used a mystery
customer approach to collect and report on the performance of pharmacists or support staff
[376-379]. One study compared the accuracy of guideline adherent counselling by 30
pharmacies in Australia receiving and not receiving regular feedback [378]. Those receiving
feedback were found to demonstrate greater adherence to practice guidelines than those not
receiving feedback. Another study with 20 community pharmacists from London
investigated the potential of feedback in enabling pharmacists to identify drug-related
problems (DRPs) through a clinical medication review programme; those who regularly
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received feedback of performance were more likely to have identified the DRPs more
accurately than those who had not received feedback [380]. Those receiving feedback were
also more likely to suggest appropriate courses of actions to the patients. Feedback collated
and reported through mystery customer studies is less likely to reflect long term
performance. This method is more suited to investigating pharmacists’ and support staff’s
communication and counselling skills [377]. Benefits around feedback relating to long term
performance collected and disseminated through external sources is hence a novel area of
research within community pharmacy.
Anecdotal evidence suggests that pharmacists currently receive feedback resulting from
various audits taking place within their pharmacy organisations, especially larger chain
organisations [381]. However, there is a lack of detail on the audit processes, content and
outcomes [381]. Further research in this area is warranted.
7.4.3 Factors associated with innovation adoption
Analysis of the results around pharmacists’ adoption of e-MAS into practice revealed very
similar findings to the qualitative data around factors associated with adoption of
reclassified medicines innovations. In relation to e-MAS, themes around benefits to
professional role development and pharmacy; benefits to the patients; opportunity to have
feedback of practice performance, and greater acquaintances with patients all relate to
perceived advantage of innovations as per the diffusion model [131]. Desire to see whether
their effort had been worthwhile to save Government resources through service provision
as a source of motivation relates to observability. Complaints around technical elements, the
so deemed lengthy consultation recording process relates to perceived complexity of
innovation adoption [131]. Adjustments made by practitioners to suit their workload
demands such as by delegating certain tasks to support staff relates to re-invention [131].
Service roll out matching the need of pharmacies and their business interests related to
compatibility [131]. Again the importance of trialability was not identified [131], which may
be due to the fact that participants had already passed the stage of trilability when this
investigation was carried out. In addition, patient acceptance and use of the service; issues
of clear practice guidelines; and issues around communications with GPs related to external
factors associated with innovation adoption [131]. The resource issue within pharmacy
relates to internal ‘contextual’ factors [131]. These factors will be quantified for their
importance to service adoption in the next phase of the research.
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7.5 SUMMARY OF CHAPTER 7
Key benefits, facilitators and barriers to the adoption of e-MAS into practice by community
pharmacists were identified. Benefits of e-MAS to professional role development, to the
patients and to Government were explained by participants. Innovative features within the
service such as the concept of ‘one pharmacy registration’ were also noted for contribution
to minor ailment management. Participants were hence; supportive of the service, but its
adoption into practice was hindered by issues such as remuneration, reimbursements,
formulary restrictions, and technical elements of the service, lack of access to patient
medical records and patient abuse and misuse of the service. Feedback of practice
performance through e-pharmacy received a cautious welcome from participants as a
potential information source to encourage service adoption. With the issues such as
resolving the ownership of such performance feedback data, privacy and confidentiality,
pharmacists’ confidence; feedback in the long term could potentially be a useful tool to
facilitate service adoption by pharmacists and could be extended to other areas of e-
pharmacy. These facilitators and barriers identified relate to factors associated with
innovation adoption as described by Rogers [131]. These findings are important on their
own to inform service development. Key themes and illustrative quotes will also be used to
develop the questionnaire items to quantify factors associated with the service adoption by
pharmacists using a wider sample of the population of community pharmacists in Scotland.
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8 CHAPTER 8: PHARMACISTS’ ADOPTION OF E-
MAS (QUANTITATIVE)
8.1 INTRODUCTION TO THE CHAPTER
This chapter presents data collected from the mailed survey around pharmacists’ adoption
of e-MAS. Since the nationwide rollout of the service in 2006, there has been no large scale
evaluation of this service from any stakeholders’ perspective [96]. The following were the
research objectives.
8.2 OBJECTIVES
1. To quantitatively investigate the adoption of e-MAS into practice by community
pharmacists.
2. To quantify facilitators/barriers associated with adoption of e-MAS by community
pharmacists.
3. To investigate the utility of Rogers’ diffusion model in exploring objectives 1 and 2
above.
8.3 DEVELOPMENT OF QUESTIONNAIRE ITEMS
Pharmacists’ adoption of e-MAS was the main outcome measure. An eight item facilitator
scale, mainly measuring benefits to professional practice and patients; and a 10 item barrier
scale were designed based on the literature review (Chapter 1), qualitative interviews
(Chapter 7), and theoretical model of diffusion of innovations [131] (table 8.1 and table 8.2).
Respondents were asked to indicate which of the listed facilitators and barriers applied to
them, with multiple selections allowed. Two open questions encouraged respondents to list
any other facilitators/barriers not included in the scale.
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Table 8.1: Development of eight item e-MAS ‘facilitator’ scale
Scale measure Practice
relevance
Supporting statement from interviews Rogers’
description of
the theme
Rogers’ broader
category
Financial benefits to me Financial
benefits
“Our pay size is actually very good. I think, one of the
reasons for this is when we are doing with minor ailment
[service]. “
Advantage Attributes of
innovations
Financial benefits to my
pharmacy
Financial
benefits
“I just hope that the funding for it continues and makes [our
time] worthwhile.”
Advantage Attributes of
innovations
Opportunity for
enhanced working with
GPs
Inter-
professional
relationship
“GPs don’t understand fully what the minor ailment service
is about.”*
Advantage Attributes of
innovations
Opportunity for more
effective patient treatment
Enhanced
access to
medicines
“... I’ve been quite delighted when I can actually help people
[in need] feel all right“
Advantage Attributes of
innovations
Opportunity to know my
patients better due to
registration process
Benefits to
practice
“You definitely do get to know people, patients more
efficiently.”
Advantage Attributes of
innovations
Opportunity to better
meet patient expectations
Relevance to
local needs
“Where we are here, it’s not a very well to do area. Things
like Zanprol [omeprazole]...are too expensive for people to
buy here...that would more come under the minor ailment
[service] “
Compatibility Attributes of
innovations
Opportunity to extend
my professional role
Role
development
“I’m happy that our role is...getting bigger...” Advantage Attributes of
innovations
Availability of electronic
feedback relating to my
practice
Feedback of
practice
performance
“Its always good to have a good criticism to be able to affect
yourself.”
Advantage Attributes of
innovations
*positive quote not identified
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Table 8.2: Development of 10 item e-MAS ‘barriers’ scale
Scale measure Practice
relevance
Supporting statement from interviews Rogers’ description
of the theme
Rogers’ broader
category
Lack of satisfactory
reimbursement
Financial
benefits
“But it’s a trade cost that we’re reimbursed, it’s
not the profit that we would normally make...”
(Dis)Advantage Attributes of
innovations
Lack of satisfactory
remuneration
Financial
benefits
“...if the capitation fee you get each month makes
up for any loss of profit...”
(Dis)Advantage Attributes of
innovations
Time for recording
consultations or supply
Resource
implications
“they’re [patients] not going to wait us doing that
[record consultations and countersign]...”
Complexity Attributes of
innovations
Lack of access to patients’
medical records
Patient medical
records
“I think, if we could get to see the patients’
history, as you know towards e-MAS...”
Complexity Attributes of
innovations
Technical components of the
electronic service
Technical
component
“that has been the single biggest influencing
factors on my prescribing practices...”
Complexity Attributes of
innovations
Inadequate resources of my
pharmacy
Organisational
resources
“A lot of shops are one pharmacist” Organisational Organisational
Lack of opportunity for
enhanced working with GPs
Inter-
professional
relationship
“GPs don’t understand fully what the minor
ailment service is about. “
External factor External factor
Lack of clear practice
guidelines
Practice
guidelines
“...it’s easier to prescribe everything by brand,
you can save things getting thrown back [rejected
for reimbursement]
External factor External factor
Low number of patients
presenting for the service
Patient
acceptance of
service
“...how many people actually know about it.
...only about 20% of the people that could be
registered, are registered.”
External factor External factor
Suspected misuse/overuse
of the service by some
customers
Misuse/overuse “...sometimes they [patients] are just coming in
and looking for cough bottles for the cupboard”
External factor Attributes of
innovations
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8.4 DATA ANALYSIS
Descriptive analysis was performed on the outcome measure; and to quantify responses to
the facilitator and barrier scale. Binary logistic regression was performed to identify key
factors associated with the level of service adoption using similar analytical procedures as
in Chapter 6. Responses to open questions were analysed using content analysis as detailed
in Chapter 2.
8.5 RESULTS
Demographic characteristics of respondents (N=563) appear in Chapter 6 (section 6.3). Only
the results relevant to e-MAS are presented here.
8.5.1 Level of e-MAS adoption
A high majority (over 84%) of the participants ranked their level of adoption of e-MAS at
either 4 or 5 (the highest adoption ranking) on the five point ordinal scale. The results are
summarised in table 8.3.
Table 8.3: Pharmacists’ adoption of e-MAS
Please indicate how often do you or your support staff deliver e-MAS service (N= 490)
1* 2 3 4 5†
n (%) n (%) n (%) n (%) n (%)
2
(0.4%)
15
(3.1)
60
(12.2)
135
(27.6)
278
(56.7)
*1 represented ‘not at all’; †5 represented ‘very frequently’ in the questionnaire.
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8.5.2 Responses to facilitator scale
Among the eight listed facilitators of e-MAS, the opportunity to extend professional role
was the most frequently highlighted by the respondents (469, 83.3%). Three other benefits
of e-MAS were also highly rated: the opportunity for more effective patient treatment (442,
78.5%); the opportunity to better meet patient expectations (419, 74.4%); and financial
benefits to the pharmacy (296, 52.6%). A minority of around one in five perceived the
opportunity for enhanced working with GPs to be a benefit, as shown in figure 8.1.
Figure 8.1ponses to facilitator scale
* % add up to >100% as multiple selections were allowed; arranged in descending order of %.
0 20 40 60 80 100
Financial benefits to me
Availability of electronic feedback
relating to my practice
Opportunity for enhanced working with
GPs
Opportunity to know my patients better
due to registration process
Financial benefits to my pharmacy
Opportunity to better meet patient
expectations
Opportunity for more effective patient
treatment
Opportunity to extend my professional
role
% of respondents
Responses to e-MAS facilitator scale (N= 563)*
n=469
n=442
n=419
n=296
n=273
n=121
n=45
n=80
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8.5.3 Barriers to the provision of e-MAS
Key barriers noted by most participants were the suspected misuse/overuse of the e-MAS
service by some customers (423, 75.1%) and the time required for recording customer
consultations and/or supply (345, 61.3%). Approximately 40% (224) perceived the lack of
access to patients’ medical records a barrier (figure 8.2).
Figure 8.2spondents’ barriers to adoption of e-MAS
* % add up to >100% as multiple selections were allowed; arranged in descending order of %
0 10 20 30 40 50 60 70 80 90
Inadequate resource of my pharmacy
Low number of patients presenting for the
service
Lack of opportunity for enhanced working
with GPs
Lack of clear practice guidelines
Technical components of the electronic
service
Lack of satisfactory reimbursement
Lack of satisfactory remuneration
Lack of access to patients' medical records
Time for recording consultations or supply
Suspected misuse/overuse of the service by
some customers
% of participants
Responses to e-MAS barrier scale (N=563)*
n=423
n=345
n=224
n=158
n=147
n=146
n=109
n=85
n=68
n=55
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8.5.4 Responses to open questions
A total of 33 and 60 respondents respectively provided comments on the two open
questions around any other facilitators and barriers.
Most of the themes that were identified related to the items already presented within the
eight-items facilitator scale and hence merely reinforced the validity of the scale. The most
prominent theme was enhanced patient access to medicines contributed by e-MAS. Two
quotes around the theme ‘role development’ were not realised through the review of
literature or qualitative focus groups and interviews (Chapter 7). The requirements around
pharmacists’ personal involvement in every aspect of consultation and generation of e-MAS
prescription after each consultation were perceived as enhancing pharmacists’ images in
society. These comments contradict those identified in the qualitative phase where the
impracticality of such personal involvement was criticised by most participants.
Ten respondents considered that e-MAS offered no benefits to either pharmacists or
patients (table 8.4).
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Table 8.4: Benefits identified by the respondents through responses to open questions*
Response
categories
Number of
responses
Exemplar quotes (Respondent code)
Enhanced
patient access to
non-prescription
medicines
12 “Ability to supply whatever treatment is required
without worrying whether customer can afford it,
or that I am trying to increase my sales.” R63
“Encourages health care of "lower class" as they
get advice and free goods to their own benefit.”
R358
“...benefit in supplying to children for certain
products.” R200
No benefits,
very much
against the
service
10 “E-MAS is a mistake, one of the worst ideas so far.
Reinforcing bad mentality of getting everything
for nothing.” R11
“I have nothing positive to say about e-MAS.”
R358
Role
development
6 “Increased perception among patients of
pharmacists’ expertise in drugs and treatment.”
R52
“Utilising clinical knowledge/skills obtained at
university plus by doing CPD plus training to be
independent prescriber” R121
“Pharmacist to counsel patients rather than some
untrained person selling products.” R305
“Able to counter prescribe bit on prescription so
enhanced role in patient eyes.” R407
Benefits to the
Health Board/
Government
3 “Less NHS time/ money wasted on unnecessary
visits to the Drs, appointments more readily
available to patients more ill.” P309
Financial
benefits
1 “Business growth, negotiation in OTC purchase
price due to increased purchase volume.” R184
Patient
acquaintance
1 “Keep customers coming to my pharmacy.” R46
Other 1 “Accuracy” R131
* Some respondents provided more than one comments
Responses to the open question around ‘additional barriers’ also related to the issues
covered by the 10-item barrier scale. Lack of clear practice guidelines and restricted
formularies was the most prominent theme. Lack of consistent guidelines and SOPs to deal
with inappropriate requests were blamed by a few to have encouraged misusers to shift
their registration status across pharmacies to obtain the desired medicines. Issues around
lack of support from other health professionals and resources were also raised by a few
respondents.
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Table 8.5: Barriers to provision of e-MAS identified by respondents through responses to
open questions* (note: this table extends to two pages)
Response
categories
Number of
responses
Exemplar quotes (Respondent code)
Practice
guidelines/
formularies
16 “Need clear list of products allowed on e-MAS service.”
R339
“Staff unsure when Ok to supply + product to supply.”
R342
“Widespread inconsistency in how different pharmacies
deliver service e.g. some do not promote it or are very
strict in what they prescribe. Some pharmacists only
prescribe what is on local 'guidelines' even though they
will be reimbursed for supplying any non-black listed
GSL or P product.” R139
“Other pharmacies supplying contra the requirements,
patients expecting similar from us.” R358
Misuse/ abuse
of the service by
some customers
13 “Patients demanding a particular product without
satisfactorily justifying the need- leading to stockpiling
and unnecessary use of medicines.” R319
“Patients not interested in pharmacists' clinical advice or
input they just want their list of medicines supplied.” R47
“Aggressive customers e.g. furious plasters are not
allowed + verbally abusive because plasters are on the
leaflet!” R195
Lack of support
from GPs and
practice nurses
12 “GPs/ nurses referring patients for this service with a
note specifying what I should prescribe. This defeats
totally the intended purpose of e-MAS.” R73
“1. GPs and Health visitors etc sending patients to
pharmacy rather than deciding with 'it' at the end of the
consultation. 2. Wouldn't it be great if you could do the
prescribing course then set up your own practice in the
pharmacy, rather than the patient still registered at the GP
and you work for them!” R404
“GPs/ nurses referring patients to me for painkillers on e-
MAS after prescribing antibiotics on GP10.” R186
Resource issues 7 “Not enough staff in shop.” R295
Poor stock control, Stock what they [head office] like, not
what’s on the formularies.” R305
“Lack of trained staff” R272
*some respondents provided more than one comment
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Categories Number of
responses
Exemplar quotes (Respondent code)
Reimbursement/
implications for
over the counter
sales
5 “Causing decrease in profit as slower payment plus
decreased cost of medicines.” R273
“Loss of OTC sales which is more profitable.” R87
Time issues around
recording
consultation
4 “Find it difficult to ask patient to sign form when only
advice given.” R102
Lack of opportunity
to advertise
3 “Leaflets and advertising doesn’t explain service
properly.” P513
Technical
component of the
service
3 “IT issues e.g. those affecting pack selection for
endorsement and e-transfer of details.” R471
“Slow computers” R305
Remuneration 3 “Lapsing- waste of time. Very difficult to retain
numbers” R193
Language barriers
with patients
1 “Lack of language resources when dealing with non-
English speaking patients” R10
Other 2 “Have the people who introduce new schemes even
worked in a pharmacy.” P459
“Patients not knowing postcode/ GP name etc.” R471
8.5.5 Multivariate analysis
Binary logistic regression analysis was performed to identify the key facilitators/barriers
associated with respondents’ ratings of adoption of the service. Responses to the barriers,
facilitators and demographic characteristics were used as explanatory variables. Responses
to the barrier scale were reversed scored to make all items positive before the analysis so as
to ease interpretation of the output. Scores on the adoption scale were used as the outcome
measure. Based on the distribution of responses, the five point e-MAS implementation scale
was converted to two point (binary) scale whereby points 1, 2 and 3 in the five point scale
were labelled as ‘low implementation’ with points 4 and 5 in the scale merged and labelled
as ‘high implementation’. Categories within demographic characteristics: the age, number
of years registered with RPSGB and size of pharmacy ownership, were also combined to
form binary variable as explained in Chapter 6 (section 6.6.2). Univariate cross tabulation
analysis was performed on the outcome measure with all the explanatory variables. Those
variables showing significant association with the outcome measure based on Chi-square
statistics P value ≤0.05 were entered into stepwise logistic regression using the Forward LR
method.
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Univariate analysis showed that six items from the facilitator scale, four items from the
barrier scale and four demographic characteristics were significantly associated with the
outcome ‘adoption’ (table 8.6- 8.8). Approximately 91% of the respondents who agreed with
e-MAS as having financial benefits to their pharmacy were likely to rank their adoption as 4
or 5 in the five point scale as compared to only approximately 77% of the respondents who
did not agree with the financial potential of the service. The other associations should be
interpreted similarly. Only the significant associations are presented below. The rest appear
in Appendix VIII.
Table 8.6: Cross tabulation analysis of facilitators with the outcome ‘adoption’ of e-MAS into
practice showing significant associations
Scale items Categories Low adoption
n(%)*
High
Adoption
n(%)*
P value
Financial benefits to my
pharmacy (N= 490)
Yes 23
(9.1)
231
(90.9)
<0.001
No 54
(22.9)
182
(77.1)
Opportunity for more
effective patient treatment
(N=490)
Yes 45
(11.8)
335
(88.2)
<0.001
No 32
(29.1)
78
(70.9)
Opportunity to know my
patients better due to
registration process
(N=490)
Yes 21
(9.0)
212
(91.0)
<0.001
No 56
(21.8)
201
(78.2)
Opportunity to better
meet patient expectations
(N=490)
Yes 44
(12.2)
316
(87.8)
<0.001
No 33
(25.4)
97
(74.6)
Opportunity to extend
my professional role
(N=490)
Yes 56
(13.6)
356
(86.4)
0.005
No 21
(26.9)
57
(73.1)
Availability of electronic
feedback relating to my
practice (N= 490)
Yes 3
(4.5)
64
(95.5)
0.011
No 74
(17.5)
349
(82.5)
* Represent values within each row categories; Low adoption: Score 3 or below; High
adoption: Score 4 or above
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Table 8.7: Cross tabulation analysis of barriers with the outcome ‘adoption’ of e-MAS into
practice showing significant associations
Scale items* Categories Low
adoption
n(%)†
High
Adoption
n(%)†
P
value
Technical component of
the electronic service
(N= 490)
Yes 47
(13.1)
313
(86.9)
0.011
No 30
(23.1)
100
(76.9)
Lack of clear practice
guidelines (N=490)
Yes 56
(14.0)
343
(86.0)
0.048
No 21
(23.1)
70
(76.9)
Low number of patients
presenting for the
service(N=490)
Yes 43
(10.0)
388
(90.0)
<0.001
No 34
(57.6)
25
(42.4)
Lack of access to patient
medical records (N=490)
Yes 37
(12.6)
256
(87.4)
0.031
No 40
(20.3)
157
(79.7)
* Items reversed scored † represent values within each row categories; Low adoption: Score 3 or
below; High adoption: Score 4 or above
Table 8.8: Cross tabulation analysis of demographic characteristics with the outcome
‘adoption’ of e-MAS into practice
Scale items Categories Low
adoption
n(%)†
High
Adoption
n(%)†
P value
Innovativeness (481) Cautious or
deliberate
57
(20.0)
228
(80.0)
0.004
Role model or
venturesome
19
(9.7)
177
(90.3)
Age (N= 482) 39 years or
under
32
(10.8)
264
(89.2)
0.001
40 years and
over
42
(22.6)
144
(77.4)
Number of years
registered with RPSGB
(N=483)
10 years or
under
27
(10.9)
221
(89.1)
0.004
11 years or
over
49
(20.9)
186
(79.1)
Size of pharmacy
ownership (N= 473)
Independent
or small
multiple
31
(21.2)
115
(78.8)
0.045
Medium sized
or large
multiple
44
(13.5)
283
(86.5)
†represent values within each row categories; Low adoption: Score 3 or below; High adoption:
Score 4 or above
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Regression analysis resulted in five explanatory variables making a significant contribution
to the outcome- pharmacists’ levels of e-MAS adoption, as presented in table 8.9. The
highest impact on e-MAS adoption was with the statement ‘low number of patients
presenting for the service’. Those agreeing with this statement being a barrier to service
provision were approximately 15 times less likely to have scored 4 or 5 in the five-point
adoption scale than those disagreeing with this statement. Other factors found important
were: financial aspects; perceived opportunities provided by the service for more effective
patient treatment; greater acquaintance with the patients due to registration requirements;
access to patient medical records; and pharmacists’ younger age. (Table 8.9)
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Table 8.9: Binary logistic regression model of the outcome e-MAS adoption with the explanatory variables
Items retained in the model Wald P value
Exp(B)
(odds
ratio†)
95.0% C.I. for
EXP(B) Model if item removed
Lower Upper Model Loglikelihood
Change in -2
Log
likelihood
P value of
the
Change
Financial benefit to my pharmacy
6.704 .010 2.357 1.232 4.512 -144.425 7.013 .008
Opportunity for more effective patient
treatment 5.339 .021 2.230 1.129 4.402 -143.530 5.223 .022
Opportunity to know my patient
better due to registration process 4.716 .030 2.074 1.074 4.006 -143.361 4.886 .027
Low number of patients presenting
for the service* 55.227 <.001 14.502 7.163 29.360 -170.609 59.381 <.001
Lack of access to patients’ medical
records* 5.246 .022 2.049 1.109 3.784 -143.561 5.285 .022
Age (39 years and under or 40 years
and over) 8.452 .004 2.532 1.353 4.736 -145.285 8.733 .003
Constant
13.391 <.001 .128
*Items reversed scored; †for score 4 or above
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The highly significant model (chi-square value <0.001) in table 8.10 below suggests that the
multivariate model, with the addition of the six variables, significantly improved the
outcome prediction over when only the regression constant was included. Both the Cox and
Snell R square and Nagelkerke R square values suggest that explanatory variables were
useful (a value close to 0 suggests that the variables are useless and close to 1 indicates that
the outcome is predicted perfectly) [295]. The Hosmer and Lemeshow test goodness of fit
statistic was not significant suggesting that the observed data are not significantly different
from the values predicted by the model; justifying that the variables retained through
analysis were very reliable.
Table 8.10: Regression model summary (Note: this table is divided into three parts within this
page)
Omnibus Tests of Model Coefficients
Chi-
square Df P value
Step 3.985 1 .046
Block 112.579 7 <0.001
Model 112.579 7 <0.001
Df: Degree of freedom
-2 Log likelihood ratio and R square values.
-2 Log
likelihood
Cox & Snell R
Square
Nagelkerke R
Square
281.837 .219 .378
Hosmer and Lemeshow Test statistics
Chi-square P value
6.628 0.577
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8.6 SUMMARY AND DISCUSSION OF KEY FINDINGS
8.6.1 Adoption of e-MAS into practice
Over 84% of the respondents rated their level of e-MAS adoption 4 or above on the five
point ordinal scale. Only two respondents rated their level of adoption as ‘not-at-all’ and
this was despite the service being a core component of the community pharmacy contract
[96]. The results showing an overall high level of adoption of the service is encouraging to
stakeholders given that this survey was undertaken when nationwide rollout was still in its
infancy.
8.6.2 Facilitators/barriers to service adoption
The opportunity for pharmacy role development offered by e-MAS was supported by
approximately four out of five of the respondents. Three out of four perceived that this
service had enhanced the opportunity to meet patient expectations and to treat them more
effectively, than prior to the service introduction. A similar proportion also accepted that
there had been a financial benefit realised with the service. This is worth noting in the light
of findings from the qualitative interviews and literature review, where dissatisfaction
around the current remuneration and reimbursement patterns were very strongly
expressed by most participants. In responses to the barrier scale, approximately 28% and
26% of respondents reflected concerns around remuneration and reimbursements
respectively. This dissatisfaction with remuneration is most likely to be related to
preference for fee per consultation over a capitation payment as well as the issue associated
with lapsing of patients not using the service at least once a year. Issues around lack of
satisfaction with reimbursement are most likely to be related to e-MAS not accounting for
the profit of the medicines supplied as was realised in the qualitative phase.
One response reflected that financial benefits resulted from the opportunity to negotiate the
purchase price of medicines with the wholesalers due to an overall increase in volume of
medicines supplied since the inception of e-MAS. This might indicate that whether the
nationwide rollout of e-MAS is leading to increased overall supply of medicines within
some communities. Evidence from grey literature suggests that some 87% of patients have
been known to use self care for minor ailments and would not seek any health care
professionals’ advice [382]. If nationwide rollout of the service is encouraging these
individuals to abandon self care, this would be contrary to Government aims to strengthen
patient self care (Chapter 1). ‘Sensitivity’ analysis in economic studies suggests that
increased use of pharmacy services due to enhanced access by those previously least
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interested in seeking health care services for minor ailment management, can eliminate any
cost savings that are supposed to be brought about by the service roll out [344]. However
evidence around long term economic and patient clinical outcomes brought about by
pharmacy services usage versus self care or other models of care for minor ailment
management remains poorly understood [383,384].
Approximately 8% of respondents suggested that e-MAS had improved financial benefits to
individual pharmacists. This might reflect the proportion of organisations incentivising e-
MAS performance. Nonetheless, many respondents owned their pharmacy who might
interpret financial benefit to pharmacy as their own.
Greater inter-professional working remains one of the key aims of the service with
pharmacists able to directly refer patients to their GPs or out of hour primary care services
[96]. However 4 out of 5 respondents were yet to realise enhanced collaboration. The need
for further measures to enable greater inter-professional working is supported by this
finding.
Results also indicate that the majority of respondents were yet to receive any individualised
feedback of performance around e-MAS activities from the NSS. At the time this survey
was conducted, individual Health Board e-MAS utilisation data were, however, available to
all pharmacists via the NHS NSS Website [222]. Future strategies to deliver such feedback
relating to performance of individual pharmacists/pharmacies are under development
[385].
The issue of misuse/overuse of the service by some members of public was regarded a
barrier to service adoption by a large proportion of respondents. A few referred to the lack
of or ambiguities within e-MAS practice guidelines on how to handle these patients.
Inconsistent responses from pharmacies around customer requests relating to suspected of
misuse/overuse were deemed to be encouraging patients to register with other pharmacies
in an attempt to gain access to these medicines. Comparison of previous studies undertaken
in Scottish community pharmacy reflects that convenience of access to medicines may
contribute to this issue. A survey undertaken in all 1,091 community pharmacies in
Scotland in 2000 (response rate: 79.1%), reported that approximately 68% of respondents
acknowledged experiencing requests for medicines with potential for abuse/misuse [386], a
proportion less than identified in this survey. As greater numbers of patients are registering
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with e-MAS [222], it is imperative that pharmacies are given appropriate strategies and
training around how to effectively deal with these issues. Research to date on such
pharmacy related strategies mostly relate to substance misuse [386,387]. A survey of 180
community pharmacies from South Wales (response rate: 89%) found refusing sales,
claiming that medicines were ‘out of stock’ (63%), or referring patients to GPs (25%) as
among the most common strategies. Future research is needed to broaden these issues by
considering how pharmacists can minimise e-MAS requests from those trying to stockpile
medicines for future use. Appropriate measures are also important from an economic
perspective. A recent national audit around wastage due to stockpiling of unwanted
prescription medicines by patients was estimated to cost the NHS in England £100m [388].
Results of this survey prompt the need to counteract the likely increase in medicine misuse
associated with increased access.
The lengthy process of recording each patient consultation or medicines supply was cited
as the second most common barrier to service adoption. A retrospective data analysis of
seven PCTs in England involved with similar schemes reported as few as 1% of the claims
made for remuneration related to ‘consultation only’ activities [344]. Such figures could
imply that pharmacists are under pressure (from patients and themselves) to supply
medicines after each consultation, hence resulting in very few consultations without
medicine supplies. The qualitative data (Chapter 7) shows that such low number of claims
around ‘consultation only’ could also be attributed to difficulty in recording this activity
due to resource implications and patient reluctance to wait for stages requiring patient
signature.
Inadequate resources within the pharmacy setting as a barrier to service adoption were
identified by approximately only one in ten respondents. Such resource constraints might
be related to issues such as lack of pharmacists to adequately deal with personal
involvement or strain on existing staff created by the walk in nature of the service.
8.6.3 Factors associated with innovation adoption
The multivariate analysis further allowed quantification of the factors associated with
adoption of the innovative e-MAS service by community pharmacists. E-MAS is a core
component of the community pharmacy contract in Scotland. From the perspective of
diffusion of innovations, the core contract represents ‘authority’ decisions from the
Government to adopt the service rather than ‘optional’ or ‘contingent’ types of decision
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making discussed in earlier Chapters around reclassified medicines. Hence every pharmacy
should be in a position to offer the service when eligible patients present. The importance of
patient acceptance having the most determinant influence on e-MAS adoption into practice
within multivariate analysis was hence less surprising from this view point.
Approximately 12% of the respondents had agreed that low number of patients presenting
for the service was a problem in service adoption. Lack of the so deemed enough
opportunity to promote the service as raised by the interview participants could be one of
the reasons for low number of patients presenting for the service. In addition, this issue
could also be explained by the deprivation of the geographical areas the pharmacies
represented. The Scottish Index of Multiple Deprivation (SIMD) report 2009 showed that
approximately 10% of Scottish population live in the least deprived areas with deprivation
indexes 19 and 20 (1= most deprived, 20= least deprived) [389] where relatively low
number of patients are likely to fulfil the eligibility criteria for service registration. A recent
analysis of nationwide e-MAS utilisation data found area deprivation significantly related
to numbers of patients registered and medicines supplied [390]. Findings from the
multivariate analysis of the data within this study are further endorsed by this latest report.
Apart from the above, perceived benefits of the innovative service such as financial benefits,
opportunity for more effective patient treatment; and low perceived complexity associated
with need for patient medical records were strongly associated with the outcome. Younger
pharmacists had higher levels of adoption; however, perceived innovativeness again, did
not show influence. Many of these findings resemble factors associated with pharmacists’
adoption of innovative reclassified medicines as presented in Chapter 6. The association of
these factors around their importance in innovation adoption by adopters were found to be
in the direction as suggested by Rogers [131].
8.7 SUMMARY OF CHAPTER 8
E-MAS was found to be adopted into practice by community pharmacists in Scotland.
Perceived benefits agreed by the majority related to financial advantage, professional role
development, the opportunity to offer more effective patient treatment and to meet patient
expectations. Barriers to adoption were issues of service misuse by some patients and, the
timely process for recording consultation or supply. Multivariate analysis indicated that:
number of patients presenting for the service was most strongly related to pharmacists’
level of adoption of the service.
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9 CHAPTER 9: GENERAL DISCUSSION
9.1 INTRODUCTION TO THE CHAPTER
This Chapter summarises key aims, objectives and findings identified throughout the thesis
with emphasis on the achievement or otherwise, of the research aim and objectives.
Research strengths and limitations are highlighted by critically appraising the methods
employed at different stages. Relevance of the findings to policy, practice and theory, future
directions and final conclusions are presented.
9.2 REVIEW OF THE THESIS
The general literature review was undertaken and presented as two distinct sections.
Within the first section, the literature around Government policies enhancing opportunities
for new pharmacy services around minor ailment management was reviewed. Foundations
of modern pharmacy practice development were laid by the Nuffield report [31] which
highlighted the need for reform of the nature of community pharmacy services, funding
and research in the forthcoming decades. Subsequent key White and Green papers from the
UK Health Departments, prior to and post devolution, were reviewed. It appears that all of
the devolved Governments were keen to enhance pharmacy’s role in minor ailment
management and to support self care through professional advice and guidance. The policy
documents that were identified repeatedly promised extra funding and professional
development opportunities for pharmacy and also identified that enhanced minor ailment
management would bring: professional role development opportunities; extended use of
professional skills; enhance reputation with the society; as well as contribute to freeing up
GPs thus reducing waiting times; and bringing about significant health benefits in the
longer term. This enhanced minor ailment management was proposed through two key
policy interventions, both of which would mainly enhance patient access to non-
prescription medicines. The first was the ongoing reclassification of medicines which
would allow more medicines previously available only on prescription to be reclassified to
P and GSL status and thus available for over the counter purchase. However, those patients
who could not afford these medicines were deemed to benefit less. Hence minor ailment
services such as the e-MAS in Scotland were piloted and subsequently introduced
throughout Scotland around the time of the commencement of this PhD. This service allows
those patients exempt from prescription charges to be eligible to obtain non-prescription
medicines free of charge.
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A review of peer reviewed, published research literature from the UK around enhanced
management of minor ailments from community pharmacy was conducted. This review
identified that the current literature was limited in the key policy intervention areas
identified above, especially around community pharmacists’ perspectives of new services
adoption and associated barriers and facilitators. Core limitations of the published
literature related to a general lack of robust qualitative studies as well as lack of large scale
quantitative evaluation of new services. These limitations aided the formulation of research
aims, objectives, choice of methodologies and methods of this study resulting in the
generation of original, novel data which contribute significantly to the published literature.
The importance of theoretical frameworks allowing the researcher to systematically collect,
generate, interpret and analyse the data to facilitate understanding of the change process
and factors affecting innovation adoption was realised in the latter phase of the literature
review in Chapter 1. Through critical appraisal of the available theoretical frameworks,
application of Rogers’ diffusion of innovations model [131] was deemed an appropriate
foundation to support this research. The diffusion model was used to interpret the findings
of the qualitative phase of this research followed by its application in designing the
quantitative research instrument.
The overall aim of this PhD was to investigate Scottish community pharmacists’ adoption of
innovative medicines and services aimed at enhanced minor ailment management. Data
were generated and collected to: evaluate the process related aspects of innovation
adoption from community pharmacists’ perspectives; investigate pharmacists’ adoption of
newly reclassified medicines and e-MAS; and from these to extract key factors affecting
innovation adoption thereby allowing consideration of the wider relevance of these factors
to new pharmacy services. A critique of available methodologies in undertaking the
research and justification of the choice of a mixed methodology was presented in Chapter 2.
Current developments around enhanced minor ailment management were deemed by
pharmacists participating in the qualitative interviews as contributing to their role
development and image in society. The twenty participants, who were identified through a
two staged sampling process, mostly agreed that inception and implementation of e-MAS
and the ongoing reclassification of medicines were key changes around enhanced minor
ailment management within pharmacy. However, participants reflected diverse attitudes
towards embracing change. Where current changes were embraced reluctantly by many
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who deemed the current pace as fast and furious, others were keen to contribute to
developments taking place within pharmacy and were excited about ongoing changes. The
eagerness of these individuals to play a more proactive role in leading and introducing
change to the public was noted. Regardless of practice setting and ownership model, the
merits of each innovation appeared to be considered at the individual level. Hence an
organisational level decision to implement an innovation did not necessarily translate to
adoption at the individual level.
Facilitators/barriers specific to pharmacists’ adoption of both key innovations were
identified. Where many of these facilitators/barriers were similar for both, a few were
unique to the medicines/service evaluated. The importance of pharmacist perceived
benefits to patients, to pharmacists’ role development, training opportunities, sources of
information, access to patient medical records, new service/medicines fitting local needs,
‘good’ patient behaviour, clear practice guidelines, support at organisational and external
level were highlighted. Certain newly reclassified medicines were deemed to have been
highly adopted into practice by the interview participants, and others least adopted or not
adopted at all based, based on the above key facilitators/barriers. Detailed investigation of
the feedback of practice performance relating to the adoption of e-MAS was also
undertaken. Interestingly, participants voiced a cautious welcome to such information
sources.
When considered from the theoretical point of view, the facilitators and barriers identified
in the qualitative phase matched closely to the factors associated with innovation adoption
as suggested by Rogers’ diffusion of innovations model [131]. Most of the perceived
attributes of innovations; organisational and external contextual factors as suggested by
Rogers were observed.
The results of the qualitative interviews led to the emergence of research objectives for the
next phase of the research. Key objectives of the cross sectional survey were to: quantify
pharmacists’ adoption of the above innovations around enhanced minor ailment
management from pharmacy; quantify the importance facilitators/barriers to the adoption;
and from these to derive factors associated with pharmacists’ adoption of innovations. A
systematic review of international peer reviewed literature, mainly around pharmacists’
adoption of newly reclassified medicines, undertaken prior to the survey enabled the
strengths and limitations of the existing literature to be addressed, aiding design of the
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quantitative research instrument. Twenty-eight facilitators/barriers specific to pharmacists’
adoption of newly reclassified medicines were identified from the systematic review. The
systematic review provided evidence from the existing literature that decision making by
professionals is a complex phenomenon and that multivariate research designs are most
appropriate in researching innovation decision making. Rather than evaluating all
innovations as one development, factors associated with the adoption of innovations would
best be quantified by evaluating as diverse innovations as possible using the same
population.
Four newly reclassified medicines and e-MAS were evaluated in the cross sectional survey
of all community pharmacies in Scotland. The survey was piloted with a sample of 50
community pharmacies prior to the main survey. The reclassified medicines selected for
evaluation had been adopted into practice to varying degrees. Chloramphenicol eye drops
for bacterial conjunctivitis had most support and were adopted highly, whereas simvastatin
for the prevention of coronary events in adults with moderate risk was least supported and
adopted. Adoption of omeprazole aimed at management of peptic disorder was higher
compared to studies undertaken immediately post reclassification [122]. Naproxen, the
most recent medicine to be reclassified for the management of dysmenorrhoea had already
been adopted by over four out of five respondents and its non-prescription status was also
supported by the majority. Results from descriptive, bivariate and multivariate analyses
provided the conclusions that: perceived benefits to pharmacy, professional role and to
patients; observability of such benefits; compatibility of therapeutic area to existing ranges
of pharmacy medicines, pharmacists’ expectations and to pharmacy business interests;
confidence and perceived complexity of adoption process; and patient acceptance and
affordability of the medicines were the most consistent and strongest factors associated
with pharmacists’ adoption decisions regarding reclassified medicines. Adoption of e-MAS
was also influenced by similar factors with patient acceptance showing the strongest
association.
Rogers’ diffusion of innovation model was useful in content development and
interpretation of the quantitative data. However, the items that measured pharmacists’
facilitators/barriers belonging to each of the theoretical factors did not correlate well
enough to constitute ‘one factor’ in principal component factor analysis. Hence, each barrier
and facilitator was interpreted as a separate factor for relevance to practice.
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The findings from both the qualitative and quantitative phases have key relevance to the
practice of pharmacy around and beyond the area of enhanced minor ailment management.
It is important to discuss the rigour and weaknesses of the method that were adopted in
this study before such relevance is discussed.
9.3 DISCUSSION OF METHOD: QUALITATIVE INTERVIEWS
AND FOCUS GROUPS
Although debates exist as to whether the concept of ‘rigour’ applies to qualitative research
as it does to quantitative, qualitative research conducted without sufficient consideration of
rigour is often labelled as being ‘no different than fictional journalism’ [391]. The following
section highlights strengths and limitations of the qualitative focus groups and interviews
undertaken within this research.
9.3.1 Internal validity
Internal validity in qualitative research refers to whether the findings are ‘correct’ and
‘precise’ [392] or the extent to which findings represent reality, so ‘issues of credibility and
truth take prominence’ [393]. Criteria to establish internal validity in the qualitative phase
of this PhD are based on Creswell’s validity framework [169] and Paterson’s reactivity
framework (figure 9.1) [394]. Each of these is discussed below.
Figure 9.1: Framework to enhance the internal validity of qualitative study*
Clarifying researcher bias from the outset of the study (reflexivity)
Engagement and observation in the field
Peer review or debriefing
Triangulation
External audits
Reactivity
*adapted from [169,394]
9.3.1.1 Clarifying researcher bias from the outset of the study
In qualitative research, the researcher acts as an ‘instrument’ of data generation and hence it
is imperative that the background of the researcher be explicitly stated as this might
influence choice of research design, data generation and analysis [169]. The student
researcher is a pharmacist registered with the Nepal Pharmacy Council and had no
previous experience of Scottish community pharmacy. This means that the researcher had
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no bias to any potential outcome of the studies or had any preconceived ideas about what is
happening or should be happening in pharmacies. Background knowledge and experience
around minor ailments and non-prescription medicines was gained through undergraduate
and postgraduate pharmacy training, work experience as an industrial pharmacist and
lecturer in Nepalese academia. However, review of the literature allowed the researcher to
become acquainted with the hopes and expectations of pharmacy stakeholders in Scotland
and other UK nations. Two key stakeholders of community pharmacy partly funded this
research. These were: the Community Pharmacy Scotland (CPS) an organisation
representing Scottish community pharmacy owners; and NHS NSS, a non-departmental
public body which provides national strategic support service and expert advice to the
NHS. However, neither had any influence on study design, methodology, method, data
collection/generation, analysis or dissemination.
The researcher’s interest in diffusion of innovations arose after commencing the PhD. There
was no pressure on the part of the researcher to justify or refute the theoretical framework
applied to this research. Participants were never aware of the theoretical assumptions
during the interviews; and similarly the topic guide was not designed to ‘impose’ on the
participants the need to support or refute theory. It has been argued that preconceptions
about theoretical lenses used to review the data are not ‘biased’ as long as the researcher
acknowledges them prior to undertaking the research [204]. One approach to enhancing
reflexivity is by considering the data from different theoretical viewpoints.
The researcher very much agrees with this in Chapter 1 saying that no theoretical
framework is right or wrong to undertake research as long as there appears a sound basis to
utilise the theory. Had any other theoretical framework been adopted, it is likely that some
of the findings and interpretations would have matched to those identified in this study,
whereas others might have not.
The topic guide was designed in accordance with the research aims and objectives.
Although the researcher sought views from one of the funding bodies, the NHS NSS, the
final decision lay with the researcher, under the guidance of the supervisory team. In
addition, participants were provided with the opportunity to share views and experiences
on related items not covered by the topic guide but relevant to the subject area being
investigated.
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Data analysis methods were selected following critique and consideration of available
methods. The student received formal training from many different sources listed in
Appendix X (General) around both the qualitative and quantitative and mixed
methodology research, and evidence syntheses through systematic review of literature.
Given the information gleaned from the literature reviews it was considered inappropriate
to utilise a grounded theory approach as theories and hypotheses were not being generated
or a semi-quantitative technique such as content analysis, which may have led to the
omission of important information.
9.3.1.2 Engagement and observation in the field
Engagement and observation should be undertaken to allow the researcher to ‘learn from
the culture’ where the research is to be undertaken [169]. This criterion was partially
fulfilled by conducting field visits to three community pharmacies located within two
Scottish Health Boards, prior to undertaking the qualitative work. This allowed the
researcher to become acquainted with the practical constraints relevant to ‘real life’ working
situations of community pharmacy that could never have been realised solely through the
literature review. This also provided a glimpse of day to day activities in Scottish
community pharmacies, encompassing e-MAS and supply of newly reclassified medicines.
To an extent, these visits allowed the researcher to build empathy with community
pharmacists. Pharmacies were also clearly told that such observations in any way did not
include data collection hence eliminating any need for ethical review. A pilot focus group
conducted prior to the actual focus groups and interviews with four locum community
pharmacists allowed the researcher to further build empathy and gauge reaction to specific
questions. However, it should be acknowledged that these participants were university
lecturers and as such their understanding of the researchers’ questions might have been
different from ‘full study’ participants. Nonetheless, this experience provided valuable
changes to the topic guide. These experiences of conducting focus groups by the researcher
were gained in addition to two previous experiences as a focus group note taker at the
commencement of the PhD.
9.3.1.3 Peer review or debriefing
Peer review or debriefing are known to keep a ‘check’ on the research process by asking the
researcher hard questions about the methods, meaning and interpretations [169]. University
regulations require that students regularly present at informal settings of school research
student symposia, allowing the student to be ‘challenged’. In addition, the researcher
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presented poster and oral communications at several national and international pharmacy
practice conferences. The student had meetings with his principal supervisor
approximately once per week; and with other members of the supervisory team
approximately once per month or when needed. Emerging research issues and directions as
well as the interpretation of emerging findings were regularly discussed within these
meetings.
9.3.1.4 External audit
A number of peer reviewed papers including conference proceedings and a project report
submitted to the NHS NSS were rigorously peer reviewed with feedback. Of note, one full
paper around the quantitative evaluation of e-MAS adoption by pharmacists was published
in the International Journal of Pharmacy Practice [395] and several others are in draft form.
9.3.1.5 Triangulation
The findings from the systematic review of literature (Chapter 4) and the cross sectional
survey (Chapter 6 and 8) were compared with those obtained from the qualitative phase
(Chapter 3 and 7) to identify similarities and differences thereby facilitating triangulation of
the results.
9.3.1.6 Member checking
Member checking is also known as respondent validation [396] and requires the transcripts
and reports of data analysis to be sent back to the participants for verification. However, the
feasibility of this process was carefully debated by the researcher. Issues considered were
the tremendous demand this process places on participants, and that there are potential
issues of recall bias [396]. Respondent validation is of particular use in action research
where the researcher and participants work co-operatively to facilitate ongoing changes
[396]. For these reasons, member checking was not undertaken.
9.3.1.7 Reactivity
Reactivity relates how the research participants and the researcher respond to each other
during the research process; or the negative or unintended effect on research subjects
because of the experience of being investigated [394]. There are five sources of reactivity in
qualitative research involving face to face interactions. ‘Emotional valence’ [394] which
arises from the lack of trust of participants with the researcher could determine the nature
of the data shared with the researcher. The telephone contact by the researcher with
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participants prior to the scheduled focus groups was intended to minimise this effect. In
addition, participants were given background information about the researcher. They were
also given ample opportunity to contact the researcher and supervisory team members to
clarify any issues. The researcher took great care not to directly empathise or disagree with
participants’ points of view.
It has been stated that physical characteristics of the researcher such as appearance, age,
race and personality are taken into account when determining emotional valence. However,
participants appeared highly comfortable and relaxed in the face to face interactions and
although this is more difficult to gauge over the telephone, there appeared to be no major
issues in the telephone interviews. Another important consideration in reactivity is the
importance of the ‘distribution of power’ which arises from the perceptions of the
participants or the researcher that the other has more or less status of authority than
themselves [394] and these perceptions could either be occupational or social. One
pharmacist who was sent an invitation to participate expressed the feeling that she would
feel intimidated while facing a researcher and chose not to participate. Hence it is likely that
those participating had either not consider this or were more relaxed and comfortable. In
addition, the researcher tried to be as friendly and keen as possible by engaging before the
interviews, sharing his background as well as by comforting the participants asking ‘how
was your day?’; sharing researcher’s own experiences of the day, and his research;
considering calling later if they were having a ‘bad day’ or a busy session (during telephone
interviews). The lunch session prior to the focus groups further provided an opportunity to
build relationships just prior to data collection. It is also worth stressing that the researcher
was a trained ‘novice’ in qualitative research, and himself had apprehensions about
conducting the interviews ‘to the best of his ability’. However, it is still possible that nerves
might have reduced some depth and breadth of questioning. This effect was minimised as
the interviews progressed.
A further bias around reactivity relates to the importance of ‘lively interactions’ during data
collection. A bored, tired and discouraged researcher is known to pass his/her disinterest to
the research participants [394]. The researcher had sufficient gaps between interviews and
hence fatigue was not an issue. In addition these gaps provided opportunities to review
reflect and learn from the experiences. The use of standardised participant information and
the opportunity to discuss research aims and objectives also minimised the fourth factor
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contributing to reactivity arising from the lack of understanding on part of the participants
about ‘goal of the interaction’ [394].
The last issue around reactivity arises from the ‘shoulds’ of behaviour expected from
research participants [394]. Participants were informed at length that there were no right or
wrong answer to any question and were given assurance about the confidentiality and
anonymity of the data. The researcher was keenly interested to identify both barriers and
facilitators of practice change and hence did not in any way seek to influence the
participants as either advocates or cynics of change.
9.3.2 Reliability
Reliability can be defined as the degree to which findings are independent of accidental
circumstances of the research [397]. This requires the researcher to reassure the readers that
similar results would have been produced if the research were to be repeated using same or
similar methods [392]. Reliability is sought both in terms of the consistency or replicability
of the original data as well external reliability, as well as whether the interpretations
obtained from the analysis would be reproduced if performed by an independent analyst
(internal reliability) [392].
Debate exists over whether qualitative research can be truly tested for reliability as
rigorously as quantitative approaches. However, it has been argued that it should still be
possible, for example conducting and analysing social interactions in a way that can be
subjected to empirical testing [397]. Although it is almost impossible for an independent
researcher to come up with a completely identical set of results and conclusions, the data
collection and analysis processes should convince the reader of transparency and
replicability. Perakyla [397] reviews two ways of doing so.
Firstly, reliability is enhanced by ensuring good quality recording of the conversations
between researcher and participants, ensuring that the whole of conversations are subjected
to analysis. Analysis based only on field notes could be vulnerable to speculation about
their integrity and reliability [397]. The recording of all interviews and focus groups in this
study was conducted using digital and audio recorders of high quality. In addition,
experienced researchers undertook note taking during face to face interview settings,
although this was not feasible during telephone interviews. The transcribing of all focus
groups and interviews was performed by the student researcher himself without any
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secretarial support. Transcripts were reviewed and cross checked for reliability by the
principal supervisor. This was important given that English was a second language of the
researcher and that different dialects, slang and accents of participants from diverse
geographical areas. Ambiguities were identified and rectified, some of which may have
significantly altered the meaning of the data and subsequent interpretation.
Secondly it is important to guarantee accountability of the process of how interpretation
was achieved. In doing so, the process of inter-rater reliability [396] was used to enhance
the rigour of the data analysis process. This inter-rater reliability check was performed in
the transcripts of one of the focus groups of greatest duration. The researcher used both the
‘top bottom’ as well as ‘bottom top’ approach to analysis using framework technique [248].
The second coder used only the ‘bottom top’ approach and was unaware of the main
coding framework developed by the researcher. No disagreements that could significantly
alter the meaning were identified. The student also had opportunities to discuss and defend
the coding with two other supervisors. Although these did not code the data
independently, checks were performed to ensure that analysis was dependable, consistent
and ‘making sense’. No major disagreements were identified although analysis was an
iterative process. Notes taken by more experienced researchers during the focus groups as
well as the discussions that had taken place between researchers were also considered for
the basis of analysis to ensure the reliability of the data coding.
9.3.3 External validity
External validity relates to the degree of generalisation of the results to other contexts,
which in this study could be to other pharmacists or pharmacies in Scotland, UK or
elsewhere. The term theoretical generalization is often used instead of empirical
generalization when describing the external validity of qualitative research [396].
Researchers who use qualitative research to inform the development of quantitative
research instruments (as the case with this study) might be less interested in the external
validity of the qualitative data. However, many of the results obtained within the
qualitative phase, such as evaluation of the process related aspects of innovation adoption,
in this thesis, are ‘main’, independent findings in their own right. The issue of external
validity hence needs to be considered separately here.
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Sampling is often raised as an important point when considering the external validity of
qualitative research. The focus groups and interviews in this study used a two staged
sampling process whereby the Health Boards were purposively sampled followed by
random sampling of the pharmacies within those boards. Anticipated difficulty in
pharmacy recruitment was the main drivers behind random sampling. The random
sampling method did not inflict disadvantages over a purposive sampling method. The
diversity of the respondent demography that was observed perhaps justifies that a random
sampling approach was as appropriate as a more ‘truly ‘qualitative approach of purposive
sampling. Recruitment of focus groups and interview participants across different Health
Boards was staged, with a few weeks in between them. This allowed the researcher to
confirm that diverse experiences and demographic characteristics were being achieved
through the recruitment process.
The issue of participants’ interests in the subject area might limit the external validity of the
findings. It is likely that only those who had either very strong positive or very strong
negative opinions around pharmacy change and innovation might have participated in the
research resulting in non-respondent bias. The theoretical saturation that was assumed to
have been achieved during latter stage of data collection allowed the researcher to propose
that the whole spectrum of opinions had been captured. However, one can never be
‘certain’ of theoretical saturation given the low sample size in the qualitative study.
The dominance of some focus group members is relevant to external validity. Some levels
of dominance were unavoidable despite efforts of the researcher and facilitators. It was
often as difficult dissuading dominant speakers from speaking as persuading the ‘shy’
participants to speak.
Considering these weaknesses and strengths, the external validity of the findings most
likely extends to pharmacies operating in similar contexts to the participants. This also
extends to other pharmacies of those represented Health Boards followed by pharmacies in
other Health Boards in Scotland, and finally in the other UK nations and beyond with
similar socioeconomic conditions and pharmacy regulations.
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9.4 DISCUSSION OF METHOD: SYSTEMATIC REVIEW OF
LITERATURE
Discussion around the systematic review method has already been presented in Chapter 3.
9.5 DISCUSSION OF METHOD: MAILED SURVEY
This section will discuss how the issue of rigour was addressed during the quantitative
phase of this research.
9.5.1 Internal validity
Aspects of internal validity are deemed particularly important in quantitative studies when
measurements depend on personal responses to questions [210]. The following types of
internal validity are applicable to the quantitative research instrument used in this study
namely: face validity, content validity, criterion validity and construct validity.
9.5.1.1 Face validity
Face validity is a superficial subjective assessment of the presentation and relevance of the
questionnaire [190]. The assessment is mainly around: whether the questions within the
questionnaire appear to be relevant, reasonable, unambiguous and clear. The use of an
expert panel from within and out with the school allowed for the face validity of the
questionnaire to be assessed. Some of the expert panel were practising pharmacists, a few
had much experience with pharmacy practice research and, one external reviewer
contributed expertise around innovations research. The content and wording of the
questionnaires were carefully selected to avoid ambiguity and the items were derived from
the quotes from the transcripts of the qualitative interviews. All these measures allowed
reassurance that the questionnaire would be successful in enabling the collection of
information required for the research aims and objectives to be answered.
9.5.1.2 Content validity
Content validity refers to the extent to which the items within a questionnaire adequately
cover the domains under investigation [210]. The thorough review of the literature
undertaken prior to the survey, the results of qualitative interviews, the systematic review
of literature and the theoretical framework applied to this study were used to enhance the
content validity of the questionnaire. Given the level of background research that was
undertaken prior to the survey instrument development, it is less likely that any important
issues associated with innovation adoption around ongoing reclassification of medicines
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were missed. However, content focused around the evaluation of e-MAS had to be limited
to make the evaluation ‘brief’ and also owing to the constraints in space within the
questionnaire. One example, highlighting this issue is around e-MAS formulary and
treatment protocols, which were both evaluated within the item ‘practice guidelines’.
One important criterion in enhancing content validity where associations are being
explored relates to considering and accounting for all known confounders. To that end, a
range of demographic characteristics were measured alongside the 24 items
facilitator/barrier scale.
The number of innovative medicines and services evaluated in this study also merit
discussion in terms of their adequacy to inform factors associated with decision making.
There is no minimum number of innovations that need to be evaluated for the derivations
of these important factors. However, similar research with innovative services with doctors’
adoption of innovations utilised five new medicines licensed for primary care [328]. The
number of innovations evaluated within this study is hence justifiable.
9.5.1.3 Criterion validity
Criterion validity refers to the extent to which a method of measurement of outcomes
agrees with the results which would be obtained if measurement of the outcomes were
conducted by using alternative objective measures or ‘gold standards’ [210]. The semantic
differential scales have been widely validated in other health service research and
pharmacy practice settings; for example, in assessing the degree of pain in a scale of 1 to 10
[398]; or to measure pharmacists’ satisfaction with their profession [399]. Although
measuring the actual packs of the newly reclassified medicines that were supplied by the
respondents or by asking for the number of patient consultation with e-MAS would have
been more objective measures of the outcomes; adjusting these for size of pharmacy,
location, population served and so on would have been hugely challenging. For example,
five packs of omeprazole a day could be rated as a very high level of adoption by a
pharmacist in a rural settings given the size of the population; whereas this may not be so
for a pharmacist located in a urban high street setting. These relative differences were best
handled by using the semantic differential scales. Nonetheless, due to the cross sectional
design the responses were prone to recall bias. Assessment of criterion validity for the
outcome acceptance is perhaps less relevant as objective measures are less applicable to
measure support for the given innovation.
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Predictive utility is often described as the ability of a questionnaire to predict the outcomes
through gold standard or objective measurement of the similar outcomes in the future
within the same population. Such a process was not feasible to undertake within a time and
resource constraints of a PhD.
9.5.1.4 Construct validity
Construct validity refers to substantiation that the instrument is measuring the underlying
concept it intends to measure. This was relevant to the 24 item scale measuring barriers and
facilitators to adoption, the constructs of which were deemed to be belonging to factors
affecting innovation adoption by Rogers’ diffusion of innovation model [131]. The validity
of the theoretical constructs could not be fully established in terms of both ‘convergent
validity’, which requires that the scale should correlate with other related variables; and
‘discriminant validity’, which requires that the items within the construct should not
correlate with dissimilar variables. The conclusion that was derived from the results of the
factor analysis was that although each of the 24 item scale could still be related to the
theoretical concepts of diffusion of innovations model as described in Chapter 4; in practice,
they still represent unique barriers and facilitators. Downsizing the 24 item scale that has
been developed in this study to smaller number of items for future research with
pharmacists’ adoption of reclassified medicines is not recommended.
9.5.2 Reliability
As many as seven different reliability tests have been proposed to be applicable for
quantitative research [190]. However the following three are relevant for the questionnaire
that was used in the survey and are discussed in detail:
9.5.2.1 Test re-test reliability
This relates to assessing the stability of a measure over a time which is not expected to
change. It is conducted by taking repeated administration of the same questionnaire to the
same participants and is done by measuring the weighted kappa coefficient for the ordinal
data and Cohen’s kappa coefficient for the nominal data [190]. In the main survey, this was
not feasible to undertake due to the resource and time constraints this process would have
demanded. The higher sample size above 100 required to estimate the kappa statistics [400]
meant that this would require additional strain even to establish this reliability in the pilot
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study. Respondent identification requirement for the test retest reliability meant that this
was also against the anonymity clause on the research as advised by the NoSREC.
9.5.2.2 Split half reliability
Split half reliability relates to dividing an item within a construct into two halves and then
measuring the correlation between the items [190]. The lack of interpretable outcomes from
the factor analyses meant that this could not be undertaken.
9.5.2.3 Internal consistency reliability
Test of internal consistency reliability was performed on the outputs of factor analysis. This
measures whether items within a construct produce similar scores and are computed by
values such as Cronbach’s alpha as described in Chapter 4. The dismissal of factor analysis
meant that internal consistency reliability was also less relevant for this survey.
9.5.3 External validity
Two measures were conducted to estimate the external validity of the survey results. The
estimation of sample size that was conducted prior to the survey is one measure to confirm
the external validity of the findings. The non-respondent analysis that was also conducted
reflected that there were no significant differences in the late and early respondents in
terms of outcomes; as well as the demographic characteristics that were retained as
important in univariate, bivariate and multivariate analysis. This reflects that external
validity of the results of this survey, from a statistical point of view, was established.
However, given that one is never certain about how the non-respondents might behave,
one cannot be certain of this.
The external validity of the findings of the survey most importantly extends to the
pharmacies located within Scotland followed by the rest of the UK nations and beyond
depending upon the similarity of pharmacy regulations and socioeconomic status of other
countries with Scotland. In addition, the findings are most relevant to the medicines and the
service that were evaluated.
The cross sectional nature of the survey to identify factors associated with innovation
adoption also contributes to limitations around generalisability of the findings. As the
outcomes and factors were measured in the same time point, it is difficult to confirm, for
example whether the opinions that were measured informed the innovation adoption
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decisions; or that whether decisions to adopt or reject the innovations followed the
opinions. This provides the conclusion that prospective designs best suit innovation
adoption research.
In addition only one pharmacist from each pharmacy was asked to respond. It is likely that
those least interested in the issues around innovations might not have responded.
However, the three introductory questions used in the opening page of the questionnaire
booklet (Chapter 5, section 5.8.2) tried to minimise the bias by asking those participants
who may not necessarily be ‘innovative’ but were interested in the issues about innovations
to participate. This might have minimised non-response bias in terms of innovativeness of
respondents.
9.6 RELEVANCE TO PRACTICE
This section describes the relevance of the findings of this study to the area of enhanced
minor ailment management from community pharmacy; and beyond where appropriate.
The relevance to practice discussed here is grounded in the study findings.
9.6.1 Relevance to the process of new service introduction in
community pharmacies
9.6.1.1 Bridging the gap between policy makers and practitioners
There is a need to bridge any communication gaps existing between community
pharmacists and policy makers surrounding decisions made around future pharmacy
innovations. Pharmacists need to be involved in discussions ideally prior to piloting and
implementation of new pharmacy services. All pharmacists need to be notified of
developments in a timely and appropriate manner so that they can prepare themselves and
their staff by acquiring new knowledge and skills. The lack of acquaintance with, for
example, the, reclassification of medicines and inadequate time to prepare the necessary
knowledge and skills were often highlighted as a matter of concern during the qualitative
interviews and responses to open questions in the survey. This is also key to avoiding the
‘embarrassment’ arising through lack of timely notifications as experienced by the
participants in this study. Consultations that are usually organised by the Royal
Pharmaceutical Society (RPS) and the MHRA around future pharmacy innovations could
be further strengthened by actively involving more practitioners in consultations. However,
this assumes that a majority of pharmacists will indeed follow through in participation.
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9.6.1.2 Importance of strengthening diffusion network
Pharmacists who are keen to actively contribute to any developments need to be given an
appropriate forum and process to express their views. A few participants in both the
qualitative interviews and surveys strongly advocated that they embraced change in a
positive way. There is a need to identify these pro-active pharmacists who can act as
‘movers and shakers’ or assume the role of opinion leaders within their organisations and
local practices forums to persuade others less interested in innovations to also become
involved.
9.6.1.3 Importance of strengthening pharmacist patient communications
Strengthening of pharmacist patient communication is warranted. Patients need to be made
more aware of the benefits of following pharmacists’ advice around medicines supply/non-
supply decisions. Revisions of currently available tools such as the WWHAM approach
[401] to dealing with medicine requests might be necessary, especially in enabling
pharmacists and pharmacy support staff to deal with excessively demanding customers.
This may be warranted with new services with which patients may not be familiar with
service requirements or limitations. Enhancing the image of the pharmacy as a health care
centre is also necessary. From pharmacists’ perspectives most patients regarded pharmacies
as places to obtain medicines rather than undergoing consultation for the appropriateness
of supply. Although not raised by the participants in this study, greater involvement of
patients in decision making around pharmacy innovations could also generate future
research questions around whether such moves could address the communication issue.
9.6.1.4 Advertising and naming of newly reclassified medicines
Wider discussions around the need for changes in regulations around media
advertisements of newly reclassified medicines are required. Advertising should emphasise
the importance of the pharmacy consultations as well as product limitations. In addition,
very distinct names should be used for P and POM versions of medicines to reduce patient
and pharmacist confusion and associated potential medication errors. This may also
simplify training needs and promoting support staff undertaking supply.
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9.6.2 Key facilitators/barriers to innovation adoption
9.6.2.1 Benefits to the profession and enhanced image in society
Future services should enable pharmacists to undertake new roles and enhance their image
in society. Role development could be best facilitated by maximising the utilisation of
pharmacists’ current skills or by training pharmacists to undertake new roles. The new
roles within innovative services need to be compatible with existing resources, pharmacy
environment and pharmacists’ desires. New services will not guarantee role development
unless pharmacists are convinced of the benefits of the innovations to patients, as realised
with the case of newly reclassified simvastatin.
9.6.2.2 Benefits to patients
It is important that pharmacists are convinced of the benefits of innovative services to
patients. Lack of evidence of efficacy is likely to deter pharmacists from supplying newly
reclassified medicines. Belief in the evidence base enables high acceptance and adoption of
medicines. These issues were realised in the qualitative phase and systematic review of
literature; and further substantiated in the mailed survey where tendency to supply and
support the reclassified status of medicines were consistently associated with belief in
evidence base or vice versa in bivariate/multivariate analyses. Patient feedback was often
expressed as an indicator of evidence base as well as the reports in journals which they
consider as ‘unbiased’; and two studies identified in the systematic review [228,283].
Future decisions to reclassify medicines, where possible, should be substantiated through
evidence of efficacy which has been generated in over the counter settings and for the
licensed indications and dosages licensed for such settings. Appropriate mechanisms to
provide feedback to pharmacists about emerging evidence are also important. Importance
of benefits to patients in decision making also appeared important in relevance to e-MAS;
further substantiating the importance of this innovation attribute.
9.6.2.3 Sources of information and training opportunities
Pharmacists should be provided with full information about innovative medicines and
services to support knowledge gain and skills development to enhance their competence
and confidence to undertake the adoption. Although perhaps an issue for minority
pharmacists in the population, a few participants in this study expressed difficulties in
accessing sufficient information sources, for example, around the adoption of newly
reclassified medicines. Pharmacists’ use of information sources that have been designed for
patients can raise concerns, as such sources are likely to be less appropriate and
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comprehensive from a professional point of view. Pharmacies can also benefit from external
sources such as the professional body and proprietor organisations taking greater
responsibilities to train pharmacy support staff. Appropriate training around new services
for pharmacy support staff is a vital part of adoption and will facilitate pharmacists in
undertaking new and cognitive roles.
In terms of new innovative services and the process of change there is also a case for greater
pharmacist training around leadership, organisational and motivational skills than just
those relating to the specific service. Such training will allow pharmacists to delegate
routine tasks to support staff with greater confidence; with such delegation being key to
undertaking future innovative roles. Hence limiting such access to certain pharmacy
services could be more appropriate within existing constraints.
9.6.2.4 Access to patient medical records
Greater access to patient medical records is important in enabling community pharmacists
undertaking new roles or to undertake existing roles more effectively. Indeed, access is
important for services other than minor ailments, such as for the chronic medication
service, and to facilitate the practice of pharmacists with non-medical prescribing
qualifications that are located within the community. Electronic sharing of patient data held
by general practitioners, at least for the services that are integrated within e-pharmacy,
could be the way forward. Results from various phases of this study have substantiated
that pharmacists’ perceived needs for access to patient medical records is more likely to be
greater for some medicines and services than others.
9.6.2.5 Resources within the community pharmacy setting
Differences in the perceived adequacy of pharmacy resources were not strongly associated
with adoption of innovative services and medicines. However, with pharmacists focusing
more time towards direct patient care, smaller pharmacies with potentially less available
infrastructure and resource may have less capacity for development of the infrastructure in
the future. In addition, the busy working environment within community pharmacies was
often cited in the qualitative phase as being unsuited for lengthy patient risk assessment
activities, such as those required for the supply of sumatriptan and simvastatin. Resource
barriers to undertaking risk assessment activities could be diminished by remunerating
pharmacies for undertaking such activities thereby reducing pressure to make sale or
supply after each consultation. Nevertheless, many of the risk assessment requirements
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highlighted by participants reflected gaps between stakeholders and pharmacists; as the
guidelines often state such requirements are often not mandatory.
9.6.2.6 Availability of service guidelines
Clear and explicit clinical and process guidelines are important in supporting pharmacists
to adopt innovative roles. Within services around enhanced minor ailment management,
for example, points of patient referral to GPs could be made more explicit. For the
Government funded services such as e-MAS, user friendly pharmacy guidelines could be
related to ensuring that pharmacists are remunerated and reimbursed appropriately.
Guidelines are also likely to enable pharmacists avoid litigation issues around any errors
attributed by the confusions. Guidelines need to be regularly updated for recent changes in
the pharmaceutical market. In addition, harmonisation of service guidelines across the
Health Boards are likely to benefit pharmacists working as locums, where any such
differences are rooted around local public health problems or to local Health Board policies.
9.6.2.7 Financial benefits
New services should confer financial benefits on pharmacies or at least should not diminish
existing financial situations. These benefits were often associated with high regard and
adoption into practice. When implementing Government funded services that are
anticipated to generate savings, pharmacies could be incentivised with a fraction of such
savings. Capitation based payments could be argued to be an effective means of
remunerating pharmacies for future services. However, the criticism of this type of
remuneration structure as discussed earlier in Chapter 7 and 8, such as lack of focus on
quality and consistency of patient care need to be addressed.
9.6.2.8 Patient acceptance of service
As identified by participants in this research, high patient cost implications of new services
are likely to deter many patients who may prefer using GP services and hence are key to
patient acceptance and utilisation of innovative pharmacy services. Such cost implications
might even lead to pharmacists voluntarily referring patients to their GPs as seen with the
case of treatment with medicines such as simvastatin indicated for long term conditions .
As pharmacy services benefit from the advantage of increased access, balance between
‘reasonable’ service fees (for services not funded by the Government) so as to ensure
sustainability of pharmacy as business entities; and relevance to prescription charges or GP
waiting times need to be maintained. New services should also be compatible with local
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patient demography as these are associated with potential interest/disinterest to pharmacy
businesses.
Direct to consumer advertisements, although found to have high a bearing on patient
acceptance of new medicines/services, were deemed by participants to be inappropriate.
Future changes in regulations around advertising of newly reclassified medicines needs to
gather greater consensus from diverse stakeholders.
9.6.3 Post diction versus prediction of innovation adoption by
pharmacists
Although this study evaluated recently introduced services, factors identified as associated
with innovation adoption could be used to predict the success of future services. Medicines
belonging to therapeutic categories such as ß-blockers, diuretics, calcium-channel blockers,
angiotensin-converting-enzyme inhibitors, HMG–coenzyme A reductase inhibitors, inhaled
corticosteroids, short- and long-acting ß2-adrenergic agonists and bisphosphonates are
among over 100 candidates for reclassification to P status [402]. Acceptance and potential
adoption of innovative services can be predicted by asking pharmacists several questions
around the key factors associated with decision making identified from this study as
follows:
1. Is the service/medicine novel to the existing range of medicines/services?
2. Are service elements likely to see benefits pharmacists’ role development and image
in society?
3. Are pharmacies likely to financially benefit from the innovations?
4. Is there a need for further training to enhance capacity development in pharmacy?
5. Are pharmacists likely to have sufficient knowledge and expertise to be able to train
their support staff and develop SOPs?
6. Will every pharmacy be able to resource capacity developments required for the
delivery of the new medicines/services? If not how can they be resourced?
7. Are service delivery procedures too complex to be carried out in a retail pharmacy
environment?
8. Do pharmacists perceive that the benefits of innovations to patients are sufficient
and are based on evidence?
9. Is the service compatible with pharmacy business interests and practice
environment in diverse settings?
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10. Are patient cost implications likely to deter patient use of services?
11. Are pharmacists likely to adopt the service without access to patient medical records
even if the requirements say otherwise?
12. Will there be a need for greater inter-professional collaboration and communication
and how can they be ensured?
9.7 FUTURE WORK
The following research questions are proposed which are grounded in the findings and
limitations of this study.
1. What are the barriers and facilitators to pharmacists’ adoption of innovative services
specific to different stages of adoption into practice and organisational implementation,
such as during the launch of medicines into the market and at times removed from
launch. Such investigations will further illuminate the relevance of the
facilitators/barriers at distinct stages and could aid direction of future interventions.
Potential methods: Case studies around specific innovations.
2. What are the key indicators of ‘role development’ and ‘novelty’ within new services?
Identification of these key indicators could enable anticipation of their acceptance and
adoption by pharmacists.
Potential methods: In depth qualitative studies.
3. What are the key factors leading to non-adoption/rejection of innovations after an initial
decision to implement/adopt them? Research could provide further answers to
disinterests in provision of services like reclassified simvastatin after the so stated heavy
‘push’ by some organisations during the initial stages of this pharmacy innovation.
Potential methods: Prospective qualitative/quantitative studies.
4. Why are certain practitioners less interested and supportive of change? Research could
provide further perspectives on resistance to change. Limited evidence suggests that
intensive educational strategies can facilitate innovation adoption.
Potential methods: Qualitative in depth studies, case studies of least innovative
community pharmacists.
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5. If and how could feedback of practice performance from electronic sources such as e-
pharmacy facilitate adoption of innovative services or bring about changes within
individual areas of practice? These types of studies could further generate evidence
around whether such costly procedures are worthwhile in pharmacy settings and to
distinguish between the transient and real long term applications of such information.
Potential methods: Large scale controlled trials measuring both short term and long term
outcomes.
6. What are stakeholders’ opinions about the ownership of pharmacy feedback data?
Resolving these issues could aid future provision of any personalised feedback to
practitioners.
Potential method/s: Delphi studies involving major stakeholders of pharmacy practice
changes.
7. Is service delivery affected by incentivising pharmacists for performance based
payments, and if so how? Findings from such studies could explore the usefulness of
such incentives in encouraging pharmacists adopt innovative services, without
compromising the ethical underpinnings.
Potential methods: Mixed method studies combining case studies with quantitative
evaluation of service delivery.
8. What are the triggers to patient acceptance and adoption of innovative pharmacy
services, a factor that was so consistently and strongly shown to influence pharmacists’
adoption of innovative services in this study? What are the triggers to use and non-use
of pharmacy or other health care professionals for minor ailments? These studies can
benefit development of future interventions to directing patients for appropriate care
services and to enable service development in pharmacy so as to encourage patient
utilisation.
Potential methods: Mixed method studies utilising in-depth interviews, patient
responses to vignettes around minor ailment scenarios, household diary studies.
Prospective funding for this study is already being sought by the researcher.
9. How do perceptions of minor ailments match/differ across pharmacists, other health
care professionals and patients? Answer to this question could enable further
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identification of triggers to patients seeking health care, focusing on disparities in
concepts across the health care professionals.
Potential methods: Case studies, qualitative in depth interviews
10.What is the long term impact of innovative pharmacy oriented services around minor
ailments in terms of economic and humanistic outcomes? These studies require
consideration of the negative impact of increased access such as misuse of e-MAS as
identified in this study and to date no considered by current economic evaluation
models. Participants in this study were keen to be aware of the economic savings to
diverse stakeholders to understand whether or not their efforts had been worthwhile.
Potential method/s: Patient cohort studies, long term cost effectiveness, cost benefit and
full economic evaluation
11. What are the financial impacts on pharmacies of innovative services funded by the
Government such as the e-MAS? How can sustainability of the service be assured?
Which remuneration system best promotes the sustainability of pharmacy services?
Potential methods: Prospective case studies, prospective quantitative economic
evaluation studies.
9.8 CONCLUSIONS
This doctoral research has investigated community pharmacists’ adoption of innovative
medicines and services aimed at minor ailment management. In doing so, a range of
methods were applied constituting a mixed methodology, including systematic review of
the literature. These generated original data which can inform future developments in
services both related and unrelated to minor ailment management. To date, findings have
been presented at national and international conferences and one peer reviewed paper
published.
Pharmacists regarded the ongoing changes in practice around enhanced minor ailment
management to be contributing to their role development and enhanced image in society.
However, many factors were found to be key to individual pharmacists’ positive and
negative perceptions about such innovative medicines and services. The four newly
reclassified medicines studied and the Scottish minor ailment service (e-MAS), were
adopted into practice by participants of this study to varying degrees. For example,
chloramphenicol eye drops for bacterial conjunctivitis had most support for the reclassified
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status and were adopted highly; whereas simvastatin for the prevention of coronary events
in adults with moderate risk and, despite five years of reclassification was least supported
and adopted. Descriptive, bivariate and multivariate analysis of the cross sectional survey
data evaluating the five innovative medicines/services revealed that the following factors
were key to pharmacists’ decision making in relation to adoption of innovative medicines
and services aimed at minor ailment management:
1. pharmacists’ perceived benefits of innovations to pharmacy (financial);
2. pharmacists’ perceived benefits of innovations to professional role;
3. pharmacists’ perceived benefits to patients;
4. pharmacists’ perceived compatibility of innovations to existing medicines/services;
to pharmacy business interests; and to pharmacists’ expectations;
5. patient acceptance and affordability of medicines/services;
6. pharmacists’ confidence and low perceived complexity of adoption;
Differences in the adoption of the medicines and services evaluated across respondents
were less explained by differences in adequacy of resources or sources of information. This
might indicate that the new services around minor ailments have not yet demanded
reorientation of existing services; and hence in most cases, it is likely that diverse pharmacy
organisations are coping well with the resource implications raised by these innovations.
Hence the issue of how pharmacists’ perceive the characteristics of innovations such as
potential for financial benefits to pharmacy are key to predicting whether future
innovations in similar areas will be successfully adopted.
In addition to the factors associated with innovation adoption decisions, many issues
around process related aspects of innovation adoption were also identified in this study. In
particular, participants identified the need to be given a more effective voice around how
and which pharmacy innovations are introduced in pharmacy in the future. Innovative
pharmacists expressing interest in contributing to ongoing changes within the profession
were also identified. Pharmacists like these can act as movers and shakers within their
organisations and local practice forums to persuade others less comfortable about the issue
of innovations. Timely notifications, information and training around future innovations
are essential to prepare pharmacists for service delivery. A need for greater efforts from
wider stakeholders to enhance public respect for the profession was also identified.
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The theoretical framework of Rogers’ diffusion of innovations model was applied in this
study to interpret the research findings as well as to aid the design of the research
instrument. However, the facets of practice elements consisted within the theoretical factors
as proposed by Rogers model did not collate together in statistical analysis. Hence,
although many of the practice elements were relevant to theoretical factors as proposed by
Rogers’ diffusion of innovation model, future evaluation using this theoretical model
should not collapse the scale items designed in this study. As suggested by Rogers’
diffusion model, however, attributes of innovations such as the relative advantage of
innovative medicines/services, observability of benefits such as observable treatment
outcomes of medicines, compatibility to pharmacy ranges of medicines and business
interests; were positively associated with innovation adoption. Complexity of innovation
adoption was negatively associated. Not all attributes of innovations such as the trialability
were identified. External contextual factors such as patient acceptance of innovative service
also had a high place in pharmacists’ decision making.
The limitations of this study, mainly the low response rates in both qualitative and
quantitative studies; limited number of innovations evaluated; and the perspective of only
one stakeholder of change means that the results and recommendations need to be taken
cautiously by the readers.
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11 APPENDIX I (CHAPTER 1)
Table 11.1: Example of search strategy employed for review of literature II in Ovid MEDLINE
(R)
# Search History
1. Minor ailment$
2. Self care
3. Drugs, Non-prescription/ or OTC$.mp.
4. over the counter$.mp.
5. over-the-counter$.mp.
6. pharmacy only.mp.
7. general sales list$.mp.
8. 1 or 2
9. 3 or 4 or 5 or 6 or 7
10. Pharmacist$.mp. or Pharmacists
11. Community Pharmacy Services/ or community
pharmacist$.mp.
12. 10 or 11
13. 8 and 12
14. 9 and 12
Date: 17-01-2008
Description of databases used
Ovid MEDLINE (R)
Produced by the US National Library of Medicine and is a source for bibliographic and
abstract coverage of biomedical literature. MEDLINE encompasses information from the
areas of allied health. It claims to have more than 9.5 million records from more than 4,800
journals until 2008 (1).
International Pharmaceutical Abstracts (IPA)
International Pharmaceutical Abstracts is produced by the American Society of Health-
System Pharmacists. This has an index of more than 750 pharmaceutical, medical, and
health-related journals (1).
CINAHL
This provides coverage of literature related to allied health related topics (with a focus on
nursing literature) and also provides access to selected conference proceedings. Until 2008,
it had index of over 2,900 journals from the fields of nursing and seventeen allied health
disciplines (1).
Appendix - 2 -
EMBASE
EMBASE provides access to biomedical and pharmacological literature. It has index of
more than 7,000 peer reviewed journals (2).
PsychINFO
This database covers published literature originated from various disciplines since the
1800s, including coverage of several pharmacy practice and related journals.
Approximately 2400 journals were indexed until 2008 of which over 99% of the journals are
claimed to be peer reviewed (3)
References to descriptions of databases used
(1) EBSCO. EBSCO support. Available from: http://support.ebscohost.com. Accessed
03 March 2008.
(2) Elsevier B.V. EMBASE Biomedical answers. Available from:
http://www.info.embase.com/about/what.shtml. Accessed 02 March 2008.
(3) American Psychological Association. PsycINFO. Available from:
http://www.apa.org/psycinfo/. Accessed 05 June 2008.
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A comparison of the merits and demerits of telephone interviews and focus
groups.
Telephone interviews and focus groups are known to differ in the following key areas.
Items Discussion
Response rate Telephone interviews offer better response rate than focus groups (1,2).
Bias Telephone interviews are claimed to possess smaller interviewer effect
(3) and a lower tendency for socially desirable effect bias (1,3); both due
to lack of face to face interaction of participants and the researcher
within the former method.
Data collection Distraction of participants by the activities of work environment are
more prone to telephone interviews (4).
Telephone interview method could be less effective in collective data
with participants with language or hearing problems such as the
elderly where focus groups can be more effective (3).
Telephone interviews can allow researcher to collect data from
geographically dispersed population (4).
Nature of data Telephone interviews are likely to miss the interaction among the
participants due to the one to one approach of interviewing (4).
Exploration of similarities and differences in the views of the
participants can hence be better undertaken with focus group data (5).
Confidentiality Greater confidentiality and anonymity for discussing sensitive topics is
aided by telephone interview approach as compared to focus group
approaches.
Cost
effectiveness
Telephone interviews tend to incur lower resource implications to
researcher minimising costs associated with travel and venue
arrangements associated with focus groups (6).
Minimising harm
to participants
Telephone interviews can offer greater personal safety for both
interviewer and interviewee and thus could benefit researchers where
such risks are anticipate (3).
References to Appendix 2.
(1) McNair A, Gardiner P, SandyJR, Williams AC. A qualitative study to develop a tool to
examine patients’ perceptions of NHS orthodontic treatment. Journal of Orthodontics 2006;
33[2]:97-106
(2) Westrick SC, Mount JK. Evaluating telephone follow-up of a mail survey of community
pharmacies. Research in Social and Administrative Pharmacy 2007; 3(2): 160-82.
(3) Carr E, Worth A. The use of telephone interviews for research. Journal of Research in
Nursing 2001;6 [1]: 511–525.
(4) Novick G. Is there a bias against telephone interviews in qualitative research? Research
in Nursing & Health 2008, 31[4]: 391-398.
(5) Morgan DL, Scannell AU. Planning focus groups. London: SAGE Publications; 1998.
(6)Kaplowitz MD, Hoehn JP. Do focus groups and individual interviews reveal the same
information for natural resource valuation? Ecological Economics 2001;36:237-247.
(7) Musselwhite K, Cuff L, McGregor L, King KM. The telephone interview is an effective
method of data collection in clinical nursing research: a discussion paper. International
Journal of Nursing Studies 2007;44: 1064-1070.
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Date as postmark
Dear
Community pharmacists’ views
prescription medicines.
I am a PhD student at The Robert Gordon University and am currently doing a research study on the
above title.
Recently, changes in practice have arisen in relation to the non
ongoing reclassifications and the introduction of the electronic
linked formularies.
The aim of this project is to investigate community pharmacists’ views on
relation to non-prescripti
decision making processes, the role of initiatives such as e
support. Your views will help us understand the practice support needs of communit
and will play an important role in the design of information feedback on e
National Services Scotland (NSS).
Taking part will involve coming to a focus group discussion session, not lasting longer than 90
minutes, with some other community pharmacists from your area. This will take place on
June, 2008 at 6.30 pm for
will be reimbursed and light supper will be provided from 6.30 pm.
Enclosed are further details of the study and about information regarding your participation in the
focus group. If you are willing to take part, please complete and send the reply slip in the pre
envelope or via fax at 01224
If you have any questions, please do not hesitate to contact myself (01224
v.paudyal@rgu.ac.uk) or any members of the research team below.
Yours sincerely,
Vibhu Paudyal,
PhD Student
School of Pharmacy & Life Sciences
Research team: Mr Vibhu Paudyal, Dr Derek Stewart, Dr Denise Hansford,
Cunningham (01224-262533 or s.cunni
II (CHAPTER 3
(No appendix to chapter 2 exist)
Focus group invitation letter
on changing practice in relation to non
-prescription m
-Minor Ailment Service (e
on medicines. In particular, we are interested in the factors affecting
-MAS and information services as practice
7:15 pm start at .................(see the map attached). All travelling expenses
-262555 by 26th of May, 2008.
(01224- 262509 or d.hansford@rgu.ac.uk
ngham@rgu.ac.uk).
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Focus group reminder letter
Date as postmark
Dear
This is a reminder to the invitation we had sent you regarding a request to take part in a
focus group session. To date, I have not received a reply from you. I apologize if you have
recently returned the reply slip.
If however, you have not, as I mentioned to you in the first letter, the aim of this project is
to investigate community pharmacists’ views on changing practice in relation to non-
prescription medicines. In particular, we are interested in the factors affecting decision
making processes, the role of initiatives such as e-MAS and information services as practice
support. Your views will help us understand the practice support needs of community
pharmacists and will play an important role in the design of information feedback on e-
MAS use from Information Service Division Scotland (ISD), a division of NHS National
Services Scotland (NSS).
The focus group will last no longer than 90 minutes and will also involve some other
community pharmacists from your area along with you. This will take place on 3rd of June,
2008 at 6.30 pm for 7:15 start at ..........(see the map attached).
If you are willing to take part, please complete and send the reply slip in the pre-paid
envelope or via fax at 01224-262555 by 26th of May 2008.
All travelling expenses will be reimbursed and light supper will be provided from 6.30 pm.
If you have any questions, please do not hesitate to contact myself (01224-262559 or email:
v.paudyal@rgu.ac.uk) or any members of the research team below.
Yours sincerely,
Vibhu Paudyal
PhD student,
School of Pharmacy & Life Sciences
Research team: Mr Vibhu Paudyal, Dr Derek Stewart, Dr Denise Hansford (01224- 262509 or
d.hansford@rgu.ac.uk), Dr Scott Cunningham (01224-262533 or s.cunningham@rgu.ac.uk)
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Date as postmark
Dear
Thank you for agreeing to take part in the focus group discussion to be held in .........on 3rd
of June at 6.30 PM. We will be meeting in room number PA7 on the ground floor.
As I have explained to you earlier, the aim of the project is to investigate community
pharmacists’ views on changing practice in relation to non-prescription medicines. In
particular, we are interested in the factors affecting decision making processes, the role of
initiatives such as e-MAS and information services as practice support. Your views will
help us understand the practice support needs of community pharmacists and will play an
important role in the design of information feedback on e-MAS use from Information
Service Division Scotland (ISD), a division of NHS National Services Scotland (NSS).
We will provide you with a light supper and reimburse your travel expenses.
We eagerly look forward for your participation on the day. Please bring along the consent
form and the copyright clearance form with you or alternatively they will be available in
the venue. If you cannot attend for any reasons, please call us at:
Mr Vibhu Paudyal: 01224-262559 or v.paudyal@rgu.ac.uk
Thank you again for agreeing to take part. We look forward to meeting you on 3rd of June.
Yours Sincerely,
Vibhu Paudyal
PhD student
School of Pharmacy & Life Sciences
Version no: FG01; Date: 01-May- 2008
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Focus group participant information sheet
Before you decide to take part in the study, I kindly request you to take some time to read
the information provided below relating to the project. It is important for you to
understand why the research is being done and what it will involve. Please feel free to
discuss this with others or to ask us about matters you find difficult to understand after
reading this. Take time to decide whether you wish to take part. Thank you for reading this.
1. What is the purpose of the study?
The aim of this project is to investigate community pharmacists’ views on changing practice
in relation to non-prescription medicines. In particular, we are interested in the factors
affecting decision making processes, the role of initiatives such as e-MAS and information
services as practice support. Your views will help us understand the practice support needs
of community pharmacists and will play an important role in the design of information
feedback on e-MAS use from Information Service Division Scotland (ISD), a division of
NHS National Services Scotland (NSS).
ISD aims to provide community pharmacists with information feedback relating to the non-
prescription medicine supply through e-MAS in the near future for your practice support.
Your views will play important role in the way these services will be delivered to you in
order to support your practice.
2. Do I have to take part?
No. It is up to you to decide whether to take part. If you do decide to take part, you will be
requested to keep this information sheet for your record and be asked to sign a consent
form. If you decide to take part, you are still free to withdraw at any time and without
giving a reason. A decision to withdraw at any time, or a decision not to take part, will not
affect your relation with the university or the National Services Scotland.
3. Why have I been chosen?
You have been selected from a random list of community pharmacies from your health
board.
4. If I decide to take part what should I do?
If you are willing to take part, please complete the reply slip and return in the pre-paid
envelope provided or via fax at 01224-262555. We will then send you with a consent form
and copyright clearance forms which you can bring along in the focus group or
alternatively you could sign them on the venue just before the commencement of the focus
group.
5. What will happen to me if I take part?
You will be invited to participate in a group interview session that will last no longer than
90 minutes which will be audio recorded and transcribed into a paper document. There will
be some other community pharmacists along with you to discuss the matters as mentioned
above in item 1 above. All such transcripts, subsequent data analysis and all reporting of
the study results will be anonymous.
6. What will happen to the results of the research study?
The results of the research study will be disseminated through publication at conferences
and in journals. A brief report of the result of the study will be available by December, 2008
and you may obtain a free copy from the RGU contact list provided below.
7. What are the possible benefits of taking part?
You will have a chance to share your views among other colleagues related to the issues
around the topics and the way you would like to see information feedback to be presented
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to you for your practice support. Your views may play an important role relating to the
future provision of methods of medicine use data feedback to community pharmacists.
8. What are the possible disadvantages and risks of taking part?
You may feel discomfort with some issues if other members of the group divulge any
confidential matters about themselves or about other participants. Participants will be
reminded about this at the beginning of the session and in the consent form. You can
request to stop discussing any matter which you find uncomfortable or you can withdraw
at any time.
9. Will my taking part in this study be confidential?
All information collected will remain strictly confidential and your name will not appear in
any transcript, report or other publications. Audio records of the group discussions will be
destroyed after submission of the final research paper from the project. In addition, all data
will be stored securely in a password/lock protected facilities within the School of
Pharmacy at all times and access will be restricted to members of the research team.
10. Who has reviewed the study?
North of Scotland Research Ethics Committee decided that this study does not need to go
through full ethical review process. The study has been peer reviewed by the Robert
Gordon University Research Degrees Committee.
11. Who is organising and funding the research?
This research is organized and funded jointly by the School of Pharmacy at The Robert
Gordon University, Aberdeen and ISD. The PhD student is also supported by a grant from
Community Pharmacy Scotland (CPS).
12. Contact for further information
If you have any questions or require any further information, please contact:
at the School of Pharmacy & Life Sciences, The Robert Gordon University
Mr Vibhu Paudyal v.paudyal@rgu.ac.uk 01224 262559
Dr Denise Hansford d.hansford@rgu.ac.uk 01224 262509
Dr Scott Cunningham s.cunningham@rgu.ac.uk 01224 262533
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Focus group consent form
Title of the project: Community pharmacists’ views on the changing practice in relation to
non-prescription medicines.
Name of the principal researcher: Vibhu Paudyal, school of Pharmacy & Life Sciences, The
Robert Gordon University, Aberdeen
1 I confirm that I have read and understand the information sheet dated
01/05/08 version FG01 for the above study.

2 I understand that my participation includes my involvement in a group
interview session lasting 90 minutes or less.

3 I agree that the interview will be audio recorded and transcribed into a
paper document.

4 I understand that my name will not be included anywhere in the report of
the findings.

5 I understand that I have an obligation to respect the privacy of other
members of the discussion group by not disclosing any personal
information that they share during the discussion.

6 I understand that my participation in this study is entirely voluntary and I
am free to withdraw at any time without giving a reason.

7 I agree to take part in the above study. 
________________________ ________________ ____________________
Name of participant Date Signature
_________________________ ________________ ____________________
Name of Person taking consent Date Signature
(if different from researcher)
_________________________ ________________ ____________________
Researcher Date Signature
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Focus group copyright clearance form
Research Project: Community pharmacists’ views on changing practice in relation to non-
prescription medicines.
Date: 03/06/08
Location :
The purpose of this agreement is to ensure that your contribution is used according to best
practice and in strict accordance with your wishes. All material will be preserved for the life
of the research project and may be used in publication, education, lectures, broadcasting
and on the internet.
All contributions will be anonymised and all identifying materials will be stored separately
to preserve anonymity and confidentiality.
I hereby assign the copyright in my contribution to The Robert Gordon University School of
Pharmacy and Life Sciences research project.
Signed___________________________________ Date______________
Name in Block Capitals_____________________________________________
Signed for Project___________________________ Date______________
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Date as postmark
Dear Pharmacist,
Community pharmacists’ views on e-MAS performance feedback requirements.
I am a PhD student at The Robert Gordon University and am currently undertaking a
research study on the above title.
The aim of this project is to investigate community pharmacists’ views on the role of
information services in the context of changing practice in relation to non-prescription
medicines. Your views will help us understand the practice support needs of community
pharmacists and will play an important role in the design of information feedback on e-
MAS use from NHS National Services Scotland.
Taking part will involve a telephone interview, not lasting longer than 20 minutes.
Enclosed are further details of the study and information regarding your participation. If
you are willing to take part, please complete the research ethics form/reply slip stating a
convenient date, time and phone number to call you and post it in the pre-paid envelope
provided or via fax to 01224-262555 by ________________, 2008.
If you have any questions, please do not hesitate to contact myself (01224-262559 or
v.paudyal@rgu.ac.uk) or any members of the research team below.
Yours sincerely,
Vibhu Paudyal,
PhD Student
School of Pharmacy & Life Sciences
Research team: Mr Vibhu Paudyal, Dr Derek Stewart (d.stewart@rgu.ac.uk 01224 262432),
Dr Denise Hansford (01224- 262509 or d.hansford@rgu.ac.uk), Dr Scott Cunningham (01224-
262533 or s.cunningham@rgu.ac.uk).
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Date as postmark
Dear Pharmacist,
This is a reminder to the invitation we had sent you regarding a request to take part in a
telephone interview. To date, I have not received a reply from you. I apologize if you have
recently returned the reply slip.
If however, you have not, as I mentioned to you in the first letter, the aim of this project is
to investigate community pharmacists’ views on the role of information services in the
context of changing practice in relation to non-prescription medicines. Your views will help
us understand the practice support needs of community pharmacists and will play an
important role in the design of information feedback on e-MAS use from NHS National
Services Scotland.
Taking part will involve a telephone interview, not lasting longer than 20 minutes.
Enclosed are further details of the study and information regarding your participation. If
you are willing to take part, please complete the research ethics form/reply slip stating a
convenient date, time and phone number to call you and post it in the pre-paid envelope
provided or via fax to 01224-262555 by________________, 2008.
If you have any questions, please do not hesitate to contact myself (01224-262559 or email:
v.paudyal@rgu.ac.uk) or any members of the research team below.
Yours sincerely,
Vibhu Paudyal
PhD student,
School of Pharmacy & Life Sciences
Research team: Mr Vibhu Paudyal, Dr Derek Stewart (d.stewart@rgu.ac.uk 01224 262432), Dr
Denise Hansford (01224- 262509 or d.hansford@rgu.ac.uk), Dr Scott Cunningham (01224-
262533 or s.cunningham@rgu.ac.uk)
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Telephone interview participant information sheet
INFORMATION SHEET 16/07/08 version T-1
Before you decide to take part in the study, I kindly request you to take some time to read
the information provided below relating to the project. It is important for you to
understand why the research is being done and what it will involve. Please feel free to
discuss this with others or to ask us about matters you find difficult to understand after
reading this. Take time to decide whether you wish to take part. Thank you for reading this.
1. What is the purpose of the study?
The aim of this project is to investigate community pharmacists’ views on changing practice
in relation to non-prescription medicines and the role of information services in this
context. Your views will help us understand the practice support needs of community
pharmacists and will play an important role in the design of information feedback on e-
MAS use from NHS National Services Scotland.
ISD (Information Service Division, NHS) aims to provide community pharmacists with
information feedback relating to the non-prescription medicine supply through e-MAS for
your practice support. Your views will play important role in the way these services will be
delivered to you in order to support your practice.
2. Do I have to take part?
No. It is up to you to decide whether to take part. If you do decide to take part, you will be
requested to keep this information sheet for your records and be asked to sign a consent
form. If you decide to take part, you are still free to withdraw at any time and without
giving a reason. A decision to withdraw at any time, or a decision not to take part, will not
affect your relation with the university or the National Services Scotland.
3. Why have I been chosen?
You have been selected from a random list of community pharmacies from your health
board.
4. If I decide to take part what should I do?
If you are willing to take part, please complete the research ethics form/reply slip and
return in the pre-paid envelope provided or via fax at 01224-262555.
5. What will happen to me if I take part?
You will be invited to participate in a telephone interview session that will last no longer
than 20 minutes which will be audio recorded and transcribed into a paper document. All
such transcripts, subsequent data analysis and reporting of the study results will be
anonymous.
6. What will happen to the results of the research study?
The results of the research study will be disseminated through publication at conferences
and in journals. A brief report of the result of the study will be available by December, 2008
and you may obtain a free copy from the RGU contact list provided below.
7. What are the possible benefits of taking part?
Your views may play an important role relating to the future provision of methods of
medicine use data feedback to community pharmacists.
8. What are the possible disadvantages and risks of taking part?
You may feel slight discomfort with the issue of confidentiality of the telephone interview
and the recording of the conversation. A high level of security in relation to the access of the
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audio recordings and transcripts will be maintained. Only the principal researcher and the
members of the supervisory teams will have access to the data and audio recordings.
9. Will my taking part in this study be confidential?
All information collected will remain strictly confidential and your name will not appear in
any transcript, report or other publications. Audio records of the interview will be
destroyed after submission of the final research paper from the project. In addition, all data
will be stored securely in a password/lock protected facilities within the School of
Pharmacy at all times and access will be restricted to members of the research team.
10. Who has reviewed the study?
North of Scotland Research Ethics Committee advised that this study does not need full
NHS ethical review. The study has been peer reviewed by the Robert Gordon University
Research Degrees Committee.
11. Who is organising and funding the research?
This research is organized and funded jointly by the School of Pharmacy at The Robert
Gordon University, Aberdeen and ISD. The PhD student is also supported by a grant from
Community Pharmacy Scotland (CPS).
12. Contact for further information
If you have any questions or require any further information, please contact:
at the School of Pharmacy & Life Sciences, The Robert Gordon University
Mr Vibhu Paudyal v.paudyal@rgu.ac.uk 01224 262559
Dr Derek Stewart d.stewart@rgu.ac.uk 01224 262432
Dr Denise Hansford d.hansford@rgu.ac.uk 01224 262509
Dr Scott Cunningham s.cunningham@rgu.ac.uk 01224 262533
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Telephone interview consent, copyright clearance form and reply slip
Title of the project: Community pharmacists’ views on e-MAS performance feedback
requirements.
Name of the principal researcher: Vibhu Paudyal, school of Pharmacy & Life Sciences, The
Robert Gordon University, Aberdeen
Please tick(√) in the box
1 I confirm that I have read and understand the information sheet dated
16/07/08 version T-1 for the above study.

4 I understand that my participation includes my involvement in a
telephone interview session lasting 20 minutes or less.

5 I agree that the interview will be audio recorded and transcribed to a
paper document.

6 I understand that my name will not be included anywhere in the report of
the findings.

7 I understand that all materials will be preserved for the life of the research
project and may be used in publication, education, lectures, broadcasting
and on the internet.

6 I understand that my participation in this study is entirely voluntary and I
am free to withdraw at any time without giving a reason.

7 I agree to take part in the above study and hereby assign my contribution to
the Robert Gordon University School of Pharmacy & Life Sciences research
project.

________________________ ________________ ____________________
Name of participant Date Signature
_________________________ ________________ ____________________
Researcher Date Signature
I will be available on the following date, time and telephone number
Date: ____________________ Time: _____________________ (8AM to 5:15 PM)
Telephone number: ____________________(work/mobile/home)
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Focus group Topic Guide June 2008
Introduction
My name is Vibhu and I am a PhD student here in the school of pharmacy. With me is our
experienced colleague for my support. She is …. Focus group is a research method by which a
particular topic of interest is discussed to collect the views and experience of people by sitting
together in a group setting. Let me refresh you with the topics we are going to discuss tonight. We
will be talking about your experiences of the things that have influenced your practice with non-
prescription medicines and your views about some aspects of performance data feedback relating to
these medicines.
Housekeeping
I will make an audio recording of the conversation to make sure that I do not miss important points
that you have to say by not relying only on my memory or the notes. If you find it uncomfortable at
any stage just give me a shout so that I can turn off the recorder for you. Also important is not to
disclose each others private matters, things which could be uncomfortable in a group setting. We will
allow the person to finish what he or she has to say before we express our own views for some
technical reasons with the recording.
Great, welcome again and thank you very much for coming. We expect to finish this session within
90 minutes time from now and will try not to exceed the limit. It would be perfect if everyone has a
chance to say something about each of the topics.
Areas of discussion
-Great, let’s start the session by simply introducing each other? (Will depend on situation) 2 min
-Could you please describe an occasion where you dispensed a non-prescription product today or
last time? 3 min
-In your experience, what are the things that have changed/influenced your practice with regards to
non-prescription medicines? 5 min
(Probes: EBM, CPDs, Drug industry literature, peer influence, feedback, remuneration/reclassification)
-Could you please explain in what way the things that you found useful helped support your
practice in this context? 5 min
-How about the things that you found least useful or the things that you found were lacking? 7 min
(Ask for specific examples if they do not appear in the discussion)
-Let us now move into areas of reclassified medicines, how do you decide whether to adopt or not a
newly reclassified medicines? 8 min
-Does it vary from medicines to medicines? (Simvastatin, Omeprazole, chloramphenicol etc) 3 min
-How about information support when it comes to recently reclassified medicines. Were they enough
and supportive? 5 min
(Ask what do they expect and what were lacking if it does not appear in the discussion)
-Let’s get into e-MAS now. How did you feel about it when it was first introduced and how is it
affecting your practice now? 8 min
(Probe a bit about decision making)
-Now I just would like to inform you that National Services Scotland are trying to support your
practice by giving you feedback about non-prescription medicine supplies through e-MAS. To do
this they need to understand the needs in this particular area. This means basically showing you the
performance feedback regularly about how you or your company/ health board is doing. What sort
of data would you think would be most useful to you? 5 min
-Now I will take you through preliminary feedback information generated on e-MAS usage. How do
you think these sorts of information could support your practice? (You could think of any data you
would like to see, for example relating the medicines, pharmacies, patients/patient populations etc.) 10 min
-What could be the best way to deliver the information to you so that it can be easily accessible to
look when you require? 7 min
-Which other areas of NPMs might be worth getting such performance feedback? 5 min
-Would feedback on individual medicines be any useful? 3 min
-Summary of the discussion (If time allows) 4 min
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Telephone interview topic guide, June 2008
Introduction
Hi *****,. Hello, good morning/afternoon/evening. Just to remind you, I am Vibhu calling from Aberdeen. I am
a PhD student in Robert Gordon Uni, School of Pharmacy. So, how was the day? Great, *****, thank you again
for your willingness to participate. We will be talking about information support relating to non-prescription
medicine supply. This is specially focussed on the e-MAS performance feedback data to be provided to you in
the future by NHS National Services Scotland.
Housekeeping
As you are aware, this conversation is being audio recorded to make sure that I do not miss important points
that you have to say by not relying only on my memory or the notes. If you find it uncomfortable at any stage,
just give me a shout so that I can turn off the recorder for you. Great, we expect to finish this session within 20
minutes time from now and will try not to exceed the limit.
Demography:
So, *****, may I get a few details about your demographics. Ok, could I ask your…(Fill in the demography table
form) 1 min
Areas of discussion
-Are there any areas where you need more information/literature/training support in the context of decision
making for non-prescription medicine supply? 2.5min
-How about the support tools for decision making when it comes to newly reclassified medicines? (Probe with
individual products) 3.5 min
-How do you think performance feedback can help you in your practice with NPMs, such as giving you a report
of performance of the last few days/month relating to your product supply or other activities? 3 min
-Now I just would like to inform you that National Services Scotland are trying to support your practice by
giving you feedback about non-prescription medicine supplies through e-MAS. To do this they need to
understand the needs in this particular area. This means basically showing you the performance feedback
regularly about how you or your company/ health board is doing. What sort of data would you think would be
most useful to you? 4 min
-How about the examples of data I sent you and the examples of how GPs are using it. How do you think you
could make use of your performance feedback in the context of your own practice? 3 min
-What could be the best way to deliver the information to you so that it can be easily accessible to look when
you require? 2 min
-Which other areas of NPMs might be worth getting such performance feedback? 1min
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Ethics committee reply in response to initial queries around process of obtaining
ethical approval
Dear Vibhu
Thank you for your email.
I will try and answer all your queries
1 Yes you can use the new form.
2 You can come through the Nosres committee
3 You will need to book your application through the Central Allocation System (you can
get the number on the NRES website)
4 The R&D form should be almost completed using the new form but you have to complete
bits which are only relevant to R&D.
5 When you are ready to submit you send everything to the North of Scotland Research
Ethics Office Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
You only need to submit one copy of everything as we have to photocopy it about 20 times.
6 If you want to send an informal query to myself that is no problem at all. Put it in an
email providing as much information as possible and I will get back to you as soon as
possible.
I am not in the office until Thursday but if you need clarification on any of the above points
just let me know.
Kind regards
Rachel
Dr Rachel Venables
Acting Scientific Advisor
North of Scotland Research Ethics
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
Tel: 01224 558480
Monday - Thursday 8.00am - 4.00pm
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Research Project outline for initial Research Ethics Committee
Robert Gordon University
Faculty of Health & Social Care
School of Pharmacy & Life Sciences
Implementation of electronic-Minor Ailment Service in Scotland: Study of community
pharmacists’ early views, experiences and challenges.
Electronic minor ailment service (e-MAS) refers to a service introduced in the new community
pharmacy contract in Scotland. E-MAS allows members of the public who are exempt from
prescription charges to register with a community pharmacy of their choice and receive non-
prescription treatment for minor ailments supplied by pharmacists free of charge or where
appropriate to get advice or onward referral to other health practitioners. Introduction of this service
has arisen through implementation of Scottish Government’s policy to ensure that a safe culture for
self care practice is established even among those that cannot afford to buy non-prescription
medicines. This project will be carried out in collaboration with the National Medicine Utilization
Unit (NMUU) of NHS Scotland. The NMUU are responsible for planning the medicine data feedback
provision to healthcare practitioners in Scotland.
Objectives:
1. What are the views, experiences and challenges faced by the community pharmacists (CPs)
concerning the introduction and ongoing operation of e-MAS?
2. What quality mechanisms are in place to support and develop the practice by individual CPs
including the supply data feedback that is currently provided on non-prescription drug
management supply through e-MAS?
3. For the future, what are community pharmacists’ preferences regarding the type, method of
presentation, and additional support related to data feedback provision for the supply of non-
prescription medicines through e-MAS?
Methodology: This research has been designed in two parts.
A. Focus groups: Four focus groups will be held in different Health Boards of Scotland consisting of
8-12 NHS contracted community pharmacists in each group. Focus groups are planned to last
not more than 90 minutes and will conducted using a semi-structured approach utilising a pre-
defined topic guide Health Boards will be selected based on different levels of e-MAS utilisation,
from which random sample of pharmacies will be selected. An invitation letter with study
information including extent of participation will be sent to each potential pharmacist
participant. Those willing to participate will be returning a consent form. Data will be analysed
using qualitative framework analysis to identify consequent themes.
B. Postal questionnaire: Results of data analysis from the focus groups will be used to inform
questionnaire development. This will be sent to all community pharmacists’ premises in
Scotland. This will aim to quantify and correlate the differences in the views of community
pharmacists across several groups of interests (for example job nature of community
pharmacists, geographical deprivation area in which they work etc). The questionnaire should
take no more than 10-15 minutes to complete. Data will be analysed using univariate
/multivariate statistical methods. Research practice and data storage throughout all parts of the
study will comply with the RGU Research Governance & Ethics Policy.
Other relevant information: Chief Investigator: Vibhu Paudyal (B Pharm, MSc Clin. Pharmacology);
Funding/Collaborators: Community pharmacy Scotland (CPS), NMUU NHS Scotland); Nature of
Project: PhD Research supervised by Dr D Hansford and Dr S Cunningham; Project peer reviewed
by: Robert Gordon University Research Degrees committee. This will be the first study to be
undertaken in this particular area since the new contract for Scottish community pharmacists came
into effect in 2006.
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Further correspondence with the Ethics Committee
Dear Vibhu
Thanks for your email.
Could I just clarify a few points with your regarding your proposal.
How will the focus group participants be recruited?
Do you intend to use consent forms, if so can you let me see a copy?
How will the questionnaires be returned will the be anonymous or anonymised and if so
why.
I look forward to hearing from you soon.
Kind regards
Rachel
Dr Rachel Venables
Acting Scientific Advisor
North of Scotland Research Ethics
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
Tel: 01224 558480
Monday - Thursday 8.00am - 4.00pm
Dear Vibhu
Thanks for your email and clarification there are a few issues that I have with your
documentation.
Letter of Invitation/PIS
I think you need to supply more information about the study. I have attached a model PIS
which you may wish to adapt for your study.
You can not say that it has been approved by the Ethics Committee, you could say that the
study is classed as a service evaluation and has not had to go through ethical review (or
something similar).
Questionnaires
It would be better if the questionnaires were anonymous and no study ID number was
placed on them. If you are going to send reminders, then it is better that it is a blanket
reminders and only one reminder gets sent. Then you do not need to collect any
identifiable information.
Consent Form
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I have attached the standard format that we usually recommend. Also I don't think you
need to have I do not agree to take part in the study. If participants want to take part then
they should just sign the consent form and if they don't they should not need to respond to
you.
I look forward to hearing from you soon.
Kind regards
Rachel
Rachel Venables PhD
Acting Scientific Advisor
North of Scotland Research Ethics
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
Tel: 01224 558480
Monday - Thursday 8.00am - 4.00pm
Ethics committee decision
Dear Vibhu
Thank you for responding to my queries, I think we have covered everything!
After review of your information and discussion with the Vice Chair of Committee 1 we
feel that your project is a service evaluation and would not require a formal ethics
application.
If you need any further information, please don't hesitate to contact me.
Good luck with your project.
Kind regards
Rachel
Rachel Venables PhD
Acting Scientific Advisor
North of Scotland Research Ethics
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
Tel: 01224 558480
Monday - Thursday 8.00am - 4.00pm
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Ethics committee responses to request for the conduction of telephone interviews
Dear Vibhu
My apologies that you have not received a reply from us sooner. We have had staffing
shortages in the office and I am just back from annual leave.
I will review your proposal and get back to you by the end of the week.
Again, my apologies for the delay in the response time.
Kind regards
Rachel
North of Scotland Research Ethics
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
Tel: 01224 (5)58474
01224 (5)58503
Office Hours: Mon-Fri 9am- 4pm
Dear Vibhu
Thank you for your email.
Can I ask you to clarify the following please:
The information does not make it clear that you are asking them to take part in a telephone
interview rather than focus group.
After you have transcribed the interview are you going to send them a copy of the
transcript for verification.
I look forward to hearing from you soon.
Kind regards
Rachel
North of Scotland Research Ethics
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
Tel: 01224 (5)58474
01224 (5)58503
Office Hours: Mon-Fri 9am- 4pm
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Ethics committee decision
Dear Vibhu
Thank you for clarifying the points requested.
After further review we feel that the changes to your project still ensure that this is a service
evaluation and would not require a formal ethics submission.
If you need any further information, please don’t hesitate to contact me.
Good luck with your project
Kind regards
Rachel
Rachel Venables PhD
Ethics Co-ordinator
North of Scotland Research Ethics
Summerfield House
2 Eday Road
Aberdeen
AB15 6RE
Tel: 01224 558480
Monday - Thursday 8.00am - 4.00pm
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An exemplar focus group transcript
C: Ok, this is working perfect.
F1: Frightened to say anything, just listening
(Laughs from other participants)
C: Well, this is working as well. So lets just start with a brief introduction. *****, shall we start
from you?
M1: About myself then?
C: Please,
M1: *****, I live in ***(Name of a place), qualified in 1976. So, therefore, been community
pharmacist for nearly 30, 32 years (Laughs). And, and I am employed by ***(Name of a
pharmacy). I have worked all my career for ***(Name of a pharmacy) person employees but
….but..not financial, now, I am at the stage where, pension, important, is there anything else?
And I got family in... So, em… I’m qualified Manchester University. Did much of it from
***(Name of a place) but did most of my early years down in *** (name of a place) in various
managing positions in*** (name of a place). Then went to *** (name of a place) as manager and I
think, bad to get out there, out there for the sake of my sanity, to be honest em... and came back
to ***(Name of a place) on relief, as, came in as a relief pharmacist in the branches in the
***(Name of a place) area. That was about 14 years ago, stayed there ever since. I’m technically
relief but at the moment I am spending quite a lot of time in ***(Name of a place), simply
because there’s a vacancy there, so I’m covering the vacancy. Will be on relief later somewhere
else, think so and Em… supplementary prescriber, but not much opportunity to use it at the
moment particularly being on relief but hoping when things settle down, em.. can make
conversion to independent prescriber.
C: Ok, *****,
F1: *****, community pharmacist in ***(Name of a place) but I have worked in a rural
community for quite a number of years, em…just working in an independent pharmacy rather
than a big companies. ...
C: Right, Mr *****,
M2: *****, first, I worked for a hospital for sometime, then, worked in retail. Then, I’m for about
for about 30 years, in a rural pharmacy now.
C: *****
F2: *****, I settled working ***(Name of a pharamcy) for many, quite a few years. Then went to
do locums when my children were young, did locums about, may be, 12 years or something,
near about. And, I’ve, I am now working in ***(Name of a place) as a manager with the ***(name
of a pharmacy).
M3: I’m *****, I qualified in 2003, em.., spent my, my career so far in community pharmacy in
and around ***(Name of a place)shire. Most of been it rural setting until the last year or so when
I’ve moved into a, an urban setting within ***(Name of a place), much busier environment. And,
I’ve, only worked for two companies. A small to medium sized chain and I’ve moved to a large
chain of the Cooperative group and, just, still, still a learning curve for me just now.
C: Good, so, just to enter into the topics of non-prescription medicines, could you describe an
occasion where you supplied or dispensed a non-prescription medicine today or last time?
We’ll go round about in first occasion and then…
M3: Head lice seems to be popular within ***(Name of a place) now, it’s only today, I’ve had
couple of eMASes to, to, to, to supply, if you’re meaning from any title?
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C: yes, from any title,
F2: Head lice treatments and paracetamol for children.
M1: For me in the last few days has been, coming quite strong antihistamines, the season
starting to allergic children, children, with, reactions, groin obviously, the small children
(smiles)
C: So, you see a lot of seasonal changes, in relation to demand of these….
M1: Starting to change now,
M3: yes.
F1: As I said, purely minor ailments scheme you are talking about, or just ….?
C: No, anything, anything,
F1: People, people buying things at the counter as well, in general, the sale and supply.
C; yes, in general, yes.
F1: Yes, I’ve had a dry skin, head lice, paracetamol, anti-histamines and I think, I’ve had all of
them today. And, mouth ulcers… I don’t know is this endless working in a chemist shop
everyday without thinking about it So, ya, lots of things.
M2: I agree with, ah,.. head lice. I had two patients at work today, keep with the season Piriton,
quite a lot of that, two complaints about the cetrizine, which I supplied, that it doesn’t work, so
supplied 2 lots of Priton and em.., we put on e-MAS, so, Calpofren, Calpol, Eumovate, did,
couple of hydrocortisone steroids, those on e-MAS, as well as Aunguentum-N for trial , child, 2
year old, had, very, very allergic skin, she is allergic to milk, so, I supplied with special formula,
Neocode, and so, so that’s a job in order she was also heaping, received the Eumovate and
doctors are off today and I dispensed it.
C: Great, let’s enter to the main area of discussion now. Ah, have you seen in recent years,
changes, any changes, significantly affecting your practice in relation to non-prescription
medicines?
F1: Possibly pseudoephedrine sales pack size em.., prior to that paracetamol..., these are the
regulated changes you have to implement.
C: yes, anything, regulatory or anything significant, you would like to …..
M3: Changes, lot, lot of areas have been fairly steady.., stream…, fairly settled down, in a recent
while, accounting for past two three years, seems to be reasonably fairly predictable level of
demand.
M1: The second concern for the level of demand, may be driven by the level of advertising, not
for, not for e-MAS, but, I wasn’t even aware that, there was, there was an OTC naproxen coming
out until, until it was pointed out on television. To me, I would think I would read in my journal
and chemist but its not as early, for cover to cover. But, that, I would, then coming and asking
for OTC naproxen which I wasn’t even aware. I might, I don’t know if I’m alone.
F2: I knew it was coming.
M1: the, em, I must have missed the…
M2: It’s a great help to have that but its, em, difficult to explain to a man, without insult him
(smiles and laughs by other participants).
(Too many speaking at a time, loss of conversation, 5 seconds)
M1: So, just highlighting the point here that changing from POMs to Ps is fine if it’s given us an
extra, a weapon in the armoury if you’re like but if its driven by television advertising, not quite
so sure, that people coming and asking for potent medication, I might not be satisfied. I think, it
should be, led by us (supported by F1), not led by television.
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F2: TV advert, I think, is appropriate for them, so they make decision for the things they
want……….
F1: I think, Curanail must be on the teli (TV) just now as well. ‘Cause, ’cause I’ve had somebody
asking for that and that’s such an expensive item, something I would not generally recommend
first line, but, because its on the television, advertise…..
M3: (overlap of conversation)
F1: yes, also, sorry, I also don’t want that anymore.
C: So, do you mean when changes do happen, from POM to P or P to GSL, this, do these
television advertisement and things are ……
F1: From POM to P, is, is the big one, because it’s the thing, people couldn’t purchase earlier,
gets advertised on teli, oh… this is great, this is great stuff and they come in and, they ask for,
they don’t come in and what’ve you got for period pain? What’ve you got for fungal nail
infection? This is just can I say, can I have the stuff that’s advertised on the television? The
power of advertising is quick, and you negotiate with your patient. Put something else in there,
you didn’t want it there in the first place. Yes, I can treat your nail infection if you leave it just
up to me, let me decide how I going to treat you. This is you get the same, you can’t walk into a
GP practice and say to the doctor, I come on with such and such I saw on teli. The GP wont
listen to it. And, I found that quite frustrating, generally changes from POM to Ps is, is, is the
main one, which you get Coronia advertised on the teli, Askits for whatsoever, may be on GSL
for ages and people buying them on Tescos, there, that doesn’t really affects me so much as the,
ones that can only be get from pharmacies, from a POM to P where they come in to up to our
door...
M2: I think, chloramphenicol has been best POM to P
(agreed by al others)
F1: That’s really good one, ya
(agreed by others)
F2: What a demand from the customers…..
(Lost data due to many speaking at a time) for few seconds
C: So, what do you think should be done to make things easier for you to actually make people
understand the rationale behind reclassifications and the evidence based supply from
pharmacies? Are there anything that…
M1: Just cut the advertisings (smiles)
F2: You’ll see things like Chloramphenicol, I think its purely...
M2: That’s the worse thing
F1: And then they wonder when you’re asking them all the questions. So I just thought why the
teli could not have it like………..
F1: So, the difficult area has been adverts. I think people will see them and buy past from
another place.
M1Yes…
F2: And if they not get it, then just try up somewhere else
F1: they just go some place yes, yes.. and that’s with minor ailments as well. You know because
we’ve somebody asking for some irrelevant items, sorry but I need to register for minor ailment
before we can treat you. And then they re-register and then they don’t come back (smiles).
C: So, how about the information support you get when things get reclassified from POM to P?
(silence)
Looking into specific examples of recent reclassifications like Simvastatin and Omeprazole?
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F1: What did you say that? Sorry,
C: Information support, materials like trainings as well as information materials for supply?
M1: You do get trainings
11:47
M3: You do get trainings but it seems to be driven by the company who is about to make a small
fortune of promoting the products themselves , its its not standardized. So it can be difficult to
integrate to your own, your own branches.
F1: We have the ***** (a health board) Prescriber, when new drugs come in the market, *****
health board look at it and evaluate them and they tell the GPs that this is the new product and
this is gonna be OK for such and such but don’t use it for.... They have some kind of evaluation
process when new drugs are coming out for the prescribers. But if there’s a new things come out
for pharmacists itself whether its from POM to P or what.. its the drugs companies that do all
the training and ..., there is no sort of evaluation thing there
M2: Usually the products which are established, we find out from like what the truth is about
it.
F1: We usually see in the Chemist and Druggist, or from the reps
F1: Sometimes you have to actively look out, seek out that information, even for the
standardised...., oh by the way this one which is coming out, is that not something that is in the
journal about reclassification which tells you all, its quite muddled isn’t it? There’s a lot of stuffs
that haven’t changed for ages, there’s not something specific new things...highlighted in the
colour or something.
C: So are there any ideal ways of delivering you the information when reclassification happens?
F1: Yeah.., we know that going to be in pharmaceutical journal, all that sort of....
M2: They can send us a sort of standardized card with all the information instead of all
promotional information, you got to fight the way through to find the information you really
want. The card would then allow to acquiesce the change and secondly would give you the
standard information. I think you would have to put the cost against the company. Its unfair to
ask pharmaceutical journal to bear the cost.
M1: Its also a problem..., before launch its often in glossy magazines or newspapers whether it is
news or whether it is promotional. I have been asked for something that appears on daily mail
or whatever, newspaper that does a new medical drug. Now if I don’t read that particularly
newspaper, I won’t have a clue what they are talking about. Its often there before its says its
available from.... These, these, if you like editorials are often set up months before paper goes to
press, months before magazines goes to press. Often its not on the shelf at all or often I don’t
know anything about it. I don’t have any datasheet on it. So, I think.., that, that doesn’t only
happen with over the counter drugs, it can also happen with prescription drugs. People asking
about new wonder drug for rheumatoid arthritis, which they read about in the Sunday post,
doctor on Sunday post. I think they come back to something, might be there’s not enough
respect for medicines in the country. They still got, I still have got people asking for
Coproximol, doctor could in theory prescribe it or.... So if you are living in that sort of society
there’s not enough respect for the role of pharmacists and then coming in and asking for
something in e-MAS rather than coming and asking say can you give me something to treat for
athlete’s foot?, coming and asking for… And that indicates to me a lot of respect. I will say I will
prescribe you what I think is suitable for you. I won’t say as quite bluntly to the patient as this
but ...., you tell me what your condition is and I will tell you what is suitable in a much friendly
way as to...
M3: you felt like you are an obstacle to the patient to get what they want.
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M2: With e-MAS, you do have patients coming with virtually the shopping list and that is
wrong.
M1: that’s not what it is for
M2: Thats not what it is for. I’ve had a patient.... I said you cant., it wasn’t set up to be like this.
What he did was to turn around to another chemist and register wherever they want.
C: We’ll get into e-MAS later (laugh from the participants). So, relating to reclassified products,
were there or are there any products that have (been) welcomed much in the community
pharmacy and are there any products which haven’t been through ……so well?
F1: Oh, well, Chloramphenicol, has been fantastic,. I would say Imigran has been a waste of
time (agreed by others)
M3: Zocor?
F1: Zocor has been a waste of time as well.
M3: omeprazole,… that’s the price
F1: yeah very expensive
M2: Price sensitive, yeah.., exactly.
M3: Absolutely, well the thing like Feminax Ultra, that have got into swing... it seems to be very
well received, I mean, that’s what I sampled, about three people have came back and said, its
wonderful.
M1: I haven’t had a chance to sell it but yeah it’s a kind of product that you’d like to watch
what you’re using it for (Laughs)
M2: I’ve never used it for many years, but em.., exactly what you said
M1: Naproxen, is for, for Migraine, I haven’t been able to sell it yet because Buccostem is not
particularly migraine product but, that would be one I might welcome. I don’t see why can I sell
it for migraines but cant sell it for any other conditions. So, that would be one I might think
should go or should be less restricted. I don’t know if anybody else think the same.. the same I
think the license is restricted on that. Chloramphenicol will certainly go along with that, would
have wished that for years..
F1: Getting back to what you were saying that the trainings before these products come out. It’s
the reps doing it, ‘cause it’s the only one that we get for POM to P for certain conditions. Its not
that we are allowed to use the actual drug for what we want to use it for. We cant do it (agreed
by others). ….. migraines, sickness thing. I mean, I mean, the naproxen is another one, they
could just bring in naproxen off POM to P ... generic naproxen tablets but ... specific product, its
not for migraine or whatever, what was it called again? Feminax Ultra, that was it. We are,
we’re restricted to what we can actually, I mean where naproxen is the drug to use for over the
counter restricted in what we can use it for.
M1: I do have a concern about using the brand names for the existing, put a different product. I
have a concern on that for a long time that, when you get ..., the name...extra ... plus and told
that its confusing for the hospitals if there is an overdose because, basically the database will
actually show ... as being Salicylate product. And of course, you can actually have everything
now with under the sun under its product name and I don’t, I’d have liked to call some other
than Feminax Ultra to be honest because now its ... we have people are coming in and
requesting it, then its totally different product, you are talking about from the traditional ...? I’m
not really very keen on hanging a new product on an old well excepted, well excepted name, I
think they should call it something, there’s, must be plenty of options to call it something else.
(Two speaking at a time for few seconds, doesn’t seem to be a data)
F2: Its quite confusing, when they have fancy products like Cansten and they bring out counter
pack which is obviously…, it’s the same but its misleading
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F1: oh yeah, god, yeah.. you see, you see Sudafed, I’ve seen people looking at Sudafed in the
supermarket, I felt like ….., its not Pseudoephedrine, its phenylephrine and that’s not the same
as you buy in the chemist shop, you go to your chemist, you can’t, ... looking at the packet,
thinking it’s the same, its not. But as you said, because it’s a branded the same, the pack looks
almost the same, it’s called Sudafed, they called Sudaphed…,
F2: very similar to….just now ’ ‘cause I got mixed up myself, my staff got an stuck with it and
….
F1: sometimes its Sudafed and sometimes its Sudafed non-drowsy congestions or something,
there’s two...
F2: They are two different packs and all look the same.
M3: Is it decongestion, decongestion relief?
F1: Its something like that, two different.., for decongestion but the packs look very similar. And
I think its very misleading, its obviously a marketing ploy for big brands.
M1: Once you got a good brand name, you hang something else on to it and….
F1: And as you said the Feminax one ‘cause its completely different ingredient and ….
C: So, are there any other products which haven’t been going really well in pharmacy that have
been reclassified in the past?
M1: have or haven’t?
C: Haven’t.
M2: Sold cheaper Colpermin and ..., didn’t go at all.
M3: What happened to Zantac when it first came out?
F2: That gets called, I don’t know… why
F1: You get it generic or Pepcid AC
M2: Yeah...
C: How about Simvastatin, is it doing well?
M2: no.
M3: I don’t think, we even stock it anymore.
F1: No.
M2: So expensive, the doctor’s formula and they get points for getting so many people on statins
(laughs)….
M3: 10 milligrams just do for two weeks. If, if its hitting target audience of….., I’m sure when it
was first sent out, it was targeted towards the working, it may all 40s, 50s GPs but stayed on 40
milligrams depending on weight. Ten’s not gonna really cut it.
M1: I think that was targeted…, they worried well rather than …., which is the reason it didn’t
work well as even if you were doing cholesterol testing in the pharmacy.
F2: When you’re doing cholesterol testing, did you sell any…or…?
F1: No, did referrals]
M1: No, I either offered dietary advice because the cholesterol testing wasn’t, wasn’t even
differentiating high density and low density, so….and they didn’t look into anything else, I
mean,the.., whether the patient had a history of or a family history of stroke, whether diabetic.
So, I mean.., in isolation, I think it was pretty much useless exercise. (F2: You stopped doing it?)
I stopped it long time ago. I did it if somebody demands, we stock as a matter of policy. I didn’t
agree with it. I did it when it was contractually required me to….. but I’ve.., ah…, never sold a
pack of Simvastatin in life. Never had any intention to …do it.., I was quite happy to offer
advice to people if they had a high total cholesterol read and as to whether people benefit and if
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they come back after certain amount of time to see if it had improved doing that. But, no I
think, my time is really devoted elsewhere really honest in that one.
C: Is it the same experience you had Mr *****?
M2: Yes, oh yes, I was looking at one pack of Zocor, the retail pack.., the heart.. ,one more…..
F2: I think it depends as well on what area you are targeting, because if you are in a, an affluent
area, probably, ***(Name of a place), people may be motivated to pay twelve pounds or
whatever, canna remember. But if you’re in a poorer area like ***(Name of a place)..
(interrupted)
M1: Don’t think I sold very much when I was on relief on ***(Name of a place) earlier ,…people
say.., London perhaps might be somewhere….. but …
F2: People may be motivated in that situation because they could probably afford it.
M1: They’re worried, they’re worried
(Loss of conversation for a couple of seconds due to too many speaking at a time)
F1: they’re worried well, things like that they’re worried well
C: So, are there any other factors than cost, do you think is responsible for its..?
M3: A big factor for me at least, if, if I’m ..pressed for time filling out whole Imigran or, or, I cant
remember if Zocor had, had the same problem, but... I find that, I find that taxing if I have to
even find..
F1: Customers don’t want it either, they got to go through big ..., they don’t worry.
M3: they just, just want to get quick service
C: So, what could be done to encourage, this chronic medications to be brought into community
pharmacy in the future? Are there any support lacking or is that the whole idea behind such
reclassification not very good? What do you think can be done in the future?
F1: Chronic long term medications like the, Simvastatin?
C: Yes.
F1: So, what would make us..?
C: Yes, be, you know more, make public more trust, you know or make community pharmacists
more equipped or more competent to supply these kind of, products in the future?
M1: Sorry, coming back to.., sort of , not to be worried about…,but you have to have some more
access to records, some access to patient records to actually be aware of what you actually
treating someone actually, actually..,needs treatment. There’s a….,at the moment we would
have people coming and asking for Zocor and they need treatment. We wouldn’t have people
coming in….did…yes, they are worried well. But its should be targeted towards what is
appropriate, not, not desired (smiles).
M2: Unless you have the, em.., access to records…. to see what we want to., some can been
treated with statin or ... and come in and if you are able to sell for example at reasonable
price…Simvastatin…, and ask for Simvastatin..and they have already treatment with statin, give
another one and the only way we could have be possible is only if we had access to the records,
kind of dangerous in a sense if you think about it.
M3: Seems to be more successful, hearing the names, seems to be more successful with shorter
and acute conditions rather than going...
M1: The successful ones as I say is the ones Zovirax, Chloramphenicol, first the Loperamide, I
can remember when that came OTC, so those three products were successful because…
F1: We’re really kind of first port of call for acute things and they, really people are coming if
there’s something wrong with them but if it’s a long term chronic thing, they come in and we
can direct into their GP for the long term chronic thing.
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F2: I think most people are probably more comfortable anyway with the long term chronic
conditions to be seen by their GPs. Most of these, well, not, not Simvastatin, that, lot of these
products have short term license which...quite use for more than five days before we refer them
to GPs, so we’re quite restricted by product license to, to what we can do and what we cant do.
M1: There’s problem with…, when things go from P to GSL, Are they been restricted or
controlled enough when they are sold outside pharmacy? I mean paracetamol are sold in local
garage, I mean, em…, number of items…..
M2: I think your point..,… interesting about the Sudafed and phenylephrine, you got glaucoma,
you don’t have ... phenylephrine from Tesco.
F1: From Tesco? Yeah.., everybody is worried about it, can I have six packets Madam?
M2: Yeah
M1: I have seen it but a lot of the major supermarkets will have enforcement in, in another
terms. I don’t know, I never have tried to go through, Tesco, Tesco to see how many
paracetamol you get, get through there but that will ……, anyway its not got computerized.
F1: Paracetamol
F2: paracetamol, but I don’t think, sudaphed.
F1: But they only do it for paracetamol because it’s a suicide risk isn’t it.
M1: So, I limit to sell X as being a professional but Tesco can sell 2X, 3X,
F2: Well, paracetamol, they don’t sell two packets,
F1: yeah, but you can go and buy two packs of sudaphed.
F2: yeah, you are right and….just try it
F1: Just try it?
(Loss of data due to too many people speaking at a time)
C: Going back to the information support, when there the reclassification happens (do occur),
do you prefer some source of information over others, depending upon where the information
is coming from?
M3: A, a, an impartial source, not the manufacturers. I always get sceptical when I see their,
their, their, their data coming through. Its usually, a good journal would be the pharmaceutical
journal. When I happen to see it, …..,it looks like that I might not pick it up but when I do, I
want to read about it….that’s, that’s usually the source.., will be happy to..,
F1: The announcements in pharmaceutical journal is usually what I pick up….yeah…And you
do look at the manufacturers thing, so that thinks about bias,
F2: Chemist and Druggists
M1: Yeah, Chemist and Druggists…
C: So, lets move into another area now. How about the influence of this…, literature
surrounding evidence based medicine supply, affecting your practice with non-prescription
medicines? Do you see, them.., affecting your practice a lot? For example literatures coming up
in journals and new information supports…, suggesting evidence based supply and things?
F1: Tryin’ to think of any example.
(Silence)
M3: Only slight, most of the medicines available as non-prescriptions are so well established.
….It tends to almost..,the..,evidence is something we actually know, whether, whether…,its..,
occasionally.., those are..,Simethicone being more effective over Dimethicone for headlice?
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F1: Yeah, I was thinking something about the paracetamol, Ibuprofen, evidence base about the
kids treatment, not to give together or something. And where, where did that information came
from? I can’t remember where that came from. Things about using paracetamol and Ibuprofen
together ….
M2: If you give them, they tend to reinforce the renal toxicity
F1: But did that come through the health board or…?
F2: I saw that, I don’t think..,
M2: Journal,
F1: A journal?
M2: I think so.
F1: yeah.., evidence based, as you said..,what else was you…..?
M3: There is one, one, one of the Dimethicone related products which was in a study which was
seen to be X percent more effective than, than than, than…, I can’t remember…, permethrin or
something like that.
F1: When I see in a journal something like that, you get a sort of sort of clock it. I mean by the
time you flick through the journal, you see titles, I mean interesting titles and then you, if you
read something that somebody done some study on.., and they don’t mean a brand, they talk
about dimethicone base on.., or a Malathione base and then you kind of read that oh..,OK, I will
start recommending Malathione base instead. So I suppose if you do read something and its an
evidenced base paper on, on the things that you can sell over the counter, its not all something
you’re looking for, its just something you have to see.. and then that would may be affect what
you recommend.
C: Are these CPDs and things affecting your decision making? CPDs?
F1: Whats a CPD?
(A laugh from other participants)
C: continued professional development, training and things.
M3: I, still,..because..,, related to recent POM to Ps, because I’m still sceptical of the CPD,
because they provide the CPD articles on, on, on the recent switch. But I’m still sceptical …….,
specially on the CPD things…that’s lovely, thanks for telling that but I’m still not quite
necessarily choose that product over, over something which has been successful for, with other
patients or customers before.
M1: not occasions, presumably with head lice but, the health board has a formulary. Now, I do
try to stick to that, what the recommendations are from that and it doesn’t include any
preparations that are designed to be used in 20 minutes or applied and washed off again. And
that, I’ve had few arguments in that particular circumstance where the ***(Name of a place)
formulary certainly says it should be left over the night, washed off in the morning…which
rules out the (F1: See on the telis and its on the teli…). Yes…, If you’re asking me to write on e-
MAS, I am writing what, what, what I believe is going to, sort of.., I wont have an arguments.
Well, argument probably is too strong a word, a debate shall we say, em.., patients who want
what is quicker to use and I’ve refused prescribing because may be quick to use but the
evidence doesn’t back up its use. Now, that’s I think what we should be doing. But, it can be
quite difficult. We also have problems, if going to be honest, with doctors sending the patients
down, asking for the things on e-MAS. Now, em..,probably, it is saving the doctor’s budget, the
whole point of e-MAS was, was to actually, prevent people having to go to see doctors with
minor ailments. If they’re already in the doctor’s surgery receiving an antibiotic, then why does
is the doctor telling patients to come to us for…, paracetamol?
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C: Great, well, lots of interest in e-MAS. Now, lets get into e-MAS now. (Big laugh from all the
participants). So, how big this was a change in your contract when it first came? *****, may I
start with you please?
F2: We piloted in ***(Name of a place), so we’ve been doing MAS for seven, over seven, seven
years now. Em.., I think initially, people didn’t understand if its available. Its quite hard work to
register patients. But now, more people know about it. Not, not everyone knows about it, I think
we still have got ground work to tell people about it and how it does affected work? It can be
very annoying some days, (agreed by M2), very busy and you’ve got lots of them and in other
days, you don’t see them at all. And I think..,(smiles), .., when you’re really busy, there’s lots of
people turn out and looking for something, see e-MAS ...
M1: its not a very stable programme, isn’t it?
F2: not its not, its not (smiles), but people tend to have their.., have their…, I suppose their
aspirations to what they want. A... said that.., I’d been to the doctor and he’s told them to come
down for paracetamol which he ... handle well or recommend and they just want paracetamol.
So its trying to get round them, its not the service that they use as and when needed, its for a
child who must be ill or…
M2: I want paracetamol, paracetamol, Ibuprofen, I don’t want to pay for it (laughs)
F1: I’ve run out of paracetamol for my _______ can I have some more please? There’s wrong
with the child, I’ve just run out of it. Why you give me paracetamol. I use it every night.
M3: That’s.., em.., I’ve only…em, they kind of keep.., em.., the paper based, the minor ailments
or ‘Direct Care’ or something, came in force for about a year into my having qualified. So, its
just another thing which was easy to…., what I studied in….but... Firstly, that I was trying to
treat it as a normal day to day pharmacy life, if, if I am dealing with the prescriptions are done
in line But we have a sort of customer who wants to speak to me, , Oh, come in, speak to me.
But, when ..,minor ailments…, direct care.., treated it as a (F1: Prescription).., well, no, not
immediately, I, I made a mistake while I was trying to deal with it, then, they are back it they
are not…, They then took me, it took me sometime to think.., you know, actually.., I couldn’t
have to tell these people, this, this, is the service gonna be, twenty minutes wont.., and these
other people who…
F2: That’s what I said, I suppose, if you go and speak to the person, first, the.., usually, the girls
will take it quite quicker, the information. Then you go down and speak to them and …..I want
paracetamol and then, you have to say, well, no…. (too many speaking at a time) …give you
what you aiming, em…, and then see, well, now be 15-20 minutes because..
F1: I think, kind of.., when it was first introduced, people were coming in and they wanted their
paracetamol. Because you, because it was a pilot project, we were trying to encourage people to
use the service and tell them about and everything was like and “oh, do you know the minor
ailments?”, we are introducing the minor ailments service for them. When they were coming
and asking for something, normally they would have just come in and asked, they would have
done the WHAAM questions then sell it the way I ... But because we have been used to the pilot
project to encourage people to do the minor ailments service, get people registered on it, telling
them about of being free or whatever. It is quite time consuming and now, now, when you have
somebody coming in to buy Calpol when their kid when they have got teething, you get now
the staffs kind of say..,getting on their minor ailments for their child’s name or whatever, goes in
for a while for prescriptions or waiting or whatever, when I get down, I have to go out and talk
to them whereas prior to that the girls could have done the WHAAM questions and sold it. So,
yeah.., has increased my workload.
C: How about getting paid for it advice with this..e-MAS?
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(Laugh from participants)
F1: Just a little bit on the minor ailments, we…,referral or advice only or something. No, its so
much hassles. I only use the prescriptions when I am dispensing. I don’t, I don’t do blank ones
for… Do you do blank ones for advice or referral only? (asking other participants)
F2: No, I do very very little but not as we should…
F1: I’ve never done it, not at all.
C: why don’t you do it regularly?
F1: because you have to go on to the file on the computer, finding them up to do and then you
print it sign off and then, then all, all you saying is go to your doctor. That will just take a long
time, they’re not going to wait us doing that.
(Too many participants speaking at a time for a couple of seconds)
M1: ….referral mean piece of paper on to the doctor. That might be a different issue…..I have, I
have seen this, this patient and …
F1: but what about advice? You give people advice all the time…
M1: I, I think, its more…..
F2: It depends, the.., how ill the person is? It will be wee while that I go and phone the doctor
saying that this person here, what I feel.., needs to be seen and they get an appointment.
Whereas if they go across themselves, might be until next week..
C: How about formulary support for this e-MAS?
F1: What is that support?
C: Formulary
F1: Formulary
F2: Bad (Smiles)
M2: Yes.
M1: well again I think, ‘cause the health ….., probably the same because a test…, ***(Name of a
place) was a test belt. It was one of the two original sites. So it’s the same formulary now as it
was when …(F2: years ago)…. and also the difficulty is that, that you can’t prescribe anything
that’s, that’s got P license on it, ...? not in the formulary. So you’re getting variations between
pharmacies as to what and what is not being prescribed. We also get the situations, sort of
strange ones where branded names are allowed to be picked. The flocona, the fluconazole issue
(agreed by other participants). If you’re, if you prescribe a particular drug fluconazole under
PGD, you can supply it but its, its only endorsed and put through the computer in a certain way
only. So you are actually giving a more expensive product ……(too many speaking at a
time)…even if we have cheaper drugs on the shelves.
F1: I’ve had so many things refused for picking up wrong things off the computer as I do
everything branded one. I don’t do anything generic anymore. I do branded, apart from
paracetamol and Ibuprofen. The stuffs…. because you are allowed to do it and not getting, not
paid for it.
(Loss of transcript due to too many people speaking at a time)
F1: …it picked up the second things like off the computer, things like beclomethaosone nasal
spray because it’s printed off in 200 which is damn this cheap, which is cheaper than the OTC
thing as I wasn’t getting paid for it, ...? doing that. Fluconazole nasal spray..
C: Sorry, I interrupt you here, how about the definitions of minor ailments as listed in the
formulary? Do they cover the ailments you see everyday?
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M1: Pretty well, pretty much, there’s not enough choice of products in there I would see but
there is.., the groupings is OK.
C: Could you shade more light on that. How is there not enough choices relating to the
products?
F1: Well, the formulary is just there as a guide ‘because you can prescribe any P or GSL
medicine, almost everything, except the blacklisted….
F2: More Patient Group Directions for… em.., Naproxen (laugh by F1).., Naproxen or in
fluconazole. I mean why we given Diflucan if we give ..., when we can give Fluconazole generic
reduced price. So the Patient Group Directions for some of these products over acyclovir
another ones. So, you that there are lots of products that have Patients Group Directions where
we could give the generic version and save the Health board some money. But you’ve got to
prescribe the branded product.
M3: that’s what the GPs have been, bashed overhead for prescriptions…for seventy percent
generic prescribing rate . It’s the target they have to reach.
M1: The thing is that we don’t have PGDs, of course we cant give the POM version, which,
which is, which is what the problem.. You are talking round the samples because you have to,
somebody have to write the PGDs. That means saves money for the long term ... long term
because we ... supply
F2: Things like Canesten, as I mentioned early, ...right pack because you’ve got POM pack and P
pack, identical. I’m not always convinced (Laughs) … lots and lots of people…I’ve given the
POM pack you know,
F1: but its just, its just paperwork, patients getting the treatment as needed. Its purely the
endorsement, endorsement, the computer system and things, if you are handwriting you are all
right. (Laughs)
F2: But then do they pay attention to your endorsement?
F1: Yeah
F2: Are you sure?
F1: Yeah
F2: I don’t think they do.
F1: I’ve got picked up……..for something not allowed
C: Earlier we discussed that in some occasions cost actually is a factor, where you cant supply
the product you wanted to because patients cant afford it. Is e-MAS helping you in that context?
F1: me, yes (agreed by all), mine is a quite deprived area, so yeah..
M3: It also makes it quite prone to abuse (agreed by all) but I’ve been quite delighted when I can
actually……, to help people feel all right remedy ... conditions to what you’re already looking
for ‘cause that helps me further.
M2: In the case of e-MAS, all these worried well and parents…,sort of all bloody shopping list
(Laughs). That’s difficult…
M1: That might’ve been due to the fact that the surgeries are closed on Saturdays ‘cause quite a
lot of e-MAS in my case comes in on Saturdays for acute things because they have occurred on
Saturdays and either patient decided to come to pharmacy first although we referred to NHS 24
who recommended going into the…...
F2: Annoying thing is, they come in to the pharmacies, can have something and you start
questioning about and discover that NHS 24 have referred them and that really irritates me.
Because, in some cases telling me what I’ve, what I’ve got to prescribe (agreed by others) by
NHS 24 and that one is very irritating.
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M1: I don’t know that’s, that’s, the thing what they are calling and saying…..
F2: NHS 24 probably have told them to go to the pharmacy and get something from e-MAS.
M1:I have worked I have worked on the couple of occasions on the, on the, outlines of the NHS
24 lines in each of the three (smiles from everybody) as an adviser , I walked the floor of each of
the NHS 24 centres and never heard actually anybody say, go to, go to pharmacy and ask for
advice and see if he could help…..
F2: These people come in and say they are told to get such and such but that means, I mean….
M1: Well, I mean as I see, nobody ever says that but.., em….., what people come in and say to
you is that, somebody saying, somebody actually saying, may be, may be two different things
and that, as I said, they’re quite good at referring and, and what they do, problem is for right
supply as they don’t think NHS 24 knows what ... emergency supply prescriptions and that
their definitions might not be the same So, em…..
C: So, are there any support you would like to see in relation to e-MAS in the future? Anything,
any support information related?
F2: Clarification to the doctors that they see patients they prescribe and not send them over to
the pharmacy.
M1: particular problems with products we can only sell them on specific situation. Say,
hydrocortisone, for, not for a face relief, for example. Doctors send them down leaving,
Hydrocortisone can either be prescribed by us or sold by us under the same term as we can. We
kind of find that quite difficult, it’s quite difficult to refuse as well to be honest.
M2: Also be nice if the formulary let us do just generic (agreed by others), dispensing, that
would be nice.
F1: yes, that would be, that would be a big help actually. Generic dispensing for the minor
ailments formulary, yeah..
M1: But also I mean, how do we feed in, can we feed into the, the government bodies for what
we would like to see in formulary.
F1: Yes, that’s why they are doing that.
C: How would generic prescribing through e-MAS would help you?
M1: No, no, I am saying the, what I think OK, got Chloramphenicol or Fucithalmic can we
prescribe that? How, who do we I take that to, to as a suggestion? Definitely, expand the
formulary. Yes, I think, hold on well this would be useful, I would, just, just on top of my head
but…
M2: something to expand the formulary
F1: more PGDs to use POMs
M1: But yeh, how, belong to, its, its national?
F2: Because it’s a local formulary, a local group working on a formulary in ***(Name of a place)
because we have new formulary coming out.
M1: But its now gone national, so I mean, is there any way we should be sort of saying to
national …….
F2: I mean why do we have the national formulary and the local formulary, can we not just have
one?
M1: Ya, interesting, when you say information feedback, information service division Scotland,
so we are actually talking Scotland. Here its now Scottish system and but, why do we need local
formularies (agreed by others) and why then, say, how dare do you get hold of people to say,
we think this should be in the formulary now. Its, the formulary is out of date. There are things
we don’t agree with.., the things being there under…,things with.., I’m not saying that’s a
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wholesale thing, we want to make wholesale changes to the formulary but formulary is
designed as products on the market, now when, the products is being released…..now…..
F1: There’s a lot of products that are available an allowed on e-MAS that are not in the
formulary (agreed by M1). In fact, I don’t pay even much attention to the formulary any more. If
it just says its allowed, then do it and I…
M1: So they go to your pharmacy and they come to mine, say...,my my husband got from *****’s
and …
F1: I found the formulary quite restricting, cause the things that I recommend fairly regularly
weren’t in the formulary. So, how do you get things put in the formulary or makes the
formulary much bigger and better and then, and then ban everything else…. (smiles)
M1: Oh, just haven’t I thought really is, that’s, its be
(Loss of transcripts as people speaking on top of each other).
C: Ok, lets get into another area of information supp, support related to e-MAS. As we know
this is electronically managed, managed system, every performance relating to e-MAS is
recorded in Edinburgh. So its possible to give you feedback relating to how e-MAs is
performing in your shop and how products are being dispensed. Are there any areas where
you’d like to see those data feedback given back to you in the future relating to e-MAs?
F1: This is like the SPA data, the doctors get back from the prescribing, is that right? So you
wondering if we’re interested in getting the information like how much it has cost or things like
that?
C: Any, any information you can think of.
F2: Do not get at least in a month or we used to get least in a month what the cost was…of the
things what we supplied, what cost was in a month. I don’t know... from prescription
pricing…..
M3: may be because you were one of the pilots (smiles).
F2: No, …...
F1: How many things you prescribed that , how may times you prescribed ? (this participant
asking question to F2 to make sure)
F2: I told you a list of everything what we are prescribing. What the total cost, I mean, the total
cost of as paid is (loss of data) 100 pounds or something like that.
F1: Its interesting because its just not a lot of money.
F2: We used to get that but I don’t think we get it now.
C: Yes, can you think of any areas you would like, you think would be helpful to look at the
picture of how e-MAS is performing?
F1: Total number of items we’ve dispensed, I suppose I can count the labels, but it’d be
interesting to get back, what, what we’ve done previous months.
F2: …What we are prescribing…. Just what we’ve actually prescribed in preceding months, and
what was…, may be, may be more feedback (Loss of data)
M1: If it would be just by BNF groupings, perhaps, I wouldn’t say every single line but as I said,
X number of histamines or X analgesics,
F2: And may be a trend overall what’s been prescribed, would that be helpful? From all, all the
pharmacies in ***(Name of a place)s, in different lines, I don’t knowing ……,
F1: They are collecting that already I would think, for what we’ve prescribed , from somebody,
some place and why is …..
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F2: It would make nice, to see how we compare to other people,
F1: Ah, business, that’s private,
F2: I know, not individually, I mean as a comparison to ***(Name of a place), all the……..
F1: And then you’ll see how the head lice are fleeing at the door, because the e-MASes….
C: Interesting, why would you like to see, compare with other people, how does that help your
practice or decision making?
F2: I just like to be nosy and (laugh from everbody). Know whats happening in the world. Well,
may be I’m quite insular when they gave me some restricted formulary and we all might think
oh, thought using that particular product and information (by M2), yes ‘cause I do restrict the
availability of the limited number of products.
C: So, looking into what peers are doing (yes by F1 and F2), does that help you making future
decision making? *****,
M3: May be interesting in public health capacity, to see if there any particular spikes in any
particular areas of geographical region, any problems and….. To me, to me as a pharmacist,
dealing with what’s coming in your door at that particular time, so it may be more strategic
level interesting . But just from, perhaps to see, may be open eyes a little, (smiles), to look at
other options, perhaps, wonder why there’s, I’m prescribing so much of a particular item.
Ya, may be useful, especially, evidence based changes perhaps ……… allowed.
M1: It’d be interesting to know if its, if it’s saving any money. Because the whole idea was to
save doctor’s surgery time. Has it actually happened? Has the waiting time decreased, to be
seen by doctors, has gone down, for, for minor ailments? And if it has and is saving money, and
I’m not saying this because I am one from multiple but are we going to more loaded onto us
simply to save doctor’s and it’s unfair its working at the moment.
F1: It’s not fair, no, no. You know, they pay for the dispensing fees and they pay for the cost of
the drugs and the number of people on your list.
F2: Not, certainly not, both the number of patients that is following, because a lot of these
people has been in my list since day one are now off the list... The, the initial people in my list
have been on it for seven years. A lot of them, some of them have moved away, no longer
around but they are certainly not paying or not using the service and …
M2: But then you have got loads of them every second day and you give something on the
minor ailments and you’re getting paid for the cost of the drugs and not for the hassles it is
causing.
M1: But that’s what I was coming to….. really, if, if I’m doing doctor’s role he is getting paid.
That’s why I see in… once a month or once in ten years (agreed by other participants), its, its,
still, its better for the patient to be honest and I don’t see why someone who registered and
haven’t moved to, to somewhere else which is fair enough to go to another doctors, re-register
and then ...? Can’t stay on and then, by the time, I’m still available to write prescription for that
patient. And then I’ve to re-register them if they disappeared if there’s, well, renew their
registration.
F2: If you are talking about registration with e-pharmacy, then, just, in general, you go to that
pharmacy for everything you do at the doctor’s.
M1: And that, may get this with the chronic, chronic medications being computerized (agreed
by F1).
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F2: As I just said, people who are registered with me, they may get prescription with you. But
that, they don’t realize that they can take their e-MAS to…, stop coming to me for their e-MAS,
things like that.
M1: They change it round, change it round (smiles from everybody), somebody’s rota but
somebody re-registered with me simply because I was the only one…, on the Sunday rota.
You’ve got to keep coming to me-you can’t keep jumping backwards and forwards.
F2: you can’t.
C: Are there any trends of data you’d like to see relating to product supply in specific?
F1: Specific to your individual….business?
C: yes, individual… business, your practice, your pharmacy or you as a pharmacist?
M1: I’m quite happy, that sort of…….. measures the number which we are in much control of
and…to be honest.
M3: I’ll be little bit worried about, one, one angle of, of, of having this. Now working for
multiple…, this may or may not happen but if…, put on e-MAS further up the chain, so, well
you, you have to achieve X numbers products, products in this category you supply in given
period of time. Why you are not doing ‘cause there are so many folk registered, you’re, you’re
below, below the national average or something like that.
F1: …..Head office using the information of the individual pharmacists for their prescribing. The
information that we get back from what we are prescribing would be used by some head office
some place, rather than each individual pharmacist who is doing it. Somebody else looking at it
may be thinking, as you said, oh, it looks so many people registered...? so many scraps. ‘Cause
(smiles)
C: If that information be provided to you in confidence, would, would that be better rather than
your company or boss, say…?
F1: It could be actually, ‘cause you get locums or relief, because they should sign on the minor
ailments, you have to put registration under it, so doesn’t matter which branch or whatever you
are, may be collate that for each individual person so you can see what you’ve been prescribing.
But you already know what you have been prescribing, so…,
M1: I don’t think that’s of any benefit (agreed by F1) because if you are prescribing ethically,
anyway, then the price shouldn’t be an issue. The number of items shouldn’t either be, and I’m
prescribing something because its necessary not…
F1: a list of disallowed items, ‘cause when I get the old ones back, and when I came in the shop
and when I see its coming back but a locum or a relief person say what they’ll do wouldn’t see
that
M3: That, that’d be interesting.
F2: community pharmacy, not just something …
M3: there seems to be a little bit…
(Overlapped conversation)
F2: I’m sure its not the only…
C: Mr *****, you own the shop and are there any business, may be data of any business interests
you would like to see, e-MAS performance from you shop?
M2: Because, I am just a sale trader, I would like to see what the, analysis of, for example, the
group is, the area, ***(Name of a place), and then, see mine, little bit (smiles), as that, oh, is that
what… oh…just what you said ...perhaps, I am actually more closely, this allergy question,
because there’s so much of that being prescribed over the whole area, what am I doing wrong?
or am I right. Or I may come to the conclusion we haven’t got this particular problems, so am I
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doing anything wrong? It would be nice to, to, to see region wide analysis and that of specific
shop analysis and the two could be laid, literally one on top of the other. Gives you some clues
…. (agreed by one of the female participants which seems to change her position).
M3: We could even see, em.., if there’s a new pharmacy, for, say, the staffs weren’t automatically
picking up, this should be an e-MAS referral rather than, turning straight to the counter…
M2: But unfortunately, have colleagues here…but.., problem of head office (This participant is
from independent pharmacy), may be, em..., misuse this information (agreed by one female
participant). Therefore have to specifically addressed to the pharmacist, so they don’t go to the
head office, only to the Practioner.
C: Right, Will it be interesting to see such data, I mean when changes happen, for example when
you think that Simvastatin is not doing well in my shop. Would you like to see what others are
doing?
M2: Yes,
C: Are there any individual products you can think of, getting feedback in the future about how
is it performing in your shop relating to any specific product supply?
M2: Well, just of interest, if you’re saying that, that, to expand the thing, I would like to see what
happens generally region wide to, em…, UTI products. Trimethoprim (called by F1), Exactly,
this is what I was trying to get out.
C: So, I’ve some data from e-MAS generated recently, not very recently but last year (smiles
from participants) from e-MAS warehouse which will be hopefully, be given back to you in the
near future. I’ll show you some slides and graphs and we can discuss further things about what
might be interesting to look at or get information feedback in the future.
***(Note taker), would you like to ask anything in the mean time I log on this computer?
N: Not really, I’d like to make comment on something we spoke about earlier. Em..just, ‘cause
had a situation recently which happened to a doctor, who went to GP and was told she had a
psoriasis and told she should go to her pharmacy and ask for hydrocortisone because you work
in a pharmacy and I, I said, is that the best thing to do? And he said, well, if you go in and tell
her, tell them, its for your doctor who has got which is for psoriasis, they wont give it to you
and I thought that was really interesting because for me, that just highlighted a lack of
communication, not well acknowledged from GP but also the lack of communications between
the two disciplines.
F1: The GPs don’t realise that we’re restricted to the license whereas they can prescribe
whatever they want.
C: So these are few of the slides from e-MAS. Can you see *****, Yes? Em, this is the number of
patients registered during this period, July 2006 to June 2007 from e-MAS. So each bar actually
represents different health boards. So as we’re saying earlier, ***(Name of a place) is T,
F1: This is percentage of the population, is this not?
C: Ya, percentage of the population eligible to register e-MAS.
F2: Ayrshire and Arran has got a bigger population than ***(Name of a place), it is ….
M1: They were on the test as well, so there….. Percentage of the population.
F2: I think, it’s more ……highly populated.
M3: The pharmacies are bigger, greater coverage, ‘cause the Arbraoth and Forfar?
F1: So, the number of patients registered for e-MAS in Scotland and then registrations, what’s?...
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(This shows difficulty of interpreting the graphs as designed, multiple questions about the first
graph)
M1: As a percentage,
F1: Percentage of what?
C: Eligible, eligible patients.
F1: So, the number of the eligible, patients, there’s only, in the best, there’s only quarter of them
who are actually registered. There’s a lot of people out there where they don’t have a….. Yes,
that’s interesting to the government and the health board, but that’s not interesting to the
individual community pharmacist. (This participant is talking about the slide showing number
of people registered on e-MAS).
F2: It is really, ‘because you can register a few more. (Conflict between the participants)
M1: only thing, is of course is…….
F1: The health boards only have to…Its up to them ‘cause they don’t like to advertise..
F2: Ya…but there’s some concern and you know that eligible to join, you could may be ……
F1: Well, I still think that the health boards are the ones that should be really interested in these
figures but not individuals… . These figures are not on individual basis. (expressed views
before second slide was shown).
(Loss of transcript due to too many speaking at a time)
M1: But its also, I mean, since it is only two people that are entitled to free prescription, so, then
its not a true……, ‘cause obviously the richer areas of the country, the poorer areas of the
country, obviously, em… people pay for their prescriptions and they cant register for e-MAS.
So, therefore, I don’t understand…
F1: That’s the percentage of eligible population. So….
M1: Number of patients registered, is it?
F1: Number of, percentage of eligible people.
M1: So, registration, sorry I am just taking it as a, sorry is its only the people who don’t pay for
the prescription or…? (Agreed by the moderator). So, that’s the fact that there is no skewing
because of it.
C: so, would you to, this to be broken down into individual pharmacies, further? When each bar
would represent….?
F1: No, that’s very sensitive. If you get that, that’s very sensitive if you break it down into
individual pharmacies and show it to everybody...
F2: I don’t think they could do it for individual pharmacy, cause you will know….
F1: They can do it..they can get the statistics and do it but is it the right thing to get out to
everybody? That’s quite sensitive information when you…
F2: But then, when you have how many eligible patients, in ***(Name of a place) to join e-MAS
because some will go to *****’s, some will come to me, some will go to the other pharmacies, and
we have other people who don’t get prescriptions at all.
F1: But you’re gonna way to show the number of eligible people registered at each pharmacy?
C: No, not, I don’t have that, it will be there if you ask for, so…..
M3: If you, if you’re to receive to your pharmacy solely, the number of patients registered
compared to the mean…
F1: Ya, that would be all right.
F2: the number of people that were registered against the number of “could be registered” per
pharmacy
M3: But, that would just be a sniff of information, but it wouldn’t, it wouldn’t be for practical
use other than say, oh right, I’m doing right, I’m doing badly. You’d, probably be, just to see,
whether or not, although the mean is well, you’re above the mean, you’re still miles off for what
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you should really be for, in terms of national. It might, ya, suppose… I don’t , I don’t know the
depth of…..
C: So, this is the total number of items dispensed during that period in Scotland, this is the
pooled data for Scotland. And, this is the top ten items dispensed through e-MAS during that
period. So, are these, these sort of data interesting to see, to compare whether your shop…?
M2: Yes, interesting
F1: ya, this one is particularly interesting
(Laugh from M3)
I mean you could tell them that what’s your most popular items, paracetamol, ibuprofen, head
lice treatment, we already know that, we know what we are prescribing. Its interesting, but its
not something I would need to look at. You’re trying to cut down...
M1: If you ask me is that right then top ten, I would have got most of it…..
M3: That, that, that’d would be something, em..almost….. annual basis, that’d would be nice to
see….I don’t, I don’t need to be informed up to date . Your practice, don’t think changes
dramatically over short space of time.
F1: Yes, probably once a year or something.
C: And this is the gross ingredient cost of the items
F1: No interest at all, not bothered. (this is about the GIC graph) Smiles from other participants.
C: So, this is again comparing each health board with Scottish average, the items dispensed per
thousand MAS registrations.
F1: That’s interesting, isn’t it, ***(Name of a place), where ….along there..
(Silence)
M1: going over the average, you know, is that the average, dotted..?
C: Yes, the dotted is the Scottish average. This is the items dispensed per thousand MAS
registrations.
F1: So, we all are doing the same amount of work.
(Participants analysing the graphs keenly)
C: If instead, this, your shop’s data is compared with the Scottish average, how that data be
useful to you?
F2: Not very much,
M1: Not very much, the Scottish average, ‘cause, ‘cause, looking at some of the ones up there,
can’t understand why Border and Fife would be substantially less than ***(Name of a place) or
em… Dumfries and Galloway, for example, it seems to...
M3: Going at a tangent but I remember, when it was rolled out in Fife, it was just a huge push to
register and very little in terms of follow up. Now you’re registered when going to do
something, and don’t know what the colleague, em…….. is interested…. He has a , had a huge
drop off because most people simply registered on the, in June, July something and then they
thought...
M1: It seems to me, just looking there, why in certain parts of the country, they could do with a
push (advertising by M3), advertising in December. So they can’t really, don’t, the actual, if they
don’t work in those parts of the country, it really wouldn’t be
M3: It wouldn’t be for any help……
F1: So, the number of items dispensed per every thousand registrations, so that tells you sort of
how much work you are doing, So its just sort of….
M3: how many active people you have
F1:That, that’s because I was always thinking about Fife. They probably have thousands and
thousands people registered but they probably are doing the same amount of work as us. But,
because its per thousand, it shows you that they’re low but they are not actually doing the same
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amount of work as us. But they have far more, far more, thousands people registered. (agreed
by M3)
M3: That’s true, ya,
M1: you know, in ***(Name of a place) , the percentage…, the two spins back, then, em.. Fife…
isn’t it
(Participants trying to understand the slides, Laugh)
(Laughter from all participants)
F1: These things are all interesting, ya.
M1: Ayrshire and Arran and ***(Name of a place) is one and two, isn’t it?, in terms of number of
people registered. So, why is, why is ***(Name of a place)
M3: ..Quite large multiples….., thy might be quite interested to see that.
F2: Because ***(Name of a place) have got quite restrictive ……..
F1: These kinds of figures are interesting to health board, health board level.
M2: Other thing, and..,that, that, number of items per thousand registration, six hundred seems
to be an awful lot
M3: Six hundred items per thousand registrations?
F1: Ya,
F2: That’s ……more than half of the registered, isn’t it…..
C: So, in average, one patient was supplied with one product during this nine months which is
………….
C: So, this is e-MAS data for an individual shop which we were discussing earlier. So, this is the
number of items dispensed as per BNF chapters.
So, this shows the skin preparations, sorry..
F1: Oh yes, chapter in BNF
C: yes,
F1: Right, and the different colours are …
C: Ya, the top colour, the top number of items dispensed in this chart is skin preparations, I
think. So, this sort of data can be possibly generated from your shop and given back to you.
(Long silence)
So will this be something helpful or alerting or useful in any way?
M3: Well, the only two ways you could see that it should be for over a long period of time to see
a trend. So, perhaps over a short period of time, ... formats of the ...? target to, to increase your,
your work effort into promoting your, …….thinking about head lice or something similar, that
would be a big push towards…. Promoting antihistamine use, trying to think some drugs….,
and then, then quantify how much that effort was rewarded with how many prescriptions you
received, getting close to business targets. Money… ya, you could, you could review your
performance, you could review your individual pharmacy’s performance how it is done but…
F1: So, they’ve got ear at the bottom, is that ear and they have put the number of items
dispensed in whichever part of BNF and so that…. I don’t know which one is which (shows
difficult in interpreting the data as is shown in the slides F1 discussing with M1).
M1: I think, in terms of estimating work load might be useful, in terms of negotiating with my
boss to say I need more staff to … (Smile from all participants). I’ve actually got evidence here,
how much the work load of e-MAS is. In terms of actually anything else, its probably store of
items what I would hope I would know anyway (agreed by F1). Em…again, see, looking at
it……
F1: Things like that might be useful for the health board if they, kind of …, public health
campaign on, such and such.., if there were something we could do on minor ailments to help
that public health.., then they could then look at that and see for individual groups but… for
individual pharmacist, I don’t see, not much interesting (smiles).
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M1: And again as I said, we want to prove how much we are saving the country’s money by
doing this, instead of going to the doctors’. That sort of data is interesting.
F1: how much you saved on an individual GP’s cost by seeing so many of their patients, cause
they’re registered at that practice.
F2: How many patients that come in to see us would actually have gone to GP in the first place
and how many still we’ve got in each….
M1: That’s, that’s an interesting question. Do we have the data to say how many head lice
they’ve got in a surgery? Cause, that, that sort of converse data you’ve got there, are we writing
new scripts or are we writing scripts that the doctors or practice nurses would have been
responsible for writing. Therefore we are saving the country money, because we’re doing it
cheaper than the cost of a doctor. Doctor’s consultation been cheaper than our time….
F1: Why we’re doing it cheaper? Because we are mugs.
C: So, means linking GP data with e-MAS?
M1: Yes trying to tie the two up, because in isolation, it doesn’t mean actually anything, I don’t
think.
M3: I’m sure, it would be perfect either way ‘because we, we will have some new patients which
have never gone to the GP practice for that condition before and…. So,
M1: yes, or he couldn’t, he couldn’t do, couldn’t get an appointment for that…
M3: yes, it could be.
M1: This information might be useful to the people who negotiate the contracts for..., the
chemists contractors bodies because it can prove, the, the workload that has been, we’re taking
on, as I said, the doctors used to take them. And, what we should be paid for it. As, on an
individual basis, probably I wouldn’t say, not to me personally,
F2: Ya, probably interesting, but I don’t think it’ll be of much use.
F1: Exactly, interesting but not of much use.
M1: I mean, I don’t mind being sort of more available on the……., I don’t mind you know what
I am doing, quite well censored (smiles quite happy to send a few more troubles someone
around you. (Smiles). But, em…., I, I don’t think it’ll be much, unless you going to change the
practice by having the data available, as I see, that would change ….
F1: I mean, GPs have a lot information they get feedback from prescriptions but they then have
targets to reach so many seventy year, seventy years olds with whatever conditions to protect
them from heart problems and in the long term it’s saving NHS loads of money, hospital beds
and whatever. You know minor ailments, the little irritating things, nothing as big as the low
cost things. And I think , really the most I would be interested in it is, how much times are we
saving the GPs in a particular practice, we are saving a lot more time for the anothers, who
we’re helping the best to make my time valuable because we’re getting paid c**p for it basically
(smiles).
And I think, that, that would be more interesting to me to find about the GP practice who we
are working better with, which of their patients…
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M1:…….what ***** said comes to me as a pharmacist, fine I can choose to read it or, or, not read
it or pick the buttons out of what I want to read. I wouldn’t want to go into the management of
the company who would then be comparing me with next branch, branch of.. I don’t, I don’t
mind being compared to colleagues who is in the same street. But, I don’t want to be compared,
I don’t want to be compared to Montrose or Forfar where, two totally different communities but
they could be the next branches I’d probably be compared to. Forfar doing this or, em…. or
they might be compared to me if I was better than that. I don’t think that’s a, a fair comparison
to make. But that’d be either…….
F2: …they could judge you based on how good you are on those figures. You are prescribing for
what you have need to prescribe for whereas somebody else might be prescribing, you know,
because they want to get the figures up or something. Whereas, you are prescribing
professionally and…I think you’ve got your professional conscience you’re prescribing, what
you should be prescribing, you’re doing it appropriately, you know just to see the Joe Bloggs up
the road just given any old drugs somebody comes in and asks for (agreed by other
participants).
F1: They come with shopping list and …
M1: even, even within the same company, (F2:you cant compare, I don’t think) but I mean, ah..,
as I said, you’re trying to ... the bosses ... (Smiles)
(Loss of transcripts due to too many speaking at a time)
C: So, are there any interesting things in terms of patient outcomes, for example whether your
advice or referral did work, were the diagnosis same from the GPs, linking…. (The moderator
actually meant to ask do you want to see these sorts of data but its articulated it in the way are
there any currently? my mistake)
M1: Are there any of that.
F1: Very rarely…
F2: I think, occasionally, somebody come back and say- that product you sold me is so good
(smiles)
F1: that stuff you gave me on e-MAS really worked for me…..what was that? Can you
remember?
(Loss of data as many participants speaking at a time)
M2: The product…. this morning, no they said they were c***p…(Laughs)
M3: Suppose, we might have some benefit, you may, may see more with…, single pharmacist,
single GP practice, one small town without any influence from pharmacies, fifteen, twenty miles
away…
F1: Twenty different, yeah…health centres
M3: Yeah, but if you’re in a centre of the town, very difficult to ..., because if they, even if they
had a prescription,…., the only way, normally you can check is either by sheer luck by the
patient coming back to prescription or perhaps telling you, they, they go somewhere else, you
see….
M1: The only feedback you get is very good or very bad. (Agreed by all participants)
F1: That’s right, yes.
F1: if there is something allergic reaction, they come back and tell you and if it wont when the
previous, the doctor previously hadn’t prescribed, that hadn’t worked, they come back and ,oh,
it’s a…, my experience since…, only…
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M3: There would be benefit having a means of the GP seeing what you have done, em, with the
piece of paper or with, with, sorts of access to an electronic records to see, to see what the
pharmacist has prescribed already, the two connect….
M2: That would be great idea, that’s what you were saying about…, having access to records….
M1: Two way access, yeah..., they need to know what we are, we’re doing just now as……
F1: That’d soon be ...? with e-MAS. Patient will go out into the same day and then appear at
doctor’s surgery what we’ve been doing.
F2: You think so?
F1: Oh, big brother is watching us (Laughs)
(Loss of transcript due to too many people speaking at a time)
C: So, yeah, this is the data from the same shop, em, the individual preparations broken down
for individual preparations. No we can see the anti-infective items have shown the most….., in
these four quarters.
So, these sorts of data GPs are getting, more used to of it, I mean...,to encourage generic
prescribing as well as to see whether they are sticking to guidelines. And also when changes
happen in guidelines or legislations and things.
So, for example, this is a compliance, percentage compliance, graph, bar graph of GPs. This is a
threshold, so we can see some GP contractors are yet to achieve the target while some of them
are well beyond the target. So, I mean, each bar represents different GP contractors.
So, what do you think, in which forms would you like these data, if to be provided to you
would be most beneficial or most easier to interpret and
M3: That, that would be useful.
F2: Well, that’s right, to find out what we’ve been prescribing…,
(Well the participants change their views here after being shown that the GPs are utilizing these
data a lot, before they were saying we know what we prescribe)
F1: We don’t stick to the formulary because the, the national formulary, is different from the
local one. (Agreed by M3). So, compliance with the national formulary is what we’ll get back I
would think.
M3: Oh yeah, absolutely, exactly, its not, its not standardized enough..
F1: I mean did we, did we make the formulary bigger and scrap everything else and just allow
the things on this formulary, allowed in the minor ailments, which, I think is a great idea
because it would restrict a whole lot of things but as it stands just now with all these P and
GSLs…
F2: I think… the… national formulary which is, more usable and, and everybody used the same
formulary.
F1: But, then, that could be quite interesting. But then, you wouldn’t be not allowed to do it with
formulary because you’re only to prescribe the things on the list…
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C: Physically, what way would you like these information to be provided to you, electronically,
paper or in training, as a training material or CPD material?
F1: Four of us here will say paper and one will say computer (Laugh from other participants).
This is the age gap…
M3: Its very very easy to press delete, and specially if great deal of electronic information
afterwards... going over the bins….
F1: They’re trying to get away from the paper. I’ve had a argument at other meetings and
they’re trying to get away from the paper based, electronics is the way is the way to go, we
should be going into electronic messages and checking on your, on your e-MAS on your, your
computers, checking you registrations, may be go in and check some kind of statistics…that
are..Its just going to be, if it just would be some kind of annual thing that you know analysis and
it …I’m not interested in monthly, just looking it too frequently, but may be once a year or once
every six months. A paper thing coming through, then, then I would open it and you could take
it home, you never look at it. Its just a time, time consuming, you want to analyse these type of
things, you need time to look at
M1: No, I would, I would go for computers. See, I wouldn’t …..
F1: I wouldn’t think you were a computer man
M1: Oh yes, yes, its just….I could just press the start button and scroll the mouse
(Loss of transcription due to too many people speaking at a time)
M1: (talks about NHS.net) So, I mean, the IT has got to travel on a pace
(Loss of transcript due to too many people speaking at a time)
F2: I was just wondering how electronic transfer of prescriptions, obviously you can do that….
M1: And, and, and, and.., yes, I’ve got, because I was a prescriber, I have actually at home NHS
net. So, actually I can use from a home PC, NHS net address. But I cant, I can’t use it at work.
C: So, would graphs be more helpful or texts, numbers?
M1: I think bar charts or graphs (Agreed by all)
M3: Yes
F1: yes, visual
C: I mean, in real situation, when you are in shop, would you have time to interpret all these
data and you know, look at it? What would be the best way to deliver it, so that you …
M2: As, for the graphs ... good... axis is, no, its not difficult to, understand but fundamentally, if
its graphically produced. Whereas if it is text, I don’t think……,when you read it again, different
story in your mind. I think its got to be graphical.
M1: I think, its got to be graphical
M3: But the head lice stuff, she really want to know more. I’m sure if they wanted to produce
graph, they could, information services, then produce ... raw data
M1: Cutting back on computer if you like to..
C: Yeah, one last question, we are nearly end of the discussion. How do you perceive change in
general em..., in your practice?
M1: Right, Ok the, with, sorry I’ll go first. Em..., I think the difficulty, may be in the future is the
services have been cut, funds are going out much more localized. So its been costed locally. So,
***(Name of a place) health board is getting …ah, a pool of money. Some of that is going to
Angus, some of that is going to ***(Name of a place) and Kinross, some of that is going to
***(Name of a place). Within those areas, even the same schemes that are coming out or not
coming out identical myself as a pharmacist to travel across borders, I can dispense, I’ve got,
don’t know if you gave up baby scheme, its different in Angus from what is it in ***(Name of a
place). And in Angus, the ID you require is different from ***(Name of a place). In ***(Name of a
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place) you need Scottish, or a ***(Name of a place) local ID card. In Angus, you just need
photographic proof. And I can supply the morning after pills, in anywhere in Angus, because
done the training scheme that covers Angus, but can’t in Fife because you have to be, registered,
you’ve done the fife training which is, there are slightly different age groups so, whether its free
or not to supply to children under the age of 16 is different. And I’ve got a concern that people
start moving, may working on Grampian on Saturday and they go working in Fife next month.
Just, just odd day here and there, (F1:you got to sign all these PGDs) but I can’t, I can’t, I can’t
possibly be signed to all these different PGDs and always very good that local means of being
addressed of, specific example Chlamydia testing because ***(Name of a place) has particularly
problem of teenage pregnancies and it’s, it’s an issue. But the, the funds available locally for
them to decide how to spend it but it does make it quite difficult for us if we got local
formularies all over the place and if Angus is doing one thing and even within ***(Name of a
place) we’ve got three different CHPs doing three totally different, em…, things. So, em…, I’ve
concerns about sort of going from (C: one place to…), well, again, even within Britain now, we
have the English doing MURs, Scotland doesn’t. We’ve got minor ailments and urgent supply
PGDs, they don’t, we are charging five pounds they are charging £7.10 or the exemption rates,
may be good, may be not but it doesn’t mean that we’re having pharmacists who move across
areas totally, it may be minor differences between areas and countries in the past. There is now
scope from massive differences between as to what we can supply what we can’t, how you
supply, will we be paid for it?
C: *****, how do you perceive change in general, do you welcome or….?
F1: Oh yeah, I welcome change in general if its gonna be advantageous for us. I don’t like these
excess paper working things. At the moment, we have this smoking cessation programme and
has gone on to the computer and I don’t know if you guys have got loaded on your computer?
Now the people in NHS ***(Name of a place) can log you in into, em.., even open clinics, just
people just can come in and book people into it. I don’t like extra paperwor... why does I have to
book in for sometime. In some clinics, some ...which to me is just a pain in the b*** and excess
computer garbage for me to look at ... thing and that
We can go into say have had a heart attack in ***(Name of a place) smoking cessation
programmes up in your area, where do you live, you know... you know, every Thursday. And
they done it and I don’t even go and look at it personally. So the things change is good if there’s
an advantage but change sometimes is just extra paper work for statistics and such things like
that.
C: Mr *****,
M2: ……For, to, the, em…, list of products been expanded we can use on e-MAS. What from
my… has been good and switch from POM to have been adequate but Trimethoprim, I ‘m really
looking forward to, a lot and ya, I think, its and its going to get better.
C: *****,
F2: Em…., well quite like change but I sometimes feel that, feel that, actually a lot of different
things is happening in different areas and particularly, these locums are coming out and you’re
not sure who is signed up for what and which, what each person can do. And I think,
sometimes people don’t realize what they can do and what they can’t do and do their own
things sometimes…. And I’m quite for change, but I do find that there’s lot happening, its quite
fast and furious and I think in a busy working day when you’re, you’re particularly busy, you
don’t always have time to absorb it. In that day, at the moment, right I’ll need to do, what’s the
things then,…. So there’s a lot happening that, we, we’ve to understand and put into practice for
the staffs to make sure that they’re all understanding what’s happening. So, I think all these
things are done in our own time when you are very busy.
F1: Please don’t choose the minor ailments service for quite a wee while, acute medication, the
electronic thing, the
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M3: Right, yeah, …generally change, I am quite happy to, it’s the, it doesn’t, it doesn’t upset me
too much. Occasionally found, especially when there is excess bureaucracy or this, em.., or
agreed to put it in a great deal of work trying to achieve the minimum amount of work required
to meet the change. And, when I feel, does ... sometimes doing embarrassing trying to tackle
something……,but I don’t… I do like inform ... NHS, that I have achieved this and that I shall
send the performa ... At at least appreciate the targets to enforce.., got to get this done by certain
point…. . em..,and tick, that’s done, but probably wont be quite. I will get round to it eventually.
I do need to prodding with a stick from time to time to
But its all coordinated through NHS Scotland or so, ... it has to be done and that’s the only
people that are going to annoy you about change and
M1: Perhaps, so it could be, em.., super pharmacies, not super-pharmacies, who do every single,
not the ...super-pharmacies as we are here just now, em…., I’m thinking about the pharmacies
that will have walk in clinics, the big pharmacies have got walk in clinics, neo-vaccinations
(agreed by F1), they’ve been doing EHC, Chlamydia testing, they’ve been ...? Some in the
middle are doing bit ..., somebody in there are purely, simply dispensing.
F1: and I believe that we’re tryin’ introduce some kind of enhanced Methadone service as well,
so, like the community pharmacies…, I mean the key workers, there is a lot……,
M1: so, is there a source that we have to take on of these changes things? Honestly, honestly, the
single pharmacist, without the complete ... prescribing, vaccination,
(Loss of data due to too may people speaking at a time)
F2: I struggled with one pharmacist... I’m on own
M1: And that’s not including those that are doing nursing home, MDS or compliances
dispensing, so
(Participants laughing, Loss of transcripts due to too many people talking at a time)
C: Ok, we’re into 90 minutes. Thank you very much for the discussion and I would like to turn
off the recorder now.
(Participants in good mood, still amusing among themselves).
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Title Exploring community pharmacists’ decision-making relating to new non-
prescription medicines
Background Community pharmacies are among the key providers of health care services
to members of the general public. In the UK, new community pharmacy
services are being introduced alongside revised contractual frameworks. New
non-prescription medicine services, which constitute a large proportion of
these changes, are aimed at increasing the role of the community pharmacist
in patient care, encouraging self care and hence potentially reducing general
practitioner (GP) waiting times (1-3).
The ongoing reclassification of prescription only medicines (POM) to
pharmacy (P) medicines is one of such initiatives (4-5) taking place in
Scotland. Reclassification of medicines is an ongoing process and allows
customers to buy reclassified medicines in a community pharmacy under the
direction of a pharmacist, without the need of a prescription.
One of the fundamental, and perhaps obvious, minimum requirements for
these services is that they are adopted into practice by community
pharmacists. Such adoption decisions are not always straightforward and may
require learning new behaviours and new ways of working. Pharmacists’
adoption decisions relating to new services have, to date, been given little
attention by researchers. In particular there is a lack of studies on newly
reclassified medicines.
Research on adoption decisions in health care in general is dominated by
studies focusing on the medical profession. Of note is the emphasis on the
facilitated diffusion of the emergent evidence base into standard medical
practice (6-8). It is important that a similar evidence based focus is given to
community pharmacy related developments. There is a need to facilitate
community pharmacy practice change by identifying key elements that
influence the adoption decisions at individual practitioner level.
An initial review of the pharmacy-based literature, carried out by the
researcher, has demonstrated that there is a dearth of publications and hence
research in this area. Of the few published literature reviews relating to
practice change, the focus has largely been on organizational implementation
issues. In addition, some reviews have focused on a wide range of pharmacy
related services, on subjects such as challenges encountered when
implementing ‘extended services’, ‘cognitive services’ and ‘new services’ in
community pharmacy (9-11).
It would appear that there are several reasons for carrying out a systematic
review of the pharmacy based literature: few studies on different elements of
practice change; lack of a standard methodological approach; the constant
stream of innovations, reclassified medicines and services. It is key that we
understand fully this adoption decision process. In addition, focus on
individual practitioner issues is also justified, given the centrally important
role of their involvement in delivering new services and associated roles in
preparing the organization in doing so. It is therefore particularly relevant at
the outset to systematically review the published literature in this field of
community pharmacy practice.
The remainder of this protocol describes the specific objectives and proposed
methodology for the systematic review.
Appendix - 52 -
Objectives 3. To review and critique the methodologies, methods and models to
investigate factors associated with community pharmacists’ decision
making around reclassified medicines described in peer reviewed
published literature.
4. To enlist and describe the importance of facilitators/barriers
identified from the peer reviewed published literature to community
pharmacists’ decision making around reclassified medicines.
Inclusion
criteria
Study population, sites
 No set criteria of study sites.
Study design
 No set criteria for type of studies. For illustration, both qualitative and
quantitative including interventions and mixed methods will be
considered.
 Reviews and systematic reviews of studies
Language
English
Date limit
1990 to date
Exclusion
criteria
 Literature based only on conceptual models/basis, i.e without
empirical evidence will be excluded.
 Studies based on patient or GP perspective of new services will be
excluded.
 Studies focusing only on extended service delivery with no particular
relevance to non-prescription medicine services will be excluded.
Databases  PsychINFO
 MEDLINE
 CINAHL
 EMBASE
 IPA
 Cochrane library
 Business source premier
Other
literature
search tools
 NHS Scotland community pharmacy e-library search fields
 Conference abstracts (International social pharmacy workshop,
International Pharmaceutical federation FIP congress and manual
search for BPC abstracts, Health Services Research and Pharmacy
Practice conference (published in International Journal of Pharmacy
Practice), European Society of Community Pharmacy (ESCP), United
Kingdom Clinical Pharmacy (UKCPA, published in Pharmacy World
and Science)
 Bibliography of identified literature
 Google and Google Scholar
Journal titles
for manual
searching
 International Journal of Pharmacy Practice
 Pharmacy World and Science
 Family Practice
 BMC Family Practice
 Annals of Pharmacotherapy
 Journal of Clinical Pharmacy and Therapeutics
 Journal of Social and Administrative Pharmacy
 American Journal of Health Systems Pharmacy
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Search terms
(To be used with
appropriate wild
card and
truncation)
Reclassified medicine
Non prescription medicine
Over the Counter (OTC) medicine
Minor ailment
Self medication
Pharmacy
Pharmacist
Self care
Practice change
Service adoption
Service implementation
Factor
Decision
Decision making
Barrier
Facilitator
Diffusion
Pharmaceutical care
Pharmacy practice
Driver
Extended service
Change
Change management
Change agent
Social network
Champion
Management
Leader
Search term
combinations
for scoping
search
Combination 1
Non-prescription medicine or over the counter medicine or minor ailment
or reclassified medicine or self care or self medication
AND
Pharmacy or pharmacist
Combination 2
Non-prescription medicine or over the counter medicine or minor ailment
or reclassified medicine or self care or self medication
AND
Decision or decision making or adoption or implementation or change or
practice change or innovation or diffusion
Combination 3
Non-prescription medicine or over the counter medicine or minor ailment
or reclassified medicine or self care or self medication
AND
Barrier or facilitator or driver or motivator or factor
Combination 4
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Non-prescription medicine or over the counter medicine or minor ailment
or reclassified medicine or self care or self medication
AND
Leadership or management or social network or influence or champion or
change agent
Combination 5
Extended service or practice change or change management
AND
Community pharmacist or community pharmacy
Software to
manage
references
Refworks
Quality
assessment
Quality assessment forms have been developed appropriate for each research
design likely to be encountered. However studies will not be excluded based
on poor quality as eliciting the current methodological trend in the subject
area is one of the set objectives.
Study
selection
This will be conducted in three stages
 Initial screening of titles to be carried out against the inclusion criteria
to look for potentially relevant papers
 Screening of full papers
 Removing any duplicate publications of same studies
Number of
researchers
involved
1. Principal investigator (VP) to screen for titles and abstracts
2. VP and DS (as a second reviewer) to screen full papers
3. Any conflicts to be resolved by discussion with SC, DS and DT
Data
extraction
1. A detailed form to be developed
2. Data extraction to be cross checked for reliability by second reviewer
(DS).
3. Any disagreements will be resolved by discussion with SC, DS and
DT.
4. If not resolved, the disagreement will be reported in the final review.
Strategies to
deal with
missing data
from
published
papers
None (due to time constrains)
Data
synthesis
It is difficult to anticipate strategies for data synthesis in the beginning due to
uncertainty of the potential data that will be retrieved. Depending on the data
that will be retrieved, it is most likely that syntheses could be narrative.
Strategy for
dissemination
of results
PhD thesis, conference abstracts and a publication in peer reviewed journal
Strategy to
deal with any
amendments
in the
protocol
during the
process
Any deviation from the set strategy will be well recorded after being agreed
by the research team.
Potential
audience
Policy makers, pharmacy practitioners and researchers
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Description of databases used for literature searching in systematic review
International Pharmaceutical Abstracts, PsychINFO, Ovid MEDLINE (R), CINAHL,
EMBASE (as in Appendix I)
Business Source Premier (BSP)
This database contains literature from management and marketing journals and is a good
source of evidence from business and management sources. This database claims to have
an index of more than 2,300 journals dating back from 1886 (1).
Cochrane Library
The Cochrane Library contains intervention related literature. Searching this library
provides functionality of accessing several databases simultaneously, which include
Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of
Effects (DARE), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane
Methodology Register (CMR), Health Technology Assessment Database (HTA) and NHS
Economic Evaluation Database (NHS EED) (2).
References to descriptions of databases
(1) EBSCO. EBSCO support. Available from: http://support.ebscohost.com. Accessed 03
June 2008.
(2) Cochrane Collaborations. Cochrane Handbook for Systematic Reviews of Interventions
2008. Available from: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook500/.Accessed
03 June 2008.
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Table 3.2: Search strategies used for systematic review literature retrieval
(Note: this table extends has four parts)
Search strategy I employed for databases IPA, BSP and CINAHL
Search
Terms Search Options Actions
S1 Decision or adopt or implement or
diffusion or barrier or facilitator or driver
or motivator or leader or network or
champion or change agent
Limiters - Published Date from:
19900101-20091231; Publication Year
from: 1990-2009; English Language;
Expanders - Apply related words
Search modes - Boolean/Phrase
S2 Non-prescription or nonprescription or
over the counter or deregulation or
reclassified or self care or self medication
or extended service or change management
or practice change or new service or
innovation
Limiters - Published Date from:
19900101-20091231; Publication Year
from: 1990-2009; English Language;
Expanders - Apply related words
Search modes - Boolean/Phrase
S3 Pharmacy or Pharmacist Limiters - Published Date from:
19900101-20091231; Publication Year
from: 1990-2009; English Language;
Expanders - Apply related words
Search modes - Boolean/Phrase
S4 S1 and S2 and S3 Search modes - Boolean/Phrase
Search strategy II employed for databases IPA, BSP and CINAHL
Search
Terms Search Options Actions
S1 pharmacy or pharmacist Limiters - Published Date from:
19900101 -20091231; Publication Year
from: 1990-2009;
English Language;
Expanders - Apply related words
Search modes - Boolean/Phrase
S2 Non-prescription or nonprescription or over
the counter or minor ailment or reclassified
or self care or self medication or extended
service or change management or practice
change or new service or innovation seems
very in focus
Limiters - Published Date from:
19900101-20091231; Publication Year
from: 1990-2009; English Language;
Search modes - Boolean/Phrase
S3 S1 and S2
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Search strategy I employed in Medline, EMBASE and PsychINFO
# Search Options # Search Options
1 nonprescription$.mp 17 implement*.mp
2 over the counter$.mp 18 diffus*.mp
3 non-prescription$.mp 19 barrier$.mp
4 minor ailment$.mp 20 facilitat*.mp
5 reclassif*.mp 21 driver$.mp
6 self care.mp 22 motivat*.mp
7 self medicat*.mp 23 leader*.mp
8 extend* service$.mp 24 network*.mp
9 chang* manag*.mp 25 champion$.mp
10 practice chang*.mp 26 change agent$.mp
11 new service$.mp 27 13 or 14
12 innovat*.mp 28
7 or 12 or 3 or 4 or 8 or 10 or 2 or 9 or 1 or 5 or 11 or
6
13 pharmacy$.mp 29
26 or 22 or 18 or 21 or 16 or 15 or 23 or 20 or 25 or 24
or 17 or 19
14 pharmacist$.mp 30 28 and 27 and 29
15 decision$.mp 31 28 and 27
16 adopt*.mp
[mp= ti (title) $ truncation * wildcard]
Search strategy II employed in Medline, EMBASE and PsychINFO
# Search Options # Search Options
1 non prescription$.mp 8 pharmacy$.mp
2 over the counter$.mp 9 non-prescription$.mp
3 minor ailment$.mp 10 6 or 4 or 1 or 3 or 9 or 2 or 5
4 reclassif*.mp 11 recommend*.mp
5 self care.mp 12 supply*.mp
6 self medicat*.mp 13 8 or 7
7 pharmacist$.mp 14 11 or 12
15 13 and 10 and 14
[mp= ti (title) $ truncation * wildcard]
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Systematic review quality assessment form
(Quantitative and mixed method studies)
(A completed example- Blenkinsopp et al 2004)
A. Appraisal item: Aim
Appraisal question: Is the research explicit about its aims and objectives
Quality indicators Quick answers if
any
Notes/ Details
Was there a clear statement of the aims of
the research?
Yes
Was there a clear statement of the
objectives of the research
Yes
If there a mention of why the aim was
important?
Yes
Any basis of how aims and objectives
emerged?
Yes
B. Appraisal item: Design
Appraisal question: How defensible is the research design?
Quality indicators Quick answers if
any
Notes/ Details
Is there a clear mention of study design? Yes
Is there a discussion for the rationale of
study design?
No
If the study is carried out in multiple
phases or multiple method, is there a clear
mention of the reason for doing so?
No
Is there a discussion of the limitation of
study design?
No
Is there a discussion of strength of study
design?
No
C. Ethics
Quality indicators Quick answers if
any
Notes/ Details
Was ethics committee advice sought No
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D. Appraisal item: Sample/ Participants
Appraisal question: How defensible is the selection of participants/ cases/ documents
Quality indicators Quick answers if
any
Notes/ Details
Is there a mention of study
location, how and why they have
been chosen?
Yes
Is there a description of any
population of interest and how
sample selection relates to it?
Yes
Is there a justification of sample
size?
No
Is the recruitment strategy clearly
explained?
No No mention of how many further
samples were recruited to reach the
desired number
Is there documentation of reasons
for non-participation among
sample approached or any efforts
being made?
No
E. Appraisal item: Data collection
Appraisal question: How well was the data collection carried out?
Quality indicators Quick answers if
any
Notes/ Details
Is there a justification of the procedure
of data collection?
No
Are the issues about validity of the data
collection tool addressed?
Yes Piloted and reviewed by
academic committee.
However pilot sample was
very low
Is there a discussion of who conducted
the data collection and was there any
bias likely? If so. how did the researcher
addressed the issue?
Unclear Not clear about the
contribution of each author,
bias likely due to conflicting
interest, mentioned clearly
Is there a clear mention of procedure of
data collection?
Yes
Was it likely that study settings may
have influenced data collection?
Yes Authors familiarity to the
pharmacists in the area
Were the data collection method
modified during the study, if so are the
reasons clearly stated?
Yes Following pilot,
questionnaire was modified
but does not mention what
was modified
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F. Appraisal item: Data analysis
Appraisal question: Was the data analysis sufficiently rigorous?
Quality indicators Quick answers if
any
Notes/ Details
Is there a mention of clear procedure for
data management and/or analysis?
No No mention of software
used
Has the procedure been justified? No
Is there a mention of what the tests
applied intend to measure?
No
G. Appraisal item: Findings/results
Appraisal question: How credible are the findings?
Quality indicators Quick answers if
any
Notes/ Details
Are findings/ conclusions supported by
the study
Are P values and other relevant values
provided?
Yes
Is there a discussion of why particular
significance was issued to specific sets of
data?
No Does not indicate if there
were qualitative data that
might have been important
Are key messages highlighted or
summarized in the report?
Yes
Is there a discussion on how the findings
add to what is already known about the
topics? (supported by literature review)
No Perhaps due to no previously
available studies
Are any new areas of interest emerged
during the research mentioned?
Not explained
Is there a discussion of any practice,
policy implications of the findings?
Yes
Is there a discussion of limitation of the
findings presented?
No
Are findings discussed in relation to the
aims/ objectives of the research?
Yes
Is there a discussion of generalizability of
the findings or how far are the findings
transferable to wider population?
No
Could researcher’s position may have
biased conclusions that were drawn.
Yes Lead author paid advisor to
Johnson & Johnson MSD on
the switch of simvastatin
10mg reclassification
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Quality assessment form (Qualitative studies)
Appraisal item: Aim
Appraisal question: Is the research explicit about its aims and objectives
Quality indicators Quick answers if
any
Notes/ Details
Was there a clear statement of the aims of
the research?
Was there a clear statement of the
objectives of the research
If there a mention of why the aim was
important?
Any basis of how aims and objectives
emerged?
B. Appraisal item: Design
Appraisal question: How defensible is the research design?
Quality indicators Quick answers if
any
Notes/ Details
Is there a clear mention of study design?
Is there a discussion for the rationale of
study design?
If the study is carried out in multiple
phases or multiple method, is there a clear
mention of the reason for doing so?
Is there a discussion of the limitation of
study design?
Is there a discussion of strength of study
design?
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C. Appraisal item: Sample/ Participants
Appraisal question: How defensible is the selection of participants/ cases/ documents
Quality indicators Quick answers if
any
Notes/ Details
Is there a mention of study
location, how and why they have
been chosen?
Is there a description of any
population of interest and how
sample selection relates to it? (eg
typical, extreme etc)
Is there a description of how
particular participants, documents
or cases were chosen?
Is the recruitment strategy clearly
explained?
Is there documentation of reasons
for non-participation among
sample approached/ non-
inclusion of selected cases/
documents?
D. Appraisal item: Data collection
Appraisal question: How well was the data collection carried out?
Quality indicators Quick answers if
any
Notes/ Details
Is there a justification of the procedure of
data collection?
Is there a discussion of who conducted the
data collection and was there any bias
likely? If so. how did the researcher
addressed the issue?
Is there a clear mention of procedure of
data collection?
Was it likely that study settings may have
influenced data collection?
Were the data collection method modified
during the study, if so are the reasons
clearly stated?
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E. Appraisal item: Data analysis
Appraisal question: Was the data analysis sufficiently rigorous?
Quality indicators Quick answers if
any
Notes/ Details
Is there a mention of clear procedure for
data management and/or analysis?
Has the procedure been justified?
Is there a mention of how descriptive
categories, themes and category emerged?
Are contradictory data, extreme cases or
alternative positions explained?
Are association of data with any typology
created justified?
Has the researcher explained potential
bias/influence arising from analyst
position?
F. Appraisal item: Findings/results
Appraisal question: How credible are the findings?
Quality indicators Quick answers if
any
Notes/ Details
Are findings/ conclusions supported by
the study
Is there a discussion of why particular
significance was issued to specific sets of
data?
Are key messages highlighted or
summarized in the report?
Is there a discussion on how the findings
add to what is already known about the
topics? (supported by literature review)
Are any new areas of interest emerged
during the research mentioned?
Is there a discussion of any practice, policy
implications of the findings?
Is there a discussion of limitation of the
findings presented?
Are findings discussed in relation to the
aims/ objectives of the research?
Is there a discussion of generalizability of
the findings or how far are the findings
transferable to wider population?
How does researcher’s position may have
biased conclusions that were drawn. Any
alternative explanations suggested?
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Quality assessment form (Reviews of literature)
Review: _________________________________________________________________
Article ID: Quality assessor:
A. Appraisal item: Aim
Appraisal question: Is the research explicit about its aims and objectives
Quality indicators Quick
answers if
any
Notes/
Details
Was there a clear statement of the aims of the
review?
Was there a clear statement of the objectives of the
review?
If there a mention of why the aim was important?
Any basis of how aims and objectives emerged?
B. Appraisal item: Review method
Appraisal question: How defensible is the review method adopted?
Quality indicators Quick
answers if
any
Notes/
Details
Is there a clear mention of review method such as
narrative, systematic or general review?
Is there a discussion for the rationale of method
adopted?
Were the inclusion and exclusion criteria of the
literature reviewed clearly explained and how
appropriate are they?
Is there a mention of search strategy employed for
literature search mentioned and are they
appropriate?
Is there a mention of database used to search
literature and were they
Were personal contacts with experts made to
retrieve more literature
Were unpublished literature searched?
Were literature other than in English language
included?
Were hand searching used to retrieve literature
from core journals in the field?
Were there more than one assessor for the studies?
Is there quality assessment criteria mentioned?
Is there a discussion of the limitation of method
selected?
Is there a discussion of strength of review method?
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C. Appraisal item: Data analysis
Appraisal question: Was the data analysis sufficiently rigorous?
Quality indicators Quick answers if
any
Notes/ Details
Is there a mention of clear procedure for
data management and/or analysis?
Has the procedure been justified?
Is there a mention of what the tests applied
intend to measure?
Has the researcher explained potential
bias/influence arising from analyst
position?
D. Appraisal item: Findings/results
Appraisal question: How credible are the findings?
Quality indicators Quick answers if
any
Notes/ Details
Are findings/ conclusions supported by
the study
Are key messages highlighted or
summarized in the report?
Is there a discussion of any practice, policy
implications of the findings?
Is there a discussion of limitation of the
findings presented?
Are findings discussed in relation to the
aims/ objectives of the research?
Is there a discussion of generalizability of
the findings or how far are the findings
transferable to wider population?
How does researcher’s position may have
biased conclusions that were drawn. Any
alternative explanations suggested?
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Systematic review data extraction form
(A completed example- Blenkinsopp et al 2004)
Review: _________________________________________________________________
Article ID: 1 Reviewer: VP
General Information Data extracted Any comment
Title: OTC simvastatin supply- what changes in
practice and education do pharmacist want
First author Blekinsopp,J
Author affiliation Univ. of Bradford, UK
Publication type Journal peer reviewed
Source of article Pharmaceutical Journal (Vol 273) 7 Aug 2004 Database search
Aims and objectives Data extracted Any comment
Aim Investigate and appraise the changes required in
practice and the training requirements of
community pharmacists to enable them to supply
simvastatin 10mg over the counter appropriately.
Objectives 1. To investigate and appraise the changes
required in practice to enable the
appropriate supply of simvastatin.
2. To investigate pharmacists’ training
requirements for the appropriate supply of
OTC simvastatin.
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Method Data extracted Any comment
Study design Structured questionnaire (Both qualitative and
quantitative research aspects)
Recruitment 200 random pharmacists, postal questionnaire
(piloted to 10 pharmacist)
Not clear how
further samples
were selected to
reach the targeted
sample of 200. Low
number of pilot
participants
Place of study Leeds/ Bradford area UK
Piloting and any
modification
To 10 pharmacists, modification done Modification not
reported
Inclusion criteria Those who agreed to participate through
telephone interview
Exclusion criteria Not agreeing to participate during pre-contact
Any interventions None
Any reminders used None
Analysis method used Descriptive analysis, Cross tabs
Any statistical
technique used
Chi-square tests
Results Data extracted Any comment
Number of
participants or
response rate
50% -
Quantitative results Data extracted Any comment
Views on changing
practice
61% believed profession is ready for the
additional responsibility of the supply of
medicines through greater prescribing role, 25%
disagreed and 14% unsure.
Views on
reclassification
Views on whether reclassification was a good
idea: 40 % agreed, 24% disagreed, 36 % unsure.
Those having consultation area were more likely
to agree (P=0.028) than those without one. Those
agreeing that this was a good idea were more
likely to agree profession being ready for more
prescribing role.
Adoption of
reclassified medicine
If made available over the counter 60% stated
they would be happy to supply, 18% would not
and 22% unsure
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Facilitators/barriers to adoption of reclassified medicines
Facilitators/barriers to
decision making
Data extracted Any comment
Risk assessment 67% willing to take blood cholesterol test in
pharmacy, 18% would not and 15% unsure
With risk factors identified, 63% willing to identify
the need for statins, 19 % would not and 18% unsure
Guideline Protocol and guidelines should be in place (100%
agreed)
Training 96% agreed or strongly agreed that additional
trainings are required. 63% preferred Centre for
Pharmacy Postgraduate Education, RPSGB by 40%
and National Pharmaceutical Association by 20%.
Desirable contents of training package were
pharmacology, adverse effects (100%), other
interventions to reduce risk (97%), pathophysiology
and major risk factors (94%) and advice on
counselling about statins (91%).
Competence/ confidence 39% believed examination of competence is required,
45% disagreed and 16% unsure.
Access to patient records 50% would like patient records to be available with
16% wanting records of past two years, 20% for past
five years, 6% did not believe that patient medical
records not needed
Record of supply
66% agreed supply should be recorded, 22% said
should not and 12% unsure
Method to keep record: 57% mentioned PMR was the
best option to keep record, 35% favoured patient held
records
Need for
communication with
GPs
34% said GPs should be notified of the supply
Resources Views on whether reclassification was a good idea: 40
% agreed, 24% disagreed, 36 % unsure. Those having
consultation area were more likely to agree (P=0.028)
than those without one.
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Results from open ended questions
Data extracted Any comment
Pharmacists additional comments displayed concerns
not related to the proposed simvastatin product
highlighting gaps in knowledge about the proposed
switch.
Verbatim comments on importance of training
requirements
Qualitative
results
appears only
in discussion
section
Conclusions and
future direction
suggested
Data extracted Any comment
Conclusions 1. Need for consultation area highlighted for
proposed switch.
2. Need for recording the supply highlighted
because long term products currently on
non-prescription status are very few and
as opposed to other existing short term
OTC products where patients may not
inform health professionals, this should
not be the case for simvastatin.
3. Though PMR system was the most
popular, authors argue this is least
effective when it comes to sharing with
others and therefore, Patient held records
are recommended.
4. Presents CPPEs as well established, known
for providing well-presented and effective
training packages.
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List of studies excluded after full text screening
S.N Title and source Reason/s for exclusion
1 Soon, J.A, Levine, M. Ensom, M.H.H; Gardner, J.S;
Edmondson, H.M; Fielding, D.W. The developing role
of pharmacists in patient access to emergency
contraception. Disease Management & Health
Outcomes 2002;10:601-11.
Community pharmacists’
perspectives of medicines
reclassification not presented
2 Achanta, A.S; Temkin, C.W; Rhodes, C.T. Attitudes
and opinions towards regulatory aspects of non-
prescription medicines. Clinical Research &
Regulatory Affairs 2003;20:1-14. DOI 10.1081/CRP-
120018736
Results section do not
distinguish the opinions of
community pharmacists
against others
3 Scott E.M; Paschalides, S.C. Pharmacists' views on
emergency hormonal contraception one year after
deregulation. HSRPP Conference 2003, Belfast.
Does not specify whether
pharmacist participants were
based in community.
4 Chapman, J.L; Zechel, A; Carter, Y.H; Abbott, S.
Systematic review of recent innovations in service
provision to improve access to primary care. British
Journal of General Practice 2004; 54: 374-381.
Community pharmacists’
perspectives of medicines
reclassification not presented
5 L.A. Conard and M.A. Gold, Emergency
contraceptive pills: A review of the recent literature,
Current Opinion in Obstetrics & Gynecology 2004: 16:
389–395.
Community pharmacists’
perspectives of medicines
reclassification not presented
6 Sutkin, G; Grant, B; Irons, B.K; Borders, T.F. Opinions
of West Texas pharmacists about emergency
contraception. Pharmacy Practice 2006;4(4): 151-155.
Results section do not
distinguish the opinions of
community pharmacists
against others
7 Taylor, J.G; Berger, B.A; Anderson-Harper, H.M;
Pearson, R.E. Pharmacist readiness for greater
involvement in OTC product selection: implications
for education. American Journal Pharmaceutical
Education 2000;64:133–40.
Community pharmacists’
perspectives of medicines
reclassification not presented
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15 APPENDIX V
(CHAPTER 5)
Copy of main questionnaire
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Post it note message attached to questionnaire
Dear Pharmacist, Your
input into this research is
very valuable to us. It
would be great to get the
questionnaire back from
you by _________(date)
Signature
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16 APPENDIX VI (CHAPTER 6)
I. Factor analysis of 24-item scales belonging to naproxen
Kaiser-Meyer-Olkin measure of sampling adequacy (KMO) was 0.818 and Barlett’s test of
sphericity was significant (p= <0.001)
Visual inspection of Scree plot and tabulation of the factors having Eigenvalues greater
than 1 showed that seven components were extracted (table 5.1-5.2, figure 5.1).
Table 16.1: % Variance of components explained (naproxen)
Component Initial Eigenvalues Rotation Sums of Squared Loadings
Total
% of
Variance
Cumulative
% Total
% of
Variance
Cumulative
%
1 4.617 19.239 19.239 3.283 13.681 13.681
2 2.415 10.062 29.301 1.961 8.169 21.850
3 1.379 5.744 35.045 1.654 6.893 28.743
4 1.316 5.485 40.530 1.649 6.872 35.615
5 1.174 4.893 45.423 1.630 6.792 42.407
6 1.124 4.685 50.108 1.463 6.095 48.502
7 1.008 4.200 54.308 1.393 5.806 54.308
Extraction Method: Principal Component Analysis.
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Figure 16.1: Scree plot (naproxen)
Component Number
242322212019181716151413121110987654321
Eigenvalue
6
5
4
3
2
1
0
Scree plot (naproxen)
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Table 16.2: Rotated component matrix (naproxen)
Component
1 2 3 4 5 6 7
This is/was a good opportunity to extend my role as a
health professional .788
This product matches with the business/service
ambitions of my pharmacy .811
This product has potential for good financial returns
for my pharmacy .679
I believe that this product is a welcome addition to the
range of pharmacy medicines .739
I believe that the OTC regimen for this product is likely
to be effective .598
My customers often complain about the cost of this
product (not including e-MAS supply) † .613
Insufficient resources (e.g. staff, space etc) within my
pharmacy has limited the practice of this product † .523 .423
It is likely that customers could misuse this product † .596
Customers not accepting my advice around this
product makes me less likely to adopt this product † .573
I find the processes involved in the supply of this
product complex † .432
Introduction of this product may have represented a
‘step too far’ for OTC products † .542
It has been my management’s decision rather than my
own as to if/ how far to adopt into practice † .764
I get adequate support from my professional body to
adopt this product .577
I feel confident about my ability to supply this product .563
I have access to sufficient sources of information
relating to this product .741
It is easy for me and/or my customers to know if
treatment with this product is effective .548
Lack of proper way to communicate with the local
medical practice is a barrier to adopt this product † .710
Lack of access to patient medical records makes it
difficult to adopt this product into practice † .432 .590
I believe this product has potential to engender patient
satisfaction
-
.457
I believe there are high risks of adverse events
associated with this product † .757
I am happy to delegate the task of supplying this
product to support staff .729
I am/would be comfortable going off guidelines to
supply this product .650
Many customers ask for this product by name*
The similarity of POM and P packs of this product
could create confusion † *
Extraction Method: Principal Component Analysis. Rotation method: Varimax with Kaiser
Normalization. † : items reversed scored; Values below 0.4 are suppressed. * with values less than 0.4
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II. Factor analysis of 24-item scales belonging to simvastatin
Kaiser-Meyer-Olkin measure of sampling adequacy (KMO) was 0.805 and Barlett’s test of
sphericity was significant (p= <0.001)
Visual inspection of scree plot and tabulation of the factors having Eigenvalues greater than 1
showed that six components were extracted (tables 5.3-5.4, figure 5.2).
Table 16.3: % Variance of components explained (simvastatin)
Component Initial Eigenvalues Rotation Sums of Squared Loadings
Total
% of
Variance
Cumulative
% Total
% of
Variance
Cumulative
%
1 4.233 17.639 17.639 3.537 14.737 14.737
2 2.808 11.702 29.340 2.255 9.395 24.132
3 1.515 6.313 35.654 1.925 8.020 32.152
4 1.340 5.584 41.238 1.741 7.252 39.404
5 1.227 5.114 46.352 1.537 6.406 45.810
6 1.072 4.468 50.819 1.202 5.009 50.819
Extraction Method: Principal Component Analysis.
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Figure 16.2: Scree plot (simvastatin)
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Table 16.4: Rotated component matrix (simvastatin)
Items Component
1 2 3 4 5 6
This is/was a good opportunity to extend my role as a
health professional .777
This product matches with the business/service
ambitions of my pharmacy .820
This product has potential for good financial returns
for my pharmacy .651
It has been my management’s decision rather than my
own as to if/ how far to adopt into practice † .803
I feel confident about my ability to supply this product .622
Lack of proper way to communicate with the local
medical practice is a barrier to adopt this product † .480 .427
I believe this product has potential to engender patient
satisfaction .516
I believe that the OTC regimen for this product is likely
to be effective .539
My customers often complain about the cost of this
product (not including e-MAS supply) † .526
Insufficient resources (e.g. staff, space etc) within my
pharmacy has limited the practice of this product † .643
I believe there are high risks of adverse events
associated with this product † .541
I am/would be comfortable going off guidelines to
supply this product .446
Many customers ask for this product by name .485
Introduction of this product may have represented a
‘step too far’ for OTC products † .621
I get adequate support from my professional body to
adopt this product .758
I am happy to delegate the task of supplying this
product to support staff .694
It is likely that customers could misuse this product † .487
Customers not accepting my advice around this
product makes me less likely to adopt this product † .674
The similarity of POM and P packs of this product
could create confusion † * .599
I find the processes involved in the supply of this
product complex † -.658
I have access to sufficient sources of information
relating to this product .606
Lack of access to patient medical records makes it
difficult to adopt this product into practice † .495
I believe that this product is a welcome addition to the
range of pharmacy medicines .787
It is easy for me and/or my customers to know if
treatment with this product is effective*
Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser
Normalization. Component scores less than 0.4 are suppressed; † : items reversed scored * has
value below 0.4.
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III. Factor analysis of 24-item scales belonging to chloramphenicol
KMO measure of sampling adequacy was 0.807 and Barlett’s test of sphericity was significant at
<0.001. Eight components could be extracted (tables 5.5-5.6, figure 5.3).
Figure 16.3: Scree plot of chloramphenicol
Table 16.5: % Variance of components explained (chloramphenicol)
Component Initial Eigenvalues Rotation Sums of Squared Loadings
Total
% of
Variance
Cumulative
% Total
% of
Variance
Cumulative
%
1 4.407 18.362 18.362 2.622 10.926 10.926
2 1.844 7.683 26.046 2.139 8.911 19.836
3 1.511 6.298 32.344 1.849 7.706 27.542
4 1.219 5.079 37.423 1.736 7.235 34.777
5 1.191 4.962 42.385 1.304 5.433 40.211
6 1.082 4.507 46.892 1.293 5.388 45.598
7 1.055 4.394 51.286 1.207 5.029 50.628
8 1.000 4.167 55.454 1.158 4.826 55.454
Extraction Method: Principal Component Analysis.
Component Number
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Table 16.6: Rotated component matrix of chloramphenicol
Items Component
1 2 3 4 5 6 7 8
My customers often complain about the cost of this
product (not including e-MAS supply)† .444
Insufficient resources (e.g. staff, space etc) within
my pharmacy has limited the practice of this
product †
.649
I find the processes involved in the supply of this
product complex† .609
I believe there are high risks of adverse events
associated with this product† .575
Introduction of this product may have represented
a ‘step too far’ for OTC products† .502
I feel confident about my ability to supply this
product .564
I believe that this product is a welcome addition to
the range of pharmacy medicines .661 .408
I have access to sufficient sources of information
relating to this product .656
I believe that the OTC regimen for this product is
likely to be effective .672
This is/was a good opportunity to extend my role
as a health professional .794
This product matches with the business/service
ambitions of my pharmacy .811
I get adequate support from my professional body
to adopt this product .625
Lack of proper way to communicate with the local
medical practice is a barrier to adopt this product† .671
Lack of access to patient medical records makes it
difficult to adopt this product into practice† .547
It is likely that customers could misuse this
product† .488 .562
I am happy to delegate the task of supplying this
product to support staff .455
Many customers ask for this product by name .773
This product has potential for good financial
returns for my pharmacy
-
.535
It has been my management’s decision rather than
my own as to if/ how far to adopt into practice† .742
Customers not accepting my advice around this
product makes me less likely to adopt this product† .599
I am/would be comfortable going off guidelines to
supply this product .741
The similarity of POM and P packs of this product
could create confusion†
-
.519
I believe this product has potential to engender
patient satisfaction .771
It is easy for me and/or my customers to know if
treatment with this product is effective*
Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser
Normalization; † : items reversed scored Values below 0.4 are suppressed. * with values less than 0.4
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Table 16.7: Univariate statistics of 24-item scale items and demographic characteristics with
the outcome ‘omeprazole acceptance’ showing non-significant associations (Note: this table
extends up to two pages)
Scale items/ variables Categories Low
acceptance
n (%)
High
acceptance
n (%)
P
value
My customers often complain
about the cost of this product
(not including e-MAS supply) †
(N= 548)
Low agreement 160
(36.7)
276
(63.3)
0.187
High agreement 33
(29.5)
79
(70.5)
Insufficient resources (e.g. staff,
space etc) within my pharmacy
has limited the practice of this
product† (N= 549)
Low agreement 78
(39.6)
119
(60.4)
0.124
High agreement 115
(32.7)
237
(67.3)
It is likely that customers could
misuse this product † (N= 549)
Low agreement 93
(39.1)
145
(60.9)
0.130
High agreement 101
(32.5)
210
(67.5)
The similarity of POM and P
packs of this product could
create confusion† (N= 549)
Low agreement 57
(38.8)
90
(61.2)
0.358
High agreement 137
(34.1)
265
(65.9)
I believe there are high risks of
adverse events associated with
this product† (N= 546)
Low agreement 79
(38.5)
126
(61.5)
0.208
High agreement 112
(32.8)
229
(67.2)
It has been my management’s
decision rather than my own as
to if/ how far to adopt into
practice† (N= 538)
Low agreement 77
(36.5)
134
(63.5)
0.714
High agreement 113
(34.6)
214
(65.4)
I get adequate support from my
professional body to adopt this
product (N=545 )
Low agreement 99
(39.3)
153
(60.7)
0.054
High agreement 92
(31.4)
201
(68.6)
Lack of proper way to
communicate with the local
medical practice is a barrier to
adopt this product† (N=542)
Low agreement
94
(39.8)
142
(60.2)
0.051
High agreement 96
(31.4)
210
(68.6)
I am/would be comfortable
going off guidelines to supply
this product (N=544 )
Low agreement 164
(36.0)
291
(64.0)
0.363
High agreement 27
(30.3)
62
(69.7)
Innovativeness (N= 544) Cautious or
Deliberate
115
(35.2)
212
(64.8)
1.00
Role model or
venturesome
76
(35.0)
141
(65.0)
Gender (N= 545) Male 65
(30.8)
146
(69.2)
0.090
Female 128
(38.3)
206
(61.7)
† Items reversed scored
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Variables Categories Low
acceptance
n (%)
High
acceptance
n (%)
P
value
Age (N= 546) 39 Years and
under
131
(38.5)
209
(61.5)
0.074
40 years and over 63
(30.6)
143
(69.4)
Relief (N= 554) Yes 12
(30.8)
27
(69.2)
0.652
No 184
(35.7)
331
(64.3)
Second (N= 554) Yes 5
(23.8)
16
(76.2)
0.369
No 191
(35.8)
342
(64.2)
Locum (N= 554) Yes 7
(43.8)
9
(56.3)
0.656
No 189
(35.1)
349
(64.9)
Non-store (N= 554) Yes 0
(0.0)
1
(100.0)
1.00**
No 196
(35.4)
357
(64.6)
Prescriber (N= 551) Yes 48
(33.1)
97
(66.9)
0.569
No 147
(36.2)
259
(63.8)
Postgraduate (N= 549) Yes 28
(31.8)
60
(68.2)
0.503
No 167
(36.2)
294
(63.8)
Location*** (N= 497) Urban 53
(34.4)
101
(65.6)
0.929
Suburban 77
(36.0)
137
(64.0)
Rural 47
(36.4)
82
(63.6)
Size of ownership (N= 536) Independent or
small multiple
51
(30.9)
114
(69.1)
0.211
Medium or large
multiple
137
(36.9)
234
(63.1)
* % represents proportion within row categories; ** Fischer’s exact test *** Locums/relief
excluded
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II. Regression analysis univariate outputs
Table 16.8: Univariate statistics of 24-item scale items and demographic characteristics with
the outcome ‘omeprazole adoption’ (note: this table extends up to four pages)
Scale items Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
This is a good opportunity to
extend my role as a health
professional (N= 548)
Low agreement 237
(89.8)
27
(10.2)
<0.001
High agreement 163
(57.4)
121
(42.6)
This product matches with the
business/service ambitions of
my pharmacy (N= 548)
Low agreement 283
(86.3)
45
(13.7)
<0.001
High agreement 117
(53.2)
103
(46.8)
This product has potential for
good financial returns for my
pharmacy (N= 542)
Low agreement 297
83.0)
61
(17.0)
<0.001
High agreement 100
(54.3)
84
(45.7)
My customers often complain
about the cost of this product
(not including e-MAS supply) †
(N= 548)
Low agreement 326
(74.8)
110
(25.2)
0.048
High agreement 72
(64.9)
39
(35.1)
Insufficient resources (e.g. staff,
space etc) within my pharmacy
has limited the practice of this
product† (N= 548)
Low agreement 161
(82.1)
35
(17.9)
<0.001
High agreement 238
(67.6)
114
(32.4)
It is likely that customers could
misuse this product † (N= 548)
Low agreement 174
(73.4)
63
(26.6)
0.855
High agreement 225
(72.3)
86
(27.7)
Customers not accepting my
advice around this product
makes me less likely to adopt
this product† (N= 544)
Low agreement 238
(75.6)
77
(24.4)
0.087
High agreement 157
(68.6)
72
(31.4)
I find the processes involved in
the supply of this product
complex † (N= 545)
Low agreement 171
(83.0)
35
(17.0)
<0.001
High agreement 226
(66.7)
113
(33.3)
I am happy to delegate the task
of supplying this product to
support staff (N= 545)
Low agreement 293
(79.0)
78
(21.0)
<0.001
High agreement 104
(59.8)
70
(40.2)
Many customers ask for this
product by name (N= 546)
Low agreement 372
(75.9)
118
(24.1)
<0.001
High agreement 26
(46.4)
30
(53.6)
* % represents proportion within row categories; †Items reversed scored
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Scale items Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
I feel confident about my ability
to supply this product (N= 547)
Low agreement 70
(97.2)
2
(2.8)
<0.001
High agreement 329
(69.3)
146
(30.7)
I believe that this product is a
welcome addition to the range
of pharmacy medicines (N= 548)
Low agreement 204
(92.7)
16
(7.3)
<0.001
High agreement 196
(59.8)
132
(40.2)
I have access to sufficient
sources of information relating
to this product (N= 545)
Low agreement 95
(84.8)
17
(15.2)
0.002
High agreement 302
(69.7)
131
(30.3)
I believe that the OTC regimen
for this product is likely to be
effective (N= 547)
Low agreement 224
(90.0)
25
(10.0)
<0.001
High agreement 175
(58.7)
123
(41.3)
The similarity of POM and P
packs of this product could
create confusion† (N= 547)
Low agreement 110
(75.9)
35
(24.1)
0.416
High agreement 289
(71.9)
113
(28.1)
It is easy for me and/or my
customers to know if treatment
with this product is effective
(N= 543)
Low agreement 205
(82.7)
43
(17.3)
<0.001
High agreement 190
(64.4)
105
(35.6)
I believe this product has
potential to engender patient
satisfaction (N= 527)
Low agreement 238
(83.2)
48
16.8)
<0.001
High agreement 144
(60.3)
95
(39.7)
I believe there are high risks of
adverse events associated with
this product† (N= 544)
Low agreement 156
(76.8)
47
(23.2)
0.124
High agreement 240
(70.4)
101
(29.6)
Introduction of this product
may have represented a ‘step
too far’ for OTC products† (N=
545)
Low agreement 121
(84.6)
22
(15.4)
<0.001
High agreement 276
(68.7)
126
(31.3)
It has been my management’s
decision rather than my own as
to if/ how far to adopt into
practice† (N= 536)
Low agreement 160
(76.9)
48
(23.1)
0.121
High agreement 231
(70.4)
97
(29.6)
I get adequate support from my
professional body to adopt this
product (N= 543)
Low agreement 198
(79.5)
51
(20.5)
0.002
High agreement 197
(67.0)
97
(33.0)
†Items reversed scored
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Scale items/ variables Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
Lack of proper way to
communicate with the local
medical practice is a barrier to
adopt this product† (N= 540)
Low agreement 191
(80.9)
45
(19.1)
<0.001
High agreement 202
(66.4)
102
(33.6)
Lack of access to patient medical
records makes it difficult to
adopt this product into practice†
(N= 545)
Low agreement 244
(78.5)
67
(21.5)
0.001
High agreement 153
(65.4)
81
(34.6)
I am/would be comfortable
going off guidelines to supply
this product (N= 542)
Low agreement 338
(74.6)
115
(25.4)
0.033
High agreement 56
(62.9)
33
(37.1)
Innovativeness (N= 543) Cautious or
Deliberate
251
(77.2)
74
(22.8)
0.008
Role model or
venturesome
145
(66.5)
73
(33.5)
Gender (N= 544) Male 143
(68.8)
65
(31.3)
0.136
Female 252
(75.0)
84
25.0)
Age (N= 545) 39 Years and
under
252
(73.9)
89
(26.1)
0.711
40 years and over 147
(72.1)
57
(27.9)
Experience (N= 546) 10 years and
under
212
(74.4)
73
(25.6)
0.469
11 years or over 186
(71.3)
75
(28.7)
Owner (N= 553) Yes 59
(62.1)
36
(37.9)
0.016
No 343
(74.9)
115
(25.1)
Manager (N= 553) Yes 306
(76.5)
94
(23.5)
0.002
No 96
(62.7)
57
(37.3)
Relief (N= 553) Yes 26
65.0)
14
(35.0)
0.342
No 376
(73.3)
137
26.7)
Second (N= 553) Yes 13
(61.9)
8
(38.1)
0.378
No 389
(73.1)
143
(26.9)
†Items reversed scored
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Variables Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
Locum (N= 553) Yes 14
(87.5)
2
(12.5)
0.257**
No 388
(72.3)
149
(27.7)
Non-store (N= 553) Yes 0
(0.0)
1
(100.0)
0.273**
No 402
(72.8)
150
(27.2)
Prescriber (N= 550) Yes 102
(69.9)
44
(30.1)
0.425
No 298
(73.8)
106
(26.2)
Postgraduate (N= 549) Yes 59
(65.6)
31
(34.4)
0.115
No 341
(74.3)
118
(25.7)
Location*** (N= 494) Urban 113
(73.4)
41
(26.6)
0.68
Suburban 158
(74.9)
53
(25.1)
Rural 91
(70.5)
38
(29.5)
Size of ownership (N= 535) Independent or
small multiple
122
(74.8)
41
(25.2)
0.451
Medium or large
multiple
265
(71.2)
107
(28.8)
** Fischer’s exact test; *** Locums/ Relief excluded
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Table 16.9: Univariate statistics of 24-item scale items and demographic characteristics with
the outcome ‘naproxen acceptance’ (note: this table extends up to four pages)
Scale items Categories Low
acceptance
n (%)
High
acceptance
n (%)
P
value
This is a good opportunity to
extend my role as a health
professional (N= 547)
Low agreement 95
(46.8)
108
(53.2)
<0.001
High agreement 29
(8.4)
315
(91.6)
This product matches with the
business/service ambitions of
my pharmacy (N= 547)
Low agreement 103
(38.7)
163
(61.3)
<0.001
High agreement 21
(7.5)
260
(92.5)
This product has potential for
good financial returns for my
pharmacy (N= 542)
Low agreement 98
(30.8)
220
(69.2)
<0.001
High agreement 25
(11.2)
199
(88.8)
My customers often complain
about the cost of this product
(not including e-MAS supply) †
(N= 546)
Low agreement 91
(24.9)
274
(75.1)
0.072
High agreement 32
(17.7)
149
(82.3)
Insufficient resources (e.g. staff,
space etc) within my pharmacy
has limited the practice of this
product† (N= 548)
Low agreement 53
(30.1)
123
(69.9)
0.006
High agreement 71
(19.1)
301
(80.9)
It is likely that customers could
misuse this product † (N= 548)
Low agreement 69
(25.3)
204
(74.7)
0.205
High agreement 56
(20.4)
219
(79.6)
Customers not accepting my
advice around this product
makes me less likely to adopt
this product† (N= 544)
Low agreement 79
(25.9)
226
(74.1)
0.036
High agreement 43
(18.0)
196
(82.0)
I find the processes involved in
the supply of this product
complex† (N= 544)
Low agreement 59
(33.1)
119
(66.9)
<0.001
High agreement 64
(17.5)
302
(82.5)
I am happy to delegate the task
of supplying this product to
support staff (N= 545)
Low agreement 91
(28.2)
232
(71.8)
<0.001
High agreement 33
(14.9)
189
(85.1)
Many customers ask for this
product by name (N= 544)
Low agreement 106
(23.8)
339
(76.2)
0.281
High agreement 18
(18.2)
81
(81.8)
* % represents proportion within row categories; †Items reversed scored
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Scale items Categories Low
acceptance
n (%)
High
acceptance
n (%)
P
value
I feel confident about my ability
to supply this product (N= 547)
Low agreement 29
(51.8)
27
(48.2)
<0.001
High agreement 95
(19.3)
396
(80.7)
I believe that this product is a
welcome addition to the range
of pharmacy medicines (N= 549)
Low agreement 83
(50.6)
81
(49.4)
<0.001
High agreement 41
(10.6)
344
(89.4)
I have access to sufficient
sources of information relating
to this product (N= 545)
Low agreement 29
(32.2)
61
(67.8)
0.024
High agreement 94
(20.7)
361
(79.3)
I believe that the OTC regimen
for this product is likely to be
effective (N= 547)
Low agreement 80
(42.6)
108
(57.4)
<0.001
High agreement 44
(12.3)
314
(87.7)
The similarity of POM and P
packs of this product could
create confusion† (N= 547)
Low agreement 39
(28.5)
98
(71.5)
0.069
High agreement 84
(20.5)
326
(79.5)
It is easy for me and/or my
customers to know if treatment
with this product is effective
(N= 543)
Low agreement 61
(32.1)
129
(67.9)
<0.001
High agreement 63
(17.8)
290
(82.2)
I believe this product has
potential to engender patient
satisfaction (N= 527)
Low agreement 82
(31.5)
178
(68.5)
<0.001
High agreement 34
(12.7)
233
(87.3)
I believe there are high risks of
adverse events associated with
this product† (N= 546)
Low agreement 95
(23.8)
305
(76.3)
0.399
High agreement 29
(19.9)
117
(80.1)
Introduction of this product
may have represented a ‘step
too far’ for OTC products† (N=
546)
Low agreement 54
(40.9)
78
(59.1)
<0.001
High agreement 70
(16.9)
344
(83.1)
It has been my management’s
decision rather than my own as
to if/ how far to adopt into
practice† (N= 537)
Low agreement 57
(27.3)
152
(72.7)
0.037
High agreement 63
(19.2)
265
(80.8)
I get adequate support from my
professional body to adopt this
product (N= 542)
Low agreement 76
30.0)
177
70.0)
<0.001
High agreement 46
(15.9)
243
(84.1)
†Items reversed scored
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Scale items/ variables Categories Low
acceptance
n (%)
High
acceptance
n (%)
P
value
Lack of proper way to
communicate with the local
medical practice is a barrier to
adopt this product† (N= 540)
Low agreement 58
(25.9)
166
(74.1)
0.150
High agreement 64
(20.3)
252
(79.7)
Lack of access to patient medical
records makes it difficult to
adopt this product into practice†
(N= 545)
Low agreement 69
(24.3)
215
(75.7)
0.366
High agreement 54
(20.7)
207
79.3)
I am/would be comfortable
going off guidelines to supply
this product (N= 543)
Low agreement 108
(23.1)
359
(76.9)
0.445
High agreement 14
18.4)
62
(81.6)
Innovativeness (N= 542) Cautious or
Deliberate
79
(24.3)
246
(75.7)
0.321
Role model or
venturesome
44
(20.3)
173
(79.7)
Gender (N= 543) Male 52
(24.8)
158
(75.2)
0.408
Female 71
(21.3)
262
(78.7)
Age (N= 545) 39 Years and
under
76
(22.4)
263
(77.6)
0.999
40 years and over 47
(22.8)
159
(77.2)
Experience (N= 546) 10 years and
under
60
(21.2)
223
78.8)
0.382
11 years or over 65
(24.7)
198
(75.3)
Owner (N= 552) Yes 21
21.9)
75
78.1)
0.949
No 104
(22.8)
352
(77.2)
Manager (N= 552) Yes 94
(23.6)
304
(76.4)
0.444
No 31
(20.1)
123
79.9)
†Items reversed scored;
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Variables Categories Low
acceptance
n (%)
High
acceptance
n (%)
P
value
Relief (N= 552) Yes 10
(25.6)
29
(74.4)
0.791
No 115
(22.4)
398
(77.6)
Second (N= 552) Yes 2
(9.5)
19
(90.5)
0.187**
No 123
(23.2)
408
(76.8)
Locum (N= 552) Yes 2
(12.5)
14
(87.5)
0.544**
No 123
(22.9)
413
(77.1)
Non-store (N= 552) Yes 0
(0.0)
1
(100)
1.00**
No 125
(22.7)
426
(77.3)
Prescriber (N= 549) Yes 33
(22.9)
111
(77.1)
0.956
No 90
(22.2)
315
(77.8)
Postgraduate (N= 547) Yes 18
(20.5)
70
(79.5)
0.687
No 106
(23.1)
353
(76.9)
Location*** (N= 495) Urban 33
(21.4)
121
(78.6)
0.646
Suburban 47
(22.1)
166
(77.9)
Rural 33
(25.8)
95
(74.2)
Size of ownership (N= 534) Independent or
small multiple
51
(30.9)
114
(69.1)
0.004
Medium or large
multiple
71
(19.2)
298
(80.8)
** Fischer’s exact test; *** Locums/ Reliefs excluded
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Table 16.10: Univariate statistics of 24-item scale items and demographic characteristics with
the outcome ‘naproxen adoption’ (note: this table extends up to four pages)
Scale items Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
This is a good opportunity to
extend my role as a health
professional (N= 551)
Low agreement 156
(76.5)
48
(23.5)
<0.001
High agreement 134
(38.6)
213
(61.4)
This product matches with the
business/service ambitions of
my pharmacy (N= 551)
Low agreement 193
(72.3)
74
(27.7)
<0.001
High agreement 98
(34.5)
186
(65.5)
This product has potential for
good financial returns for my
pharmacy (N= 546)
Low agreement 206
(64.4)
114
(35.6)
<0.001
High agreement 82
(36.3)
144
(63.7)
My customers often complain
about the cost of this product
(not including e-MAS supply) †
(N= 550)
Low agreement 215
(58.6)
152
(41.4)
<0.001
High agreement 74
(40.4)
109
(59.6)
Insufficient resources (e.g. staff,
space etc) within my pharmacy
has limited the practice of this
product† (N= 552)
Low agreement 114
(64.4)
63
(35.6)
<0.001
High agreement 177
(47.2)
198
(52.8)
It is likely that customers could
misuse this product † (N= 552)
Low agreement 153
(55.6)
122
(44.4)
0.231
High agreement 139
(50.2)
138
(49.8)
Customers not accepting my
advice around this product
makes me less likely to adopt
this product† (N= 548)
Low agreement 171
(55.7)
136
(44.3)
0.138
High agreement 118
(49.0)
123
(51.0)
I find the processes involved in
the supply of this product
complex† (N= 548)
Low agreement 120
(67.0)
59
(33.0)
<0.001
High agreement 170
(46.1)
199
(53.9)
I am happy to delegate the task
of supplying this product to
support staff (N= 549)
Low agreement 199
(61.0)
127
(39.0)
<0.001
High agreement 92
(41.3)
131
(58.7)
Many customers ask for this
product by name (N= 548)
Low agreement 255
(57.0)
192
(43.0)
<0.001
High agreement 36
(35.6)
65
(64.4)
* % represents proportion within row categories; †Items reversed scored
Appendix - 95 -
Scale items Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
I feel confident about my ability
to supply this product (N= 551)
Low agreement 47
(83.9)
9
(16.1)
<0.001
High agreement 244
(49.3)
251
(50.7)
I believe that this product is a
welcome addition to the range
of pharmacy medicines (N= 552)
Low agreement 135
(81.8)
30
(18.2)
<0.001
High agreement 155
(40.1)
232
(59.9)
I have access to sufficient
sources of information relating
to this product (N= 548)
Low agreement 60
(66.7)
30
33.3)
0.004
High agreement 227
49.6)
231
(50.4)
I believe that the OTC regimen
for this product is likely to be
effective (N= 549)
Low agreement 139
(73.5)
50
(26.5)
<0.001
High agreement 151
(41.9)
209
(58.1)
The similarity of POM and P
packs of this product could
create confusion† (N= 550)
Low agreement 86
(62.3)
52
(37.7)
0.011
High agreement 203
(49.3)
209
(50.7)
It is easy for me and/or my
customers to know if treatment
with this product is effective
(N= 546)
Low agreement 131
(68.9)
59
(31.1)
<0.001
High agreement 156
(43.8)
200
(56.2)
I believe this product has
potential to engender patient
satisfaction (N= 530)
Low agreement 164
(62.6)
98
(37.4)
<0.001
High agreement 117
(43.7)
151
(56.3)
I believe there are high risks of
adverse events associated with
this product† (N= 549)
Low agreement 228
(56.7)
174
(43.3)
0.002
High agreement 61
(41.5)
86
(58.5)
Introduction of this product
may have represented a ‘step
too far’ for OTC products† (N=
549)
Low agreement 95
(71.4)
38
(28.6)
<0.001
High agreement 194
(46.6)
222
(53.4)
It has been my management’s
decision rather than my own as
to if/ how far to adopt into
practice† (N= 539)
Low agreement 112
(53.6)
97
46.4)
0.557
High agreement 167
(50.6)
163
(49.4)
I get adequate support from my
professional body to adopt this
product† (N= 545)
Low agreement 161
(63.4)
93
(36.6)
<0.001
High agreement 125
(43.0)
166
(57.0)
†Items reversed scored;
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Scale items/variables Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
Lack of proper way to
communicate with the local
medical practice is a barrier to
adopt this product† (N= 543)
Low agreement 135
(59.7)
91
(40.3)
0.009
High agreement 152
(47.9)
165
(52.1)
Lack of access to patient medical
records makes it difficult to
adopt this product into practice†
(N= 548)
Low agreement 169
59.1)
117
(40.9)
0.002
High agreement 119
(45.4)
143
(54.6)
I am/would be comfortable
going off guidelines to supply
this product (N= 546)
Low agreement 252
(53.6)
218
(46.4)
0.189
High agreement 34
(44.7)
42
(55.3)
Innovativeness (N= 542) Cautious or
Deliberate
199
(60.7)
129
(39.3)
<0.001
Role model or
venturesome
91
(41.7)
127
(58.3)
Gender (N= 547) Male 123
(58.3)
88
(41.7)
0.038
Female 164
(48.8)
172
(51.2)
Age (N= 548) 39 Years and
under
163
(47.8)
178
(52.2)
0.003
40 years and over 127
(61.4)
80
(38.6)
Experience (N= 549) 10 years and
under
133
(46.7)
152
(53.3)
0.002
11 years or over 159
(60.2)
105
(39.8)
Owner (N= 556) Yes 62
63.9)
35
36.1)
0.020
No 231
(50.3)
228
(49.7)
Manager (N= 556) Yes 206
(51.4)
195
(48.6)
0.361
No 87
(56.1)
68
(43.9)
Relief (N= 556) Yes 18
(45.0)
22
(55.0)
0.397
No 275
53.3)
241
(46.7)
†Items reversed scored;
Appendix - 97 -
Scale items / variables Categories Low
adoption
n (%)
High
adoption
n (%)
P
value
Second (N= 556) Yes 8
(38.1)
13
(61.9)
0.253
No 285
(53.3)
250
(46.7)
Locum (N= 556) Yes 11
(68.8)
5
(31.3)
0.293
No 282
(52.2)
258
(47.8)
Non-store (N= 552) Yes 1
(100.0)
0
(0.0)
1.00**
No 292
(52.6)
263
(47.4)
Prescriber (N= 553) Yes 80
(54.8)
66
(45.2)
0.606
No 211
(51.8)
196
(48.2)
Postgraduate (N= 547) Yes 39
(43.3)
51
(56.7)
0.064
No 252
(54.7)
209
(45.3)
Location*** (N= 497) Urban 77
(50.0)
77
(50.0)
0.742
Suburban 114
(53.3)
100
(46.7)
Rural 70
(54.3)
59
(45.7)
Size of ownership (N= 534) Independent or
small multiple
114
(69.1)
51
(30.9)
<0.001
Medium or large
multiple
167
(44.8)
206
(55.2)
** Fischer’s exact test; *** Locums/ Reliefs excluded
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Table 16.11: Bivariate analysis showing correlations of the outcome ‘simvastatin acceptance’
and ‘simvastatin adoption’ with the 24-items scale displaying Kendals’ T values of of <.2
Statements Kendal’s T
correlation
values with
‘simvastatin
acceptance’
Kendal’s T
correlation
values with
‘simvastatin
adoption’
I am happy to delegate the task of supplying this product
to support staff
¥ .118***
I find the processes involved in the supply of this
product complex† .135*** .142***
I feel confident about my ability to supply this product .164*** .150***
My customers often complain about the cost of this
product (not including e-MAS supply) † 0.028 .070
Insufficient resources (e.g. staff, space etc) within my
pharmacy has limited the practice of this product† -.080* .002
It is likely that customers could misuse this product† -.077* -.060
Customers not accepting my advice around this product
makes me less likely to adopt this product† 0.003 .036
I have access to sufficient sources of information relating
to this product .097** .088*
The similarity of POM and P packs of this product could
create confusion† -0.065 -.085*
I believe there are high risks of adverse events associated
with this product† .115*** .026
It has been my management’s decision rather than my
own as to if/ how far to adopt into practice† -.084* .137***
Introduction of this product may have represented a
‘step too far’ for OTC products†
¥
-.099***
I get adequate support from my professional body to
adopt this product
.113*** .078*
Lack of proper way to communicate with the local
medical practice is a barrier to adopt this product† -0.053 .062
Lack of access to patient medical records makes it
difficult to adopt this product into practice† .094** .140***
I am/would be comfortable going off guidelines to
supply this product
.113*** .093*
*P≤0.05; ***P≤0.01;***P≤0.001 †Items reversed scored ¥Correlation values ≥.2 and appears in
Chapter 6
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Table 16.12: Bivariate analysis showing correlations of the outcome ‘simvastatin acceptance’
and ‘simvastatin adoption’ with self innovativeness and demographic characteristics
displaying Kendals’ T values of of <.2
Variables Kendal’s T correlation
values with ‘simvastatin
acceptance’
Kendal’s T correlation values
with ‘simvastatin adoption’
Innovativeness 0.047 0.040
Gender -0.040 -.085*
Age 0.048 0.048
Experience 0.025 0.034
Type of pharmacy 0.049 0.072
Owner -0.012 0.011
Manager .095* 0.072
Relief -0.022 -0.077
Second -0.048 -0.006
Locum -0.055 -0.001
Non-store -0.019 0.019
Prescriber 0.032 -0.005
Postgraduate
qualification -0.010 -0.052
Location -0.038 0.013
*P≤0.05
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Table 16.13: Bivariate analysis showing correlations of the outcome ‘chloramphenicol
acceptance’ and ‘chloramphenicol adoption’ with the 24 items scale displaying Kendals’ T
values of <.2
Statements Kendal’s T
correlation values
with
‘chloramphenicol
acceptance’
Kendal’s T
correlation values
with
‘chloramphenicol
adoption’
This product has potential for good financial
returns for my pharmacy .166***
¥
It is likely that customers could misuse this
product† .154*** .074
My customers often complain about the cost of
this product (not including e-MAS supply) † .091 .150***
Customers not accepting my advice around
this product makes me less likely to adopt this
product†
.098* .112***
I am happy to delegate the task of supplying
this product to support staff .004
.196***
Many customers ask for this product by name .098* .130***
Insufficient resources (e.g. staff, space etc)
within my pharmacy has limited the practice
of this product†
.156*** .161***
I find the processes involved in the supply of
this product complex† .181***
¥
I have access to sufficient sources of
information relating to this product .119*** .134***
The similarity of POM and P packs of this
product could create confusion† .104*** .129***
It is easy for me and/or my customers to
know if treatment with this product is
effective
.132*** .174***
I believe there are high risks of adverse events
associated with this product† .195*** .129***
I believe this product has potential to
engender patient satisfaction .083* .016
It has been my management’s decision rather
than my own as to if/ how far to adopt into
practice†
.105*** .004
Lack of access to patient medical records
makes it difficult to adopt this product into
practice†
.132*** .148***
Lack of proper way to communicate with the
local medical practice is a barrier to adopt this
product†
.119*** .134***
I get adequate support from my professional
body to adopt this product .095* .070
I am/would be comfortable going off
guidelines to supply this product
.041 .052
*P≤0.05; ***P≤0.001; †Items reversed scored ¥ Correlation values ≥.2 and appears in Chapter 6
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Table 16.14: Bivariate analysis showing correlations of the outcome ‘chloramphenicol
acceptance’ and ‘chloramphenicol adoption’ with innovativeness and demographic
characteristics displaying Kendals’ T values of <.2
Variables Kendal’s T correlation
values with
‘chloramphenicol
acceptance’
Kendal’s T correlation
values with
‘chloramphenicol
adoption’
Innovativeness 0.073 .147***
Gender 0.032 .098*
Age -0.039 -.184***
Number of years
registered with the RPSGB -0.032
-.154***
Type of pharmacy 0.009 .126***
Owner -0.012 0.028
Manager -0.009 0.014
Relief 0.071 -0.040
Second -0.058 -0.043
Locum -0.012 0.029
Non-store -0.012 -0.019
Prescriber -0.021 -0.051
Postgraduate qualification 0.000 -0.073
Location 0.019 -0.013
*P≤0.05; ***P≤0.001;
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Non-respondent analysis
Table 16.15: Non-significant univariate associations relating to non-respondent analysis (Note: this table extends up to eight pages)
Respondent category with age
Age Total
29 and
under 30-39 40-49 50-59
60 and
above
Category as per
time of response
Early
respondents
Count 167 104 81 80 14 446
% within Category
as per time of
response
37.4% 23.3% 18.2% 17.9% 3.1% 100.0%
Late
respondents
Count 46 26 11 21 4 108
% within Category
as per time of
response
42.6% 24.1% 10.2% 19.4% 3.7% 100.0%
Total Count 213 130 92 101 18 554
% within Category
as per time of
response
38.4% 23.5% 16.6% 18.2% 3.2% 100.0%
P=0.387
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Respondent category with number of years registered with the RPSGB
Number in years Total
5 years
and under 6-10 11-15 16-20
20 or
above
Category as per
time of response
Early
respondents
Count 144 82 40 44 138 448
% within Category
as per time of
response
32.1% 18.3% 8.9% 9.8% 30.8% 100.0%
Late
respondents
Count 44 16 12 7 28 107
% within Category
as per time of
response
41.1% 15.0% 11.2% 6.5% 26.2% 100.0%
Total Count 188 98 52 51 166 555
% within Category
as per time of
response
33.9% 17.7% 9.4% 9.2% 29.9% 100.0%
P=0.318
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Respondent category with type of pharmacy ownership
Type of pharmacy Total
Independen
t
Small
multiple (2-
4 stores)
Medium
sized stores
(5-25 stores)
Large
multiples
(over 25
stores)
Category as per
time of response
Early
respondents
Count 82 55 79 221 437
% within Category
as per time of
response
18.8% 12.6% 18.1% 50.6% 100.0%
Late
respondents
Count 17 14 13 62 106
% within Category
as per time of
response
16.0% 13.2% 12.3% 58.5% 100.0%
Total Count 99 69 92 283 543
% within Category
as per time of
response
18.2% 12.7% 16.9% 52.1% 100.0%
P=0.376
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Respondent category with owner status
Owner Total
Yes No
Category as per
time of response
Early
respondents
Count 79 375 454
% within Category
as per time of
response
17.4% 82.6% 100.0%
Late
respondents
Count 18 90 108
% within Category
as per time of
response
16.7% 83.3% 100.0%
Total Count 97 465 562
% within Category
as per time of
response
17.3% 82.7% 100.0%
P=0.968
Respondent category with manager status
Manager Total
Yes No
Category as per
time of response
Early
respondents
Count 328 126 454
% within Category
as per time of
response
72.2% 27.8% 100.0%
Late
respondents
Count 79 29 108
% within Category
as per time of
response
73.1% 26.9% 100.0%
Total Count 407 155 562
% within Category
as per time of
response
72.4% 27.6% 100.0%
P=0.945
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Respondent category with relief status
Relief Total
Yes No
Category as per
time of response
Early
respondents
Count 32 422 454
% within Category
as per time of
response
7.0% 93.0% 100.0%
Late
respondents
Count 8 100 108
% within Category
as per time of
response
7.4% 92.6% 100.0%
Total Count 40 522 562
% within Category
as per time of
response
7.1% 92.9% 100.0%
P=1.000
Respondent category with ‘second’ status
Second Total
Yes No
Category as per
time of response
Early
respondents
Count 17 437 454
% within Category
as per time of
response
3.7% 96.3% 100.0%
Late
respondents
Count 4 104 108
% within Category
as per time of
response
3.7% 96.3% 100.0%
Total Count 21 541 562
% within Category
as per time of
response
3.7% 96.3% 100.0%
P=1.000
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Respondent category with locum status
Locum Total
Yes No
Category as per
time of response
Early
respondents
Count 14 440 454
% within Category
as per time of
response
3.1% 96.9% 100.0%
Late
respondents
Count 2 106 108
% within Category
as per time of
response
1.9% 98.1% 100.0%
Total Count 16 546 562
% within Category
as per time of
response
2.8% 97.2% 100.0%
P=0.711
Respondent category with non-store status
Non-store Total
Yes No
Category as per
time of response
Early
respondents
Count 0 454 454
% within Category
as per time of
response
.0% 100.0% 100.0%
Late
respondents
Count 1 107 108
% within Category
as per time of
response
.9% 99.1% 100.0%
Total Count 1 561 562
% within Category
as per time of
response
.2% 99.8% 100.0%
P=0.434 (Fisher’s exact test)
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Respondent category with prescriber status
Prescriber Total
Yes No
Category as per
time of response
Early
respondents
Count 116 333 449
% within Category
as per time of
response
25.8% 74.2% 100.0%
Late
respondents
Count 30 78 108
% within Category
as per time of
response
27.8% 72.2% 100.0%
Total Count 146 411 557
% within Category
as per time of
response
26.2% 73.8% 100.0%
P=0.772
Respondent category with postgraduate qualification status
Postgraduate
qualification Total
Yes No
Category as per
time of response
Early
respondents
Count 76 374 450
% within Category
as per time of
response
16.9% 83.1% 100.0%
Late
respondents
Count 15 92 107
% within Category
as per time of
response
14.0% 86.0% 100.0%
Total Count 91 466 557
% within Category
as per time of
response
16.3% 83.7% 100.0%
P=0.564
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Respondent category with pharmacy location
Location Total
Urban
Sub-
urban Rural
Locum/
Relief
Category as per
time of response
Early
respondents
Count 138 179 120 16 453
% within Category
as per time of
response
30.5% 39.5% 26.5% 3.5% 100.0%
Late
respondents
Count 30 52 21 5 108
% within Category
as per time of
response
27.8% 48.1% 19.4% 4.6% 100.0%
Total Count 168 231 141 21 561
% within Category
as per time of
response
29.9% 41.2% 25.1% 3.7% 100.0%
P=0.285
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Examples of e-MAS performance feedback data presented to focus groups and
interview participants as vignettes
Number of patients registered for eMAS in
Scotland, July 2006 - June 2007
A Ayrshire and Arran
B Borders
F Fife
G Greater Glasgow and Clyde
H Highland
L Lanarkshire
N Grampian
R Orkney
S Lothian
T Tayside
V Forth Valley
W Western Isles
Y Dumfries and Galloway
Z Shetland
APPENDIX: Examples of feedback data shown to participants
MAS items dispensed in Scotland, July 2006 to
March 2007
Appendix - 111 -
Drug Name
Examples of use in
MAS No of items
Paracetamol Pain, fever 84,609
Ibuprofen Pain, fever, inflammation 32,230
Simple Linctus Cough 32,096
Malathion Scabies, head lice, crablice 24,877
Chloramphenicol Eye infections 17,698
Pholcodine Cough 17,315
Clotrimazole Vaginal thrush, athlete'sfoot 16,179
Pseudoephedrine
Hydrochloride Nasal congestion 15,855
Emollients Dry scaly skin 13,229
Aciclovir Cold sores 12,556
TOP 10 MAS items dispensed in Scotland July 2006 to March 2007
Gross Ingredient Cost (GIC) of MAS items dispensed in
Scotland,
July 2006 to March 2007
Appendix - 112 -
Individual pharmacy level data
e-MAS data for a community pharmacy
Individual pharmacy level data
e-MAS data for a community pharmacy
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Applications of PRISM data in GP prescribing
 Prescriber can see whether prescribing
reflects policies
 Adherence to the guidelines
 To look for cost effective prescribing
 To compare with peers, other health boards
and with national averages.
PRISM data: Compliance with a formulary
C
on
tr
ac
to
rs
Appendix - 114 -
18 APPENDIX VIII (CHAPTER 8)
Table 18.1: Univariate analysis with non-significant association of explanatory variables with
the outcome measure (Note: this table extends up to two pages)
Facilitators
Scale items Categories Low adoption*
n(%)
High
adoption†
n(%)
P
value
Financial benefits to me (N=
490)
Yes 5
(13.2)
33
(86.8)
0.827
No 72
(15.9)
380
(84.1)
Opportunity for enhanced
working with GPs (N=489)
Yes 10
(9.5)
95
(90.5)
0.068
No 67
(17.4)
317
(82.6)
*Represents 3 or below in the five point scale; † Represents 4 or above in the five point scale; %
represent proportion within row category
Barriers
Scale items* Categories Low adoption
n(%)
High
adoption
n(%)
P
value
Lack of satisfactory
reimbursement (N= 490)
Yes 52
(14.4)
308
(85.6)
0.252
No 25
(19.2)
105
(80.8)
Lack of satisfactory
remuneration (N=490)
Yes 49
(13.9)
303
(86.1)
0.109
No 28
(20.3)
110
(79.7)
Time for recording consultation
or supply (N=490)
Yes 22
(11.8)
165
(88.2)
0.078
No 55
(18.2)
248
(81.8)
Suspected misuse/overuse of
the service by some customers
(N=490)
Yes 19
(15.3)
105
(84.7)
1.000
No 58
(15.8)
308
(84.2)
Inadequate resources of my
pharmacy (N= 490)
Yes 68
(15.3)
377
(84.7)
0.539
No 9
(20.0)
36
(80.0)
Lack of opportunity for
enhanced working with GPs
(N= 490)
Yes 66
(15.8)
352
(84.2)
1.000
No 11
(15.3)
61
(84.7)
*Items reversed scored
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Demographic characteristics
Variables Categories Low adoption
n(%)
High
adoption
n(%)
P
value
Gender (N= 483) Male 26
(13.4)
168
(86.6)
0.353
Female 49
(17.0)
240
(83.0)
Owner (N=490) Yes 18
(21.2)
67
(78.8)
0.174
No 59
(14.6)
346
(85.4)
Manager (N= 490) Yes 54
(15.0)
305
(85.0)
0.591
No 23
(17.6)
108
(82.4)
Relief (N= 490) Yes 2
(5.7)
33
(94.3)
0.148
No 75
(16.5)
380
(83.5)
Second (N= 490) Yes 4
(25.0)
12
(75.0)
0.295*
No 73
(15.4)
401
(84.6)
Locum (N= 490) Yes 2
(13.3)
13
(86.7)
1.000*
No 75
(15.8)
400
(84.2)
Non-store (N= 490) Yes 0
(0.0)
1
(100.0)
1.000*
No 77
(15.7)
412
(84.3)
Pharmacist prescriber (N=
487)
Yes 17
(13.8)
106
(86.2)
0.677
No 58
(15.9)
306
(84.1)
Postgraduate qualification
(N= 485)
Yes 11
(13.4)
71
(86.6)
0.692
No 64
(15.9)
339
(84.1)
Location (N= 437)** Urban 20
(15.3)
111
(84.7)
0.405
Suburban 29
(14.9)
165
(85.1)
Rural 23
(20.5)
89
(79.5)
*Fisher’s exact test; ** Locums/reliefs excluded from the analysis
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(no appendix to Chapter 9 exist)
Table 19.1: List of researchers’ training activities
Date, Organizer, Venue Title and brief description of training Category of skill
development
15-17 September 2009
Cochrane Qualitative
Research Methods Group
and University of
Sheffield
Evidence Synthesis of Qualitative Research
in Europe (ESQUIRE) Methods Workshop on
Qualitative Evidence Synthesis
Systematic
review of
literature with
diverse
methodological
applications
27th November 2008,
Writing up qualitative
research, Wellcome Trust,
Edinburgh.
Advanced skills on writing up qualitative research. Technical ability,
presentation of
research.
24th November 2008 NVivo
course intermediate
training, Robert Gordon
University
Intermediate skills on application of NVivo
qualitative data management software
Technical ability
28th October 2008 IRAS
application training, NHS
Grampian, Aberdeen
Skills on successfully completing Integrated Research
Application System
Research Ethics
and Governance
8-12 September 2008
The Robert Gordon
University, Aberdeen
PG Certificate module 2. Advanced courses on
literature critical appraisal skills, analysing data and
presenting results. The Robert Gordon University.
Technical and
project
management
skills.
22-25 April, 2008
Social Research
Association (SRA)
Scotland, Edinburgh
Quantitative training courses by Social Research
Association Scotland. Focussed on survey techniques.
Skills around design, sampling, conduction and
analysis of survey and survey results.
Technical ability
28th February- 4th March,
2008
Social Research
Association (SRA)
Scotland, Edinburgh
Qualitative research training course by Social
Research Association Scotland: Conducting,
analysing and reporting focus group and interviews
data. Specialized skills around conducting focus
groups and interviews, framework technique of
analysis and a brief session on reporting focus group
data.
Technical ability
31st January 2008
Social Research
Association (SRA)
Scotland, Edinburgh
Introduction to qualitative research: Designing a
qualitative study. Generic training about concepts
and design of qualitative research.
Project design
2nd November, 2007
Medicine and Health
Regulatory Agency
(MHRA), London
Medicine and Health Regulatory Agency (MHRA)
training day for clinical pharmacologists. Training
around procedures of new drug approval and
reclassification of medicines. London.
Knowledge in
research area.
22-26 October 2007
The Robert Gordon
University, Aberdeen
PG Certificate research Methods. Basic knowledge
and skills training around doing a PhD. Introduction
to PhD, planning and management of project.
Introduction to qualitative and quantitative methods.
Research ethics and governance issues. Literature
review techniques.
Critical
appraisal, project
management,
data analysis,
research
governance.
